Document:

Exhibit 10.37

 

Pursuant to 17 C.F.R §240.24b-2, confidential information (indicated as [***]) has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission.

 

 

 

CREDIT AGREEMENT

 

 among

 

 UNITED THERAPEUTICS CORPORATION,
 as Borrower,

 

 THE LENDERS PARTY HERETO,

 

 and

 

 WELLS FARGO BANK, NATIONAL ASSOCIATION,
 as the Administrative Agent

 

 and agreed to by

 

 CERTAIN SUBSIDIARIES OF THE BORROWER PARTY HERETO,
 as Guarantors

 

 

Dated as of December 27, 2010

 

 

WELLS FARGO SECURITIES, LLC,
 as Sole Lead Arranger and Sole Bookrunner

 

 

 

	
Prepared   by:
    	

    

 

 

TABLE OF CONTENTS

 

	
 
    	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    	
 
    
	
ARTICLE I DEFINITIONS
    	
 
    	
1
    
	
 
    	
 
    	
 
    
	
 
    	
Section 1.1
    	
Defined Terms
    	
1
    
	
 
    	
Section 1.2
    	
Other Definitional Provisions
    	
19
    
	
 
    	
Section 1.3
    	
Accounting Terms
    	
19
    
	
 
    	
Section 1.4
    	
Time References
    	
20
    
	
 
    	
Section 1.5
    	
Execution of Documents
    	
20
    
	
 
    	
 
    	
 
    	
 
    
	
ARTICLE II THE LOAN; AMOUNT AND TERMS
    	
 
    	
20
    
	
 
    	
 
    	
 
    
	
 
    	
Section 2.1
    	
Loan
    	
20
    
	
 
    	
Section 2.2
    	
Fees
    	
21
    
	
 
    	
Section 2.3
    	
Prepayments
    	
21
    
	
 
    	
Section 2.4
    	
Default Rate and Payment Dates
    	
22
    
	
 
    	
Section 2.5
    	
Conversion/Continuation Options
    	
22
    
	
 
    	
Section 2.6
    	
Computation of Interest and Fees; Usury
    	
23
    
	
 
    	
Section 2.7
    	
Pro Rata Treatment and Payments
    	
24
    
	
 
    	
Section 2.8
    	
Non-Receipt of Funds by the Administrative Agent
    	
26
    
	
 
    	
Section 2.9
    	
Inability to Determine Interest   Rate
    	
27
    
	
 
    	
Section 2.10
    	
Yield Protection
    	
28
    
	
 
    	
Section 2.11
    	
Indemnity; Eurocurrency   Liabilities
    	
29
    
	
 
    	
Section 2.12
    	
Taxes
    	
29
    
	
 
    	
Section 2.13
    	
Illegality
    	
31
    
	
 
    	
Section 2.14
    	
No New Extension of Credit After   Closing Date
    	
32
    
	
 
    	
Section 2.15
    	
Hedging Agreement Not Required
    	
32
    
	
 
    	
 
    	
 
    	
 
    
	
ARTICLE III REPRESENTATIONS AND WARRANTIES
    	
 
    	
32
    
	
 
    	
 
    	
 
    
	
 
    	
Section 3.1
    	
Financial Statements
    	
32
    
	
 
    	
Section 3.2
    	
No Material Adverse Change
    	
33
    
	
 
    	
Section 3.3
    	
Existence; Compliance with Law
    	
33
    
	
 
    	
Section 3.4
    	
Power; Authorization; Enforceable   Obligations
    	
33
    
	
 
    	
Section 3.5
    	
No Legal Bar
    	
33
    
	
 
    	
Section 3.6
    	
No Material Litigation
    	
33
    
	
 
    	
Section 3.7
    	
No Default
    	
34
    
	
 
    	
Section 3.8
    	
Ownership of Collateral; Liens
    	
34
    
	
 
    	
Section 3.9
    	
Intellectual Property
    	
34
    
	
 
    	
Section 3.10
    	
Taxes
    	
34
    
	
 
    	
Section 3.11
    	
Accuracy of Information
    	
34
    
	
 
    	
Section 3.12
    	
Federal Regulations
    	
35
    
	
 
    	
Section 3.13
    	
ERISA
    	
35
    
	
 
    	
Section 3.14
    	
Investment Company Act; Other   Regulations
    	
35
    
	
 
    	
Section 3.15
    	
Subsidiaries
    	
35
    
	
 
    	
Section 3.16
    	
Purpose of the Loan
    	
35
    
	
 
    	
Section 3.17
    	
Security Documents
    	
35
    
	
 
    	
Section 3.18
    	
Environmental Matters
    	
36
    
	
 
    	
Section 3.19
    	
Solvency
    	
37
    
	
 
    	
Section 3.20
    	
Anti-Terrorism Laws
    	
37
    
	
 
    	
Section 3.21
    	
Compliance with OFAC   Rules and Regulations
    	
37
    
	
 
    	
Section 3.22
    	
Compliance with FCPA
    	
38
    
					

 

i

 

	
 
    	
Section 3.23
    	
Mortgaged Properties
    	
38
    
	
 
    	
 
    	
 
    
	
ARTICLE IV CONDITIONS PRECEDENT
    	
40
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Section 4.1
    	
Conditions to Closing Date
    	
40
    
	
 
    	
Section 4.2
    	
Conditions to Extensions of   Credit
    	
45
    
	
 
    	
 
    	
 
    	
 
    
	
ARTICLE V   AFFIRMATIVE COVENANTS
    	
46
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Section 5.1
    	
Financial Statements
    	
46
    
	
 
    	
Section 5.2
    	
Certificates; Other Information
    	
46
    
	
 
    	
Section 5.3
    	
Payment of Obligations
    	
47
    
	
 
    	
Section 5.4
    	
Conduct of Business and   Maintenance of Existence
    	
48
    
	
 
    	
Section 5.5
    	
Compliance with Contractual   Obligations and Laws
    	
48
    
	
 
    	
Section 5.6
    	
Insurance
    	
48
    
	
 
    	
Section 5.7
    	
Inspection of Property; Books and   Records; Discussions
    	
50
    
	
 
    	
Section 5.8
    	
Notices
    	
51
    
	
 
    	
Section 5.9
    	
Addition of Material Subsidiaries   as Guarantors / Guarantee Requirement
    	
52
    
	
 
    	
Section 5.10
    	
Environmental Matters
    	
53
    
	
 
    	
Section 5.11
    	
Financial Covenants
    	
54
    
	
 
    	
Section 5.12
    	
Pledged Assets
    	
54
    
	
 
    	
Section 5.13
    	
Further Assurances, Etc
    	
55
    
	
 
    	
Section 5.14
    	
Maintenance of Mortgaged Property
    	
56
    
	
 
    	
Section 5.15
    	
Utilities and Public Access;   Parking
    	
57
    
	
 
    	
Section 5.16
    	
Additional Survey Requirements
    	
57
    
	
 
    	
Section 5.17
    	
Regulatory Approvals
    	
57
    
	
 
    	
Section 5.18
    	
Ownership of Mortgaged Properties
    	
57
    
	
 
    	
Section 5.19
    	
Casualty and Condemnation
    	
57
    
	
 
    	
Section 5.20
    	
Payment of Obligations
    	
60
    
	
 
    	
 
    	
 
    	
 
    
	
ARTICLE VI   NEGATIVE COVENANTS
    	
60
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Section 6.1
    	
Limitation on Liens
    	
61
    
	
 
    	
Section 6.2
    	
Limitation on Fundamental Changes
    	
61
    
	
 
    	
Section 6.3
    	
Limitation on Transactions with   Affiliates
    	
62
    
	
 
    	
Section 6.4
    	
Limitation on Modification of   Organizational Agreements
    	
62
    
	
 
    	
Section 6.5
    	
Maintenance of On-Going Operations at any Mortgaged   Property
    	
62
    
	
 
    	
Section 6.6
    	
Modifications
    	
62
    
	
 
    	
 
    	
 
    	
 
    
	
ARTICLE VII   EVENTS OF DEFAULT
    	
62
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Section 7.1
    	
Events of Default
    	
62
    
	
 
    	
Section 7.2
    	
Acceleration; Remedies
    	
66
    
	
 
    	
 
    	
 
    	
 
    
	
ARTICLE VIII   THE ADMINISTRATIVE AGENT
    	
66
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Section 8.1
    	
Appointment and Authority
    	
66
    
	
 
    	
Section 8.2
    	
Nature of Duties
    	
66
    
	
 
    	
Section 8.3
    	
Exculpatory Provisions
    	
67
    
	
 
    	
Section 8.4
    	
Reliance by the Administrative   Agent
    	
67
    
	
 
    	
Section 8.5
    	
Notice of Default
    	
68
    
	
 
    	
Section 8.6
    	
Non-Reliance on the   Administrative Agent and Other Lenders
    	
68
    
	
 
    	
Section 8.7
    	
Indemnification
    	
68
    
	
 
    	
Section 8.8
    	
The Administrative Agent in Its   Individual Capacity
    	
69
    
	
 
    	
Section 8.9
    	
Successor Administrative Agent
    	
69
    
	
 
    	
Section 8.10
    	
Collateral and Guaranty Matters
    	
69
    

 

ii

 

	
 
    	
Section 8.11
    	
Secured Hedging Agreements
    	
70
    
	
 
    	
 
    	
 
    
	
ARTICLE IX MISCELLANEOUS
    	
70
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Section 9.1
    	
Amendments, Waivers, Consents and   Release of Collateral
    	
70
    
	
 
    	
Section 9.2
    	
Notices
    	
72
    
	
 
    	
Section 9.3
    	
No Waiver; Cumulative Remedies
    	
74
    
	
 
    	
Section 9.4
    	
Survival of Representations and   Warranties
    	
74
    
	
 
    	
Section 9.5
    	
Payment of Expenses and Taxes;   Indemnity
    	
74
    
	
 
    	
Section 9.6
    	
Successors and Assigns;   Participations
    	
76
    
	
 
    	
Section 9.7
    	
[Intentionally Deleted]
    	
78
    
	
 
    	
Section 9.8
    	
Table of Contents and   Section Headings
    	
78
    
	
 
    	
Section 9.9
    	
Counterparts; Integration;   Effectiveness; Electronic Execution
    	
79
    
	
 
    	
Section 9.10
    	
Severability
    	
79
    
	
 
    	
Section 9.11
    	
Integration
    	
79
    
	
 
    	
Section 9.12
    	
Governing Law
    	
79
    
	
 
    	
Section 9.13
    	
Consent to Jurisdiction; Service   of Process and Venue
    	
80
    
	
 
    	
Section 9.14
    	
Confidentiality
    	
80
    
	
 
    	
Section 9.15
    	
Acknowledgments
    	
81
    
	
 
    	
Section 9.16
    	
Waivers of Jury Trial; Waiver of   Consequential Damages
    	
81
    
	
 
    	
Section 9.17
    	
Patriot Act Notice
    	
82
    
	
 
    	
Section 9.18
    	
Resolution of Drafting   Ambiguities
    	
82
    
	
 
    	
Section 9.19
    	
Subordination of Intercompany Debt
    	
82
    
	
 
    	
Section 9.20
    	
Continuing Agreement
    	
82
    
	
 
    	
Section 9.21
    	
Lender Consent
    	
82
    
	
 
    	
Section 9.22
    	
Press Releases and Related   Matters
    	
83
    
	
 
    	
Section 9.23
    	
Appointment of Borrower
    	
83
    
	
 
    	
Section 9.24
    	
No Advisory or Fiduciary   Responsibility
    	
83
    
	
 
    	
Section 9.25
    	
Responsible Officers
    	
84
    

 

iii

 

	
 
    	
Schedules
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Schedule   1.0
    	
Allocated   Loan Amount
    	
 
    
	
 
    	
Schedule   1.1
    	
Loan   Commitment Percentage
    	
 
    
	
 
    	
Schedule   2.1
    	
Principal   Amortization of Loan
    	
 
    
	
 
    	
Schedule   3.1
    	
Material   Obligations/Material Dispositions
    	
 
    
	
 
    	
Schedule   3.6
    	
Material   Litigation
    	
 
    
	
 
    	
Schedule   3.15
    	
Subsidiaries
    	
 
    
	
 
    	
Schedule   3.17
    	
Security   Documents
    	
 
    
	
 
    	
Schedule   3.20
    	
Patriot   Act Information
    	
 
    
	
 
    	
Schedule   3.23(j)
    	
Information   regarding Mortgaged Property
    	
 
    
	
 
    	
Schedule   3.23(k)
    	
Insurance
    	
 
    
	
 
    	
Schedule   5.14
    	
Mortgaged   Property Modifications
    	
 
    
	
 
    	
Schedule   6.1(d)
    	
Existing   Liens
    	
 
    
	
 
    	
Schedule   6.3
    	
Permitted   Affiliate Transactions
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Exhibits
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
Exhibit 1.1(a)
    	
Form of   Account Designation Notice
    	
 
    
	
 
    	
Exhibit 1.1(b)
    	
Form of   Assignment and Assumption
    	
 
    
	
 
    	
Exhibit 1.1(c)
    	
Form of   Secured Party Designation Notice
    	
 
    
	
 
    	
Exhibit 1.1(d)
    	
Form of   Joinder Agreement
    	
 
    
	
 
    	
Exhibit 1.1(e)
    	
Form of   Notice of Borrowing
    	
 
    
	
 
    	
Exhibit 1.1(f)
    	
Form of   Notice of Conversion/Extension
    	
 
    
	
 
    	
Exhibit 1.1(g)
    	
Form of   Guaranty Agreement
    	
 
    
	
 
    	
Exhibit 1.1(h)
    	
Form of   Initial Guarantor Joinder Agreement
    	
 
    
	
 
    	
Exhibit 2.1(d)
    	
Form of   Note
    	
 
    
	
 
    	
Exhibit 4.1(a)
    	
Form of   Lender Consent
    	
 
    
	
 
    	
Exhibit 4.1(b)
    	
Form of   Officer’s Certificate
    	
 
    
	
 
    	
Exhibit 4.1(l)
    	
Form of   Financial Condition Certificate
    	
 
    
	
 
    	
Exhibit 5.2(b)
    	
Form of   Officer’s Compliance Certificate
    	
 
    

 

iv

 

THIS CREDIT AGREEMENT, dated as of December 27, 2010, is by and among UNITED THERAPEUTICS CORPORATION, a Delaware corporation (the “Borrower”), the entities which are parties hereto from time to time as lenders (individually, each a “Lender” and collectively, the “Lenders”) and WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association, as administrative agent for the Lenders hereunder (in such capacity, the “Administrative Agent”) and agreed to by certain Subsidiaries (as hereinafter defined) of the Borrower in their capacity as Guarantors.

 

W  I  T  N  E  S  S  E  T  H:

 

WHEREAS, the Credit Parties (as hereinafter defined) have requested that the Lenders make a Loan (as hereinafter defined) to the Borrower in an aggregate amount of $70,000,000, as more particularly described herein; and

 

WHEREAS, the Lenders have agreed to make such Loan to the Borrower on the terms and conditions contained herein.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, such parties hereby agree as follows:

 

ARTICLE I

 

DEFINITIONS

 

Section 1.1            Defined Terms.

 

As used in this Agreement, terms defined in the preamble to this Agreement have the meanings therein indicated, and the following terms have the following meanings:

 

“Account Designation Notice” shall mean the Account Designation Notice dated as of the Closing Date from the Borrower to the Administrative Agent in substantially the form attached hereto as Exhibit 1.1(a).

 

“Additional Credit Party” shall mean each Person that becomes a Guarantor by execution of a Joinder Agreement in accordance with Section 5.9.

 

“Administrative Agent” or “Agent” shall have the meaning set forth in the first paragraph of this Agreement and shall include any successors in such capacity.

 

“Administrative Questionnaire” shall mean an Administrative Questionnaire in a form supplied by the Administrative Agent.

 

“Affiliate” shall mean, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified.

 

“Agreement” or “Credit Agreement” shall mean this Agreement, as amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with the terms hereof.

 

“Allocated Loan Amount” shall mean, in respect of each Mortgaged Property, the allocated Loan amount assigned to such Mortgaged Property, as set forth on Schedule 1.0 attached hereto.

 

 

“Alternate Base Rate” shall mean, for any day, a rate per annum equal to the greater of (a) the Prime Rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus 1/2 of 1% and (c) the sum of (i) LIBOR (as determined pursuant to the definition of LIBOR), for an Interest Period of one (1) month commencing on such day plus (ii) 1%, in each instance as of such date of determination.  For purposes hereof: “Prime Rate” shall mean, at any time, the rate of interest per annum publicly announced or otherwise identified from time to time by Wells Fargo at its principal office in San Francisco, California as its prime rate.  Each change in the Prime Rate shall be effective as of the opening of business on the day such change in the Prime Rate occurs.  The parties hereto acknowledge that the rate announced publicly by Wells Fargo as its Prime Rate is an index or base rate and shall not necessarily be its lowest or best rate charged to its customers or other banks; and “Federal Funds Effective Rate” shall mean, for any day, the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve System arranged by federal funds brokers, as published on the next succeeding Business Day by the Federal Reserve Bank of New York, or, if such rate is not so published on the next succeeding Business Day, the average of the quotations for the day of such transactions received by the Administrative Agent from three (3) federal funds brokers of recognized standing selected by it.  If for any reason the Administrative Agent shall have determined (which determination shall be conclusive in the absence of manifest error) (A) that it is unable to ascertain the Federal Funds Effective Rate, for any reason, including, without limitation, the inability or failure of the Administrative Agent to obtain sufficient quotations in accordance with the terms above or (B) that the Prime Rate or LIBOR no longer accurately reflects an accurate determination of the prevailing Prime Rate or LIBOR, the Administrative Agent may select a reasonably comparable index or source to use as the basis for the Alternate Base Rate, until the circumstances giving rise to such inability no longer exist.  Any change in the Alternate Base Rate due to a change in any of the foregoing will become effective on the effective date of such change in the Federal Funds Rate, the Prime Rate or LIBOR for an Interest Period of one (1) month.  Notwithstanding anything contained herein to the contrary, to the extent that any of the determinations described in Section 2.9 are made by the applicable parties, clause (c) hereof shall not be in effect and the Alternate Base Rate shall be the greater of (i) the Prime Rate in effect on such day and (ii) the Federal Funds Effective Rate in effect on such day plus 1/2 of 1%.

 

“Alternate Base Rate Loans” shall mean Loans that bear interest at an interest rate based on the Alternate Base Rate.

 

“A.M. Best” shall mean A.M. Best Company, Inc.

 

“Applicable Percentage” shall mean, (a) for LIBOR Rate Loans, 3.75% per annum and (b) for Alternate Base Rate Loans, 2.75% per annum.

 

“Appraisal” shall have the meaning set forth in Section 4.1(d)(viii).

 

“Approved Fund” shall mean any Fund that is administered, managed or underwritten by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.

 

“Arranger” shall mean WFS.

 

“Asset Disposition” shall mean the disposition of any or all of the assets (including, without limitation, the Equity Interests of a Subsidiary or any ownership interest in a joint venture) of any Credit Party or any Subsidiary of a Credit Party whether by assignment, sale, lease, transfer, conveyance or otherwise, in a single transaction or in a series of transactions; provided, the sale of inventory by any

 

2

 

Credit Party or any Subsidiary of a Credit Party in the ordinary course of business shall not constitute an Asset Disposition.

 

“Assignment and Assumption” shall mean an assignment and assumption entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by Section 9.6), and accepted by the Administrative Agent, in substantially the form of Exhibit 1.1(b) or any other form approved by the Administrative Agent.

 

“Attributable Indebtedness” shall mean, on any date, (a) in respect of any Capital Lease of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP, and (b) in respect of any Synthetic Lease Obligation, the capitalized amount of the remaining lease payments under the relevant lease that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease were accounted for as a Capital Lease.

 

“Bankruptcy Code” shall mean the Bankruptcy Code in Title 11 of the United States Code, as amended, modified, succeeded or replaced from time to time.

 

“Bankruptcy Event” shall mean any of the events described in Section 7.1(f).

 

“Beneficiaries” shall have the meaning set forth in the Guaranty Agreement.

 

“Board” shall mean the Board of Governors of the Federal Reserve System of the United States or any successor.

 

“Borrower” shall have the meaning set forth in the first paragraph of this Agreement.

 

“Business” shall have the meaning set forth in Section 3.18(c).

 

“Business Day” shall mean any day other than a Saturday, Sunday or other day on which commercial banks in Charlotte, North Carolina or New York, New York are authorized or required by law to close; provided, however, that when used in connection with a rate determination, borrowing or payment in respect of a LIBOR Rate Loan, the term “Business Day” shall also exclude any day on which banks in London, England are not open for dealings in Dollar deposits in the London interbank market.

 

“Capital Lease” shall mean any lease of property, real or personal, the obligations with respect to which are required to be capitalized on a balance sheet of the Borrower in accordance with GAAP.

 

“Capital Lease Obligations” shall mean the capitalized lease obligations relating to a Capital Lease determined in accordance with GAAP.

 

“Cash” shall mean coin or currency of the United States or immediately available federal funds, including, without limitation, such funds delivered by wire transfer.

 

“Cash Equivalents” shall have the meaning as specified for such term under GAAP.

 

“Casualty” shall mean any damage or destruction of any portion of any Mortgaged Property as a result of a fire or other casualty.

 

“Change in Law” shall mean the occurrence, after the date of this Agreement, of any of the following:  (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any

 

3

 

law, rule, regulation or treaty or in the administration, interpretation or application thereof by any Governmental Authority or (c) the making or issuance of any request, guideline or directive (whether or not having the force of law) by any Governmental Authority.

 

“Closing Date” shall mean the date of this Agreement.

 

“Code” shall mean the Internal Revenue Code of 1986, as amended, modified, succeeded or replaced from time to time.

 

“Collateral” shall mean a collective reference to the collateral which is identified in, and at any time will be covered by, the Security Documents; provided that there shall be excluded from the Collateral (a) any account, instrument, chattel paper or other obligation or property of any kind due from, owed by, or belonging to, a Sanctioned Person or Sanctioned Entity or (b) any lease in which the lessee is a Sanctioned Person or Sanctioned Entity.

 

“Commonly Controlled Entity” shall mean any trade or business, whether or not incorporated, which is under common control with any Credit Party within the meaning of Section 4001 of ERISA or is part of a group which includes any Credit Party and which is treated as a single employer under Section 414(b) or (c) of the Code or, solely for purposes of determining liability under Section 302 of ERISA and Section 412 of the Code, which is treated as a single employer under Section 414(b), (c), (m) or (o) of the Code.

 

“Condemnation” shall mean a temporary or permanent taking by any Governmental Authority, as the result, in lieu or in anticipation, of the exercise of the right of condemnation or eminent domain, of all or any part of any Mortgaged Property, or any interest therein or right accruing thereto, including, without limitation, any right of access thereto or any change of grade affecting any Mortgaged Property or any part thereof, including, without limitation, if (a) all, or substantially all, of any Mortgaged Property is permanently expropriated, (b) any points of ingress or egress of any Mortgaged Property to public roadways are materially and permanently impaired by expropriation so as to have a Material Adverse Effect or (c) any material portion of any Mortgaged Property is expropriated so as otherwise to have a Material Adverse Effect.

 

“Consolidated” shall mean, when used with reference to financial statements or financial statement items of the Borrower and its Subsidiaries or any other Person, such statements or items on a consolidated basis in accordance with the consolidation principles of GAAP.

 

“Consolidated Depreciation and Amortization Expense” shall mean, for any period, for the Borrower and its Subsidiaries on a Consolidated basis, depreciation and amortization expense, as determined in accordance with GAAP.

 

“Consolidated EBITDA” shall mean, for any period, for the Borrower and its Subsidiaries on a Consolidated basis, an amount equal to Consolidated Net Income for such period plus (a) the following to the extent deducted in calculating such Consolidated Net Income: (i) Consolidated Interest Charges for such period, (ii) Consolidated Income Tax Expense (if positive) for such period, (iii) Consolidated Depreciation and Amortization Expense for such period, (iv) Consolidated Share-Based Compensation for such period, (v) non-cash license fees for such period, and (vi) impairment charges for such period minus (b) the following to the extent included in calculating such Consolidated Net Income:  Consolidated Income Tax Expense (if negative) for such period.

 

“Consolidated Funded Indebtedness” shall mean, as of any date of determination, for the Borrower and its Subsidiaries on a consolidated basis, the sum of (a) the outstanding principal amount of

 

4

 

all obligations, whether current or long-term, for borrowed money (including, without limitation, Obligations hereunder) and all obligations evidenced by bonds, debentures, notes, loan agreements or other similar instruments, (b) all purchase money Indebtedness, (c) all direct obligations arising under letters of credit (including, without limitation, standby and commercial), bankers’ acceptances, bank guaranties, surety bonds and similar instruments, (d) all obligations in respect of the deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business), (e) Attributable Indebtedness in respect of Capital Leases and Synthetic Lease Obligations, (f) without duplication, all Guarantees with respect to outstanding Indebtedness of the types specified in clauses (a) through (e) above of Persons other than the Borrower or any Subsidiary, and (g) all Indebtedness of the types referred to in clauses (a) through (f) above of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability Borrower) in which the Borrower or a Subsidiary is a general partner or joint venturer, unless such Indebtedness is expressly made non-recourse to the Borrower or such Subsidiary.

 

“Consolidated Income Tax Expense” shall mean, for any period, for the Borrower and its Subsidiaries on a Consolidated basis, income tax expense, as determined in accordance with GAAP.

 

“Consolidated Interest Charges” shall mean, for any period, for the Borrower and its Subsidiaries on a consolidated basis, the sum of (a) all interest, premium payments, debt discount, fees, charges and related expenses of the Borrower and its Subsidiaries in connection with borrowed money (including, without limitation, capitalized interest) or in connection with the deferred purchase price of assets, in each case to the extent treated as interest in accordance with GAAP, and (b) the portion of rent expense of the Borrower and its Subsidiaries with respect to such period under Capital Leases that is treated as interest in accordance with GAAP.

 

“Consolidated Leverage Ratio” shall mean, as of any date of determination, the ratio of (a) Consolidated Funded Indebtedness as of such date to (b) Consolidated EBITDA for the period of the four fiscal quarters most recently ended.

 

“Consolidated Net Income” shall mean, for any period, for the Borrower and its Subsidiaries on a Consolidated basis, the net income of the Borrower and its Subsidiaries, as determined in accordance with GAAP (but excluding extraordinary gains and extraordinary losses) for that period.

 

“Consolidated Share-Based Compensation” shall mean, for any period, for the Borrower and its Subsidiaries on a Consolidated basis, share-based compensation, as determined in accordance with GAAP (which includes non-cash expenses incurred in connection with stock options and STAP awards).

 

“Contractual Obligation” shall mean, as to any Person, any provision of any security issued by such Person or of any contract, agreement, instrument or undertaking to which such Person is a party or by which it or any of its property is bound.

 

“Control” shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise.  “Controlling” and “Controlled” have meanings correlative thereto.

 

“Credit Documents” shall mean this Agreement, each of the Notes, the Guaranty Agreement, any Joinder Agreement, the Security Documents, the Environmental Indemnity and all other agreements, documents, certificates and instruments delivered to the Administrative Agent or any Lender by any Credit Party in connection therewith (other than any agreement, document, certificate or instrument related to a Hedging Agreement).

 

5

 

“Credit Party” shall mean each of the Borrower and the Guarantors.

 

“Credit Party Obligations” shall mean, without duplication, (a) the Obligations and (b) all liabilities and obligations, whenever arising, owing from any Credit Party or any of its Subsidiaries to any Hedging Agreement Provider arising under any Secured Hedging Agreement.

 

“Default” shall mean any of the events specified in Section 7.1, whether or not any requirement for the giving of notice or the lapse of time, or both, or any other condition, has been satisfied.

 

“Default Rate” shall mean, when used with respect to the Obligations, an interest rate equal to (a) for Alternate Base Rate Loans (i) the Alternate Base Rate plus (ii) the Applicable Percentage applicable to Alternate Base Rate Loans plus (iii) 2% per annum and (b) for LIBOR Rate Loans, (i) the LIBOR Rate plus (ii) the Applicable Percentage applicable to LIBOR Rate Loans plus (iii) 4% per annum.

 

“Defaulting Lender” shall mean, at any time, any Lender that, at such time (a) has failed to make a Loan required pursuant to the terms of this Agreement, (b) has failed to pay to the Administrative Agent or any Lender an amount owed by such Lender pursuant to the terms of this Agreement and such default remains uncured, or (c) has been deemed insolvent or has become subject to a bankruptcy or insolvency proceeding or to a receiver, trustee or similar official.

 

“Dollars” and “$” shall mean dollars in lawful currency of the United States.

 

“Domestic Lending Office” shall mean, initially, the office of each Lender designated as such Lender’s Domestic Lending Office shown in such Lender’s Administrative Questionnaire; and thereafter, such other office of such Lender as such Lender may from time to time specify to the Administrative Agent and the Borrower as the office of such Lender at which Alternate Base Rate Loans of such Lender are to be made.

 

“Effective Date” shall have the meaning set forth in each Assignment and Assumption.

 

“Eligible Assignee” shall mean (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund and (d) any other Person (other than a natural person) approved by (i) the Administrative Agent and (ii) unless an Event of Default has occurred and is continuing and so long as the primary syndication of the Loan has been completed as determined by Wells Fargo, the Borrower (each such approval not to be unreasonably withheld or delayed); provided that notwithstanding the foregoing, “Eligible Assignee” shall not include (A) any Credit Party or any of the Credit Party’s Affiliates or Subsidiaries or (B) any Defaulting Lender (or any of its Affiliates).

 

“Engagement Letter” shall mean the letter agreement dated November 22, 2010, addressed to Mr. John Ferrari, Chief Financial Officer of the Borrower, from WFS, as amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with the terms hereof.

 

“Environmental Indemnity” shall mean the Environmental Indemnity Agreement dated as of the Closing Date by and among the Borrower, the Lenders and the Administrative Agent, and as hereinafter joined by the Guarantors pursuant to the execution of the Guaranty Agreement or a Joinder Agreement, as applicable, as amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with the terms hereof.

 

“Environmental Laws” shall mean any and all applicable foreign, federal, state, local or municipal laws, rules, orders, regulations, statutes, ordinances, codes, decrees, requirements of any

 

6

 

Governmental Authority or other Requirement of Law (including, without limitation, common law) regulating, relating to or imposing liability or standards of conduct concerning protection of human health or the environment, as now or may at any time be in effect during the term of this Agreement.

 

“Environmental Permits” shall mean any and all permits, licenses, approvals, registrations, notifications, exemptions and other authorizations under or pursuant to any Environmental Law.

 

“Environmental Report” shall have the meaning set forth in Section 4.1(d)(v).

 

“Equity Interest” shall mean (a) in the case of a corporation, capital stock, (b) in the case of an association or business entity, any and all shares, interests, participations, rights or other equivalents (however designated) of capital stock, (c) in the case of a partnership, partnership interests (whether general, preferred or limited), (d) in the case of a limited liability company, membership interests and (e) any other interest or participation that confers or could confer on a Person the right to receive a share of the profits and losses of, or distributions of assets of, the issuing Person including, without limitation, options, warrants and any other “equity security” as defined in Rule 3a11-1 of the Exchange Act.

 

“ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended, modified, succeeded or replaced from time to time.

 

“Eurodollar Reserve Percentage” shall mean for any day, the percentage (expressed as a decimal and rounded upwards, if necessary, to the next higher 1/100th of 1%) which is in effect for such day as prescribed by the Board of Governors of the Federal Reserve System (or any successor) for determining the maximum reserve requirement (including, without limitation, any basic, supplemental or emergency reserves) in respect of Eurocurrency liabilities, as defined in Regulation D of such Board as in effect from time to time, or any similar category of liabilities for a member bank of the Federal Reserve System in New York City.

 

“Event of Default” shall have the meaning set forth in Section 7.1.

 

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, modified, succeeded or replaced from time to time.

 

“Excluded Taxes” shall mean, with respect to the Administrative Agent, any Lender or any other recipient of any payment to be made by or on account of any obligation of the Borrower hereunder, (a) taxes imposed on or measured by its overall net income (however denominated), and franchise taxes imposed on it (in lieu of net income taxes), by the jurisdiction (or any political subdivision thereof) under the laws of which such recipient is organized or in which its principal office is located or, in the case of any Lender, in which its applicable lending office is located, (b) any branch profits taxes imposed by the United States or any similar tax imposed by any other jurisdiction in which the Borrower is located, (c) in the case of a Foreign Lender, any withholding tax that is imposed on amounts payable to such Foreign Lender at the time such Foreign Lender becomes a party hereto (or designates a new lending office) or is attributable to such Foreign Lender’s failure or inability (other than as a result of a Change in Law) to comply with Section 2.12(f), except to the extent that such Foreign Lender (or its assignor, if any) was entitled, at the time of designation of a new lending office (or assignment), to receive additional amounts from the Borrower with respect to such withholding tax pursuant to Section 2.12 and (d) any Taxes imposed on any “withholdable payment” payable to such recipient as a result of the failure of such recipient to satisfy the applicable requirements as set forth in FATCA after December 31, 2012.

 

7

 

“Extension of Credit” shall mean, as to any Lender, the making of a portion of the Loan by such Lender as of the Closing Date, any conversion of a portion of the Loan from one Type to another Type, and any extension of any portion of the Loan.

 

“FATCA” shall mean Sections 1471 through 1474 of the Code and any regulations promulgated thereunder or official interpretations thereof.

 

“Fair Market Value” shall have the meaning as specified for such term under GAAP.

 

“Federal Funds Effective Rate” shall have the meaning set forth in the definition of “Alternate Base Rate”.

 

“Fixtures” shall have the meaning set forth in the applicable Mortgage Instrument.

 

“Flood Hazard Property” shall mean real property designated by the Federal Emergency Management Agency as having special flood or mudslide hazards.

 

“Flood Insurance Acts” shall have the meaning set forth in Section 5.6(b)(i).

 

“Flood Insurance Policies” shall have the meaning set forth in Section 5.6(b)(i).

 

“Foreign Benefit Arrangement” shall mean any employee benefit arrangement mandated by non-US law that is maintained or contributed to by any Credit Party or any Commonly Controlled Entity.

 

“Foreign Lender” shall mean any Lender that is organized under the laws of a jurisdiction other than that in which the Borrower is resident for tax purposes.  For purposes of this definition, the United States, each state or commonwealth thereof and the District of Columbia shall be deemed to constitute a single jurisdiction.

 

“Foreign Plan” shall mean each employee benefit plan (within the meaning of Section 3(3) of ERISA, whether or not subject to ERISA) that is not subject to United States law and is maintained or contributed to by any Credit Party or any Commonly Controlled Entity.

 

“Foreign Subsidiary” shall mean any Subsidiary of the Borrower, organized under the laws of any jurisdiction outside the fifty (50) states of the United States.

 

“Fund” shall mean any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business.

 

“GAAP” shall mean generally accepted accounting principles in effect in the United States applied on a consistent basis, subject, however, in the case of determination of compliance with the financial covenants set out in Section 5.11 to the provisions of Section 1.3.

 

“Governmental Authority” shall mean the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including, without limitation, the National Association of Securities Dealers and any supra-national bodies such as the European Union or the European Central Bank).

 

8

 

“Guarantor” shall mean each Subsidiary of the Borrower that from time to time after the Closing Date becomes a party to the Guaranty Agreement pursuant to the execution of the Guaranty Agreement or a Joinder Agreement, as applicable.

 

“Guarantee Requirement” shall mean, at any time, that the Guaranty Agreement shall have been executed by each Material Subsidiary existing at such time (with each such Material Subsidiary having executed the Guaranty Agreement or joining the same pursuant to the execution and delivery of a Joinder Agreement), shall have been delivered to the Administrative Agent and shall be in full force and effect.

 

“Guaranty” or “Guaranty Agreement” shall mean the guaranty of the Guarantors set forth in the Guaranty Agreement in the form of Exhibit 1.1(g) which shall be executed by the initial Guarantor after the Closing Date and joined from time to time pursuant to the execution of a Joinder Agreement by additional Guarantors after the Closing Date, as amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with the terms hereof.

 

“Guaranty Obligations” shall mean, with respect to any Person, without duplication, any obligations of such Person (other than endorsements in the ordinary course of business of negotiable instruments for deposit or collection) guaranteeing or intended to guarantee any Indebtedness of any other Person in any manner, whether direct or indirect, and including, without limitation, any obligation, whether or not contingent, (a) to purchase any such Indebtedness or any property constituting security therefor, (b) to advance or provide funds or other support for the payment or purchase of any such Indebtedness or to maintain working capital, solvency or other balance sheet condition of such other Person (including, without limitation, keep well agreements, maintenance agreements, comfort letters or similar agreements or arrangements) for the benefit of any holder of Indebtedness of such other Person, (c) to lease or purchase property, securities or services primarily for the purpose of assuring the holder of such Indebtedness, or (d) to otherwise assure or hold harmless the holder of such Indebtedness against loss in respect thereof.  The amount of any Guaranty Obligation hereunder shall (subject to any limitations set forth therein) be deemed to be an amount equal to the outstanding principal amount (or maximum principal amount, if larger) of the Indebtedness in respect of which such Guaranty Obligation is made.

 

“Hedging Agreement” shall mean, with respect to any Person, any agreement entered into to protect such Person against fluctuations in interest rates, or currency or raw materials values, including, without limitation, any interest rate swap, cap or collar agreement or similar arrangement between such Person and one or more counterparties, any foreign currency exchange agreement, currency protection agreements, commodity purchase or option agreements or other interest or exchange rate hedging agreements, as amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with its terms.

 

“Hedging Agreement Provider” shall mean any Person that (a) has provided the Administrative Agent with a fully executed Secured Party Designation Notice, substantially in the form of Exhibit 1.1(c) and (b) enters into a Secured Hedging Agreement with a Credit Party or any of its Subsidiaries to the extent that such Person is a Lender, an Affiliate of a Lender or any other Person that was a Lender (or an Affiliate of a Lender) at the time it entered into the Secured Hedging Agreement but has ceased to be a Lender (or whose Affiliate has ceased to be a Lender) under this Agreement; provided, in the case of a Secured Hedging Agreement with a Person who is no longer a Lender or an Affiliate of a Lender, such Person shall be considered a Hedging Agreement Provider only through the stated maturity date (without extension or renewal) of such Secured Hedging Agreement.

 

“Improvements” shall have the meaning set forth in the Mortgage Instrument.

 

9

 

“Indebtedness” shall mean, with respect to any Person, without duplication, (a) all obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, or upon which interest payments are customarily made, (c) all obligations of such Person under conditional sale or other title retention agreements relating to property purchased by such Person (other than customary reservations or retentions of title under agreements with suppliers entered into in the ordinary course of business), (d) all obligations (including, without limitation, earnout obligations) of such Person incurred, issued or assumed as the deferred purchase price of property or services purchased by such Person (other than trade debt incurred in the ordinary course of business and due within six months of the incurrence thereof) which would appear as liabilities on a balance sheet of such Person, (e) all obligations of such Person under take-or-pay or similar arrangements or under commodities agreements, (f) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on, or payable out of the proceeds of production from, property owned or acquired by such Person, whether or not the obligations secured thereby have been assumed, (g) all Guaranty Obligations of such Person with respect to Indebtedness of another Person, (h) the principal portion of all Capital Lease Obligations plus any accrued interest thereon, (i) all net obligations of such Person under Hedging Agreements, (j) the maximum amount of all letters of credit issued or bankers’ acceptances facilities created for the account of such Person and, without duplication, all drafts drawn thereunder (to the extent unreimbursed), (k) all preferred Equity Interests issued by such Person and which by the terms thereof could be (at the request of the holders thereof or otherwise) subject to mandatory sinking fund payments, redemption or other acceleration, (l) the principal balance outstanding under any synthetic lease, tax retention operating lease, off-balance sheet loan or similar off-balance sheet financing product plus any accrued interest thereon, (m) all obligations of any partnership or unincorporated joint venture in which such Person is a general partner or a joint venturer and (n) obligations of such Person under non-compete agreements to the extent such obligations are quantifiable contingent obligations of such Person under GAAP principles.

 

“Indemnified Taxes” shall mean Taxes other than Excluded Taxes.

 

“Indemnitee” shall have the meaning set forth in Section 9.5(b).

 

“Information Materials” shall have the meaning set forth in Section 5.13(a).

 

“Initial Guarantor Joinder Agreement” shall mean a Joinder Agreement in substantially the form of Exhibit 1.1(h), executed and delivered by the initial Guarantor in accordance with the provisions of Section 5.9, as amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with the terms hereof.

 

“Insolvency” shall mean, with respect to any Multiemployer Plan, the condition that such Plan is insolvent within the meaning of such term as used in Section 4245 of ERISA.

 

“Insolvent” shall have the meaning pertaining to a condition of Insolvency.

 

“Intellectual Property” shall have the meaning set forth in Section 3.9.

 

“Intercompany Debt” shall have the meaning set forth in Section 9.19.

 

“Interest Payment Date” shall mean (a) as to any Alternate Base Rate Loan, the last Business Day of each calendar month and the applicable Maturity Date, (b) as to any LIBOR Rate Loan, the last day of each Interest Period, and (c) as to any portion of the Loan which is the subject of a mandatory prepayment required pursuant to Section 2.7(b), the date on which such mandatory prepayment is due.

 

10

 

“Interest Period” shall mean, with respect to any LIBOR Rate Loan,

 

(a)           initially, the period commencing on the Closing Date or conversion date, as the case may be, with respect to such LIBOR Rate Loan and ending one (1) month thereafter, subject to availability to all Lenders, as selected by the Borrower in the Notice of Conversion/Extension given with respect thereto; and

 

(b)           thereafter, each period commencing on the last day of the immediately preceding Interest Period applicable to such LIBOR Rate Loan and ending one (1) month thereafter, subject to availability to all Lenders, as selected by the Borrower by irrevocable notice to the Administrative Agent not less than three (3) Business Days prior to the last day of the then current Interest Period with respect thereto; provided that the foregoing provisions are subject to the following:

 

(i)            if any Interest Period pertaining to a LIBOR Rate Loan would otherwise end on a day that is not a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless the result of such extension would be to carry such Interest Period into another calendar month in which event such Interest Period shall end on the immediately preceding Business Day;

 

(ii)           any Interest Period pertaining to a LIBOR Rate Loan that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the relevant calendar month;

 

(iii)          if the Borrower shall fail to give notice as provided above, the Borrower shall be deemed to have selected an Alternate Base Rate Loan to replace the affected LIBOR Rate Loan;

 

(iv)          no Interest Period shall extend beyond the Maturity Date; and

 

(v)           no more than one (1) LIBOR Rate Loan may be in effect at any time.

 

“Joinder Agreement” shall mean a Joinder Agreement in substantially the form of Exhibit 1.1(d), executed and delivered by an Additional Credit Party in accordance with the provisions of Section 5.9, as amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with the terms hereof.

 

“Land” shall have the meaning set forth in the applicable Mortgage Instrument.

 

“Lender” shall have the meaning set forth in the first paragraph of this Agreement.

 

“Lender Consent” shall mean any lender consent delivered by a Lender on the Closing Date in the form of Exhibit 4.1(a).

 

“LIBOR” shall mean, for any LIBOR Rate Loan for any Interest Period therefor, the rate per annum (rounded upwards, if necessary, to the nearest 1/100 of 1%) appearing on Reuters Screen LIBOR01 Page (or any successor page) as the London interbank offered rate for deposits in Dollars at approximately 11:00 a.m. (London time) two (2) Business Days prior to the first day of such Interest Period for a term comparable to such Interest Period.  If for any reason such rate is not available, then “LIBOR” shall mean the rate per annum at which, as determined by the Administrative Agent in

 

11

 

accordance with its customary banking industry practices, Dollars in an amount comparable to the Loans then requested are being offered to leading banks at approximately 11:00 a.m. (London time), two (2) Business Days prior to the commencement of the applicable Interest Period for settlement in immediately available funds by leading banks in the London interbank market for a period equal to the Interest Period selected.

 

“LIBOR Lending Office” shall mean, initially, the office(s) of each Lender designated as such Lender’s LIBOR Lending Office in such Lender’s Administrative Questionnaire or regarding Wells Fargo, as such is otherwise designated by Wells Fargo to the Administrative Agent; and thereafter, such other office of such Lender as such Lender may from time to time specify to the Administrative Agent and the Borrower as the office of such Lender at which the LIBOR Rate Loans of such Lender are to be made.

 

“LIBOR Rate” shall mean a rate per annum (rounded upwards, if necessary, to the next higher 1/100th of 1%) determined by the Administrative Agent pursuant to the following formula:

 

	
LIBOR Rate =
    	
 
    	
LIBOR
    
	
 
    	
1.00 - Eurodollar Reserve Percentage
    

 

“LIBOR Rate Loan” shall mean that portion of the Loan the rate of interest applicable to which is based on the LIBOR Rate.

 

“LIBOR Tranche” shall mean the collective reference to LIBOR Rate Loans whose Interest Periods begin and end on the same day.

 

“Lien” shall mean any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge or other security interest or any preference, priority or other security agreement or preferential arrangement of any kind or nature whatsoever (including, without limitation, (a) any conditional sale or other title retention agreement and any Capital Lease having substantially the same economic effect as any of the foregoing and (b) the filing of, or the agreement to give, any UCC financing statement).

 

“Loan” shall mean an Alternate Base Rate Loan or a LIBOR Rate Loan, as the case may be.

 

“Loan Commitment” shall mean, with respect to each Lender, the commitment of such Lender to make its portion of the Loan in a principal amount equal to such Lender’s Loan Commitment Percentage of the Loan Committed Amount.

 

“Loan Commitment Percentage” shall mean, for each Lender, the Loan Commitment Percentage specified for such Lender on Schedule 1.1 or in the Assignment and Assumption pursuant to which such Lender became a Lender hereunder, as such percentage may be modified in connection with any assignment made in accordance with the provisions of Section 9.6(b).

 

“Loan Committed Amount” shall have the meaning set forth in Section 2.1(a).

 

“Loan Facility” shall have the meaning set forth in Section 2.1(a).

 

“Marketable Securities” shall mean (a) obligations of the U. S. Treasury, (b) U. S. Agency obligations, (c) notes or debentures issued or guaranteed by a state or political subdivision of a state, and (d) any non-convertible unsecured corporate debt obligations with a credit rating of A or higher by S&P and A2 or higher by Moody’s, which debt securities shall have a term to stated maturity not exceeding ten

 

12

 

years and are traded over any U.S. national or major regional securities exchange or foreign securities exchange.  All Marketable Securities shall be invested in accordance with the investment policy approved by the Borrower’s Board of Directors, as amended, restated or replaced.

 

“Maryland Mortgaged Property” shall mean the Mortgaged Property located in Maryland.

 

“Material Adverse Effect” shall mean a material adverse effect on (a) the business, operations, property, assets or financial condition of the Borrower or of the Credit Parties and their Subsidiaries taken as a whole, (b) the ability of the Borrower or any Guarantor to perform its obligations, when such obligations are required to be performed, under this Agreement, any of the Notes or any other Credit Document, (c) the validity or enforceability of this Agreement, any of the Notes or any of the other Credit Documents or the rights or remedies of the Administrative Agent or the Lenders hereunder or thereunder, or (d) the economic value, useful life, utility, condition, operational capacity or functional capacity of any Mortgaged Property.

 

“Material Contract” shall mean (a) any written contract or other agreement of the Credit Parties or any of its Subsidiaries involving monetary liability of or to any such Person in an amount in excess of $20,000,000 per annum, (b) any written contract or other agreement of the Credit Parties or any of their Subsidiaries representing at least $20,000,000 of the total Consolidated revenues of the Credit Parties and their Subsidiaries for any fiscal year and (c) any other written contract, agreement, permit or license of the Credit Parties or any of its Subsidiaries as to which the breach, nonperformance, cancellation or failure to renew by any party thereto, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect.

 

“Material Subsidiary” shall have the meaning set forth in Section 5.9.

 

“Materials of Environmental Concern” shall mean any gasoline or petroleum (including, without limitation, crude oil or any extraction thereof) or petroleum products or any hazardous or toxic substances, materials or wastes, defined or regulated as such in or under any Environmental Law, including, without limitation, asbestos, perchlorate, polychlorinated biphenyls and urea-formaldehyde insulation, but excluding substances of kinds and in amounts ordinarily and customarily used or stored in similar properties for the purpose of cleaning, construction or other maintenance or operations and otherwise in compliance with all, and so not to give rise to any liability under any, Environmental Laws.

 

“Maturity Date” shall mean the date that is four (4) years following the Closing Date.

 

“Moody’s” shall mean Moody’s Investors Service, Inc.

 

“Mortgage Instrument” shall mean each mortgage, deed of trust or deed to secure debt executed by the Borrower in favor of the Administrative Agent, for the benefit of the Secured Parties, as the same may be amended, modified, extended, restated, replaced, or supplemented from time to time, in accordance with the terms hereof.

 

“Mortgage Policy” shall mean, with respect to the Mortgage Instrument, an ALTA mortgagee title insurance policy issued by a title insurance company (the “Title Insurance Company”) selected by the Administrative Agent in an amount satisfactory to the Administrative Agent, in form and substance reasonably satisfactory to the Administrative Agent.

 

“Mortgaged Property” shall mean each real property of the Borrower listed in Schedule 3.23(j) and with respect to which the Borrower executed a Mortgage Instrument in favor of the Administrative Agent.

 

13

 

“Mortgaged Property Disposition” shall mean any disposition by the Borrower of any Mortgaged Property or any portion thereof, whether by assignment, sale, lease, transfer, conveyance or otherwise in a single transaction or in a series of transactions.

 

“Multiemployer Plan” shall mean a multiemployer plan as defined in Section 4001(a)(3) of ERISA.

 

“North Carolina Mortgaged Property” shall mean the Mortgaged Property located in North Carolina.

 

“Note” or “Notes” shall mean each of the promissory notes of the Borrower (if any) in favor of any of the Lenders evidencing the portion of the Loan provided by any such Lender pursuant to Section 2.1(a), individually or collectively, as appropriate, as such promissory notes may be amended, modified, extended, restated, replaced, or supplemented from time to time.

 

“Notice of Borrowing” shall mean the written notice of borrowing of a LIBOR Rate Loan or an Alternate Base Rate Loan, in each case substantially in the form of Exhibit 1.1(e).

 

“Notice of Conversion/Extension” shall mean the written notice of conversion of a LIBOR Rate Loan to an Alternate Base Rate Loan or an Alternate Base Rate Loan to a LIBOR Rate Loan, or extension of a LIBOR Rate Loan, in each case substantially in the form of Exhibit 1.1(f).

 

“Obligations” shall mean, collectively, the Loan and all other of the obligations, Indebtedness and liabilities of the Credit Parties to the Lenders and the Administrative Agent, whenever arising, under this Agreement, the Notes or any of the other Credit Documents, including, without limitation, principal, interest, fees, costs, charges, expenses, professional fees, reimbursements, all sums chargeable to the Credit Parties or for which any Credit Party is liable as an indemnitor under the Credit Documents and whether or not evidenced by a note or other instrument and indemnification obligations and other amounts under the Credit Documents (including, without limitation, any interest accruing after the occurrence of a filing of a petition of bankruptcy under the Bankruptcy Code with respect to any Credit Party, regardless of whether such interest is an allowed claim under the Bankruptcy Code).

 

“OFAC” shall mean the U.S. Department of the Treasury’s Office of Foreign Assets Control.

 

“Organizational Agreements” shall mean the articles of incorporation, charter documents, bylaws, operating agreements or any similar documents regarding any of the Credit Parties.

 

“Other Taxes” shall mean all present or future stamp or documentary taxes or any other excise or property taxes, charges or similar levies arising from any payment made hereunder or under any other Credit Document or from the execution, delivery or enforcement of, or otherwise with respect to, this Agreement or any other Credit Document.

 

“Participant” shall have the meaning set forth in Section 9.6(d).

 

“Patriot Act” shall mean the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT ACT) Act of 2001 (Title III of Pub. L. No. 107-56 (signed into law October 26, 2001)), as amended, modified, succeeded or replaced from time to time.

 

“Payment Event of Default” shall mean an Event of Default specified in Section 7.1(a).

 

14

 

“PBGC” shall mean the Pension Benefit Guaranty Corporation established pursuant to Subtitle A of Title IV of ERISA, as amended, modified, succeeded or replaced from time to time.

 

“Pension Act” shall mean the Pension Protection Act of 2006, as amended, modified, succeeded or replaced from time to time.

 

“Permitted Liens” shall have the meaning set forth in Section 6.1.

 

“Person” shall mean any natural person, corporation, limited liability company, trust, business trust, joint stock company,  joint venture, association, company, partnership, Governmental Authority or other entity.

 

“Plan” shall mean, any employee benefit plan as defined in Section 3(3) of ERISA and in respect of which any Credit Party or any Commonly Controlled Entity is (or, if such plan were terminated at such time, would under Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA.

 

“Prepayment Fee” shall mean an amount equal to the product of the following (a) the amount of aggregate Loan principal amount multiplied by (b) (i) 1.5%, regarding any prepayment from the Closing Date to and including, without limitation, the six-month anniversary of the Closing Date, (ii) 1.00%, regarding any prepayment from the day immediately following the six-month anniversary of the Closing Date to and including, without limitation, the twelve-month anniversary of the Closing Date, (iii) 0.5%, regarding any prepayment from the day immediately following the twelve-month anniversary of the Closing Date to and including, without limitation, the eighteen-month anniversary of the Closing Date, and (iv) zero, regarding any prepayment from the day immediately following the eighteen-month anniversary of the Closing Date and thereafter.

 

“Prime Rate” shall have the meaning set forth in the definition of Alternate Base Rate.

 

“Private Information” shall have the meaning set forth in Section 5.13(a).

 

“Pro Forma Basis” shall mean, with respect to any transaction, that such transaction shall be deemed to have occurred as of the first day of the four-quarter period (or twelve month period, as applicable) ending as of the most recent quarter end (or month end, as applicable) preceding the date of such transaction.

 

“Proceeds” shall mean any award, compensation or proceeds (including, without limitation, insurance proceeds) in respect of any Casualty or Condemnation regarding any Mortgaged Property and, when any such amount is to be paid by any Credit Party to the Administrative Agent or the Lenders, such amount shall include, without limitation, any and all applicable insurance deductibles and self-insurance retentions.

 

“Prohibited Transaction” shall have the meaning assigned to such term in Section 4975(c) of the Code.

 

“Properties” shall have the meaning set forth in Section 3.18(a).

 

“Property Condition Report” shall have the meaning set forth in Section 4.1(d)(xiii).

 

15

 

“Property Reports” shall mean, collectively, each Appraisal, Environmental Report, Property Condition Report, Survey and Zoning Report.

 

“Public Information” shall have the meaning set forth in Section 5.13(a).

 

“REA” shall mean any construction, operation and reciprocal easement agreement, common area maintenance agreement or similar agreement (including, without limitation, any separate agreement or other agreement between a Credit Party and one or more other parties to a REA with respect to such REA) affecting any Mortgaged Property or portion thereof.

 

“Register” shall have the meaning set forth in Section 9.6(c).

 

“Regulation U” shall mean Regulation U of the Board, as amended, modified, succeeded or replaced from time to time.

 

“Related Parties” shall mean, with respect to any Person, such Person’s Affiliates and the partners, directors, officers, employees, agents, trustees and advisors of such Person and of such Person’s Affiliates.

 

“Reorganization” shall mean, with respect to any Multiemployer Plan, the condition that such plan is in reorganization within the meaning of such term as used in Section 4241 of ERISA.

 

“Reportable Event” shall mean any of the events set forth in Section 4043(c) of ERISA, other than those events as to which the thirty-day notice period is waived.

 

“Required Lenders” shall mean, as of any date of determination, Lenders holding at least 66 2/3% of the outstanding principal amount of the Loan; provided, if there are only two (2) Lenders, then “Required Lenders” shall mean both Lenders.

 

“Requirement of Law” shall mean, as to any Person, (a) the articles or certificate of incorporation, by-laws or other organizational or governing documents of such Person, and (b) all international, foreign, federal, state and local laws, statutes, treaties, rules, guidelines, regulations, ordinances, codes, executive orders, and administrative or judicial precedents or authorities, including, without limitation, the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority (in each case whether or not having the force of law); in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.

 

“Responsible Officer” shall mean, for any Credit Party, the chairman of the board, chief executive officer, president, chief operating officer, chief financial officer, treasurer, executive vice president of strategic planning, general counsel, corporate secretary, the  vice president and associate general counsel, and vice president of  finance.

 

“Restoration” shall have the meaning set forth in Section 5.19(h).

 

“S&P” shall mean Standard & Poor’s Ratings Services, a division of The McGraw Hill Companies, Inc.

 

“Sanctioned Entity” shall mean (a) a country or a government of a country, (b) an agency of the government of a country, (c) an organization directly or indirectly controlled by a country or its

 

16

 

government, or (d) a Person or natural person resident in or determined to be resident in a country, that is subject to a country sanctions program administered and enforced by OFAC.

 

“Sanctioned Person” shall mean a Person named on the list of Specially Designated Nationals maintained by OFAC.

 

“Sarbanes-Oxley” shall mean the Sarbanes-Oxley Act of 2002, as amended, modified, succeeded or replaced from time to time.

 

“SEC” shall mean the Securities and Exchange Commission or any successor Governmental Authority.

 

“Secured Hedging Agreement” shall mean any Hedging Agreement between a Credit Party or a Subsidiary thereof and a Hedging Agreement Provider.

 

“Secured Parties” shall mean the Administrative Agent, the Lenders and the Hedging Agreement Providers.

 

“Securities Act” shall mean the Securities Act of 1933, together with any amendment thereto or replacement thereof and any rules or regulations promulgated thereunder.

 

“Security Documents” shall mean each Mortgage Instrument and all other agreements, documents and instruments relating to, arising out of, or in any way connected with any of the foregoing documents or granting to the Administrative Agent, for the benefit of the Secured Parties, Liens or security interests in the real and personal property of the Borrower to secure, inter alia, the Credit Party Obligations whether now or hereafter executed and/or filed, each as may be amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with the terms hereof, including, without limitation, UCC financing statements.

 

“Single Employer Plan” shall mean any Plan (other than a Multiemployer Plan), which is subject to the provisions of Section 302 or Title IV of ERISA or Sections 412 and 430 of the Code.

 

“STAP” shall mean the United Therapeutics Corporation Share Tracking Awards Plan, as amended, modified, extended, restated, replaced, or supplemented from time to time, and including any similar plan or plans that may be adopted by the Borrower in the future for purposes of granting awards similar to those granted under the STAP.  STAP awards convey the right to receive in cash an amount equal to the appreciation of the Borrower’s common stock, which is calculated as the positive difference between the closing price of the Borrower’s common stock on the date of exercise and the date of grant.  STAP awards require cash settlement upon exercise, and as such are classified as “other current liabilities” on the Borrower’s consolidated balance sheets, which have been prepared in accordance with GAAP as further described in the Borrower’s notes to its consolidated financial statements.  The fair value of the outstanding STAP awards is re-measured at each financial reporting date using the Black-Scholes-Merton valuation model.  Related changes in the fair value of outstanding cash settled awards at each reporting date are recognized as share-based compensation expense.  Cash used to settle STAP exercises may be materially different than the STAP expense in any financial reporting period.

 

“STAP Liability” shall mean the fair value liability for vested STAP awards as determined at each financial reporting date using the Black-Scholes-Merton valuation model in accordance with GAAP and as further described in the Borrower’s Notes to Consolidated Financial Statements.

 

17

 

“Subordinated Debt” shall mean any Indebtedness incurred by any Credit Party which by its terms is specifically subordinated in right of payment to the prior payment of the Credit Party Obligations and contains subordination and other terms acceptable to the Administrative Agent.

 

“Subsidiary” shall mean, as to any Person, a corporation, partnership, limited liability company or other entity of which shares of stock or other ownership interests having ordinary voting power (other than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the board of directors or other managers of such corporation, limited liability company, partnership or other entity are at the time owned, or the management of which is otherwise controlled, directly or indirectly through one or more intermediaries, or both, by such Person.  Unless otherwise qualified, all references to a “Subsidiary” or to “Subsidiaries” in this Agreement shall refer to a Subsidiary or Subsidiaries of the Borrower.

 

“Survey” shall have the meaning set forth in Section 4.1(d)(iv).

 

“Synthetic Lease Obligation” shall mean the monetary obligation of a Person under (a) a so-called synthetic, off-balance sheet or tax retention lease, or (b) an agreement for the use or possession of property creating obligations that do not appear on the balance sheet of such Person but which, upon the insolvency or bankruptcy of such Person, would be characterized as the indebtedness of such Person (without regard to accounting treatment).

 

“Taxes” shall mean all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges imposed by any Governmental Authority, including, without limitation, any interest, additions to tax or penalties applicable thereto.

 

“Title Insurance Company” shall have the meaning set forth in the definition of “Mortgage Policy”.

 

“Trading with the Enemy Act” shall have the meaning set forth in Section 3.20.

 

“Tranche” shall mean the collective reference to (a) LIBOR Rate Loans whose Interest Periods begin and end on the same day and (b) Alternate Base Rate Loans made on the same day.

 

“Transactions” shall mean the closing of this Agreement and the other Credit Documents (including, without limitation, the initial borrowings under the Credit Documents and the payment of fees and expenses in connection with all of the foregoing).

 

“Type” shall mean, as to any Loan, its nature as an Alternate Base Rate Loan or LIBOR Rate Loan, as the case may be.

 

“UCC” shall mean the Uniform Commercial Code from time to time in effect in any applicable jurisdiction.

 

“Wells Fargo” shall mean Wells Fargo Bank, National Association, a national banking association, together with its successors and assigns.

 

“WFS” shall mean Wells Fargo Securities, LLC, a Delaware limited liability company, together with its successors and assigns.

 

“Zoning Report” shall have the meaning set forth in Section 4.1(d)(vii).

 

18

 

Section 1.2            Other Definitional Provisions.

 

The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined.  Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms.  The words “include,” “includes” and “including, without limitation,” shall be deemed to be followed by the phrase “without limitation.”  The word “will” shall be construed to have the same meaning and effect as the word “shall.”  Unless the context requires otherwise (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, extended, restated, replaced, supplemented, amended and restated or otherwise modified (subject to any restrictions on such amendments, extensions, supplements or modifications set forth herein), (b) any reference herein to any Person shall be construed to include such Person’s successors and permitted assigns, (c) the words “herein,” “hereof” and “hereunder,” and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (d) all references herein to Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, this Agreement, (e) any reference to any law or regulation herein shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time, (f) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including, without limitation, cash, securities, accounts and contract rights and (g) all terms defined in this Agreement shall have the defined meanings when used in any other Credit Document or any certificate or other document made or delivered pursuant hereto.

 

Section 1.3            Accounting Terms.

 

(a)           Generally.  All accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including, without limitation, financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, GAAP applied on a consistent basis, as in effect from time to time, applied in a manner consistent with that used in preparing the most recently delivered audited Consolidated financial statements of the Borrower, except as otherwise specifically prescribed herein.

 

(b)           Changes in GAAP.  If at any time any change in GAAP would affect the computation of any financial ratio or requirement set forth in any Credit Document, and either the Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Borrower shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP (subject to the approval of the Required Lenders); provided  that, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (ii) the Borrower shall provide to the Administrative Agent and the Lenders financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio or requirement made before and after giving effect to such change in GAAP.

 

(c)           Financial Covenant Calculations.  The parties hereto acknowledge and agree that, for purposes of all calculations made in determining compliance for any applicable period with the financial covenants set forth in Section 5.11, after any Asset Disposition permitted by Section 6.2, (A) income statement items, cash flow statement items and balance sheet items (whether positive or negative) attributable to the property or assets disposed of shall be excluded in such calculations to the extent relating to such applicable period, subject to adjustments

 

19

 

mutually acceptable to the Borrower and the Administrative Agent and (B) Indebtedness that is repaid with the proceeds of such Asset Disposition shall be excluded from such calculations and deemed to have been repaid as of the first day of such applicable period.

 

Section 1.4            Time References.

 

Unless otherwise specified, all references herein to times of day shall be references to Eastern time (daylight or standard, as applicable).

 

Section 1.5            Execution of Documents.

 

Unless otherwise specified, all Credit Documents and all certificates executed in connection therewith must be signed by a Responsible Officer.

 

ARTICLE II

 

THE LOAN; AMOUNT AND TERMS

 

Section 2.1            Loan.

 

(a)           Amount of Loan.  Subject to the terms and conditions hereof and in reliance upon the representations and warranties set forth herein, each Lender severally, but not jointly, agrees to make available to the Borrower (through the Administrative Agent) on the Closing Date  such Lender’s Loan Commitment Percentage of a Loan in Dollars (the “Loan”) in the aggregate principal amount of SEVENTY MILLION DOLLARS ($70,000,000) (the “Loan Committed Amount”) for the purposes hereinafter set forth (such facility, the “Loan Facility”).  The Borrower shall request the Loan by submitting a Notice of Borrowing, in substantially the form of Exhibit 1.1(e), to the Administrative Agent no less than three (3) Business Days prior to the date requested for borrowing of the Loan, which borrowing date shall be a Business Day.  Upon receipt by the Administrative Agent of the proceeds of the Loan, such proceeds will then be made available to the Borrower by the Administrative Agent by crediting the account of the Borrower on the books of the Administrative Agent with the aggregate of such proceeds made available to the Administrative Agent by the Lenders and in like funds as received by the Administrative Agent (or by crediting such other account(s) as directed by the Borrower).  The Loan may consist of Alternate Base Rate Loans or LIBOR Rate Loans, as the Borrower may request in a writing delivered to the Administrative Agent; provided, however, that the Loan made on the Closing Date or any of the three (3) Business Days following the Closing Date may only consist of Alternate Base Rate Loans, unless otherwise agreed by the Administrative Agent and the Lenders, as such agreement shall be evidenced by the Administrative Agent’s acceptance of a funding indemnity letter in connection therewith.  LIBOR Rate Loans shall be made by each Lender at its LIBOR Lending Office and Alternate Base Rate Loans at its Domestic Lending Office.  Amounts repaid or prepaid on the Loan may not be reborrowed.

 

(b)           Repayment of Loan.  The principal amount of the Loan shall be repaid in accordance with Schedule 2.1.  On the Maturity Date, the remaining principal balance of the Loan and all accrued but unpaid interest and all other amounts payable with respect to the Loan shall be repaid in full.

 

20

 

(c)           Interest on the Loan.  Subject to the provisions of Section 2.4, the Loan shall bear interest as follows:

 

(i)            Alternate Base Rate Loans.  During such periods as the Loan shall be comprised of Alternate Base Rate Loans, each such Alternate Base Rate Loan shall bear interest at a per annum rate equal to the sum of the Alternate Base Rate plus the Applicable Percentage; and

 

(ii)           LIBOR Rate Loans.  During such periods as the Loan shall be comprised of LIBOR Rate Loans, each such LIBOR Rate Loan shall bear interest at a per annum rate equal to the sum of the LIBOR Rate plus the Applicable Percentage.

 

Interest on the Loan shall be payable in arrears on each Interest Payment Date.

 

(d)           Notes; Covenant to Pay.  The Borrower’s obligation to pay each Lender shall be evidenced by this Agreement and, upon such Lender’s request, by a duly executed promissory note of the Borrower to such Lender in substantially the form of Exhibit 2.1(d).  The Borrower covenants and agrees to pay the Loan in accordance with the terms of this Agreement.

 

Section 2.2            Fees.

 

The Borrower agrees to pay to (i) the Administrative Agent (for its own account) the annual Administrative Fee (as such term is defined in the Engagement Letter) and (ii) the Administrative Agent (for the account of WFS) the Structuring Fee (as such term is defined in the Engagement Letter).

 

Section 2.3            Prepayments.

 

(a)           Optional Prepayments.  The Borrower shall have the right to prepay  the Loan in whole but not in part at any time after the Closing Date, in each case on an Interest Payment Date; provided, prepayment shall also require payment of (i) all accrued, but unpaid, interest on the Loan, (ii) the applicable Prepayment Fee and (iii) all other fees, costs, expenses or other amounts then due and owing or accrued, but unpaid, pursuant to the Credit Documents.  The Borrower shall give irrevocable notice of prepayment of the Loan to the Administrative Agent not later than 11:00 a.m. (New York, New York time) three (3) Business Days prior to the date of such prepayment (and the Administrative Agent shall notify the Lenders thereof as soon as practicable).  To the extent that the  Borrower elects to prepay the Loan, amounts prepaid under this Section shall be (i) applied in accordance with Section 2.7(a) (if no Event of Default has occurred and is continuing) or in accordance with Section 2.7(b) (if an Event of Default has occurred and is continuing) and (ii) applied to the Loan of the Lenders in accordance with their respective Loan Commitment Percentages.  All prepayments under this Section shall be subject to Section 2.11 and shall otherwise require the payment of all amounts referenced in the first sentence of this Section 2.3(a).

 

(b)           Mandatory Prepayments.

 

(i)            Mortgaged Property Disposition.  Promptly following any Mortgaged Property Disposition, the Borrower shall prepay the Loan in an aggregate amount equal to one hundred percent (100%) of (A) the outstanding principal balance of the Allocated Loan Amount applicable to the Mortgaged Property being disposed of, (B) the accrued, unpaid interest on that portion of the Loan applicable to the Mortgaged Property being disposed of, (C) the applicable Prepayment Fee pro rated with respect to the Mortgage

 

21

 

Property being disposed of, and (D) any and all other accrued, unpaid amounts under any of the Credit Documents with respect to the Loan applicable to the Mortgaged Property being disposed of.  After such Mortgaged Property Disposition, the Loan shall continue as to the other Mortgaged Property and the balance of the Loan.  Such prepayment shall be made on the Interest Payment Date next following the Mortgaged Property Disposition.  The Borrower shall give irrevocable notice of prepayment of the Loan to the Administrative Agent not later than 11:00 a.m. (New York, New York time) three (3) Business Days prior to the date of such prepayment (and the Administrative Agent shall notify the Lenders thereof as soon as practicable).

 

(ii)           Application of Mandatory Prepayments.  All amounts required to be paid pursuant to this Section 2.3(b) shall be applied in accordance with Section 2.7(b).  All prepayments under this Section shall be subject to Section 2.11 and be accompanied by interest on the principal amount prepaid through the date of prepayment.

 

(c)           Hedging Obligations Unaffected.  Any repayment or prepayment made pursuant to this Section shall not affect the Borrower’s obligation to continue to make payments under any Secured Hedging Agreement, which shall remain in full force and effect notwithstanding such repayment or prepayment, subject to the terms of such Secured Hedging Agreement.

 

Section 2.4            Default Rate and Payment Dates.

 

(a)           If all or a portion of the principal amount of the Loan which is a LIBOR Rate Loan shall not be paid when due or continued as a LIBOR Rate Loan in accordance with the provisions of Section 2.5 (whether at the stated maturity, by acceleration or otherwise), such overdue principal amount of the Loan shall be converted to an Alternate Base Rate Loan at the end of the Interest Period applicable thereto.

 

(b)           Upon the occurrence of an Event of Default, the principal of and, to the extent permitted by law, interest on the Loan and any other amounts owing hereunder or under the other Credit Documents shall automatically bear interest, payable on demand, at a per annum rate which is equal to the Default Rate.  Regarding any LIBOR Rate Loan in effect upon the occurrence of an Event of Default, such LIBOR Rate Loan shall automatically (without the need for further action) be converted to an Alternate Base Rate Loan at the end of the Interest Period for such LIBOR Rate Loan.

 

(c)           Interest on the Loan shall be payable in arrears on each Interest Payment Date; provided that interest accruing pursuant to paragraph (b) of this Section shall be payable from time to time on demand.

 

Section 2.5            Conversion/Continuation Options.

 

(a)           The Borrower may elect from time to time for the Loan to be either an Alternate Base Rate Loan in its entirety or a LIBOR Rate Loan in its entirety; provided, the Loan shall not at any time be apportioned as part Alternate Base Rate Loan and part LIBOR Rate Loan.  The Borrower may elect from time to time to convert the entire Loan from an Alternate Base Rate Loan to a LIBOR Rate Loan by delivering a Notice of Conversion/Extension to the Administrative Agent at least three (3) Business Days prior to the proposed date of conversion.  In addition, the Borrower may elect from time to time to convert the entire Loan from a LIBOR Rate Loan to an Alternate Base Rate Loan by giving the Administrative Agent irrevocable written notice thereof by 11:00 a.m. (New York, New York time) one (1) Business Day prior to the

 

22

 

proposed date of conversion.  If the date upon which an Alternate Base Rate Loan is to be converted to a LIBOR Rate Loan is not a Business Day, then such conversion shall be made on the next succeeding Business Day and during the period from such initially intended conversion date to such succeeding Business Day the Loan shall bear interest as if it were an Alternate Base Rate Loan.  LIBOR Rate Loans may only be converted to Alternate Base Rate Loans on the last day of the applicable Interest Period.  If the date upon which a LIBOR Rate Loan is to be converted to an Alternate Base Rate Loan is not a Business Day, then such conversion shall be made on the next succeeding Business Day and during the period from such last day of an Interest Period to such succeeding Business Day the Loan shall bear interest as if it were an Alternate Base Rate Loan.  The entire Loan when such is in the form of an Alternate Base Rate Loan may be converted as provided herein; provided that the Loan may not be converted into a LIBOR Rate Loan when any Default or Event of Default has occurred and is continuing.  The entire Loan when such is in the form of a LIBOR Rate Loan may be converted as provided herein.

 

(b)           Any LIBOR Rate Loan may be continued as such upon the expiration of an Interest Period with respect thereto by compliance by the Borrower with the notice provisions (regarding conversions of Alternate Base Rate Loans to LIBOR Rate Loans) contained in Section 2.5(a); provided, that no LIBOR Rate Loan may be continued as such when any Default or Event of Default has occurred and is continuing, in which case such LIBOR Rate Loan shall be automatically converted to an Alternate Base Rate Loan at the end of the applicable Interest Period with respect thereto.  If the Borrower shall fail to give timely notice of an election to continue a LIBOR Rate Loan, or the continuation of LIBOR Rate Loans is not permitted hereunder, such LIBOR Rate Loan shall be automatically converted to an Alternate Base Rate Loan at the end of the applicable Interest Period with respect thereto.

 

Section 2.6            Computation of Interest and Fees; Usury.

 

(a)           Interest payable hereunder with respect to any Alternate Base Rate Loan based on the Prime Rate shall be calculated on the basis of a year of 365 days (or 366 days, as applicable) for the actual days elapsed.  All other fees, interest and all other amounts payable hereunder shall be calculated on the basis of a 360-day year for the actual days elapsed.  The Administrative Agent shall as soon as practicable notify the Borrower and the Lenders of each determination of a LIBOR Rate on the Business Day of the determination thereof.  Any change in the interest rate on a Loan resulting from a change in the Alternate Base Rate shall become effective as of the opening of business on the day on which such change in the Alternate Base Rate shall become effective.  The Administrative Agent shall as soon as practicable notify the Borrower and the Lenders of the effective date and the amount of each such change.

 

(b)           Each determination of an interest rate by the Administrative Agent pursuant to any provision of this Agreement shall be conclusive and binding on the Borrower and the Lenders in the absence of manifest error.  The Administrative Agent shall, at the request of the Borrower, deliver to the Borrower a statement showing the computations used by the Administrative Agent in determining any interest rate.

 

(c)           It is the intent of the Lenders and the Credit Parties to conform to and contract in strict compliance with applicable usury law from time to time in effect.  All agreements between the Lenders and the Credit Parties are hereby limited by the provisions of this subsection which shall override and control all such agreements, whether now existing or hereafter arising and whether written or oral.  In no way, nor in any event or contingency (including, without limitation, but not limited to, prepayment or acceleration of the maturity of any Credit Party Obligation), shall the interest taken, reserved, contracted for, charged, or received under this

 

23

 

Agreement, under the Notes or otherwise, exceed the maximum nonusurious amount permissible under applicable law.  If, from any possible construction of any of the Credit Documents or any other document, interest would otherwise be payable in excess of the maximum nonusurious amount, any such construction shall be subject to the provisions of this paragraph and such interest shall be automatically reduced to the maximum nonusurious amount permitted under applicable law, without the necessity of execution of any amendment or new document.  If any Lender shall ever receive anything of value which is characterized as interest on the Loan under applicable law and which would, apart from this provision, be in excess of the maximum nonusurious amount, an amount equal to the amount which would have been excessive interest shall, without penalty, be applied to the reduction of the principal amount owing on the Loan and not to the payment of interest, or refunded to the Borrower or the other payor thereof if and to the extent such amount which would have been excessive exceeds such unpaid principal amount of the Loan.  The right to demand payment of the Loan or any other Indebtedness evidenced by any of the Credit Documents does not include the right to receive any interest which has not otherwise accrued on the date of such demand, and the Lenders do not intend to charge or receive any unearned interest in the event of such demand.  All interest paid or agreed to be paid to the Lenders with respect to the Loan shall, to the extent permitted by applicable law, be amortized, prorated, allocated, and spread throughout the full stated term (including, without limitation, any renewal or extension) of the Loan so that the amount of interest on account of such Indebtedness does not exceed the maximum nonusurious amount permitted by applicable law.

 

Section 2.7            Pro Rata Treatment and Payments.

 

(a)           Allocation of Payments Prior to Occurrence of Event of Default.  If no Event of Default has occurred and is continuing, each payment under any of the Credit Documents or in respect of the Collateral, including, without limitation, any optional prepayment of the Loan pursuant to Section 2.3(a) but excluding any mandatory prepayment of the Loan pursuant to Section 2.3(b), shall be applied as follows:

 

FIRST, to the payment of all reasonable out-of-pocket costs and expenses (including, without limitation, reasonable attorneys’ fees) of the Administrative Agent under the Credit Documents and any protective advances made by the Administrative Agent with respect to the Collateral under or pursuant to the terms of the Security Documents;

 

SECOND, to the payment of any fees owed to the Administrative Agent pursuant to the Credit Documents;

 

THIRD, to the payment of all of the Credit Party Obligations consisting of accrued fees and interest, and including, without limitation, with respect to any Secured Hedging Agreement, any fees, premiums and scheduled periodic payments due under such Secured Hedging Agreement and any interest accrued thereon;

 

FOURTH, to the payment of the outstanding principal amount of the Credit Party Obligations, and including, without limitation, with respect to any Secured Hedging Agreement, any breakage, termination or other payments due under such Secured Hedging Agreement and any interest accrued thereon;

 

FIFTH, to all other Credit Party Obligations and other obligations which shall have become due and payable under the Credit Documents or otherwise and not repaid pursuant to clauses “FIRST” through “FOURTH” above; and

 

24

 

SIXTH, to the payment of the surplus, if any, to whoever may be lawfully entitled to receive such surplus.

 

In carrying out the foregoing, (a) amounts received shall be applied in the numerical order provided until exhausted prior to application to the next succeeding category and (b) each of the Lenders and any Hedging Agreement Provider shall receive an amount equal to its pro rata share (based on the proportion that the then outstanding portion of the Loan held by such Lender or the outstanding obligations payable to such Hedging Agreement Provider bears to the aggregate then outstanding Loan and obligations payable under all Secured Hedging Agreements) of amounts available to be applied pursuant to clauses “THIRD”, “FOURTH” and “FIFTH” above.  Prepayment under Section 2.3(a) shall be applied first to Alternate Base Rate Loans on a ratable basis and then to LIBOR Rate Loans (if any) in inverse order of Interest Period maturities.

 

Each mandatory prepayment of the Loan shall be applied to the Loan on a pro rata basis in accordance with Section 2.7(b).

 

(b)           Allocation of Proceeds from Mandatory Prepayments or Payments After Occurrence of Event of Default.  Proceeds from any mandatory prepayment of the Loan under Section 2.3(b) and proceeds arising after the occurrence and during the continuation of any Event of Default, all amounts collected or received by the Administrative Agent or any Lender on account of the Credit Party Obligations or any other amounts outstanding under any of the Credit Documents or in respect of the Collateral shall be paid over or delivered as follows (irrespective of whether the following costs, expenses, fees, interest, premiums, scheduled periodic payments or Credit Party Obligations are allowed, permitted or recognized as a claim in any proceeding resulting from the occurrence of a Bankruptcy Event):

 

FIRST, to the payment of all reasonable out-of-pocket costs and expenses (including, without limitation, reasonable attorneys’ fees) of the Administrative Agent in connection with enforcing the rights of the Lenders under the Credit Documents and any protective advances made by the Administrative Agent with respect to the Collateral under or pursuant to the terms of the Security Documents;

 

SECOND, to the payment of any fees owed to the Administrative Agent pursuant to the Credit Documents;

 

THIRD, to the payment of all reasonable out-of-pocket costs and expenses (including, without limitation, reasonable attorneys’ fees) of each of the Lenders in connection with enforcing its rights under the Credit Documents or otherwise with respect to the Credit Party Obligations owing to such Lender;

 

FOURTH, to the payment of all of the Credit Party Obligations consisting of accrued fees and interest, and including, without limitation, with respect to any Secured Hedging Agreement, any fees, premiums and scheduled periodic payments due under such Secured Hedging Agreement and any interest accrued thereon;

 

FIFTH, to the payment of the outstanding principal amount of the Credit Party Obligations, and including, without limitation, with respect to any Secured Hedging Agreement, any breakage, termination or other payments due under such Secured Hedging Agreement and any interest accrued thereon;

 

25

 

SIXTH, to all other Credit Party Obligations and other obligations which shall have become due and payable under the Credit Documents or otherwise and not repaid pursuant to clauses “FIRST” through “FIFTH” above; and

 

SEVENTH, to the payment of the surplus, if any, to whoever may be lawfully entitled to receive such surplus.

 

In carrying out the foregoing, (a) amounts received shall be applied in the numerical order provided until exhausted prior to application to the next succeeding category and (b) each of the Lenders and any Hedging Agreement Provider shall receive an amount equal to its pro rata share (based on the proportion that the then outstanding portion of the Loan held by such Lender or the outstanding obligations payable to such Hedging Agreement Provider bears to the aggregate then outstanding Loan and obligations payable under all Secured Hedging Agreements) of amounts available to be applied pursuant to clauses “THIRD”, “FOURTH”, “FIFTH” and “SIXTH” above.  Prepayment under Section 2.3(b) shall be applied first to Alternate Base Rate Loans on a ratable basis and then to LIBOR Rate Loans (if any) in inverse order of Interest Period maturities.

 

(c)           Payments - General Terms.  All payments (including, without limitation, prepayments) to be made by the Borrower on account of principal, interest and fees shall be made without defense, set-off or counterclaim and shall be made to the Administrative Agent for the account of the Lenders at the Administrative Agent’s office specified in Section 9.2 in Dollars and in immediately available funds not later than 1:00 p.m. (New York, New York time) on the date when due.  The Administrative Agent shall distribute such payments to the Lenders entitled thereto promptly upon receipt in like funds as received.  If any payment hereunder (other than payments on the LIBOR Rate Loans) becomes due and payable on a day other than a Business Day, such payment shall be extended to the next succeeding Business Day, and, with respect to payments of principal, interest thereon shall be payable at the then applicable rate during such extension.  If any payment on a LIBOR Rate Loan becomes due and payable on a day other than a Business Day, such payment date shall be extended to the next succeeding Business Day (and with respect to payments of principal, interest thereon shall be payable at the then applicable rate during such extension) unless the result of such extension would be to extend such payment into another calendar month, in which event such payment shall be made on the immediately preceding Business Day.

 

Section 2.8            Non-Receipt of Funds by the Administrative Agent.

 

(a)           Funding by Lenders; Presumption by the Administrative Agent.  Unless the Administrative Agent shall have received written notice from a Lender prior to the proposed date of any Extension of Credit that such Lender will not make available to the Administrative Agent such Lender’s share of such Extension of Credit, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with this Agreement and may, in reliance upon such assumption, make available to the Borrower a corresponding amount.  In such event, if a Lender has not in fact made its share of the applicable Extension of Credit available to the Administrative Agent, then the applicable Lender and the Borrower severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount with interest thereon, for each day from and including, without limitation, the date such amount is made available to the Borrower to but excluding the date of payment to the Administrative Agent, at (i) in the case of a payment to be made by such Lender, the greater of the Federal Funds Effective Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation and (ii) in the case of a payment to be made by the

 

26

 

Borrower, the interest rate applicable to Alternate Base Rate Loans.  If the Borrower and such Lender shall pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to the Borrower the amount of such interest paid by the Borrower for such period.  If such Lender pays its share of the applicable Extension of Credit to the Administrative Agent, then the amount so paid shall constitute such Lender’s portion of the Loan included in such Extension of Credit.  Any payment by the Borrower shall be without prejudice to any claim the Borrower may have against a Lender that shall have failed to make such payment to the Administrative Agent.

 

(b)           Payments by Borrower; Presumptions by the Administrative Agent.  Unless the Administrative Agent shall have received notice from the Borrower prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders hereunder that the Borrower will not make such payment, the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders, the amount due.  In such event, if the Borrower has not in fact made such payment, then each of the Lenders severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender, with interest thereon, for each day from and including, without limitation, the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the Federal Funds Effective Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation.

 

A notice of the Administrative Agent to any Lender or the Borrower with respect to any amount owing under subsections (a) and (b) of this Section shall be conclusive, absent manifest error.

 

(c)           Failure to Satisfy Conditions Precedent.  If any Lender makes available to the Administrative Agent funds for any portion of the Loan to be made by such Lender as provided in this Article II, and such funds are not made available to the Borrower by the Administrative Agent because the conditions to the applicable Extension of Credit set forth in Article IV are not satisfied or waived in accordance with the terms thereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest.

 

(d)           Obligations of Lenders Several.  The obligations of the Lenders hereunder to make the Loan and to make payments pursuant to Section 9.5(c) are several and not joint.  The failure of any Lender to make any Loan, to fund any such participation or to make any such payment under Section 9.5(c) on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Loan, to purchase its participation or to make its payment under Section 9.5(c).

 

(e)           Funding Source.  Nothing herein shall be deemed to obligate any Lender to obtain the funds for any portion of the Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any portion of the Loan in any particular place or manner.

 

Section 2.9            Inability to Determine Interest Rate.

 

Notwithstanding any other provision of this Agreement, if (a) the Administrative Agent shall reasonably determine (which determination shall be conclusive and binding absent manifest error) that, by reason of circumstances affecting the relevant market, reasonable and adequate means do not exist for

 

27

 

ascertaining the LIBOR Rate for such Interest Period, or (b) the Required Lenders shall reasonably determine (which determination shall be conclusive and binding absent manifest error) that the LIBOR Rate does not adequately and fairly reflect the cost to such Lenders of funding LIBOR Rate Loans that the Borrower has requested be outstanding as a LIBOR Tranche during such Interest Period, the Administrative Agent shall forthwith give telephone notice of such determination, confirmed in writing, to the Borrower, and the Lenders at least two (2) Business Days prior to the first day of such Interest Period.  Unless the Borrower shall have notified the Administrative Agent upon receipt of such telephone notice that it wishes to rescind or modify its request regarding such LIBOR Rate Loan, any portion of the Loan that was requested to be made as a LIBOR Rate Loan shall be made as an Alternate Base Rate Loan and any portion of the Loan that was requested to be converted into or continued as a LIBOR Rate Loan shall remain as or be converted into an Alternate Base Rate Loan.  Until any such notice has been withdrawn by the Administrative Agent, no further portion of the Loan shall be made as, continued as, or converted into, a LIBOR Rate Loan for the Interest Periods so affected.

 

Section 2.10         Yield Protection.

 

(a)           Increased Costs Generally.  If any Change in Law shall:

 

(i)            impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender (except any reserve requirement reflected in the LIBOR Rate);

 

(ii)           subject any Lender to any tax of any kind whatsoever with respect to this Agreement or any LIBOR Rate Loan made by it, or change the basis of taxation of payments to such Lender in respect thereof (except for Indemnified Taxes or Other Taxes covered by Section 2.12 and the imposition of, or any change in the rate of, any Excluded Tax payable by such Lender); or

 

(iii)          impose on any Lender or the London interbank market any other condition, cost or expense affecting this Agreement or LIBOR Rate Loans made by such Lender;

 

and the result of any of the foregoing shall be to increase the cost to such Lender of making or maintaining any LIBOR Rate Loan (or of maintaining its obligation to make any such LIBOR Rate Loan), or to increase the cost to such Lender or to reduce the amount of any sum received or receivable by such Lender (whether of principal, interest or any other amount) then, upon request of such Lender, the Borrower will pay to such Lender, as the case may be, such additional amount or amounts as will compensate such Lender for such additional costs incurred or reduction suffered, as a consequence of any of the Credit Documents or any Loan made by such Lender.

 

(b)           Capital Requirements.  If any Lender determines that any Change in Law affecting such Lender or any lending office of such Lender or such Lender’s holding company, if any, regarding capital requirements has or would have the effect of reducing the rate of return on such Lender’s capital or on the capital of such Lender’s holding company, if any, as a consequence of this Agreement, or the Loan made by such Lender, to a level below that which such Lender or such Lender’s holding company could have achieved but for such Change in Law (taking into consideration such Lender’s policies and the policies of such Lender’s holding company with respect to capital adequacy), then from time to time the Borrower will pay to such Lender such additional amount or amounts as will compensate such Lender or such Lender’s holding company for any such reduction suffered.

 

28

 

(c)           Certificates for Reimbursement.  A certificate of a Lender setting forth the amount or amounts necessary to compensate such Lender or its holding company, as the case may be, as specified in paragraph (a) or (b) of this Section and delivered to the Borrower shall be conclusive absent manifest error.  The Borrower shall pay such Lender the amount shown as due on any such certificate within ten (10) days after receipt thereof.

 

(d)           Delay in Requests.  Failure or delay on the part of any Lender to demand compensation pursuant to this Section shall not constitute a waiver of such Lender’s right to demand such compensation.

 

Section 2.11         Indemnity; Eurocurrency Liabilities.

 

(a)           The Borrower hereby agrees to indemnify each Lender and to hold such Lender harmless from any funding loss or expense which such Lender may sustain or incur as a consequence of (i) the failure by the Borrower to pay the principal amount of or interest on any Loan by such Lender in accordance with the terms hereof, (ii) the failure by the Borrower to accept a borrowing after the Borrower has given a notice in accordance with the terms hereof, (iii) default by the Borrower in making any prepayment after the Borrower has given a notice in accordance with the terms hereof, and/or (iv) the making by the Borrower of a prepayment of the Loan or any portion thereof, or the conversion thereof, on a day which is not the last day of the Interest Period with respect thereto, in each case including, without limitation, any such loss or expense arising from interest or fees payable by such Lender to lenders of funds obtained by it in order to maintain its portion of the Loan hereunder.  A certificate setting forth in reasonable detail as to any additional amounts payable pursuant to this Section submitted by any Lender, through the Administrative Agent, to the Borrower shall be conclusive in the absence of manifest error.  The agreements in this Section shall survive termination of this Agreement and payment of the Credit Party Obligations.

 

(b)           The Borrower shall pay to each Lender, as long as such Lender shall be required to maintain reserves under Regulation D with respect to “Eurocurrency liabilities” within the meaning of Regulation D, or under any similar or successor regulation with respect to Eurocurrency liabilities or Eurocurrency funding, additional interest on the unpaid principal amount of each LIBOR Loan equal to the actual costs of such reserves allocated to such LIBOR Loan by such Lender (as determined by such Lender in good faith, which determination shall be conclusive), which shall be due and payable on each date on which interest is payable on such LIBOR Loan, provided the Borrower shall have received at least fifteen (15) days prior notice (with a copy to the Administrative Agent) of such additional interest from such Lender.  If a Lender fails to give notice fifteen (15) days prior to the relevant interest payment date, such additional interest shall be due and payable fifteen (15) days from receipt of such notice.

 

Section 2.12         Taxes.

 

(a)           Payments Free of Taxes.  Any and all payments by or on account of any obligation of the Borrower hereunder or under any other Credit Document shall be made free and clear of and without reduction or withholding for any Indemnified Taxes or Other Taxes, provided that if the Borrower shall be required by applicable law to deduct any Indemnified Taxes (including, without limitation, any Other Taxes) from such payments, then (i) the sum payable shall be increased as necessary so that after making all required deductions (including, without limitation, deductions applicable to additional sums payable under this Section) the Administrative Agent or any Lender, as the case may be, receives an amount equal to the sum it

 

29

 

would have received had no such deductions been made, (ii) the Borrower shall make such deductions and (iii) the Borrower shall timely pay the full amount deducted to the relevant Governmental Authority in accordance with applicable law.

 

(b)           Payment of Other Taxes by the Borrower.  Without limiting the provisions of paragraph (a) above, the Borrower shall timely pay any Other Taxes to the relevant Governmental Authority in accordance with applicable law.

 

(c)           Indemnification by the Borrower.  The Borrower shall indemnify the Administrative Agent and each Lender, within fifteen (15) days after demand therefor, for the full amount of any Indemnified Taxes or Other Taxes (including, without limitation, Indemnified Taxes or Other Taxes imposed or asserted on or attributable to amounts payable under this Section) paid by the Administrative Agent or such Lender, as the case may be, and any penalties, interest and reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes or Other Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.

 

(d)           Evidence of Payments.  As soon as practicable after any payment of Indemnified Taxes or Other Taxes by the Borrower to a Governmental Authority, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.

 

(e)           Status of Lenders.  Any Foreign Lender that is entitled to an exemption from or reduction of withholding tax under the law of the jurisdiction in which the Borrower is resident for tax purposes, or any treaty to which such jurisdiction is a party, with respect to payments hereunder or under any other Credit Document shall deliver to the Borrower (with a copy to the Administrative Agent), at the time or times prescribed by applicable law or reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation prescribed by applicable law as will permit such payments to be made without withholding or at a reduced rate of withholding.  In addition, any Lender, if requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements.

 

(f)            Foreign Lenders.  Without limiting the generality of the foregoing, in the event that the Borrower is resident for tax purposes in the United States, any Foreign Lender shall deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the request of the Borrower or the Administrative Agent, but only if such Foreign Lender is legally entitled to do so), whichever of the following is applicable:

 

(i)            duly completed copies of Internal Revenue Service Form W-8BEN claiming eligibility for benefits of an income tax treaty to which the United States is a party,

 

(ii)           duly completed copies of Internal Revenue Service Form W-8ECI,

 

30

 

(iii)          in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (i) a certificate to the effect that such Foreign Lender is not (A) a “bank” within the meaning of Section 881(c)(3)(A) of the Code, (B) a “10 percent shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or (C) a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code and (ii) duly completed copies of  Internal Revenue Service Form W-8BEN, or

 

(iv)          any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in United States federal withholding tax duly completed together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower to determine the withholding or deduction required to be made.

 

(g)           Treatment of Certain Refunds.  If the Administrative Agent or a Lender determines, in its sole discretion, that it has received a refund of any Taxes or Other Taxes as to which it has been indemnified by the Borrower or with respect to which the Borrower has paid additional amounts pursuant to this Section, it shall pay to the Borrower an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by the Borrower under this Section with respect to the Taxes or Other Taxes giving rise to such refund), net of all out-of-pocket expenses of the Administrative Agent or such Lender, as the case may be, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund), provided that the Borrower, upon the request of the Administrative Agent or such Lender, agrees to repay the amount paid over to the Borrower (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) to the Administrative Agent or such Lender in the event the Administrative Agent or such Lender is required to repay such refund to such Governmental Authority.  This paragraph shall not be construed to require the Administrative Agent or any Lender to make available its tax returns (or any other information relating to its taxes that it deems confidential) to the Borrower or any other Person.

 

Section 2.13         Illegality.

 

Notwithstanding any other provision of this Agreement, if any Change in Law shall make it unlawful for such Lender or its LIBOR Lending Office to make or maintain LIBOR Rate Loans as contemplated by this Agreement or to obtain in the interbank eurodollar market through its LIBOR Lending Office the funds with which to make such LIBOR Rate Loans, (a) such Lender shall promptly notify the Administrative Agent and the Borrower thereof, (b) the commitment of such Lender hereunder to make LIBOR Rate Loans or continue LIBOR Rate Loans as such shall forthwith be suspended until the Administrative Agent shall give notice that the condition or situation which gave rise to the suspension shall no longer exist, and (c) such Lender’s portion of the Loan then outstanding as LIBOR Rate Loans, if any, shall be converted on the last day of the Interest Period for such LIBOR Rate Loans or within such earlier period as required by law into Alternate Base Rate Loans.  The Borrower hereby agrees to promptly pay any Lender, upon its demand, any additional amounts necessary to compensate such Lender for actual and direct costs (but not including, without limitation, anticipated profits) reasonably incurred by such Lender in making any repayment in accordance with this Section including, without limitation, any interest or fees payable by such Lender to lenders of funds obtained by it in order to make or maintain its LIBOR Rate Loans hereunder.  A certificate (which certificate shall include a description of the basis for the computation) as to any additional amounts payable pursuant to this Section submitted by such Lender, through the Administrative Agent, to the Borrower shall be conclusive in the absence of manifest error.  Each Lender agrees to use reasonable efforts (including, without limitation, reasonable efforts to change its LIBOR Lending Office) to avoid or to minimize any amounts which may otherwise be payable

 

31

 

pursuant to this Section; provided, however, that such efforts shall not cause the imposition on such Lender of any additional costs or legal or regulatory burdens deemed by such Lender in its sole discretion to be material.

 

Section 2.14         No New Extension of Credit After Closing Date.

 

After the initial Extension of Credit on the Closing Date, the Lenders shall have no obligation to provide any additional advance pursuant to this Agreement; provided, notwithstanding the foregoing, there shall be additional Extensions of Credit after the Closing Date in the form of conversions and continuations of the Loan pursuant to Section 2.5.

 

Section 2.15         Hedging Agreement Not Required.

 

The parties to this Agreement hereby agree that no Credit Party shall have any obligation pursuant to any Credit Document to enter into any Hedging Agreement.

 

ARTICLE III

 

REPRESENTATIONS AND WARRANTIES

 

To induce the Lenders to enter into this Agreement and to make the Extensions of Credit herein provided for, the Borrower, on behalf of each of the Credit Parties, hereby represents and warrants as of the Closing Date to the Administrative Agent and to each Lender that:

 

Section 3.1            Financial Statements.

 

The audited Consolidated balance sheets of the Borrower as of December 31, 2009, and the related Consolidated statements of income and retained earnings and of cash flows for the fiscal years ended on such dates, reported on by and accompanied by an unqualified report from Ernst & Young LLP, present fairly the Consolidated financial condition of the Borrower as at each such date, and the Consolidated results of its operations and its Consolidated retained earnings and cash flows for the respective fiscal years then ended.  The unaudited Consolidated balance sheets of the Borrower as at September 30, 2010, and the related unaudited Consolidated statements of income and retained earnings and of cash flows for the portion of the fiscal year ended on each such date, present fairly the Consolidated financial condition of the Borrower as at such date, and the Consolidated results of its operations and its Consolidated retained earnings and cash flows for the portion of the fiscal year then ended (subject to normal year-end audit adjustments).  All such financial statements, including, without limitation, the related schedules and notes thereto, have been prepared in accordance with GAAP applied consistently throughout the periods involved (except as disclosed therein).  Except as set forth in Schedule 3.1, as of the Closing Date, no Credit Party nor any of its Subsidiaries has any (a) Consolidated Funded Indebtedness in an amount in excess of $5,000,000, (b) leases with a term of three (3) years or more pursuant to which the fair market value of the leased assets is in excess of $5,000,000 or (c) Material Contracts, including, without limitation, any interest rate or foreign currency swap or exchange transaction or other obligation in respect of derivatives, that are not reflected in the audited financial statements as at December 31, 2009 referred to in this paragraph.  Except as set forth on Schedule 3.1 and except for matters occurring in the ordinary course of business, during the period from December 31, 2009, to and including, without limitation, the date hereof there has been no sale, transfer or other disposition by any Credit Party or any of its Subsidiaries to any Person other than a Credit Party or any of its Subsidiaries of any material part of its business or property.

 

32

 

Section 3.2            No Material Adverse Change.

 

Since December 31, 2009, there has been no development or event which has had or could reasonably be expected to have a Material Adverse Effect.

 

Section 3.3            Existence; Compliance with Law.

 

Each Credit Party and each of its Subsidiaries (a) is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, (b) has the power and authority, and the legal right, to own and operate its property, to lease the property it operates and to conduct the business in which it is currently engaged, (c) is qualified to do business in each jurisdiction where such qualification is required, except to the extent that the failure to qualify therein could not, in the aggregate, reasonably be expected to have a Material Adverse Effect and (d) is in compliance with all Requirements of Law, except to the extent that the failure to comply therewith could not, in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

Section 3.4            Power; Authorization; Enforceable Obligations.

 

Each Credit Party has the power and authority, and the legal right, to make, deliver and perform each Credit Document to which it is a party and, in the case of the Borrower, to borrow hereunder and has taken all necessary action to authorize the execution, delivery and performance of this Agreement and the other Credit Documents to which it is a party and, in the case of the Borrower, the borrowings on the terms and conditions of this Agreement.  No consent or authorization of, filing with, notice to or other act by or in respect of, any Governmental Authority or any other Person is required in connection with the borrowings hereunder or with the execution, delivery, performance, validity or enforceability of this Agreement or the other Credit Documents.  This Agreement has been, and each other Credit Document to which it is a party will be, duly executed and delivered on behalf of each Credit Party which is a party thereto.  This Agreement constitutes, and each other Credit Document to which it is a party when executed and delivered will constitute, a legal, valid and binding obligation of each Credit Party which is a party thereto, enforceable against each such Credit Party in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).

 

Section 3.5            No Legal Bar.

 

The execution, delivery and performance of the Credit Documents to which any Credit Party is a party, the borrowings hereunder and the use of the proceeds thereof will not violate any Requirement of Law or Contractual Obligation of the Borrower or of any of its Subsidiaries and will not result in, or require, the creation or imposition of any Lien on any of its or their respective properties or revenues pursuant to any such Requirement of Law or Contractual Obligation (other than the Liens created by the Security Documents).

 

Section 3.6            No Material Litigation.

 

Except as set forth on Schedule 3.6, no litigation, investigation or proceeding of or before any arbitrator or Governmental Authority is pending or, to the knowledge of any Credit Party, threatened in writing by or against any Credit Party or any of its Subsidiaries or against any of its or their respective properties or revenues (a) with respect to any of the Credit Documents or any of the transactions contemplated hereby or thereby, or (b) which could reasonably be expected to have a Material Adverse Effect.

 

33

 

Section 3.7            No Default.

 

No Credit Party nor any of its Subsidiaries is in default under or with respect to any of its Contractual Obligations in any respect which could reasonably be expected to have a Material Adverse Effect.  No Default or Event of Default has occurred and is continuing.

 

Section 3.8            Ownership of Collateral; Liens.

 

The Borrower has good title to all of the Collateral, and none of the Collateral is subject to any Lien except Permitted Liens.

 

Section 3.9            Intellectual Property.

 

Each Credit Party and each of its Subsidiaries owns, or is licensed to use, all trademarks, tradenames, copyrights, technology, know-how and processes (the “Intellectual Property”) necessary for the conduct of its business as currently conducted except for those the failure to own or license which could not reasonably be expected to have a Material Adverse Effect.  No material claim has been asserted and is pending by any Person challenging or questioning the use of any such Intellectual Property or the validity or effectiveness of any such Intellectual Property, nor does any Credit Party or any of its Subsidiaries know of any valid basis for any such claim.  The use of such Intellectual Property by the Credit Parties and their Subsidiaries does not infringe on the rights of any Person, except for such claims and infringements that, in the aggregate, could not reasonably be expected to have a Material Adverse Effect.

 

Section 3.10         Taxes.

 

Each Credit Party and each of its Subsidiaries has filed or caused to be filed all federal and state income and other material Tax returns and reports required to be filed and has paid all Taxes shown to be due and payable on said returns and all other material Taxes imposed upon it or any of its property by any Governmental Authority (other than any amount the validity of which is currently being contested in good faith by appropriate proceedings and with respect to which reserves in conformity with GAAP have been provided on the books of the Borrower or its Subsidiaries, as the case may be); no material Tax Lien has been filed, and no claim is being asserted, with respect to any such Tax.

 

Section 3.11         Accuracy of Information.

 

Neither this Agreement, any other Credit Document or any other document, certificate or written statement furnished by any Credit Party to the Administrative Agent or the Lenders or any of them or to any other Person providing an Appraisal, a Survey, an Environmental Report, a Property Condition Report, a Zoning Report, any other item required pursuant to Section 4.1 of this Agreement or any other due diligence item in connection with the Transactions, in each case, for use in connection with the transactions contemplated by this Agreement or the other Credit Documents (excluding the projections, financial models and business plans referred to in the next succeeding sentence), contained as of the date such written statement, information, document or certificate was so furnished any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements contained herein or therein not materially misleading.  The projections, financial models and business plans that have been or hereafter may be prepared (if any) by any Credit Party or any of its representatives and made available to the Administrative Agent or the Lenders have been or will be prepared in good faith based upon assumptions believed by the management of the Credit Parties to be reasonable, it being recognized that such projections, financial models and business plans, as they relate to future events, are not to be viewed

 

34

 

as fact and that actual results during the period or periods covered thereby may differ materially from the projected results set forth therein.  There is no fact known to any Credit Party on the Closing Date that could reasonably be expected to have a Material Adverse Effect that has not been expressly disclosed herein, in the other Credit Documents or in such other documents, certificates and written statements furnished to the Administrative Agent and the Lenders for use in connection with the transactions contemplated hereby and by the other Credit Documents.

 

Section 3.12         Federal Regulations.

 

No part of the proceeds of the Loan will be used for “buying” or “carrying” any “margin stock” within the respective meanings of each of the quoted terms under Regulation U of the Board as now and from time to time hereafter in effect.  If requested by any Lender or the Administrative Agent, the Borrower will furnish to the Administrative Agent and each Lender a statement to the foregoing effect in conformity with the requirements of FR Form G-3 or FR Form U-1, as applicable, referred to in said Regulation U.

 

Section 3.13         ERISA.

 

(a)             During the five-year period prior to the date on which this representation is made or deemed made, each Plan has complied in all respects with the applicable provisions of ERISA and the Code, except to the extent that the liability which could reasonably be expected to result from noncompliance could not reasonably be expected to have a Material Adverse Effect.  Neither any Credit Party nor any Commonly Controlled Entity has any liability with respect to a Single Employer Plan or a Multiemployer Plan.

 

(b)           Neither any Credit Party nor any Commonly Controlled Entity has any liability with respect to a Foreign Plan or Foreign Benefit Arrangement.

 

Section 3.14         Investment Company Act; Other Regulations.

 

Neither any Credit Party nor any of its Subsidiaries is an “investment company”, or a company “controlled” by an “investment company”, within the meaning of the Investment Company Act of 1940, as amended.  Neither the Borrower nor any of its Subsidiaries is subject to regulation under any federal or state statute or regulation (other than Regulation X of the Board) which limits its ability to incur Indebtedness.

 

Section 3.15         Subsidiaries.

 

Set forth on Schedule 3.15 are the Subsidiaries (direct and indirect) of the Borrower as of the last date such Schedule was required to be updated by Section 5.9.

 

Section 3.16         Purpose of the Loan.

 

The proceeds of the Loan shall be used to repay existing Indebtedness of the Borrower and otherwise for general corporate purposes.

 

Section 3.17         Security Documents.

 

The Security Documents are effective to create in favor of the Administrative Agent, for the benefit of the Lenders, a legal, valid and enforceable security interest in the Collateral described therein and proceeds thereof. In the case of the Collateral described in the Security Documents, when filings

 

35

 

specified on Schedule 3.17 in appropriate form are filed in the offices specified on Schedule 3.17, the Security Documents shall constitute a fully perfected Lien, to the extent such security interests can be perfected by filings in public filing offices, on, and security interest in, all right, title and interest of the Credit Parties in such Collateral and the proceeds thereof, as security for the Credit Party Obligations, in each case prior and superior in right to any other Person (except, in the case of Collateral, for the existence of Permitted Liens).

 

Section 3.18         Environmental Matters.

 

(a)           No Credit Party or any Subsidiary, nor to the knowledge of the Credit Parties and their Subsidiaries, any other Person, has except as otherwise disclosed in the Environmental Reports (copies of which have been provided to Administrative Agent and the Lenders), caused the Mortgaged Properties (the “Properties”) to contain any Materials of Environmental Concern in amounts or concentrations which (i) constitute a violation of, or (ii) could give rise to liability on behalf of any such party under, any Environmental Law.

 

(b)           The Properties and all operations of the Credit Parties and their Subsidiaries at the Properties are in compliance and have in the last five years been in compliance with all applicable Environmental Laws except in each case, to the extent that the failure to comply therewith could not, in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

(c)           Except for that certain notice to the Borrower from the County of Durham, North Carolina dated July 27, 2009 with respect to the daily minimum for pH, neither the Credit Parties nor their Subsidiaries have received any written or actual notice of violation, alleged violation, non-compliance, liability or potential liability with respect to environmental matters or Environmental Laws regarding any of the Properties or the business operated by the Credit Parties (the “Business”), nor do the Credit Parties or their Subsidiaries have knowledge or reason to believe that any such notice will be received or is being threatened in writing.

 

(d)           No Credit Party or any Subsidiary, nor to the knowledge of the Credit Parties and their Subsidiaries, any other Person, has except as otherwise disclosed in the Environmental Reports (copies of which have been provided to Administrative Agent and the Lenders), transported or disposed of Materials of Environmental Concern from the Properties in violation of, or in a manner or to a location that could give rise to liability on behalf of any Credit Party or any of its Subsidiaries under any Environmental Law, and no Materials of Environmental Concern have been released, generated, treated, stored or disposed of at, on or under any of the Properties in violation of, or in a manner that could give rise to liability on behalf of any Credit Party or any of its Subsidiaries under, any Environmental Law.

 

(e)           No judicial proceeding or governmental or administrative action is pending or, to the knowledge of the Credit Parties and their Subsidiaries, threatened in writing, under any Environmental Law to which any Credit Party or any of its Subsidiaries is or will be named as a party with respect to the Properties or the Business at the Properties, nor to the knowledge of the Credit Parties and their Subsidiaries are there any consent decrees or other decrees, consent orders, administrative orders or other orders, or other administrative or judicial requirements outstanding under any Environmental Law with respect to the Properties or the Business.

 

As used in this Section 3.18(e), the knowledge of the Borrower, the Credit Parties and/or the Subsidiaries, is limited to the actual knowledge of Martine A. Rothblatt - Chairman of the Board and Chief Executive Officer; John M. Ferrari - Chief Financial Officer and Treasurer; Paul A. Mahon - Executive Vice President, Strategic Planning, General Counsel and Corporate Secretary; John S. Hess, Jr.

 

36

 

- Vice President and Associate General Counsel; Roger Jeffs - President and Chief Operating Officer; David Zaccardelli - Chief Manufacturing Officer, EVP Pharmaceutical Development; Avi Halpert - Director, Construction and Corporate Real Estate; Melissa Silverman - Vice President of Finance; and Yuri Van Mierlo - Corporate Real Estate Manager.

 

Section 3.19         Solvency.

 

After giving effect to the Transactions, (a) each of the Credit Parties is solvent and is able to pay its debts and other liabilities, contingent obligations and other commitments as they mature in the normal course of business, and (b) the fair saleable value of each Credit Party’s assets, measured on a going concern basis, exceeds all probable liabilities, including, without limitation, those to be incurred pursuant to this Agreement.  After giving effect to the Transactions, none of the Credit Parties (i) has unreasonably small capital in relation to the business in which it is or proposes to be engaged or (ii) has incurred, or believes that it will incur debts beyond its ability to pay such debts as they become due.  In executing the Credit Documents and consummating the Transactions, none of the Credit Parties intends to hinder, delay or defraud either present or future creditors or other Persons to which one or more of the Credit Parties is or will become indebted.

 

Section 3.20         Anti-Terrorism Laws.

 

Neither any Credit Party nor any of its Subsidiaries is an “enemy” or an “ally of the enemy” within the meaning of Section 2 of the Trading with the Enemy Act of the United States (50 U.S.C. App. §§ 1 et seq.) (the “Trading with the Enemy Act”), as amended.  Neither any Credit Party nor any of its Subsidiaries is in violation of (a) the Trading with the Enemy Act, as amended, (b) any of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) or any enabling legislation or executive order relating thereto or (c) the Patriot Act.  None of the Credit Parties (i) is a blocked person described in Section 1 of the Anti-Terrorism Order or (ii) to the best of its knowledge, engages in any dealings or transactions, or is otherwise associated, with any such blocked person.

 

Set forth on Schedule 3.20 as of the Closing Date, and as of the last date such Schedule was required to be updated in accordance with Section 5.2, is the following information for each Credit Party:  the exact legal name and any legal names of such Credit Party in the four (4) months prior to the Closing Date, the state of incorporation or organization, the type of organization, the jurisdictions in which such Credit Party is qualified to do business, the chief executive office, the principal place of business, the business phone number, the organization identification number, the federal tax identification number and ownership information (e.g. publicly held, if private or partnership, the owners and partners of each of the Credit Parties).

 

Section 3.21         Compliance with OFAC Rules and Regulations.

 

(a)           None of the Credit Parties or any of its Subsidiaries or their respective Affiliates is in violation of and shall not violate any of the country or list based economic and trade sanctions administered and enforced by OFAC that are described or referenced at http://www.ustreas.gov/offices/enforcement/ofac/ or as otherwise published from time to time.

 

(b)           None of the Credit Parties or any of its Subsidiaries or their respective Affiliates (i) is a Sanctioned Person or a Sanctioned Entity, (ii) has a more than 10% of its assets located in Sanctioned Entities, or (iii) derives more than 10% of its operating income from investments in, or transactions with Sanctioned Persons or Sanctioned Entities.  No proceeds of the Loan will be

 

37

 

used nor have any been used to fund any operations in, finance any investments or activities in or make any payments to, a Sanctioned Person or a Sanctioned Entity.

 

Section 3.22         Compliance with FCPA.

 

Each of the Credit Parties and its Subsidiaries is in compliance with the Foreign Corrupt Practices Act, 15 U.S.C. §§ 78dd-1, et seq., and any foreign counterpart thereto.  None of the Credit Parties or their Subsidiaries has made a payment, offering, or promise to pay, or authorized the payment of, money or anything of value (a) in order to assist in obtaining or retaining business for or with, or directing business to, any foreign official, foreign political party, party official or candidate for foreign political office, (b) to a foreign official, foreign political party or party official or any candidate for foreign political office, and (c) with the intent to induce the recipient to misuse his or her official position to direct business wrongfully to such Credit Party or its Subsidiary or to any other Person, in violation of the Foreign Corrupt Practices Act, 15 U.S.C. §§ 78dd-1, et seq.

 

Section 3.23         Mortgaged Properties.

 

(a)           Compliance with Laws.  Each Credit Party, each Mortgaged Property and the use of each Mortgaged Property comply in all material respects with all applicable Requirements of Law (including, without limitation, with respect to the American Disabilities Act, parking and applicable zoning and land use laws, regulations and ordinances).  If all or any part of the Improvements at any Mortgaged Property is destroyed or damaged, said Improvements can be legally reconstructed (whether as a legal non-conforming use or otherwise) to substantially the same condition prior to such damage or destruction (except in the case of an approved legal non-conforming Mortgaged Property), and thereafter exist for the same use without violating any zoning or other ordinances applicable thereto and without the necessity of obtaining any variances or special permits, unless a change in any applicable Requirement of Law provides otherwise.  No legal proceedings are pending or, to the knowledge of any Credit Party, threatened in writing with respect to zoning violations of any Mortgaged Property.  Neither the zoning nor any other right to construct, use or operate any Mortgaged Property is in any way dependent upon or related to any property other than any Mortgaged Property, except that the Maryland Mortgaged Property is located in a parking lot district and therefore no parking for the Maryland Mortgaged Property is required to be on-site but is instead supported by public garages and public transportation, and the land use and zoning approvals associated with the Maryland Mortgaged Property have been issued with respect to the Maryland Mortgaged Property and the property located at 1110 Spring Street, Silver Spring, Maryland 20910, owned in fee simple by the Borrower and generally referred to by the Borrower as the “Phase IIB property”.  All certifications, permits, licenses and approvals, including, without limitation, certificates of completion and occupancy permits required for the legal use, occupancy and operation of any Mortgaged Property that are material have been obtained and are in full force and effect. The use being made of any Mortgaged Property is in conformity with the certificate of occupancy issued for any Mortgaged Property and all other material restrictions, covenants and conditions affecting any Mortgaged Property.  Any Mortgaged Property is duly licensed to operate in the manner currently operated, as required under any applicable Requirements of Law.

 

(b)           Leases.  No Mortgaged Property is subject to any lease or sublease, including, without limitation, any ground lease.

 

(c)           Utilities and Public Access; Parking.  (i) Each Mortgaged Property has adequate rights of access to public ways and is served by water, sewer, sanitary sewer and storm drain facilities adequate to service the applicable Mortgaged Property for its intended uses, (ii) all

 

38

 

public utilities necessary to the full use and enjoyment of each Mortgaged Property as currently used and enjoyed are located either in the public right-of-way abutting the applicable Mortgaged Property (which are connected so as to serve the applicable Mortgaged Property without passing over other property) or in recorded easements serving the applicable Mortgaged Property and such easements are set forth in and insured by the applicable Title Insurance Policy and (iii) each Mortgaged Property has sufficient parking (whether by right, pursuant to an REA or pursuant to an irrevocable easement) or is located in a parking lot district in which case no parking is required to be on-site but is instead supported by public garages and public transportation, all to the extent required to comply with all Requirements of Law.

 

(d)           Physical Condition.  Each Mortgaged Property, including, without limitation, all buildings, improvements, parking facilities, sidewalks, storm drainage systems, roofs, plumbing systems, HVAC systems, fire protection systems, electrical systems, equipment, elevators, exterior sidings and doors, landscaping, irrigation systems and all structural components, is in serviceable condition, order and repair in all material respects (ordinary wear and tear excepted).  To the knowledge of the Credit Parties and their Subsidiaries, there exists no material structural, mold or other material defects or damages in any Mortgaged Property, as a result of a casualty or otherwise, and whether latent or otherwise.  No Credit Party has received written notice from any insurance company or bonding company of any defects or inadequacies in any Mortgaged Property, or any part thereof, which would adversely affect the insurability of the same or cause the imposition of extraordinary premiums or charges thereon or of any termination or threatened termination of any policy of insurance or bond.

 

(e)           Condemnation.  No Condemnation or other proceeding has been commenced or, to the knowledge of the Credit Parties, is threatened in writing or contemplated with respect to all or any portion of any Mortgaged Property or for the relocation of roadways providing access to any Mortgaged Property.

 

(f)            Separate Lots; Assessments.  Each Mortgaged Property is assessed for real estate tax purposes as one or more wholly independent tax lot or lots, separate from any adjoining land or improvements not constituting a part of such lot or lots, and no other land or improvements is assessed and taxed together with any Mortgaged Property or any portion thereof.  To the knowledge of the Credit Parties and their Subsidiaries, there are no pending or proposed special or other assessments for public improvements or otherwise affecting any Mortgaged Property, nor to the knowledge of the Credit Parties or their Subsidiaries, are there any contemplated improvements to any Mortgaged Property that may result in such special or other assessments.

 

(g)           Boundaries.  Except to the extent affirmatively insured over under the title policies, (i) none of the Improvements which were included in determining the appraised value of any Mortgaged Property lie outside the boundaries and building restriction lines of any Mortgaged Property to any material extent, and (ii) no improvements on adjoining properties encroach upon any Mortgaged Property and no easements or other encumbrances upon any Mortgaged Property encroach upon any of the Improvements so as to materially affect the value or marketability of any Mortgaged Property.

 

(h)           Reciprocal Easement Agreements.  Neither a Credit Party nor a Subsidiary thereof has given or received any written notice with respect to any alleged or current default under any of the terms and conditions of a REA as described in any title commitment for a Mortgage Policy.  To the knowledge of each Credit Party and each of its Subsidiaries, all easements granted pursuant to any REA that were to have survived the site preparation and completion of construction of any Improvements on the Mortgaged Properties (to the extent the

 

39

 

same has been completed), remain in full force and effect and have not been released, terminated, extinguished or discharged by agreement or otherwise.  All material sums due and owing by a Credit Party or any of its Subsidiaries to other parties to any REA (or, to the Credit Parties’ knowledge, by the other parties to each REA to a Credit Party) pursuant to the terms of such REA (including, without limitation, all sums, charges, fees, assessments, costs and expenses in connection with any taxes, site preparation and construction, non-shareholder contributions, and common area and other property management activities) have been paid, and no Lien has attached on any Mortgaged Property (or to the knowledge of the Credit Parties or their Subsidiaries, threat thereof has been made) for failure to pay any of the foregoing.

 

(i)            No Flood Hazard Property.  No Mortgaged Property is a Flood Hazard Property unless flood insurance reasonably acceptable to the Administrative Agent has been provided for such Mortgaged Property.

 

(j)            Information regarding Mortgaged Properties.  Set forth on Schedule 3.23(j) is information regarding each Mortgaged Property, including, without limitation, the street address, city, county and state where located.

 

(k)           Insurance.  The insurance coverage of the Credit Parties and their Subsidiaries as of the Closing Date (or, if applicable, any subsequent date on which such schedule is required, pursuant to the terms hereof, to be updated) is outlined as to carrier, policy number, expiration date, type and amount on Schedule 3.23(k) and such insurance coverage complies the requirements set forth in Section 5.6.

 

(l)            Notices Related to Mortgaged Properties.  No Credit Party has, on or after the date hereof, been notified in writing by any Governmental Authority or any other Person that such party has rescinded or not renewed, or is reasonably likely to rescind or not renew, any material permit, license, certification, authorization, approval, consent or agreement granted to it or to which it is a party.  No Credit Party has received written notice from any insurance company or bonding company of any defects or inadequacies in any Mortgaged Property, or any part thereof, which would materially and adversely affect the insurability of the same or cause the imposition of extraordinary premiums or charges thereon or of any termination or threatened termination of any policy of insurance or bond.

 

(m)          Modifications/Alterations to Mortgaged Properties subject to Lien of Credit Documents.  Each Credit Party affirms that (i) title with respect to any and all modifications and alterations to any Mortgaged Property shall automatically (and without the need for further action) vest with the Borrower and (ii) any and all such modifications and alterations to any Mortgaged Property shall automatically (and without the need for further action) be subject to the Lien of the Credit Documents in favor of the Administrative Agent.

 

ARTICLE IV

 

CONDITIONS PRECEDENT

 

Section 4.1            Conditions to Closing Date.

 

This Agreement shall become effective upon, and the obligation of each Lender to make the initial Extensions of Credit on the Closing Date is subject to, the satisfaction of the following conditions precedent:

 

40

 

(a)           Execution of this Agreement; Credit Documents and Lender Consents.  The Administrative Agent shall have received (i) counterparts of this Agreement, executed by a duly authorized officer of each party hereto, (ii) for the account of each Lender requesting a promissory note, a Note, (iii) counterparts of the Mortgage Instruments, conforming to the requirements of this Agreement and executed by duly authorized officers of the Borrower or other Person, as applicable, (iv) counterparts of each other Credit Document, executed by the duly authorized officers of the parties thereto and (v) executed consents, in substantially the form of Exhibit 4.1(a), from each Lender authorizing the Administrative Agent to enter this Agreement on their behalf.

 

(b)           Authority Documents.  The Administrative Agent shall have received the following:

 

(i)            Articles of Incorporation/Charter Documents.  Original certified articles of incorporation or other charter documents, as applicable, of each Credit Party certified (A) by an officer of such Credit Party (pursuant to an officer’s certificate in substantially the form of Exhibit 4.1(b) attached hereto) as of the Closing Date to be true and correct and in force and effect as of such date, and (B) to be true and complete as of a recent date by the appropriate Governmental Authority of the state of its incorporation or organization, as applicable.

 

(ii)           Resolutions.  Copies of resolutions of the board of directors or comparable managing body of each Credit Party approving and adopting the Credit Documents, the transactions contemplated therein and authorizing execution and delivery thereof, certified by an officer of such Credit Party (pursuant to an officer’s certificate in substantially the form of Exhibit 4.1(b) attached hereto) as of the Closing Date to be true and correct and in force and effect as of such date.

 

(iii)          Bylaws/Operating Agreement.  A copy of the bylaws or comparable operating agreement of each Credit Party certified by an officer of such Credit Party (pursuant to an officer’s certificate in substantially the form of Exhibit 4.1(b) attached hereto) as of the Closing Date to be true and correct and in force and effect as of such date.

 

(iv)          Good Standing.  Original certificates of good standing, existence or the equivalent with respect to each Credit Party certified as of a recent date by the appropriate Governmental Authorities of the state of incorporation or organization and each other state in which the failure to so qualify and be in good standing could reasonably be expected to have a Material Adverse Effect.

 

(v)           Incumbency.  An incumbency certificate of each Responsible Officer of each Credit Party certified by an officer (pursuant to an officer’s certificate in substantially the form of Exhibit 4.1(b) attached hereto) to be true and correct as of the Closing Date.

 

(c)           Legal Opinion of Counsel.  The Administrative Agent shall have received an opinion or opinions of counsel (including, without limitation, local counsel opinions (in each case reasonably acceptable to the Administrative Agent) and opinions from the in-house general counsel of the Credit Parties) for the Credit Parties, dated the Closing Date and addressed to the Administrative Agent and the Lenders, in form and substance reasonably acceptable to the

 

41

 

Administrative Agent (which shall include, without limitation, opinions with respect to the due organization and valid existence of each Credit Party, opinions as to perfection of the Liens granted to the Administrative Agent pursuant to the Security Documents and opinions as to the non-contravention of the Credit Parties’ organizational documents and material contracts, as disclosed in the Borrower’s SEC filings).

 

(d)           Collateral.  The Administrative Agent shall have received, in form and substance reasonably satisfactory to the Administrative Agent, and to the extent provided by third parties, from a provider reasonably acceptable to the Administrative Agent:

 

(i)            a fully executed and notarized Mortgage Instrument encumbering each Mortgaged Property as to property owned by the Borrower;

 

(ii)           with respect to each Mortgaged Property, a Mortgage Policy assuring the Administrative Agent that the Mortgage Instrument with respect to such Mortgaged Property creates a valid and enforceable first priority mortgage lien on such Mortgaged Property, free and clear of all defects and encumbrances except Permitted Liens, which Mortgage Policy shall be in form and substance reasonably satisfactory to the Administrative Agent and shall provide for affirmative insurance and such reinsurance as the Administrative Agent may reasonably request, all of the foregoing in form and substance reasonably satisfactory to the Administrative Agent;

 

(iii)          evidence as to (A) whether each Mortgaged Property is a Flood Hazard Property and (B) if any Mortgaged Property is a Flood Hazard Property, (x) whether the community in which such Mortgaged Property is located is participating in the National Flood Insurance Program, (y) the applicable Credit Party’s written acknowledgment of receipt of written notification from the Administrative Agent (I) as to the fact that any Mortgaged Property is a Flood Hazard Property and (II) as to whether the community in which each such Flood Hazard Property is located is participating in the National Flood Insurance Program and (z) copies of insurance policies or certificates of insurance of the Credit Parties evidencing flood insurance reasonably satisfactory to the Administrative Agent and naming the Administrative Agent as loss payee on behalf of the Lenders;

 

(iv)          a map or plat, as applicable, and the as-built survey of the site of each Mortgaged Property (a “Survey”), in each case certified to the Administrative Agent and the Title Insurance Company in a manner reasonably satisfactory to them, dated a date satisfactory to each of the Administrative Agent and the Title Insurance Company by an independent professional licensed land surveyor reasonably satisfactory to each of the Administrative Agent and the Title Insurance Company, which map or plat, as applicable, and the survey on which they are based shall be sufficient to delete any standard printed survey exception contained in the applicable title policy and be made in accordance with the Minimum Standard Detail Requirements for Land Title Surveys jointly established and adopted by the American Land Title Association and the American Congress on Surveying and Mapping in 2005, and, without limiting the generality of the foregoing, there shall be surveyed and shown on such map or plat, as applicable, and survey the following:  (A) the locations on such site of all the buildings, structures and other improvements and the established building setback lines; (B) the lines of streets abutting the site and width thereof; (C) all access and other easements appurtenant to the site necessary to use the site; (D) all roadways, paths, driveways, easements, encroachments and overhanging projections and similar encumbrances affecting the site, whether recorded, apparent from a physical inspection of the site or otherwise known to the

 

42

 

surveyor; (E) any encroachments on any adjoining property by the building structures and improvements on the site; and (F) if the site is described as being on a filed map, a legend relating the survey to said map;

 

(v)           a reasonably satisfactory third-party environmental review of each Mortgaged Property, including, without limitation, but not limited to a Phase I environmental assessment, together with a reliance letter in favor of the Lenders (the “Environmental Report”);

 

(vi)          an opinion of counsel to the Credit Parties for each jurisdiction in which any Mortgaged Property is located;

 

(vii)         a zoning report for each Mortgaged Property (the “Zoning Report”);

 

(viii)        an MAI appraisal (in accordance with FIRREA standards) of each Mortgaged Property (the “Appraisal”);

 

(ix)           (A) searches of UCC filings in the jurisdiction of incorporation or formation, as applicable, of each Credit Party and each jurisdiction where any Collateral is located or where a filing would need to be made in order to perfect the Administrative Agent’s security interest in the Collateral, copies of the financing statements on file in such jurisdictions and evidence that no Liens exist other than Permitted Liens and (B) tax lien and judgment searches;

 

(x)            completed UCC financing statements for each appropriate jurisdiction as is necessary, in the Administrative Agent’s sole discretion, to perfect the Administrative Agent’s security interest in the Collateral;

 

(xi)           duly executed consents as are necessary, in the Administrative Agent’s sole discretion, to perfect the Lenders’ security interest in the Collateral;

 

(xii)          to the extent required to be delivered pursuant to the terms of the Security Documents, all instruments, documents and chattel paper in the possession of any of the Credit Parties, together with allonges or assignments as may be necessary or appropriate to perfect the Administrative Agent’s and the Lenders’ security interest in the Collateral; and

 

(xiii)         property condition and engineering report regarding any Mortgaged Property (the “Property Condition Report”).

 

(e)           Liability, Casualty, Property, Business Interruption and other Insurance.  The Administrative Agent shall have received copies of insurance policies or certificates and endorsements of insurance evidencing insurance meeting the requirements set forth herein.  The (i) Administrative Agent shall be named as mortgagee and lenders’ loss payee, as its interest may appear, with respect to any such insurance providing coverage in respect of any Mortgaged Property and (ii) each of the Administrative Agent, the Lenders and the Borrower, shall be named as an additional insured, as its interest may appear, with respect to any such insurance providing liability coverage, and the Credit Parties will use their commercially reasonable efforts to have each provider of any such insurance agree, by endorsement upon the policy or policies issued by it or by independent instruments to be furnished to the Administrative Agent, that it will give the

 

43

 

Administrative Agent thirty (30) days prior written notice before any such policy or policies shall be materially altered or cancelled.

 

(f)            Account Designation Notice.  The Administrative Agent shall have received the executed Account Designation Notice in the form of Exhibit 1.1(a) hereto.

 

(g)           Consents.  The Administrative Agent shall have received evidence that all boards of directors, governmental, shareholder and material third party consents and approvals necessary in connection with the Transactions have been obtained and all applicable waiting periods have expired without any action being taken by any authority that could restrain, prevent or impose any material adverse conditions on such Transactions or that could seek or threaten any of the foregoing.

 

(h)           Compliance with Laws.  The financings and other Transactions contemplated hereby shall be in compliance with all applicable laws and regulations (including, without limitation, all applicable securities and banking laws, rules and regulations).

 

(i)            Bankruptcy.  There shall be no bankruptcy or insolvency proceedings pending with respect to any Credit Party or any Subsidiary thereof.

 

(j)            Financial Statements.  The Administrative Agent and the Lenders shall have received copies of the financial statements referred to in Section 3.1, each in form and substance reasonably satisfactory to the Administrative Agent.

 

(k)           No Material Adverse Effect.  Since December 31, 2009, there shall have been no occurrence or other matter resulting in a Material Adverse Effect.

 

(l)            Financial Condition Certificate.  The Administrative Agent shall have received a certificate or certificates executed by a Responsible Officer of the Borrower as of the Closing Date, substantially in the form of Exhibit 4.1(l) stating that (i) there does not exist any pending or ongoing, action, suit, investigation, litigation or proceeding in any court or before any other Governmental Authority (A) affecting this Agreement or the other Credit Documents, that has not been settled, dismissed, vacated, discharged or terminated prior to the Closing Date or (B) that purports to affect any Credit Party or any of its Subsidiaries, or any transaction contemplated by the Credit Documents, which action, suit, investigation, litigation or proceeding could reasonably be expected to have a Material Adverse Effect, that has not been settled, dismissed, vacated, discharged or terminated prior to the Closing Date, (ii) immediately after giving effect to this Agreement, the other Credit Documents, and all the Transactions contemplated to occur on such date, (A) no Default or Event of Default exists, (B) all representations and warranties contained herein and in the other Credit Documents are true and correct, and (C) the Credit Parties are in compliance on a Pro Forma Basis with each of the initial financial covenants set forth in Section 5.11 (as evidenced through detailed calculations of such financial covenants on a schedule to such certificate) as of the last day of the fiscal quarter ending at least twenty (20) days  preceding the Closing Date and (D) the Transactions do not contravene, or otherwise conflict with, the terms of any of the Credit Parties’ then current Material Contracts and (iii) each of the other conditions precedent in Section 4.1 have been satisfied.

 

(m)          Structure.  The pro forma capital, ownership and management structure and shareholding arrangement of the Credit Parties and their Subsidiaries (and all agreements relating thereto) shall be reasonably satisfactory to the Administrative Agent.

 

44

 

(n)           Fees and Expenses.  The Administrative Agent and the Lenders shall have received all fees and expenses, if any, owing as of the Closing Date pursuant to the Engagement Letter and Section 2.2.

 

(o)           Pay-Off of Existing Indebtedness for Mortgaged Properties.  The Administrative Agent shall have received evidence of (i) the pay-off of all existing Indebtedness, if any, with regard to each Mortgaged Property, (ii) the release and termination of all Liens securing such Indebtedness and (iii) the transfer to the Borrower of all right, title and interest of any third party holding any interest in any Mortgaged Property in connection with such Indebtedness or otherwise.

 

(p)           Representations and Warranties.  The representations and warranties made by the Borrower herein, in the Credit Documents and which are contained in any certificate furnished at any time under or in connection herewith on or prior to the Closing Date shall (i) with respect to representations and warranties that do not contain a materiality qualification, be true and correct and (ii) with respect to representations and warranties that do contain a materiality qualification, be true and correct in all material respects, in each case on and as of the Closing Date.

 

(q)           Additional Matters.  All other documents and legal matters in connection with the Transactions contemplated by this Agreement shall be reasonably satisfactory in form and substance to the Administrative Agent and its counsel.

 

Without limiting the generality of the provisions of Section 8.4, for purposes of determining compliance with the conditions specified in this Section 4.1, each Lender that has signed this Agreement or a Lender Consent shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto.  All third party due diligence reports shall be commissioned by the Administrative Agent and addressed to the Administrative Agent on behalf of the Lenders and their respective successors and assigns.

 

Section 4.2            Conditions to Extensions of Credit.

 

The obligation of each Lender to make any Extension of Credit hereunder is subject to the satisfaction of the following conditions precedent on the date of making such Extension of Credit:

 

(a)           No Default or Event of Default.  No Default or Event of Default shall have occurred and be continuing on such date or after giving effect to the Extension of Credit to be made on such date unless such Default or Event of Default shall have been waived in accordance with this Agreement.

 

Each Extension of Credit and each acceptance by the Borrower of any such Extension of Credit shall be deemed to constitute representations and warranties by the Credit Parties as of the date of such Extension of Credit that the conditions set forth above in this Section 4.2 have been satisfied.

 

45

 

ARTICLE V

 

AFFIRMATIVE COVENANTS

 

The Borrower, on behalf of each of the Credit Parties, hereby covenants and agrees on the Closing Date and thereafter (a) for so long as this Agreement is in effect and (b) until no Note remains outstanding and unpaid and the Credit Party Obligations and all other amounts owing to the Administrative Agent or any Lender hereunder are paid in full, that (for the duration of time described in the foregoing subsections (a) and (b)) each Credit Party shall, and shall cause each of its Subsidiaries to:

 

Section 5.1            Financial Statements.

 

Furnish to the Administrative Agent and each of the Lenders:

 

(a)           as soon as available, but in any event within ninety (90) days after the end of each fiscal year of the Borrower, a copy of the Consolidated balance sheet of the Borrower and its Consolidated Subsidiaries as at the end of such year and the related Consolidated statements of income and retained earnings and of cash flows for such year, setting forth in each case in comparative form the figures for the previous year, reported on without qualification, by independent certified public accountants of nationally recognized standing; and

 

(b)           as soon as available, but in any event not later than forty-five (45) days after the end of each of the first three (3) quarterly periods of each fiscal year of the Borrower (commencing with the fiscal quarter ending September 30, 2010), the unaudited Consolidated balance sheet of the Borrower and its Consolidated Subsidiaries as at the end of such quarter and the related unaudited Consolidated statements of income and retained earnings and of cash flows of the Borrower and its Consolidated Subsidiaries for such quarter and the portion of the fiscal year through the end of such quarter, setting forth in each case in comparative form the figures for the previous year.

 

All such financial statements shall be complete and correct in all material respects and shall be prepared in reasonable detail and in accordance with GAAP applied consistently throughout the periods reflected therein (except as may be approved by such Responsible Officer or accountants, as the case may be, and disclosed therein).  The Borrower’s obligation to furnish such statements is subject to the final paragraph of Section 5.2.

 

Section 5.2            Certificates; Other Information.

 

Furnish to the Administrative Agent and each of the Lenders:

 

(a)           within fifteen (15) days after the delivery of the financial statements referred to in Section 5.1(a), a certificate of the independent certified public accountants reporting on such financial statements stating that in making the examination necessary therefor no knowledge was obtained of any Default or Event of Default under Section 5.11, except as specified in such certificate;

 

(b)           concurrently with the delivery of the financial statements referred to in Section 5.1(a) and within fifteen (15) days after the delivery of the financial statements referred to in Section 5.1(b), a certificate of a Responsible Officer substantially in the form of Exhibit 5.2(b) (i) stating that such Responsible Officer has obtained no knowledge of any Default or Event of Default except as specified in such certificate, (ii) including, without limitation, calculations in

 

46

 

reasonable detail with respect to compliance with Section 5.11, (iii) demonstrating compliance with the Guarantee Requirement and (iv) certifying that the financial statements delivered for such period are fairly stated in all material respects (subject to normal year-end audit adjustments);

 

(c)           concurrently with the delivery of the financial statements referred to in Section 5.1(a), a copy of any business plan for the Borrower, individually, or for the Borrower and its Subsidiaries on a Consolidated basis, that has been prepared and presented to the Board of Directors of the Borrower and that has been approved by the Board of Directors of the Borrower with respect to the fiscal year commencing immediately after the fiscal year covered by such financial statements, such plan to be accompanied by a certificate of a Responsible Officer to the effect that such plan has been prepared in good faith based on reasonable assumptions regarding the operations of the Borrower and its Subsidiaries and that such Responsible Officer has no reason to believe it is incorrect or misleading in any material respect;

 

(d)           [intentionally deleted];

 

(e)           no later than five (5) Business Days prior to the effective date thereof, a copy of any amendment, supplement, waiver or other modification to any Organizational Agreement;

 

(f)            promptly after the same become publicly available, copies of all periodic reports, proxy statements and other materials filed by the Borrower or any of its Subsidiaries with the SEC (or any successor thereto) or any national securities exchange, or distributed by the Borrower or any of its Subsidiaries to its security holders generally, as the case may be;

 

(g)           promptly following receipt thereof, copies of any documents described in Sections 101(k) or 101(l) of ERISA that any Credit Party or any Commonly Controlled Entity may request with respect to any Multiemployer Plan; provided, that if the Credit Parties or any Commonly Controlled Entity have not requested such documents or notices from the administrator or sponsor of the applicable Multiemployer Plan, then, upon reasonable request of the Administrative Agent, the Credit Parties and/or their Commonly Controlled Entities shall promptly make a request for such documents or notices and from such administrator or sponsor and the Parent shall provide copies of such documents to the Administrative Agent (on behalf of each Lender) promptly after receipt thereof; and

 

(h)           promptly, such additional financial and other information as any Lender may from time to time reasonably request.

 

Notwithstanding the foregoing provisions of Sections 5.1(a), 5.1(b), 5.2(e) and 5.2(f) as of the date items are to be furnished to the Administrative Agent and the Lenders under such Sections 5.1(a), 5.1(b), 5.2(e) and 5.2(f), to the extent the Borrower files the various financial statements, reports, statements and any other materials referred to in Sections 5.1(a), 5.1(b), 5.2(e) and 5.2(f), as applicable, with the SEC and such financial statements, reports, statements and other materials are publicly available on the SEC website, then the Borrower shall be deemed to have furnished such financial statements, reports, statements and other such information pursuant to Sections 5.1(a), 5.1(b), 5.2(e) and 5.2(f), as applicable, as of the date such applicable items become publicly available on the SEC website.

 

Section 5.3            Payment of Obligations.

 

Pay, discharge or otherwise satisfy, at or before maturity or before they become delinquent, as the case may, be all its obligations of whatever nature, except where (a) the amount or validity thereof is

 

47

 

currently being contested in good faith by appropriate proceedings and reserves in conformity with GAAP with respect thereto have been provided on the books of the Borrower or its Subsidiaries, as the case may be, or (b) the failure to do so could not reasonably be expected to have a Material Adverse Effect.

 

Section 5.4            Conduct of Business and Maintenance of Existence.

 

Continue to engage in its now current business which is comprised of the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases and to preserve, renew and keep in full force and effect its existence and to take all reasonable action to maintain all rights, privileges and franchises necessary or desirable in the normal conduct of such business.

 

Section 5.5            Compliance with Contractual Obligations and Laws.

 

Comply with all Contractual Obligations and Requirements of Law except to the extent that failure to comply therewith, in the aggregate, could not reasonably be expected to have a Material Adverse Effect.

 

Section 5.6            Insurance.

 

(a)           Maintain with financially sound and reputable insurance companies insurance in such form and upon such terms and in such amounts and against such risks as are usually insured against in the same general area by companies engaged in the same or a similar business, provided, regarding any Mortgaged Property if and to the extent of any conflict between the provisions of this Section 5.6(a) and Sections 5.6(b)-(d), the provisions of Sections 5.6(b)-(d) shall govern and control.

 

(b)           Obtain and maintain, or cause to be maintained, at all times insurance for the Credit Parties and each Mortgaged Property providing at least the following coverages:

 

(i)            comprehensive “all risk” insurance on the Improvements and the Fixtures, in each case (A) in an amount equal to one hundred percent (100%) of the “Full Replacement Cost,” which for purposes of this Agreement shall mean actual replacement value (exclusive of costs of excavations, foundations, underground utilities and footings) with a waiver of depreciation; (B) containing an agreed amount endorsement with respect to the Improvements and Fixtures waiving all co-insurance provisions; (C) providing for no deductible or self-insured retention in excess of $500,000 for all such insurance coverage; and (D) if any of the Improvements or the use of any Mortgaged Property shall at any time constitute “legal nonconforming” structures or uses, providing coverage for contingent liability from operation of building laws, demolition costs and increased cost of construction endorsements and containing an “Ordinance or Law Coverage” or “Enforcement” endorsement. In addition, Credit Parties shall obtain: (x) windstorm and mold insurance in amounts and in form and substance acceptable to the Administration Agent; (y) if any portion of the Improvements is at any time located in an area identified by the Federal Emergency Management Agency or any successor thereto as an area having special flood hazards pursuant to the National Flood Insurance Act of 1968, the Flood Disaster Protection Act of 1973, or the National Flood Insurance Reform Act of 1994, as each may be amended, or any successor law (the “Flood Insurance Acts”), flood hazard insurance of the following types and in the following amounts: (A) coverage under insurance policies issued pursuant to the Flood Insurance Acts (the “Flood Insurance Policies”) in an amount equal to the lesser of (1) the principal balance of the Loans and (2) the maximum limit of coverage available for the applicable Mortgaged

 

48

 

Properties under the Flood Insurance Acts, subject only to customary deductibles under such insurance policies; and (B) coverage under supplemental private insurance policies in an amount, which when added to the coverage provided under the Flood Insurance Policies, is not less than the principal balance of the Loans; and (z) earthquake insurance in amounts and in form and substance reasonably satisfactory to the Administrative Agent in the event any Mortgaged Property is located in an area with a high degree of seismic risk;

 

(ii)           commercial general liability insurance against claims for personal injury, bodily injury, death or property damage occurring upon, in or about each Mortgaged Property, with such insurance (A) to be in an amount reasonably acceptable to the Administrative Agent; and (B) to cover at least the following hazards: (1) premises and operations; (2) products and completed operations; (3) independent contractors and (4) blanket contractual liability;

 

(iii)          at all times during which structural construction, repairs or alterations are being made with respect to the Improvements, and only if any Mortgaged Property coverage form does not otherwise apply, (A) owner’s contingent or protective liability insurance covering claims not covered by or under the terms or provisions of the above mentioned commercial general liability insurance policy; and (B) the insurance provided for in subsection (i) above written in a so-called builder’s risk completed value form (1) on a non-reporting basis, (2) against “all risks” insured against pursuant to subsection (i) above, (3) including, without limitation, permission to occupy each Mortgaged Property, and (4) with an agreed amount endorsement waiving co-insurance provisions;

 

(iv)          workers’ compensation, subject to applicable statutory limits, and employer’s liability insurance in respect of any work or operations on or about any Mortgaged Property, or in connection with any Mortgaged Property or its operation (if applicable); and

 

(v)           pollution and remediation legal liability insurance covering legal expenses, remediation costs and loss of value for each Mortgaged Property relating to environmental issues on, under or emanating from any Mortgaged Property in such reasonable amounts as requested by the Administrative Agent; provided that (A) such insurance shall be (1) not less than $10,000,000 per Mortgaged Property per occurrence and (2) not less than $10,000,000 in the aggregate and (B) no deductible shall be in excess of $200,000.

 

(c)           Cause all insurance policies provided for under Section 5.6(b) to contain clauses or endorsements to the effect that:

 

(i)            no act or negligence of any Credit Party, or anyone acting for any Credit Party, or any other tenant or other occupant, or failure to comply with the provisions of any insurance policy, which might otherwise result in a forfeiture of the insurance or any part thereof, shall in any way affect the validity or enforceability of the insurance insofar as the Administrative Agent is concerned;

 

(ii)           the insurance policies shall not be materially changed (other than to increase the coverage provided thereby) or canceled without at least thirty (30) days’ prior written notice to the Administrative Agent and any other party named therein as an additional insured;

 

49

 

(iii)          the issuers thereof shall give written notice to the Administrative Agent if the insurance policies have not been renewed thirty (30) days prior to its expiration; and

 

(iv)          the Administrative Agent shall not be liable for any insurance premiums thereon or subject to any assessments thereunder.

 

(d)           Maintain with financially sound and reputable insurance companies having a claims paying ability rating of “A-” or better by A.M. Best Company (or such other rating agency acceptable to the Administrative Agent) liability, casualty, property and business interruption insurance (including, without limitation, insurance with respect to the Mortgaged Properties) in at least such amounts and against at least such risks as are usually insured against in the same general area by companies engaged in the same or a similar business; and furnish to the Administrative Agent, upon the request of the Administrative Agent, full information as to the insurance carried. The Administrative Agent shall be named as lender loss payable and mortgagee, as its interest may appear, and the Administrative Agent, the Lenders and the Borrower shall each be named as an additional insured with respect to any such casualty, property and liability insurance, as applicable.  If at any time the Administrative Agent is not in receipt of written evidence that all insurance required hereunder is in full force and effect, the Administrative Agent shall have the right, without notice to the Credit Parties, to take such action as the Administrative Agent deems necessary to protect its interest in each Mortgaged Property, including, without limitation, obtaining such insurance coverage as the Administrative Agent in its sole discretion deems appropriate.  All premiums incurred by the Administrative Agent in connection with such action or in obtaining such insurance and keeping it in effect shall be paid by the Credit Parties to the Administrative Agent upon demand and, until paid, shall be secured by the Mortgage Instruments and shall bear interest at the applicable Default Rate.

 

Section 5.7            Inspection of Property; Books and Records; Discussions.

 

(a) Keep proper books of records and account in which complete and correct entries in conformity with GAAP and all material Requirements of Law shall be made of all dealings and transactions in relation to its business and activities and (b) permit appropriate representatives of the Administrative Agent or any Lender to (i) visit and inspect each Mortgaged Property, visit any property where its financial records are maintained and examine and make abstracts from any of its financial records as often as may be reasonably requested, in each case (prior to the occurrence of a Default, no more frequently than once per calendar year but from and after the occurrence of any Default or Event of Default and during the continuance thereof, without limitation as to the frequency of such visits and inspections) during normal business hours and upon reasonable prior notice specifying the purpose of such visit and inspection, and (ii) discuss the business, operations, properties and financial condition of the Borrower and its Subsidiaries with Responsible Officers of the Borrower and its Subsidiaries and with the Borrower’s independent certified public accountants (any such discussion with such accountants to be in the presence of a Responsible Officer of the Borrower unless an Event of Default has occurred and is continuing). In light of the nature of the businesses in which the Borrower and its Subsidiaries will engage, it is understood and agreed that, unless an Event of Default has occurred and is continuing, the Borrower may limit the access of representatives of the Administrative Agent and any Lender to any property of the Borrower and its Subsidiaries (other than any Mortgaged Property) if the Borrower determines in good faith, after consultation with the Administrative Agent, that such access to such property would significantly disrupt the normal conduct of the business conducted on such property.

 

50

 

Section 5.8            Notices.

 

Promptly give notice in writing to the Administrative Agent (which shall promptly transmit such notice to each Lender) of:

 

(a)           the occurrence of any Default or Event of Default;

 

(b)           any default or event of default under any Contractual Obligation of any Credit Party or any of its Subsidiaries, which if not cured or if adversely determined, as the case may be, could reasonably be expected to have a Material Adverse Effect;

 

(c)           the following events, as soon as possible and in any event within thirty (30) days after any Credit Party knows thereof, if, individually or in the aggregate, the liability of a Credit Party or any of its Subsidiaries that could reasonably be expected to result would be $10,000,000 or more:  (i) the occurrence or expected occurrence of any Reportable Event or non-exempt Prohibited Transaction with respect to any Single Employer Plan; the failure to make any required contribution to a Single Employer Plan; a determination that any Single Employer Plan is in “at-risk” status (within the meaning of Section 303 of ERISA or Section 430 of the Code); the creation of any Lien in favor of the PBGC or a Single Employer Plan; the termination of any Single Employer Plan; or any withdrawal from, of the Reorganization or Insolvency of, any Multiemployer Plan or any determination that a Multiemployer Plan is, or is expected to be, in endangered or critical status (within the meaning of Section 432 of the Code or Section 305 of ERISA), or (ii) the institution of proceedings or the taking of any other action by the PBGC, any Credit Party or any Commonly Controlled Entity or any Plan with respect to the termination of, any Single Employer Plan or the withdrawal from, Reorganization, Insolvency of, or endangered or critical status of, any Multiemployer Plan;

 

(d)           promptly, upon becoming aware of the occurrence of any litigation, or any investigation or proceeding known to any Credit Party (i) affecting any Credit Party or any of its Subsidiaries which (in the Borrower’s reasonable judgment), if adversely determined, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect or otherwise involve a monetary claim in excess of $10,000,000 (with respect to any such individual matter) or $25,000,000 (with respect to all such matters in the aggregate), (ii) affecting or with respect to this Agreement, any other Credit Document or any security interest or Lien created thereunder or (iii) involving any notice of violation of a Requirement of Law or any environmental claim or potential liability under Environmental Laws which, in each case, could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect or otherwise to have exposure to any Credit Party in excess of $10,000,000 (with respect to any such individual matter) or $25,000,000 (with respect to all such matters in the aggregate);

 

(e)           any attachment, judgment, lien, levy or order exceeding $2,000,000 that may be assessed against or threatened in writing against any Credit Party other than Permitted Liens or any such attachment, judgment, lien, levy or order exceeding $250,000 that may be assessed against any Mortgaged Property;

 

(f)            promptly, any written notice of any violation received by any Credit Party from any Governmental Authority (including, without limitation, any notice of violation of Environmental Laws) which could reasonably be expected to have a Material Adverse Effect or otherwise to have exposure to any Credit Party in excess of $10,000,000;

 

51

 

(g)           with respect to each Mortgaged Property, any (i) written notice that any Governmental Authority has revoked or is likely to revoke any material Environmental Permit held by, or has refused to issue or renew, or is likely to refuse to issue or renew, any material Environmental Permit sought by, the Borrower, any Credit Party or any of its Subsidiaries; (ii) listing or proposal for listing any Mortgaged Property on any list maintained by any Governmental Authority for possible environmental investigation or remediation, including, without limitation, the National Priorities List and the Comprehensive Environmental Response, Compensation and Liability Information System list maintained by the U.S. Environmental Protection Agency and any similar list maintained by any other federal, state, local, or other authority; or (iii) development, event or condition that, individually or in the aggregate with other developments, events or conditions, could reasonably be expected to have a Material Adverse Effect; and

 

(h)           promptly of the intended sale, transfer or other disposition of any Collateral.

 

Each notice pursuant to this Section 5.8 shall be accompanied by a statement of a Responsible Officer setting forth details of the occurrence referred to therein and stating what action, if any, the Borrower proposes to take with respect thereto.

 

Section 5.9            Addition of Material Subsidiaries as Guarantors / Guarantee Requirement.

 

The Borrower will cause the Guarantee Requirement to be satisfied at all times from and after the date sixty (60) days after the Closing Date.  Each Subsidiary, designated as a Material Subsidiary by the Borrower (as described in the definition of “Material Subsidiary”), shall for all purposes of this Agreement and the other Credit Documents immediately be a Material Subsidiary and a Guarantor from the time of such designation.

 

Concurrent with its delivery of the Guaranty Agreement, the initial Guarantor shall: (a) execute and deliver (i) the Initial Guarantor Joinder Agreement, in form and substance reasonably satisfactory to the Administrative Agent, pursuant to which the initial Guarantor shall become a Guarantor and shall join as a party to this Agreement and the Environmental Indemnity and (ii) an officer’s certificate in the form attached hereto as Exhibit 4.1(b), with the appropriate exhibits thereto, in form and substance reasonably satisfactory to the Administrative Agent, and (b) cause to be delivered to the Administrative Agent a legal opinion regarding the initial Guarantor, the Guaranty Agreement, the Initial Guarantor Joinder Agreement and the Environmental Indemnity, substantially in the form of the legal opinions delivered on behalf of the Borrower on the Closing Date, addressed to the Administrative Agent and the Lenders.  The Guaranty Agreement, the Initial Guarantor Joinder Agreement, the officer’s certificate and the legal opinion shall all be delivered on or prior to the date sixty (60) days after the Closing Date to the Administrative Agent.

 

Each Subsidiary (other than such which is already a party to the Guaranty Agreement as a direct party thereto or pursuant to a prior Joinder Agreement) designated as a Material Subsidiary shall execute a Joinder Agreement, in form and substance reasonably satisfactory to the Administrative Agent, evidencing that such Subsidiary has been joined as a Guarantor; provided, notwithstanding any failure or delay in the execution of such Joinder Agreement, each such Subsidiary shall be a Guarantor from the time of such designation as a Material Subsidiary.  Concurrent with its delivery of the above-referenced Joinder Agreement, each such Material Subsidiary shall also execute an officer’s certificate in the form attached hereto as Exhibit 4.1(b), with the appropriate exhibits thereto, in form and substance reasonably satisfactory to the Administrative Agent.  The Joinder Agreement and the officer’s certificate shall all be delivered promptly (and in any event within twenty (20) Business Days after the date of designation of such Subsidiary as a Material Subsidiary) to the Administrative Agent.

 

52

 

For purposes of this Agreement and the other Credit Documents, “Material Subsidiary” shall mean any Subsidiary (a) the revenues of which for the most recent period of four fiscal quarters of the Borrower were greater than 5% of the Borrower’s consolidated revenues for such period or (b) the assets of which as of the last day of the most recently completed period of four fiscal quarters of the Borrower were greater than 5% of Borrower’s consolidated assets as of such date; provided, that if at any time (i) the aggregate amount of the revenues of all Subsidiaries that are not Material Subsidiaries exceeds 10% of the Borrower’s consolidated revenues for the most recent period of four fiscal quarters of the Borrower or (ii) the aggregate amount of the assets of all Subsidiaries that are not Material Subsidiaries exceeds 10% of the Borrower’s consolidated assets as of the last day of the most recently completed period of four fiscal quarters of the Borrower, then the Borrower shall designate sufficient Subsidiaries as “Material Subsidiaries” to eliminate such excess.  For purposes of making the determinations required by this definition, revenues and assets of Foreign Subsidiaries shall be converted into Dollars at the rates used in preparing the consolidated balance sheet of the Borrower included in the applicable financial statements of the Borrower.  The Borrower agrees that it will promptly notify Administrative Agent in writing if and when any other existing or future Subsidiaries of the Borrower should be added as Guarantors in order to meet the Guarantee Requirement and which Subsidiaries have been so added as Material Subsidiaries.

 

Notwithstanding the foregoing, and provided no Default or Event of Default shall have occurred and be continuing, if the Borrower provides the Administrative Agent with an officer’s certificate from a Responsible Officer within twenty (20) Business Days after the last day of any fiscal quarter certifying that the Guarantee Requirement and the requirements set forth for a “Material Subsidiary” in the preceding paragraph shall continue to be satisfied at all times notwithstanding the release of a Subsidiary from its status as a “Guarantor”, then the Administrative Agent shall promptly provide a letter in favor of such Subsidiary and the Borrower releasing such Subsidiary from its status as a “Guarantor”.

 

Section 5.10         Environmental Matters.

 

(a)           Comply in all material respects with, and use commercially reasonable efforts to ensure compliance in all material respects by all tenants and subtenants, if any, with, all applicable Environmental Laws and obtain and comply in all material respects with and maintain, and use commercially reasonable efforts to ensure that all tenants and subtenants obtain and comply in all material respects with and maintain, any and all licenses, approvals, notifications, registrations or permits required by applicable Environmental Laws;

 

(b)           Conduct and complete all investigations, studies, sampling and testing, and all remedial, removal and other actions required under Environmental Laws and promptly comply in all material respects with all lawful orders and directives of all Governmental Authorities regarding Environmental Laws except to the extent that the same are being contested in good faith by appropriate proceedings;

 

(c)           Upon the reasonable written request of the Administrative Agent following the occurrence of any event or the discovery of any condition which the Administrative Agent or the Lenders reasonably believe has caused (or could be reasonably expected to cause) the representations and warranties set forth in Section 3.18 to be untrue in any material respect, furnish or cause to be furnished to the Administrative Agent, at the Borrower’s expense, a report of an environmental assessment of reasonable scope, form and depth, (including, without limitation, if deemed appropriate by Administrative Agent, acting reasonably, invasive soil or groundwater sampling) by a consultant reasonably acceptable to the Administrative Agent as to whether a release or threat of release of any Materials of Environmental Concern has or may have occurred on any of the Properties and as to the compliance by any of the Credit Parties or any of their Subsidiaries with Environmental Laws at such Property.  If the Credit Parties fail to deliver

 

53

 

such an environmental report within 120 days after receipt of such written request then the Administrative Agent may arrange for the same, and the Credit Parties hereby grant to the Administrative Agent and its representatives (who agree to be bound by the confidentiality provisions of this Agreement) access to the Properties to reasonably undertake such an assessment (including, without limitation, if deemed appropriate by the Administrative Agent, acting reasonably, invasive soil or groundwater sampling).  The reasonable cost of any assessment arranged for by the Administrative Agent pursuant to this provision will be payable by the Borrower promptly following demand and if not so paid added to the obligations secured by the Security Documents; and

 

(d)           Defend, indemnify and hold harmless the Administrative Agent and the Lenders, and their respective employees, agents, officers and directors and affiliates, from and against any and all claims, demands, penalties, fines, liabilities, settlements, damages, costs and expenses of whatever kind or nature, known or unknown, contingent or otherwise, arising out of, or in any way relating to the violation of, noncompliance with or liability under, any Environmental Law applicable to the operations of any Credit Party or any of its Subsidiaries or any of their respective properties, or any orders, requirements or demands of Governmental Authorities related thereto, including, without limitation, reasonable attorney’s and consultant’s fees, investigation and laboratory fees, response costs, court costs and litigation expenses, except to the extent that any of the foregoing are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence, willful misconduct or intentional bad acts of the party seeking indemnification therefor, or the material breach of the party seeking indemnification therefor of the obligations pursuant to this Agreement or any other Credit Document.  The agreements in this paragraph shall survive repayment of the Credit Party Obligations and all other amounts payable hereunder and termination of the Loan Commitment and the Credit Documents.

 

Section 5.11         Financial Covenants.

 

Comply with the following financial covenants:

 

(a)           Maximum Consolidated Leverage Ratio Covenant.  The maximum Consolidated Leverage Ratio, calculated as of the last day of each fiscal quarter on a rolling four quarter basis commencing with the quarter ending as of September 30, 2010, shall not exceed 2.50:1.00; and

 

(b)           Minimum Liquidity Covenant.  The sum of the Borrower’s Cash plus Cash Equivalents plus the Fair Market Value of Marketable Securities minus all Consolidated Funded Indebtedness scheduled to mature during the next occurring four (4) quarters (determined on a rolling four quarter basis commencing with the quarter ending as of September 30, 2010) minus STAP Liability in excess of $50,000,000, in each case calculated as of the last day of each fiscal quarter commencing with the quarter ending as of September 30, 2010, shall not be less than $150,000,000.

 

Section 5.12         Pledged Assets.

 

(a)           Priority.  From the Closing Date until the date on which all of the Credit Party Obligations have been fully and finally paid and performed, cause each Mortgaged Property and all other Collateral to be, at all times, subject to a valid, first priority perfected Lien, in favor of the Administrative Agent on behalf of the Lenders, granted by the Credit Parties subject only to Permitted Liens.

 

54

 

(b)           Perfection of Security Interest by Filing, Etc.  Execute and deliver to the Administrative Agent and/or record or file such agreements, assignments or instruments and do all such other things as the Administrative Agent may reasonably deem necessary or appropriate (i) to assure to the Administrative Agent its security interests hereunder and under the other Credit Documents are perfected, (ii) to consummate the transactions contemplated hereby and (iii) to otherwise protect and assure the Administrative Agent of its rights and interests hereunder.  Each Credit Party hereby authorizes the Administrative Agent to prepare and file such financing statements (including, without limitation, continuation statements) or amendments thereof or supplements thereto or other instruments as the Administrative Agent may from time to time deem reasonably necessary or appropriate in order to perfect and maintain the security interests granted hereunder in accordance with the UCC.  Each Credit Party agrees to mark its books and records to reflect the security interest of the Administrative Agent in the Collateral.

 

(c)           Other Liens.  Defend its interests in the Collateral against the claims and demands of all other parties claiming an interest therein and keep the Collateral free from all Liens, except for Permitted Liens.  Neither the Administrative Agent nor any Lender authorizes any Credit Party to, and no Credit Party shall, sell, exchange, transfer, assign, lease or otherwise dispose of the Collateral or any interest therein, except as permitted under this Agreement.

 

(d)           Preservation of Collateral.  Keep the Collateral in good order, condition and repair in all material respects, ordinary wear and tear excepted; not use the Collateral in violation of the provisions of this Agreement or any other agreement relating to the Collateral or any policy insuring the Collateral or any applicable Requirement of Law; and not permit any Collateral (that is personal property) to be or become a fixture to real property or an accession to other personal property unless the Administrative Agent has a valid, perfected and first priority security interest for the benefit of the Secured Parties in such real or personal property.

 

(e)           Recovery Proceeds.  Subject to the provisions of Section 5.19 hereof, cause all net cash insurance proceeds, condemnation or expropriation awards or other net proceeds of whatever type payable by reason of theft, loss, physical destruction or damage, taking or similar event with respect to any of their respective property or assets constituting Collateral to be delivered to the Administrative Agent to the extent required by the Credit Documents or, if not so required, then to one or more of the Credit Parties.

 

Section 5.13         Further Assurances, Etc.

 

(a)           Public/Private Designation.  Cooperate with the Administrative Agent in connection with the publication of certain materials and/or information provided by or on behalf of the Credit Parties to the Administrative Agent and Lenders (collectively, “Information Materials”) and will designate Information Materials (i) that are either available to the public or not material with respect to the Credit Parties and their  Subsidiaries or any of their respective securities for purposes of United States federal and state securities laws, as “Public Information” and (ii) that are not Public Information as “Private Information”.

 

(b)           Additional Information.  Provide such information regarding the operations, business affairs and financial condition of the Credit Parties and their Subsidiaries as the Administrative Agent or any Lender may reasonably request.

 

(c)           Further Assurances.  (i) Upon the reasonable request of the Administrative Agent, promptly perform or cause to be performed any and all acts and execute or cause to be executed any and all documents for filing under the provisions of the UCC or any other

 

55

 

Requirement of Law which are necessary or advisable to maintain in favor of the Administrative Agent, for the benefit of the Secured Parties, Liens on the Collateral that are duly perfected in accordance with the requirements of, or the obligations of the Credit Parties under, the Credit Documents and all applicable Requirements of Law and (ii) the Borrower will notify the Administrative Agent in the event that any Credit Party intends to change its name on the public record of the state of its organization or its “location” (as such term is used in Article 9 of any applicable Uniform Commercial Code) at least thirty (30) days before such change is made.  Upon the exercise by the Administrative Agent or any Lender of any power, right, privilege or remedy pursuant to this Agreement or the other Credit Documents which requires any consent, approval, recording, qualification or authorization of any Governmental Authority, the Borrower or any Credit Party will execute and deliver, or will cause the execution and delivery of, all applications, certifications, instruments and other documents and papers that the Administrative Agent or such Lender may be required to obtain from the Borrower or any of its Subsidiaries for such governmental consent, approval, recording, qualification or authorization.

 

Section 5.14         Maintenance of Mortgaged Property.

 

Cause each Mortgaged Property (including, without limitation, all buildings, improvements, parking facilities, sidewalks, storm drainage systems, roofs, plumbing systems, HVAC systems, fire protection systems, electrical systems, equipment, elevators, exterior sidings and doors, landscaping, irrigation systems and all structural components, on or prior to the date on which any Mortgaged Property is scheduled to open for business and at all times thereafter (and except for times during which any of the same are being renovated, constructed, modified, restored, installed or repaired in connection with any the Administrative Agent-approved construction or renovation)) to be used, operated and maintained (at the cost and expense of the Credit Parties) (a) in a manner consistent with the practices of the Credit Parties with respect to similar facilities owned or operated by any of the Credit Parties, (b) in accordance with all applicable Requirements of Law, (c) so as to remain in a good and safe condition and repair (excepting customary and ordinary wear and tear) and (d) otherwise in accordance with the terms of this Agreement.  Except with respect to the current construction on the Maryland Mortgaged Property, the anticipated modifications to the Improvements on the Maryland Mortgaged Property in connection with a walkway and the intended expansion of the Improvements on the North Carolina Mortgaged Property, all of which are described in detail pursuant to Schedule 5.14 and are hereby approved by the Administrative Agent, the Improvements and the Fixtures shall not be removed, demolished or materially altered (except for replacement of the Fixtures in the ordinary course of business) without the prior written consent of the Administrative Agent; provided that, the Credit Parties shall have the right to improve or alter each Mortgaged Property so long as the economic value, useful life, utility, condition, operational capacity and functional capacity of such Mortgaged Property is not decreased or diminished by such improvement or alteration.  If under applicable zoning provisions the use of all or any portion of any Mortgaged Property is or shall become a nonconforming use, the Credit Parties will not knowingly and intentionally cause or permit the nonconforming use to be discontinued or the nonconforming Improvement to be abandoned without the express written consent of the Administrative Agent.  The Credit Parties (at the cost and expense of the Credit Parties) will cause each Mortgaged Property to be maintained and managed in accordance with all applicable Requirements of Law and all applicable requirements of Governmental Authorities.  The Credit Parties will not commit or suffer any active, physical waste of any Mortgaged Property or take any action that invalidates or causes the cancellation of any insurance policy with respect to any Mortgaged Property, or do or permit to be done on any Mortgaged Property anything that may in any way materially impair the value of any Mortgaged Property or (except for Permitted Liens) the Lien on any Mortgaged Property.  There shall, at all times, exist no material structural, mold or other material defects or damages in any Mortgaged Property, that is not being remediated pursuant to the Administrative Agent-approved construction or renovation.

 

56

 

Section 5.15         Utilities and Public Access; Parking.

 

Cause each Mortgaged Property, on or prior to the date on which such Mortgaged Property is scheduled to open for business and at all times thereafter (except for times during which any such services may be reasonably limited in connection with any renovation work or construction work which has been approved by the Administrative Agent or in a manner otherwise reasonably acceptable to the Administrative Agent), to have (a) adequate rights of access to public ways and be served by water, sewer, sanitary sewer and storm drain facilities adequate to service such Mortgaged Property for full utilization of such Mortgaged Property for its intended use, (b) all public utilities necessary to the full use and enjoyment of such Mortgaged Property as currently used and enjoyed which are located either in the public right-of-way abutting such Mortgaged Property (which are connected so as to serve such Mortgaged Property without passing over other property) or in recorded easements serving such Mortgaged Property and such easements are set forth in and insured by the applicable Title Insurance Policy, (c) all roads necessary for the use of such Mortgaged Property for its intended use, which such roads shall have been completed and dedicated to public use and accepted by all Governmental Authorities and (d) parking to the extent required to comply with all Requirements of Law.

 

Section 5.16         Additional Survey Requirements.

 

With regard to construction work or any other material structural improvements or alterations related to any Mortgaged Property, to the extent requested by the Administrative Agent, promptly to commission, pay for and provide to the Administrative Agent foundation and as-built surveys (in each case, in form and substance acceptable to the Administrative Agent, in its reasonable discretion, and delivered to the Administrative Agent within one hundred and twenty (120) days of its request therefor) completed as of a date and by a surveyor reasonably acceptable to the Administrative Agent and with respect to which the Administrative Agent has received a reliance letter in form and substance acceptable to it.

 

Section 5.17         Regulatory Approvals.

 

Promptly, and at its expense, to execute and deliver, or cause to be executed and delivered, all applications, certificates, instruments, registration statements, and all other documents and papers the Administrative Agent may reasonably request and as may be required by law to acquire any consent, approval, registration, qualification or authorization of any Governmental Authority or any other Person deemed necessary or appropriate for the effective exercise of any of the rights under this Agreement.

 

Section 5.18         Ownership of Mortgaged Properties.

 

Cause each Mortgaged Property to be, at all times, owned in fee simple by the Borrower.

 

Section 5.19         Casualty and Condemnation.

 

(a)           If the Borrower has knowledge of a Casualty or a Condemnation of any Mortgaged Property or any interest therein, cause the Borrower, within fifteen (15) days of obtaining such knowledge, to give notice thereof to the Administrative Agent generally describing the nature and extent of such Casualty or Condemnation.

 

(b)           To the extent a Casualty or Condemnation occurs at such time that (i) a Default has occurred and is continuing, cause any Proceeds received by the Borrower to be paid to the Administrative Agent (or if otherwise paid to the Administrative Agent shall be retained by the Administrative Agent) as security for the Credit Party Obligations and shall not be available

 

57

 

under this Section 5.19 to the Borrower until the Default has been cured and all Credit Party Obligations are made fully current, (ii) an Event of Default has occurred and is continuing, cause any Proceeds to be paid to the Administrative Agent (or if otherwise paid to the Administrative Agent shall be retained by the Administrative Agent) as security for the Credit Party Obligations and shall be subject to application pursuant to the remedies available to the Administrative Agent and the Lenders under this Agreement and at law and (iii) no Default or Event of Default has occurred and is continuing, cause any Proceeds received by the Borrower (subject to Section 5.19(h)(i) pursuant to which a certain amount of Proceeds may be eligible for retention by the Borrower in certain circumstances) to be paid to the Administrative Agent (or if otherwise paid to the Administrative Agent shall be retained by the Administrative Agent) for allocation in accordance with this Section 5.19.

 

(c)           If no Default or Event of Default has occurred and is continuing and any Mortgaged Property suffers a Casualty (which the Borrower determines, in its sole discretion after consultation with the Administrative Agent and the Lenders, can not be repaired or restored in a commercially reasonable manner) cause the Borrower to prepay, without any Prepayment Fee, the Allocated Loan Amount for such Mortgaged Property and all other amounts then due and owing or (with respect to such Mortgaged Property) accrued pursuant to this Agreement and/or the other Credit Documents in its entirety.  Upon satisfaction of all obligations in connection with this subsection (c), then the Administrative Agent shall record a release of the Lien on the applicable Mortgaged Property and the related Proceeds shall be returned to the Borrower, and the Loan shall continue, as modified, with respect to the other Mortgaged Property and the balance of the Loan.

 

(d)           If no Default or Event of Default has occurred and is continuing and any Mortgaged Property suffers a Casualty (which the Borrower determines, in its sole discretion after consultation with the Administrative Agent and the Lenders, can be repaired or restored in a commercially reasonable manner), cause the Borrower at its option to either (i) prepay, with a Prepayment Fee, the Allocated Loan Amount for such Mortgaged Property and all other amounts then due and owing or (with respect to such Mortgaged Property) accrued pursuant to this Agreement and/or the other Credit Documents; or (ii) perform a Restoration in accordance with Section 5.19(h).  To the extent the Borrower elects the option described in subsection (d)(i) and the Administrative Agent confirms satisfaction of all obligations in connection with subsection (d)(i), then the Administrative Agent shall release the applicable Mortgaged Property and the related Proceeds shall be returned to the Borrower, and the Loan shall continue, as modified, with respect to the other Mortgaged Property and the balance of the Loan.  To the extent the Borrower elects the option described in subsection (d)(ii), then Section 5.19(h) shall govern the release of the related Proceeds to the Borrower.

 

(e)           If no Default or Event of Default has occurred and is continuing and any Mortgaged Property suffers a Condemnation pursuant to which (i) such Mortgaged Property is permanently expropriated; (ii) any points of ingress or egress of such Mortgaged Property to public roadways are materially and permanently impaired by expropriation so as to have a Material Adverse Effect; or (iii) a material part of such Mortgaged Property is expropriated so as to have a Material Adverse Effect, cause the Borrower to prepay, without any Prepayment Fee, the Allocated Loan Amount for such Mortgaged Property and all other amounts then due and owing or (with respect to such Mortgaged Property) accrued pursuant to this Agreement and/or the other Credit Documents in its entirety.  Upon satisfaction of all obligations in connection with this subsection (e), then the Administrative Agent shall record a release of its Lien on the Mortgaged Property and the related Proceeds shall be returned to the Borrower, and the Loan

 

58

 

shall continue, as modified, with respect to the other Mortgaged Property and the balance of the Loan.

 

(f)            If no Default or Event of Default has occurred and is continuing and any Mortgaged Property suffers a Condemnation which is not subject to any of the provisions of Section 5.19(e)(i)-(iii), cause the Borrower at its option to either (i) prepay, with a Prepayment Fee, the Allocated Loan Amount for such Mortgaged Property and all other amounts then due and owing or (with respect to such Mortgaged Property) accrued pursuant to this Agreement and/or the other Credit Documents; or (ii) perform a Restoration in accordance with Section 5.19(h).  To the extent the Borrower elects the option described in subsection (f)(i) and the Administrative Agent confirms satisfaction of all obligations in connection with subsection (f)(i), then the Administrative Agent shall release the applicable Mortgaged Property and the related Proceeds shall be returned to the Borrower, and the Loan shall continue, as modified, with respect to the other Mortgaged Property and the balance of the Loan.  To the extent the Borrower elects the option described in subsection (f)(ii), then Section 5.19(h) shall govern the release of the related Proceeds to the Borrower.

 

(g)           Cause the Borrower to appear in any proceeding or action to negotiate, prosecute, adjust or appeal any claim for any award, compensation or insurance payment on account of any such Casualty or Condemnation and shall pay all expenses thereof.  At the Borrower’s reasonable request, and at the Borrower’s sole cost and expense, the Administrative Agent shall participate in any such proceeding, action, negotiation, prosecution or adjustment.  The Administrative Agent and the Borrower agree that this Agreement shall control the rights of the Administrative Agent and the Borrower in and to any such award, compensation or insurance payment.

 

(h)           In the event of a Casualty under Section 5.19(d)(ii) or in the event of a Condemnation under Section 5.19(f)(ii), as applicable, cause the Borrower to, within 180 days of such Casualty or Condemnation, as applicable, or as soon thereafter as shall be reasonably practicable taking into consideration the possible need to obtain permits, commence such repair or replacement within such period, and thereafter diligently prosecute such repair or replacement of the affected Mortgaged Property (i) in the case of a Casualty, to the same or greater economic value, remaining useful life, utility, condition, operation and function as existed immediately prior to such Casualty and (ii) in the case of a Condemnation, as nearly as possible to its condition prior to such Condemnation (in each case, a “Restoration”).

 

(i)            Any Proceeds from time to time which in the aggregate are in excess of $1,000,000 shall be turned over to the Administrative Agent (or at the Administrative Agent’s election, to a trustee or escrow agent who shall be selected by the Administrative Agent and whose reasonable fees shall be paid by the Borrower); provided that the Borrower shall be entitled to keep any such Proceeds which in the aggregate are not in excess of $1,000,000 to the extent the Borrower delivers evidence reasonably satisfactory to the Administrative Agent that such amounts were previously applied to the Restoration of the affected Mortgaged Property; provided, further, the Borrower shall cause all such Proceeds which are not turned over to the Administrative Agent (or an equal amount of other funds of the Borrower) to be applied to the applicable Restoration.

 

(ii)           Any such Proceeds held by the Administrative Agent for Restoration of any Mortgaged Property shall be made available to the Borrower upon its request (but no more frequently than once a month) as the Restoration progresses.

 

59

 

(iii)          Prior to the disbursement of Proceeds for Restoration, the Borrower shall have delivered to the Administrative Agent the following:

 

(A)          evidence reasonably satisfactory to the Administrative Agent of the estimated cost of Restoration;

 

(B)           evidence reasonably satisfactory to the Administrative Agent of additional funds from the Borrower in excess of the Proceeds  sufficient to complete and fully pay for the entire unpaid cost of the Restoration, free and clear of all Liens or claims of Lien; and

 

(C)           such architect’s certificates, waivers of lien, contractor’s sworn statements, plats of survey and such other evidence of cost, payment and performance as the Administrative Agent may reasonably require and approve;

 

provided, no payment made prior to the final completion of Restoration shall exceed ninety percent (90%) of the value of the work performed from time to time, as such value shall be determined by the Administrative Agent in its reasonable judgment.

 

Any surplus which may remain out of the Proceeds held by the Administrative Agent after payment of all costs of the Restoration shall be paid to, and retained by the Borrower.

 

In no event shall a Casualty or Condemnation affect the Borrower’s obligation to pay the Credit Party Obligations in accordance with the terms of this Agreement.

 

Section 5.20         Payment of Obligations.  Pay and discharge as the same shall become due and payable, all its obligations and liabilities, including (a) all tax liabilities, assessments and governmental charges or levies upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the Credit Party or such Subsidiary; (b) all lawful claims which, if unpaid, would by law become a Lien upon its property; and (c) all Indebtedness, as and when due and payable, but subject to any subordination provisions contained in any instrument or agreement evidencing such Indebtedness.

 

ARTICLE VI

 

NEGATIVE COVENANTS

 

The Borrower, on behalf of each of the Credit Parties, hereby covenants and agrees on the Closing Date and thereafter (a) for so long as this Agreement is in effect and (b) until no Note remains outstanding and unpaid and the Credit Party Obligations and all other amounts owing to the Administrative Agent or any Lender hereunder are paid in full, that (for the duration of time described in the foregoing subsections (a) and (b)) no Credit Party shall, nor shall any Credit Party cause or permit any of its Subsidiaries to:

 

60

 

Section 6.1            Limitation on Liens.

 

Create, incur, assume or suffer to exist any Lien upon any Mortgaged Property, except for (each of the following, a “Permitted Lien”):

 

(a)           Liens for taxes not yet due or which are being contested in good faith by appropriate proceedings; provided that adequate reserves with respect thereto are maintained on the books of the Borrower or its Subsidiaries, as the case may be, in conformity with GAAP;

 

(b)           mechanics’, materialmen’s, repairmen’s or other like Liens arising in the ordinary course of business which are not overdue for a period of more than ninety (90) days with respect to the North Carolina Mortgaged Property or sixty (60) days with respect to the Maryland Mortgaged Property, or which are being contested in good faith by appropriate proceedings;

 

(c)           easements, rights-of-way, restrictions and other similar encumbrances incurred in the ordinary course of business which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of the Borrower or such Subsidiary;

 

(d)           Liens in existence on the date hereof listed on Schedule 6.1(d); and

 

(e)           Liens created pursuant to the Security Documents.

 

Section 6.2            Limitation on Fundamental Changes.

 

(a) Enter into any merger, consolidation or amalgamation; (b) liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution); (c) engage in any Asset Disposition of all or substantially all of the property, business or assets of the Credit Parties, taken as a whole; or (d) consummate any Asset Disposition outside of the ordinary course of business, except:

 

(i)            any Subsidiary may be merged or consolidated with or into (A) the Borrower (provided that the Borrower shall be the continuing or surviving entity), (B) any Guarantor (provided that the Guarantor shall be the continuing or surviving entity), or (C) any Subsidiary that is not a Guarantor; provided, notwithstanding the foregoing, no Guarantor may merge or consolidate with or into another Subsidiary that is not a Guarantor unless the Guarantor shall be the continuing and surviving entity;

 

(ii)           any Guarantor may consummate Asset Dispositions in favor of the Borrower or any other Guarantor; and

 

(iii)          any Credit Party may enter into or consummate Asset Dispositions involving solely the assets and/or Equity Interests of a Subsidiary that is neither a Guarantor nor a Material Subsidiary, and does not fall within the definition of Material Subsidiary on the dates of entry into and consummation of such Asset Disposition (as at and for the trailing four (4) consecutive fiscal quarters immediately preceding such dates); provided, that (A) such Asset Disposition could not reasonably be expected to result in a Material Adverse Effect and (B) the value of the assets, as reflected in the Consolidated financial statements for the Borrower and its Subsidiaries, subject to such Asset Disposition during any calendar year shall not exceed $25,000,000 (respecting any such Asset Disposition of Equity Interests, determined on a ratable basis equal to the percentage of Equity Interests subject to such Asset Disposition).

 

61

 

Section 6.3            Limitation on Transactions with Affiliates.

 

Enter into any transaction, including, without limitation, any purchase, sale, lease or exchange of property or the rendering of any service, with any of its Affiliates other than any such transaction (a) between a Guarantor and the Borrower or any other Guarantor which is otherwise permitted by this Agreement; or (b) entered into by the Borrower or any of its Subsidiaries which is (i) otherwise permitted under this Agreement and (ii) is in the ordinary course of business; or (c) entered into by the Borrower or any of its Subsidiaries with any of its Affiliates that are arms length transactions and that could not, in the aggregate, reasonably be expected to have a Material Adverse Effect.  Notwithstanding the foregoing provisions of this Section 6.3 to the contrary, the provisions of this Section 6.3 shall not apply to transactions listed on Schedule 6.3 or transactions expressly permitted by Section 6.2 above.

 

Section 6.4            Limitation on Modification of Organizational Agreements.

 

Amend, supplement, waive, terminate or otherwise modify, or consent or agree to any amendment, supplement, waiver, termination or other modification of or to, any of the terms of any Organizational Agreement in any manner that could reasonably be expected to have a Material Adverse Effect.

 

Section 6.5            Maintenance of On-Going Operations at any Mortgaged Property.

 

Vacate any Mortgaged Property or otherwise allow any Mortgaged Property to “go dark”.

 

Section 6.6            Modifications.

 

Except with respect to the modifications addressed in Schedule 5.14, which have been approved by the Administrative Agent, permit any modification or alteration to any Mortgaged Property to the extent (a) such would diminish in any material respect any Mortgaged Property’s fair market value, economic life or utility or (b) title to any such modification or alteration would be held by any Person other than the Borrower.

 

ARTICLE VII

 

EVENTS OF DEFAULT

 

Section 7.1            Events of Default.

 

An Event of Default shall exist upon the occurrence of any of the following specified events (each an “Event of Default”):

 

(a)           Payment.  (i) The Borrower shall fail to pay any principal on the Loan or Note when due (whether at maturity, by reason of acceleration or otherwise) in accordance with the terms hereof or thereof; or (ii) the Borrower shall fail to pay any interest on the Loan or any fee or other amount payable hereunder when due (whether at maturity, by reason of acceleration or otherwise) in accordance with the terms hereof and such failure shall continue unremedied for five (5) Business Days; or (iii) any Guarantor shall fail to pay on the Guaranty in respect of any of the foregoing or in respect of any other Guaranty Obligations hereunder (after giving effect to the grace period in clause (ii)); or (iv) the Borrower or any Guarantor shall fail to pay on the Environmental Indemnity in accordance with the terms thereof and such failure shall continue unremedied for five (5) Business Days; or

 

62

 

(b)           Misrepresentation.  Any representation or warranty made or deemed made herein, in the Security Documents or in any of the other Credit Documents or which is contained in any certificate, document or financial or other statement furnished at any time under or in connection with this Agreement shall prove to have been incorrect, false or misleading on or as of the date made or deemed made; or

 

(c)           Covenant Default.

 

(i)            Any Credit Party shall fail to perform, comply with or observe any term, covenant or agreement applicable to it contained in Sections 5.1, 5.4, 5.6 (but excluding the requirements thereunder regarding the required dates for delivery of insurance certificates, which requirements shall instead be subject to Sections 7.1(c)(ii)), 5.7, 5.9, 5.11, 5.12, 5.14 and 5.17 or Article VI hereof; or

 

(ii)           Any Credit Party shall fail to comply with any other covenant contained in this Agreement or the other Credit Documents or any other agreement, document or instrument among any Credit Party, the Administrative Agent and the Lenders or executed by any Credit Party in favor of the Administrative Agent or the Lenders (other than as described in Sections 7.1(a) or 7.1(c)(i) above) and, with respect to this clause (ii) only, such breach or failure to comply is not cured within thirty (30) days of its occurrence; provided, however, that if the nature of such breach or failure to comply is such that the same can not reasonably be cured within such thirty (30) day period, such breach or failure to comply shall not constitute an Event of Default until the passage of an additional thirty (30) day period (such cure period in the aggregate not to exceed sixty (60) days from the date of occurrence of such breach or failure to comply) so long as such Credit Party shall within the initial thirty (30) day period commence such cure and thereafter diligently prosecute the same to completion;

 

(d)           Indebtedness Cross-Default.  (i) Any Credit Party or any of its Subsidiaries shall default in any payment of principal of or interest on any Indebtedness (other than the Loan and the Guaranty) in a principal amount outstanding of at least $15,000,000 for any Credit Party or any of its Subsidiaries in the aggregate beyond any applicable grace period, if any, provided in the instrument or agreement under which such Indebtedness was created; or (ii) any Credit Party or any of its Subsidiaries shall default in the observance or performance of any other agreement or condition relating to any Indebtedness (other than the Loan and the Guaranty) in a principal amount outstanding of at least $15,000,000 in the aggregate for the Credit Parties or any of its Subsidiaries or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event shall occur or condition exist, the effect of which default or other event or condition is to cause, or to permit the holder or holders of such Indebtedness or beneficiary or beneficiaries of such Indebtedness (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, with the giving of notice if required, such Indebtedness to become due prior to its stated maturity or to be repurchased, prepaid, deferred or redeemed (automatically or otherwise); or (iii) any Credit Party or any of its Subsidiaries shall breach or default any Secured Hedging Agreement beyond any applicable grace period (if any); or

 

(e)           Other Cross-Defaults.  Except as otherwise provided in Section 7.1(d), the Credit Parties or any of its Subsidiaries shall default in (i) the payment when due under any Material Contract or (ii) the performance or observance, of any obligation or condition of any Material Contract and, in the case of clauses (i) and (ii), such failure to make a payment or to perform or observe such other obligation or condition continues unremedied for a period of thirty (30) days

 

63

 

after notice of the occurrence of such default unless, but only as long as, the existence of any such default is being contested by the Credit Parties in good faith by appropriate proceedings and adequate reserves in respect thereof have been established on the books of the Credit Parties to the extent required by GAAP; provided, however, that if such default is such that the same can not reasonably be cured within such thirty (30) day period, such default shall not constitute an Event of Default until the passage of an additional thirty (30) day period (such cure period in the aggregate not to exceed sixty (60) days from the date of occurrence of such failure to make a payment or to perform or observe such other obligation or condition) so long as such Credit Party or Subsidiary shall within the initial thirty (30) day period commence such cure and thereafter diligently prosecute the same to completion; or

 

(f)            Bankruptcy Default.  (i) A Credit Party or any of its Subsidiaries shall commence any case, proceeding or other action (A) under any existing or future law of any jurisdiction, domestic or foreign, relating to bankruptcy, insolvency, reorganization or relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it a bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its debts, or (B) seeking appointment of a receiver, trustee, custodian, conservator or other similar official for it or for all or any substantial part of its assets, or a Credit Party or any of its Subsidiaries shall make a general assignment for the benefit of its creditors; or (ii) there shall be commenced against a Credit Party or any of its Subsidiaries any case, proceeding or other action of a nature referred to in clause (i) above which (A) results in the entry of an order for relief or any such adjudication or appointment or (B) remains undismissed, undischarged or unbonded for a period of sixty (60) days; or (iii) there shall be commenced against a Credit Party or any of its Subsidiaries any case, proceeding or other action seeking issuance of a warrant of attachment, execution, distraint or similar process against all or any substantial part of their assets which results in the entry of an order for any such relief which shall not have been vacated, discharged, or stayed or bonded pending appeal within sixty (60) days from the entry thereof; or (iv) a Credit Party or any of its Subsidiaries shall take any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts set forth in clause (i), (ii), or (iii) above; or (v) a Credit Party or any of its Subsidiaries shall generally not, or shall be unable to, or shall admit in writing their inability to, pay its debts as they become due; or

 

(g)           Judgment Default.  (i) One or more judgments or decrees shall be entered against a Credit Party or any of its Subsidiaries involving in the aggregate a liability (to the extent not covered by insurance) of $15,000,000 or more and all such judgments or decrees shall not have been paid and satisfied, vacated, discharged, stayed or bonded pending appeal within ten (10) Business Days from the entry thereof or (ii) any injunction, temporary restraining order or similar decree shall be issued against a Credit Party or any of its Subsidiaries that, individually or in the aggregate, is reasonably likely to result in a Material Adverse Effect; or

 

(h)           ERISA Default.  The occurrence of any of the following if, individually or in the aggregate, the liability of a Credit Party or any of its Subsidiaries that could reasonably be expected to result would be $15,000,000 or more:

 

(i)            any Person shall engage in any non-exempt Prohibited Transaction,

 

(ii)           any failure to satisfy the minimum funding standard applicable to a Single Employer Plan for a plan year under Sections 412 and 430 of the Code or Sections 302 and 303 of ERISA , whether or not waived,

 

64

 

(iii)          a Reportable Event shall occur with respect to, or proceedings shall commence to have a trustee appointed, or a trustee shall be appointed, to administer or to terminate, any Single Employer Plan, which Reportable Event or commencement of proceedings or appointment of a trustee is, in the reasonable opinion of the Required Lenders, likely to result in the termination of such Plan for purposes of Title IV of ERISA,

 

(iv)          any Single Employer Plan shall terminate for purposes of Title IV of ERISA,

 

(v)           a Credit Party, any of its Subsidiaries or any Commonly Controlled Entity shall, or in the reasonable opinion of the Required Lenders is likely to, incur any liability in connection with a withdrawal from, or the Insolvency or Reorganization of, any Multiemployer Plan, or

 

(vi)          any other similar event or condition shall occur or exist with respect to a Plan; or

 

(i)            Invalidity of Guaranty.  At any time after the execution and delivery thereof, the Guaranty, for any reason other than the satisfaction in full of all Credit Party Obligations, shall cease to be in full force and effect (other than in accordance with its terms) or shall be declared to be null and void, or any Credit Party shall contest the validity, enforceability, perfection or priority of the Guaranty, any Credit Document, or any Lien granted thereunder in writing or deny in writing that it has any further liability, including, without limitation, with respect to future advances by the Lenders, under any Credit Document to which it is a party; or

 

(j)            Invalidity of Credit Documents.  Any Credit Document shall fail to be in full force and effect or to give the Administrative Agent and/or the Lenders the security interests, liens, rights, powers, priority and privileges purported to be created thereby (except as such documents may be terminated or no longer in force and effect in accordance with the terms thereof, other than those indemnities and provisions which by their terms expressly survive) or any Lien shall fail to be a first priority, perfected Lien on a material portion of the Collateral; or

 

(k)           Subordinated Debt.  Any default (which is not waived or cured within the applicable period of grace) or event of default shall occur under any Subordinated Debt or the subordination provisions contained therein shall cease to be in full force and effect or shall cease to give the Lenders the rights, powers and privileges purported to be created thereby; or

 

(l)            Uninsured Loss.  Any uninsured damage to or loss, theft or destruction of any assets of the Credit Parties or their Subsidiaries shall occur that is in excess of $15,000,000; or

 

(m)          Change of Control.  (i) As a result of one (1) or more transactions after the date of this Agreement, any “person” or “group” of persons shall have “beneficial ownership” (within the meaning of Section 13(d) or 14(d) of the Exchange Act and the applicable rules and regulations thereunder) of more than thirty-five percent (35%) of the outstanding common stock of Borrower; or (ii) without limiting the generality of the foregoing, during any period of twelve (12) consecutive months, commencing after the date of this Agreement, individuals who at the beginning of such period of twelve (12) months were directors of Borrower shall cease for any reason to constitute a majority of the board of directors of Borrower (excluding for such calculation, directors who retire (other than for reasons of a merger involving Borrower or for reasons involving any sale or transfer of assets) or who die) during any period of twelve (12)

 

65

 

consecutive months so long as such directors are replaced by the surviving directors during such period), provided, that the relationships among the respective shareholders of Borrower on the Closing Date shall not be deemed to constitute all or any combination of them as a “group” for purposes of clause (m)(i).

 

Section 7.2            Acceleration; Remedies.

 

Upon the occurrence and during the continuance of an Event of Default, then, and in any such event, (a) if such event is a Bankruptcy Event, automatically the Loan (with accrued interest thereon), and all other amounts under the Credit Documents shall immediately become due and payable, and (b) if such event is any other Event of Default, the following action may be taken: (i) the Administrative Agent may, or upon the written request of the Required Lenders, the Administrative Agent shall, declare the Loan (with accrued interest thereon) and all other amounts owing under this Agreement and the Credit Documents to be due and payable forthwith whereupon the same shall immediately become due and payable; and/or (ii) with the written consent of the Required Lenders, the Administrative Agent may, or upon the written request of the Required Lenders, the Administrative Agent shall, exercise such other rights and remedies as provided under the Credit Documents and under applicable law.

 

ARTICLE VIII

 

THE ADMINISTRATIVE AGENT

 

Section 8.1            Appointment and Authority.

 

Each of the Lenders hereby irrevocably appoints Wells Fargo to act on its behalf as the Administrative Agent hereunder and under the other Credit Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.  The provisions of this Article are solely for the benefit of the Administrative Agent and the Lenders, and neither the Borrower nor any other Credit Party shall have rights as a third party beneficiary of any of such provisions.

 

Section 8.2            Nature of Duties.

 

Anything herein to the contrary notwithstanding, none of the bookrunners, arrangers or other agents listed on the cover page hereof shall have any powers, duties or responsibilities under this Agreement or any of the other Credit Documents, except in its capacity, as applicable, as the Administrative Agent or a Lender.  Without limiting the foregoing, none of the Lenders or other Persons so identified shall have or be deemed to have any fiduciary relationship with any Lender.  Each Lender acknowledges that it has not relied, and will not rely, on any of the Lenders or other Persons so identified in deciding to enter into this Agreement or in taking or not taking action hereunder.

 

The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Credit Document by or through any one or more sub-agents appointed by the Administrative Agent.  The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties.  The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as the Administrative Agent.

 

66

 

Section 8.3            Exculpatory Provisions.

 

The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Credit Documents.  Without limiting the generality of the foregoing, the Administrative Agent:

 

(a)           shall not be subject to any fiduciary or other implied duties, regardless of whether a Default or an Event of Default has occurred and is continuing;

 

(b)           shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Credit Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Credit Documents), provided that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Credit Document or applicable law; and

 

(c)           shall not, except as expressly set forth herein and in the other Credit Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any Credit Party or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.

 

The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in Sections 7.2 and 9.1) or (ii) in the absence of its own gross negligence or willful misconduct.

 

The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Credit Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Credit Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Article IV or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.

 

Section 8.4            Reliance by the Administrative Agent.

 

The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including, without limitation, any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person.  The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon.  In determining compliance with any condition hereunder to the making of any portion of the Loan that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent shall have

 

67

 

received notice to the contrary from such Lender prior to the making of any portion of the Loan.  The Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.

 

Section 8.5            Notice of Default.

 

The Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event of Default hereunder unless the Administrative Agent has received written notice from a Lender or the Borrower referring to this Agreement, describing such Default or Event of Default and stating that such notice is a “notice of default”.  In the event that the Administrative Agent receives such a notice, the Administrative Agent shall give prompt notice thereof to the Lenders.  The Administrative Agent shall take such action with respect to such Default or Event of Default as shall be reasonably directed by the Required Lenders; provided, however, that unless and until the Administrative Agent shall have received such directions, the Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Default or Event of Default as it shall deem advisable in the best interests of the Lenders except to the extent that this Agreement expressly requires that such action be taken, or not taken, only with the consent or upon the authorization of the Required Lenders, or all of the Lenders, as the case may be.

 

Section 8.6            Non-Reliance on the Administrative Agent and Other Lenders.

 

Each Lender expressly acknowledges that neither the Administrative Agent nor any of its officers, directors, employees, agents, attorneys-in-fact or affiliates has made any representation or warranty to it and that no act by the Administrative Agent hereinafter taken, including, without limitation, any review of the affairs of any Credit Party, shall be deemed to constitute any representation or warranty by the Administrative Agent to any Lender.  Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement.  Each Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Credit Document or any related agreement or any document furnished hereunder or thereunder.

 

Section 8.7            Indemnification.

 

The Lenders agree to indemnify the Administrative Agent in its capacity hereunder and its Affiliates and their respective officers, directors, agents and employees (to the extent not reimbursed by the Credit Parties and without limiting the obligation of the Credit Parties to do so), ratably according to their respective ratable portion of the Loan in effect on the date on which indemnification is sought under this Section, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever which may at any time (including, without limitation, at any time following the payment of the Credit Party Obligations) be imposed on, incurred by or asserted against any such indemnitee in any way relating to or arising out of any Credit Document or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by any such indemnitee under or in connection with any of the foregoing; provided, however, that no Lender shall be liable for the payment of any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements to the extent resulting from such indemnitee’s gross negligence or willful misconduct, as determined by a court of competent jurisdiction by final and nonappealable

 

68

 

judgment.  The agreements in this Section shall survive the termination of this Agreement and payment of the Notes and all other amounts payable hereunder.

 

Section 8.8            The Administrative Agent in Its Individual Capacity.

 

The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity.  Such Person and its Affiliates may accept deposits from, lend money to, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with the Credit Parties or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.

 

Section 8.9            Successor Administrative Agent.

 

The Administrative Agent may at any time give notice of its resignation to the Lenders and the Borrower.  Upon receipt of any such notice of resignation, the Required Lenders shall have the right, in consultation with the Borrower, to appoint a successor, or an Affiliate of any such bank.  If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may on behalf of the Lenders, appoint a successor Administrative Agent meeting the qualifications set forth above provided that if the Administrative Agent shall notify the Borrower and the Lenders that no qualifying Person has accepted such appointment, then such resignation shall nonetheless become effective in accordance with such notice and (a) the retiring Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Credit Documents (except that in the case of any Collateral held by the Administrative Agent on behalf of the Lenders under any of the Credit Documents, the retiring Administrative Agent shall continue to hold such Collateral until such time as a successor Administrative Agent is appointed) and (b) all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender directly, until such time as the Required Lenders appoint a successor the Administrative Agent as provided for above in this paragraph.  Upon the acceptance of a successor’s appointment as the Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) the Administrative Agent, and the retiring Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Credit Documents (if not already discharged therefrom as provided above in this paragraph).  The fees payable by the Borrower to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor.  After the retiring Administrative Agent’s resignation hereunder and under the other Credit Documents, the provisions of this Article and Section 9.5 shall continue in effect for the benefit of such retiring Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting as the Administrative Agent.

 

Section 8.10         Collateral and Guaranty Matters.

 

(a)           The Lenders and the Hedging Agreement Providers irrevocably authorize and direct the Administrative Agent:

 

(i)            to release any Lien on any Collateral granted to or held by the Administrative Agent under any Credit Document (A) upon payment in full of all Credit

 

69

 

Party Obligations (other than contingent indemnification obligations for which no claim has been made or cannot be reasonably identified by an Indemnitee based on the then-known facts and circumstances), (B) that is transferred or to be transferred as part of or in connection with any sale or other disposition permitted under Section 6.2, or (C) subject to Section 9.1, if approved, authorized or ratified in writing by the Required Lenders;

 

(ii)           to subordinate any Lien on any Collateral granted to or held by the Administrative Agent under any Credit Document to the holder of any Lien on such Collateral that is a Permitted Lien; and

 

(iii)          to release any Guarantor from its obligations under the applicable Guaranty if such Person ceases to be a Guarantor as a result of a transaction permitted hereunder.

 

(b)           In connection with a termination or release pursuant to this Section, the Administrative Agent shall promptly execute and deliver to the applicable Credit Party, at the Borrower’s expense, all documents that the applicable Credit Party shall reasonably request to evidence such termination or release.  Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent’s authority to release or subordinate its interest in particular types or items of Collateral, or to release any Guarantor from its obligations under the Guaranty pursuant to this Section.

 

Section 8.11         Secured Hedging Agreements.

 

No Hedging Agreement Provider that obtains the benefits of Sections 2.11 and 7.2, any Guaranty or any Collateral by virtue of the provisions hereof or of any Guaranty or any Collateral Document shall have any right to notice of any action or to consent to, direct or object to any action hereunder or under any other Credit Document or otherwise in respect of the Collateral (including, without limitation, the release or impairment of any Collateral) other than in its capacity as a Lender and, in such case, only to the extent expressly provided in the Credit Documents.  The Administrative Agent shall not be required to verify the payment of, or that other satisfactory arrangements have been made with respect to, Credit Party Obligations arising under Secured Hedging Agreements unless the Administrative Agent has received written notice of such Credit Party Obligations, together with such supporting documentation as the Administrative Agent may request, from the applicable Hedging Agreement Provider.

 

ARTICLE IX

 

MISCELLANEOUS

 

Section 9.1            Amendments, Waivers, Consents and Release of Collateral.

 

Neither this Agreement nor any of the other Credit Documents, nor any terms hereof or thereof may be amended, modified, extended, restated, replaced, or supplemented (by amendment, waiver, consent or otherwise) except in accordance with the provisions of this Section nor may Collateral be released except as specifically provided herein or in the Security Documents or in accordance with the provisions of this Section.  The Required Lenders may or, with the consent of the Required Lenders, the Administrative Agent may, from time to time, (a) enter into with the Borrower written amendments, supplements or modifications hereto and to the other Credit Documents for the purpose of adding any provisions to this Agreement or the other Credit Documents or changing in any manner the rights of the Lenders or of the Borrower hereunder or thereunder or (b) waive or consent to the departure from, on

 

70

 

such terms and conditions as the Required Lenders may specify in such instrument, any of the requirements of this Agreement or the other Credit Documents or any Default or Event of Default and its consequences; provided, however, that no such amendment, supplement, modification, release, waiver or consent shall:

 

(a)           reduce the amount or extend the scheduled date of maturity of any portion of the Loan or Note or any installment thereon, or reduce the stated rate of any interest or fee payable hereunder (except in connection with a waiver of interest at the increased post-default rate set forth in Section 2.4 which shall be determined by a vote of the Required Lenders) or extend the scheduled date of any payment thereof or increase the amount or extend the expiration date of any Lender’s Loan Commitment, in each case without the written consent of each Lender directly affected thereby; provided that, it is understood and agreed that (i) no waiver, reduction or deferral of a mandatory prepayment required pursuant to Section 2.3(b), nor any amendment of Section 2.3(b) or the definition of Asset Disposition, shall constitute a reduction of the amount of, or an extension of the scheduled date of, the scheduled date of maturity of, or any installment of, any portion of the Loan or Note and (ii) any reduction in the stated rate of interest on the Loan shall only require the written consent of each Lender holding a portion of the outstanding Loan; or

 

(b)           amend, modify or waive any provision of this Section or reduce the percentage specified in the definition of Required Lenders, without the written consent of all the Lenders; or

 

(c)           release the Borrower or all or substantially all of the Guarantors from obligations under the Guaranty, without the written consent of all of the Lenders and Hedging Agreement Providers; or

 

(d)           release all or substantially all of the Collateral without the written consent of all of the Lenders and Hedging Agreement Providers; or

 

(e)           subordinate any portion of the Loan to any other Indebtedness without the written consent of all of the Lenders; or

 

(f)            subordinate the liens of the Administrative Agent in the Collateral to any other liens in the Collateral (other than Permitted Liens) without the written consent of all of the Lenders; or

 

(g)           permit the Borrower to assign or transfer any of its rights or obligations under this Agreement or other Credit Documents without the written consent of all of the Lenders; or

 

(h)           amend, modify or waive any provision of the Credit Documents requiring consent, approval or request of the Required Lenders or all Lenders without the written consent of the Required Lenders or all the Lenders as appropriate; or

 

(i)            amend, modify or waive (i) the order in which Credit Party Obligations are paid or (ii) the pro rata sharing of payments by and among the Lenders, in each case in accordance with Sections 2.7(a), 2.7(b) or 9.7(b) without the written consent of each Lender and each Hedging Agreement Provider directly affected thereby; or

 

(j)            amend, modify or waive any provision of Article VIII without the written consent of the then Administrative Agent; or

 

71

 

(k)           amend or modify the definition of Credit Party Obligations to delete or exclude any obligation or liability described therein without the written consent of each Lender and each Hedging Agreement Provider directly affected thereby; or

 

(l)            amend the definitions of “Hedging Agreement,” “Secured Hedging Agreement,” or “Hedging Agreement Provider” without the consent of any Hedging Agreement Provider that would be adversely affected thereby;

 

provided, further, that no amendment, waiver or consent affecting the rights or duties of the Administrative Agent under any Credit Document shall in any event be effective, unless in writing and signed by the Administrative Agent, in addition to the Lenders required hereinabove to take such action.

 

Any such waiver, any such amendment, supplement or modification and any such release shall apply equally to each of the Lenders and shall be binding upon the Borrower, the other Credit Parties, the Lenders, the Administrative Agent and all future holders of the Notes.  In the case of any waiver, the Borrower, the other Credit Parties, the Lenders and the Administrative Agent shall be restored to their former position and rights hereunder and under the outstanding Loan and the Notes and other Credit Documents, and any Default or Event of Default waived shall be deemed to be cured and not continuing; but no such waiver shall extend to any subsequent or other Default or Event of Default, or impair any right consequent thereon.

 

Notwithstanding any of the foregoing to the contrary, the consent of the Borrower and the other Credit Parties shall not be required for any amendment, modification or waiver of the provisions of Article VIII (other than the provisions of Section 8.9).

 

Notwithstanding the fact that the consent of all the Lenders is required in certain circumstances as set forth above, (a) each Lender is entitled to vote as such Lender sees fit on any bankruptcy reorganization plan that affects the Loan, and each Lender acknowledges that the provisions of Section 1126(c) of the Bankruptcy Code supersedes the unanimous consent provisions set forth herein, (b) the Required Lenders may consent to allow a Credit Party to use cash collateral in the context of a bankruptcy or insolvency proceeding and (c) no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder, except that the Loan Commitment of such Lender may not be increased or extended without the consent of such Lender.

 

Section 9.2            Notices.

 

(a)           Notices Generally.  Except in the case of notices and other communications expressly permitted to be given by telephone (and except as provided in paragraph (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by fax as follows:

 

(i)            If to the Borrower or any other Credit Party:

 

United Therapeutics Corporation

1040 Spring Street

Silver Spring, Maryland  20910

Attention:  John Ferrari

Telephone:  240-821-1729

Fax:  301-608-3049

Email:  jferrari@unither.com

 

72

 

with a copy to:

 

United Therapeutics Corporation

1735 Connecticut Avenue, N.W.

Washington, District of Columbia 20009

Attention:  Paul Mahon, General Counsel

Telephone:  202-483-7000

Fax:  202-483-4005

Email:  paul@unither.com

 

(ii)           If to the Administrative Agent:

 

Wells Fargo Bank, National Association, as the Administrative Agent

301 South College Street, 8th Floor

Charlotte, North Carolina 28288

Attention:  John D. Altmeyer

Telephone:  704-715-8122

Fax:  704-383-3556

Email:  jack.altmeyer@wachovia.com

 

with a copy to:

 

Moore & Van Allen, PLLC

100 North Tryon Street, 47th Floor

Charlotte, North Carolina 28202

Attention:  W. Miller Abernethy, Jr.

Telephone:  704-331-1069

Fax:  704-378-2069

Email:  millerabernethy@mvalaw.com

 

(iii)          if to a Lender, to it at its address (or fax number) set forth on the signature page for such Lender to this Agreement or otherwise as forth in its Administrative Questionnaire.

 

Notices sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices sent by fax shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next business day for the recipient).  Notices delivered through electronic communications to the extent provided in paragraph (b) below, shall be effective as provided in said paragraph (b).

 

(b)           Electronic Communications.  Notices and other communications to the Lenders hereunder may be delivered or furnished by electronic communication (including, without limitation, email and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, provided that the foregoing shall not apply to notices to any Lender pursuant to Article II if such Lender has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication.  The Administrative Agent or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, provided that approval of such procedures may be limited to particular notices or communications.

 

73

 

Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an email address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return email or other written acknowledgement), provided that if such notice or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient, and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its email address as described in the foregoing clause (i) of notification that such notice or communication is available and identifying the website address therefor.

 

(c)           Change of Address, Etc.  Any party hereto may change its address or fax number for notices and other communications hereunder by notice to the other parties hereto.

 

Section 9.3            No Waiver; Cumulative Remedies.

 

No failure to exercise and no delay in exercising, on the part of the Administrative Agent or any Lender, any right, remedy, power or privilege hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.  The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.

 

Section 9.4            Survival of Representations and Warranties.

 

All representations and warranties made hereunder and in any document, certificate or statement delivered pursuant hereto or in connection herewith shall survive the execution and delivery of this Agreement and the Notes and the making of the Loan; provided that all such representations and warranties shall terminate on the date upon which the Loan Commitment has been terminated and all Credit Party Obligations have been paid in full.

 

Section 9.5            Payment of Expenses and Taxes; Indemnity.

 

(a)           Costs and Expenses.  The Borrower shall pay (i) all reasonable out-of-pocket expenses incurred by the Administrative Agent and its Affiliates (including, without limitation, the reasonable fees, charges and disbursements of outside counsel for the Administrative Agent) in connection with the syndication of the credit facilities provided for herein, the preparation, negotiation, execution, delivery and administration of this Agreement and the other Credit Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated) and (ii) all reasonable out-of-pocket expenses incurred by the Administrative Agent or any Lender (including, without limitation, the reasonable fees, charges and disbursements of any outside counsel for the Administrative Agent or any Lender) in connection with the enforcement or protection of its rights (A) in connection with this Agreement and the other Credit Documents, including, without limitation, its rights under this Section, or (B) in connection with the Loan made hereunder, including, without limitation, all such reasonable out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of the Loan.

 

(b)           Indemnification by the Borrower.  The Borrower shall indemnify the Administrative Agent (and any sub-agent thereof), each Lender and each Related Party of any of

 

74

 

the foregoing Persons (each such Person being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all actual losses, third-party claims, penalties, damages, liabilities and related but reasonable expenses (including, without limitation, the reasonable fees, charges and disbursements of any outside counsel for any Indemnitee) incurred by any Indemnitee or asserted against any Indemnitee by any third party or by the Borrower or any other Credit Party arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Credit Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, (ii) the Loan or the use or proposed use of the proceeds therefrom, (iii) any actual or alleged presence or release of Materials of Environmental Concern on or from any property owned or operated by any Credit Party or any of its Subsidiaries, or any liability under Environmental Law related in any way to any Credit Party or any of its Subsidiaries, or (iv) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by the Borrower or any other Credit Party, and regardless of whether any Indemnitee is a party thereto, provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, penalties, damages, liabilities or related expenses are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence, willful misconduct, or intentional bad acts of such Indemnitee, or any material breach by such Indemnitee of this Agreement or any other Credit Document.

 

c)             Reimbursement by Lenders.  To the extent that the Borrower for any reason fails to indefeasibly pay any amount required under paragraph (a) or (b) of this Section to be paid by it to the Administrative Agent (or any sub-agent thereof) or any Related Party of any of the foregoing, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent) or such Related Party, as the case may be, such Lender’s Loan Commitment Percentage (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount, provided that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent) in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent) in connection with such capacity.

 

(d)           Waiver of Consequential Damages, Etc.  To the fullest extent permitted by applicable law, the Credit Parties shall not assert, and hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Credit Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, the Loan or the use of the proceeds thereof.  No Indemnitee referred to in paragraph (b) above shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Credit Documents or the transactions contemplated hereby or thereby.

 

(e)           Payments.  All amounts due under this Section shall be payable promptly, but in any event not later than five (5) Business Days after written demand therefor.

 

(f)            Survival.  The agreements contained in this Section shall survive the resignation of the Administrative Agent, the replacement of any Lender, the termination of the Loan Commitment and the repayment, satisfaction or discharge of the Credit Party Obligations.

 

75

 

Section 9.6            Successors and Assigns; Participations.

 

(a)           Successors and Assigns Generally.  The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that neither the Borrower nor any other Credit Party may assign or otherwise transfer any of its rights or obligations hereunder or under any of the other Credit Documents without the prior written consent of the Administrative Agent and each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of paragraph (b) of this Section, (ii) by way of participation in accordance with the provisions of paragraph (d) of this Section or (iii) by way of pledge or assignment of a security interest subject to the restrictions of paragraph (f) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void).  Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in paragraph (d) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.

 

(b)           Assignments by Lenders.  Any Lender may at any time assign to one or more Eligible Assignees all or a portion of its rights and obligations under this Agreement (including, without limitation, all or a portion of its Loan Commitment and the portion of the Loan at the time owing to it); provided that any such assignment shall be subject to the following conditions:

 

(i)            Minimum Amounts.

 

(A)          in the case of an assignment of the entire remaining amount of the assigning Lender’s Loan Commitment and the portion of the Loan at the time owing to it or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and

 

(B)           in any case not described in paragraph (b)(i)(A) of this Section, the aggregate amount of the Loan Commitment (which for this purpose includes the Loan outstanding thereunder) or, if the applicable Loan Commitment is not then in effect, the principal outstanding balance of the portion of the Loan of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade Date” is specified in the Assignment and Assumption, as of the Trade Date) shall not be less than $5,000,000, unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed).

 

(ii)           Proportionate Amounts.  Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement with respect to the Loan or the Loan Commitment assigned, except that this clause (ii) shall not prohibit any Lender from assigning all or a portion of its rights and obligations among separate Tranches on a non-pro rata basis.

 

(iii)          Required Consents.  No consent shall be required for any assignment except to the extent required by paragraph (b)(i)(B) of this Section and, in addition:

 

76

 

(A)          the consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required unless (x) an Event of Default has occurred and is continuing at the time of such assignment, (y) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund or (z) the primary syndication of the Loan has not been completed as determined by Wells Fargo; provided that the Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five (5) Business Days after having received written notice thereof; and

 

(B)           the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required for assignments in respect of a Loan Commitment to a Person who is not a Lender, an Affiliate of a Lender or an Approved Fund.

 

(iv)          Assignment and Assumption.  The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee of $3,500 and the assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire.

 

(v)           No Assignment to a Credit Party.  No such assignment shall be made to any Credit Party or any Credit Party’s Affiliates or Subsidiaries.

 

(vi)          No Assignment to Natural Persons.  No such assignment shall be made to a natural person.

 

Subject to acceptance and recording thereof by the Administrative Agent pursuant to paragraph (c) of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of Sections 2.10, 2.11, 2.12 and 9.5 with respect to facts and circumstances occurring prior to the effective date of such assignment.  Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this paragraph shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with paragraph (d) of this Section.

 

(c)           Register.  The Administrative Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at one of its offices in Charlotte, North Carolina a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Loan Commitments of, and principal amounts of the portion of the Loan owing to, each Lender pursuant to the terms hereof from time to time (the “Register”).  The entries in the Register shall be conclusive, and the Borrower, the Administrative Agent and the Lenders may treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary.  The Register shall be available for inspection by the Borrower and any Lender, at any

 

77

 

reasonable time and from time to time upon reasonable prior notice; provided that a Lender shall only be entitled to inspect its own entry in the Register and not that of any other Lender.

 

(d)           Participations.  Any Lender may at any time, without the consent of, or notice to, the Borrower or the Administrative Agent, sell participations to any Person (other than a natural person or any Credit Party or any Credit Party’s Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of such Lender’s rights and/or obligations under this Agreement (including, without limitation, all or a portion of its Loan Commitment and/or the portion of the Loan owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Administrative Agent and the Lenders shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement.

 

Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver that affects such Participant.  Subject to paragraph (e) of this Section, the Borrower agrees that each Participant shall be entitled to the benefits of Sections 2.10, 2.11 and 2.12 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section.  To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 9.7 as though it were a Lender, provided such Participant agrees to be subject to Section 2.7 as though it were a Lender.

 

(e)           Limitations upon Participant Rights.  A Participant shall not be entitled to receive any greater payment under Sections 2.10, 2.11 and 2.12 than the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrower’s prior written consent.  A Participant that would be a Foreign Lender if it were a Lender shall not be entitled to the benefits of Section 2.12 unless the Borrower is notified of the participation sold to such Participant and such Participant agrees, for the benefit of the Borrower, to comply with Section 2.12 as though it were a Lender.

 

(f)            Certain Pledges.  Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including, without limitation, any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.

 

Section 9.7            [Intentionally Deleted].

 

Section 9.8            Table of Contents and Section Headings.

 

The table of contents and the Section and subsection headings herein are intended for convenience only and shall be ignored in construing this Agreement.

 

78

 

Section 9.9            Counterparts; Integration; Effectiveness; Electronic Execution.

 

(a)           Counterparts; Integration; Effectiveness.  This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.  This Agreement and the other Credit Documents, and any separate letter agreements with respect to fees payable to the Administrative Agent, constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof.  This Agreement shall become effective when (i) it shall have been executed by the Borrower, the Lenders (other than those executing a Lender Consent) and the Administrative Agent, on behalf of itself and the applicable Lenders pursuant to each such Lender’s Lender Consent and the Administrative Agent shall have received copies hereof and thereof (faxed or otherwise); (ii) the Administrative Agent shall have received Lender Consents from each applicable Lender in accordance with Section 9.21; and (iii) the other conditions precedent set forth in Section 4.1 are satisfied, waived or reclassified as post-closing conditions, and thereafter this Agreement shall be binding upon and inure to the benefit of the Borrower, the Guarantors, the Administrative Agent and each Lender and their respective successors and permitted assigns.  Delivery of an executed counterpart of a signature page of this Agreement by fax or email shall be effective as delivery of a manually executed counterpart of this Agreement.

 

(b)           Electronic Execution of Assignments.  The words “execution,” “signed,” “signature,” and words of like import in any Assignment and Assumption shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including, without limitation, the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

 

Section 9.10         Severability.

 

Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

Section 9.11         Integration.

 

This Agreement and the other Credit Documents represent the agreement of the Borrower, the other Credit Parties, the Administrative Agent and the Lenders with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by the Administrative Agent, the Borrower, the other Credit Parties, or any Lender relative to the subject matter hereof not expressly set forth or referred to herein or therein.

 

Section 9.12         Governing Law.

 

This Agreement shall be governed by, and construed in accordance with, the law of the State of  New York.

 

79

 

Section 9.13         Consent to Jurisdiction; Service of Process and Venue.

 

(a)           Consent to Jurisdiction.  The Borrower and each other Credit Party irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of the courts of the State of New York and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or any other Credit Document, or for recognition or enforcement of any judgment, and each of the parties hereto irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York sitting state court or, to the fullest extent permitted by applicable law, in such federal court.  Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.  Nothing in this Agreement or in any other Credit Document shall affect any right that the Administrative Agent or any Lender may otherwise have to bring any action or proceeding relating to this Agreement or any other Credit Document against the Borrower or any other Credit Party or its properties in the courts of any jurisdiction.

 

(b)           Service of Process. Each party hereto irrevocably consents to service of process in the manner provided for notices in Section 9.2.  Nothing in this Agreement will affect the right of any party hereto to serve process in any other manner permitted by applicable law.

 

(c)           Venue.  The Borrower and each other Credit Party irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement or any other Credit Document in any court referred to in paragraph (b) of this Section.  Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.

 

Section 9.14         Confidentiality.

 

Each of the Administrative Agent and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and its Affiliates’ respective partners, directors, officers, employees, agents, advisors and other representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority purporting to have jurisdiction over it (including, without limitation, any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder, under any other Credit Document or Secured Hedging Agreement or any action or proceeding relating to this Agreement, any other Credit Document or Secured Hedging Agreement or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement, (g) (i) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to the Borrower and its obligations, (ii) an investor or prospective investor in securities issued by an Approved Fund that also agrees that Information shall be used solely for the purpose of evaluating an investment in such securities issued by the Approved Fund, (iii) a trustee, collateral manager, servicer, backup servicer, noteholder or secured party in connection with the administration, servicing and reporting on the assets serving as collateral for securities issued by an Approved Fund, or (iv) a nationally recognized rating agency that requires access to information

 

80

 

regarding the Credit Parties, the Loan and Credit Documents in connection with ratings issued in respect of securities issued by an Approved Fund (in each case, it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such information and instructed to keep such information confidential), (h) with the consent of the Borrower or (i) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to the Administrative Agent, any Lender or any of their respective Affiliates on a nonconfidential basis from a source other than the Borrower.

 

For purposes of this Section, “Information” means all information received from any Credit Party or any of its Subsidiaries relating to any Credit Party or any of its Subsidiaries or any of their respective businesses, other than any such information that is available to the Administrative Agent or any Lender on a nonconfidential basis prior to disclosure by any Credit Party or any of its Subsidiaries; provided that, in the case of information received from any Credit Party or any of its Subsidiaries after the date hereof, such information is clearly identified at the time of delivery as confidential.  Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.

 

Section 9.15         Acknowledgments.

 

The Borrower and the other Credit Parties each hereby acknowledges that:

 

(a)           it has been advised by counsel in the negotiation, execution and delivery of each Credit Document;

 

(b)           neither the Administrative Agent nor any Lender has any fiduciary relationship with or duty to the Borrower or any other Credit Party arising out of or in connection with this Agreement and the relationship between the Administrative Agent and the Lenders, on one hand, and the Borrower and the other Credit Parties, on the other hand, in connection herewith is solely that of creditor and debtor; and

 

(c)           no joint venture exists among the Lenders and the Administrative Agent or among the Borrower, the Administrative Agent or the other Credit Parties and the Lenders.

 

Section 9.16         Waivers of Jury Trial; Waiver of Consequential Damages.

 

EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER CREDIT DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).  EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER CREDIT DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

 

81

 

Section 9.17         Patriot Act Notice.

 

Each Lender and the Administrative Agent (for itself and not on behalf of any other party) hereby notifies the Borrower that, pursuant to the requirements of the Patriot Act, it is required to obtain, verify and record information that identifies the Borrower and the other Credit Parties, which information includes the name and address of the Borrower and the other Credit Parties and other information that will allow such Lender or the Administrative Agent, as applicable, to identify the Borrower and the other Credit Parties in accordance with the Patriot Act.

 

Section 9.18         Resolution of Drafting Ambiguities.

 

Each Credit Party acknowledges and agrees that it was represented by counsel in connection with the execution and delivery of this Agreement and the other Credit Documents to which it is a party, that it and its counsel reviewed and participated in the preparation and negotiation hereof and thereof and that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be employed in the interpretation hereof or thereof.

 

Section 9.19         Subordination of Intercompany Debt.

 

Each Credit Party agrees that all intercompany Indebtedness among Credit Parties (the “Intercompany Debt”) is subordinated in right of payment, to the prior payment in full of all Credit Party Obligations.  Notwithstanding any provision of this Agreement to the contrary, provided that no Default or Event of Default has occurred and is continuing, Credit Parties may make and receive payments with respect to the Intercompany Debt to the extent otherwise permitted by this Agreement; provided that in the event of and during the continuation of any Default or Event of Default, no payment shall be made by or on behalf of any Credit Party on account of any Intercompany Debt.  In the event that any Credit Party receives any payment of any Intercompany Debt at a time when such payment is prohibited by this Section, such payment shall be held by such Credit Party, in trust for the benefit of, and shall be paid forthwith over and delivered, upon written request, to, the Administrative Agent.

 

Section 9.20         Continuing Agreement.

 

This Agreement shall be a continuing agreement and shall remain in full force and effect until all Credit Party Obligations (other than those obligations that expressly survive the termination of this Agreement) have been paid in full and all Loan Commitments have been terminated.  Upon termination, the Credit Parties shall have no further obligations (other than those obligations that expressly survive the termination of this Agreement) under the Credit Documents and the Administrative Agent shall, at the request and expense of the Borrower, deliver all the Collateral in its possession to the Borrower and release all Liens on the Collateral; provided that should any payment, in whole or in part, of the Credit Party Obligations be rescinded or otherwise required to be restored or returned by the Administrative Agent or any Lender, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, then the Credit Documents shall automatically be reinstated and all Liens of the Administrative Agent shall reattach to the Collateral and all amounts required to be restored or returned and all costs and expenses incurred by the Administrative Agent or any Lender in connection therewith shall be deemed included as part of the Credit Party Obligations.

 

Section 9.21         Lender Consent.

 

Each Person signing a Lender Consent (a) approves the Credit Agreement, (b) authorizes and appoints the Administrative Agent as its agent in accordance with the terms of Article VIII, (c) authorizes the Administrative Agent to execute and deliver this Agreement on its behalf, (d) is a Lender hereunder

 

82

 

and therefore shall have all the rights and obligations of a Lender under this Agreement as if such Person had directly executed and delivered a signature page to this Agreement and (e) has consented to, approved or accepted or is satisfied with, each document or other matter required under Section 4.1 to be consented to or approved by or be acceptable or satisfactory to a Lender.

 

Section 9.22         Press Releases and Related Matters.

 

The Credit Parties and their Affiliates agree that they will not in the future issue any press releases or other public disclosure using the name of the Administrative Agent or any Lender or their respective Affiliates or referring to this Agreement or any of the Credit Documents without the prior written consent of such Person, unless (and only to the extent that) the Credit Parties or such Affiliate is required to do so under law and then, in any event, the Credit Parties or such Affiliate will consult with such Person before issuing such press release or other public disclosure.  The Credit Parties consent to the publication by the Administrative Agent or any Lender of customary advertising material relating to the transactions contemplated by this Agreement and the Credit Documents using the name, product photographs, logo or trademark of the Credit Parties.  The Credit Parties consent to the publication by the Administrative Agent or any Lender of customary advertising material relating to the transactions contemplated by this Agreement and the Credit Documents using the name or logo of the Borrower.

 

Section 9.23         Appointment of Borrower.

 

Effective as of the date of execution and delivery of the Guaranty Agreement or a Joinder Agreement (as applicable), each of the Guarantors is hereby deemed to have appointed the Borrower to act as its agent for all purposes under this Agreement and to have agreed that (a) the Borrower may execute such documents on behalf of such Guarantor as the Borrower deems appropriate in its sole discretion and each Guarantor shall be obligated by all of the terms of any such document executed on its behalf, (b) any notice or communication delivered by the Administrative Agent or the Lender to the Borrower shall be deemed delivered to each Guarantor and (c) the Administrative Agent or the Lenders may accept, and be permitted to rely on, any document, instrument or agreement executed by the Borrower on behalf of each Guarantor.

 

Section 9.24         No Advisory or Fiduciary Responsibility.

 

In connection with all aspects of each transaction contemplated hereby, each of the Credit Parties acknowledges and agrees, and acknowledges its Affiliates’ understanding, that:  (a) the credit facility provided for hereunder and any related arranging or other services in connection therewith (including, without limitation, in connection with any amendment, waiver or other modification hereof or of any other Credit Document) are an arm’s-length commercial transaction between the Credit Parties and their Affiliates, on the one hand, and the Administrative Agent and WFS, on the other hand, and the Credit Parties are capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated hereby and by the other Credit Documents (including, without limitation, any amendment, waiver or other modification hereof or thereof); (b) in connection with the process leading to such transaction, the Administrative Agent and WFS each is and has been acting solely as a principal and is not the financial advisor, agent or fiduciary, for any Credit Party or any of their Affiliates, stockholders, creditors or employees or any other Person; (c) neither the Administrative Agent nor WFS has assumed or will assume an advisory, agency or fiduciary responsibility in favor of any Credit Party with respect to any of the transactions contemplated hereby or the process leading thereto, including, without limitation, with respect to any amendment, waiver or other modification hereof or of any other Credit Document (irrespective of whether the Administrative Agent or WFS has advised or is currently advising any Credit Party or any of its Affiliates on other matters) and neither the Administrative Agent nor WFS has any obligation to any Credit Party or any of their Affiliates with

 

83

 

respect to the transactions contemplated hereby except those obligations expressly set forth herein and in the other Credit Documents; (d) the Administrative Agent and WFS and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Credit Parties and their Affiliates, and neither the Administrative Agent nor WFS has any obligation to disclose any of such interests by virtue of any advisory, agency or fiduciary relationship; and (e) the Administrative Agent and WFS have not provided and will not provide any legal, accounting, regulatory or tax advice with respect to any of the transactions contemplated hereby (including, without limitation, any amendment, waiver or other modification hereof or of any other Credit Document) and the Credit Parties have consulted their own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate.  Each of the Credit Parties hereby waives and releases, to the fullest extent permitted by law, any claims that it may have against the Administrative Agent or WFS with respect to any breach or alleged breach of agency or fiduciary duty.

 

Section 9.25         Responsible Officers.

 

The Administrative Agent and each of the Lenders are authorized to rely upon the continuing authority of the Responsible Officers with respect to all matters pertaining to the Credit Documents including, without limitation, but not limited to, the selection of interest rates, the submission of requests for Extensions of Credit and certificates with regard thereto.  Such authorization may be changed only upon written notice to the Administrative Agent and evidence, reasonably satisfactory to the Administrative Agent, of the authority of the Person giving such notice and such notice shall be effective not sooner than five (5) Business Days following receipt thereof by the Administrative Agent (or such earlier time as agreed to by the Administrative Agent).

 

[remainder of page intentionally left blank]

 

84

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by its proper and duly authorized officers as of the day and year first above written.

 

BORROWER:

 

	
 
    	
UNITED   THERAPEUTICS CORPORATION, a Delaware   corporation
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   John M. Ferrari
    
	
 
    	
Name:
    	
John   M. Ferrari
    
	
 
    	
Title:
    	
Chief   Financial Officer & Treasurer
    

 

 

[signature pages continue]

 

Credit Agreement

United Therapeutics Corporation

 

 

LENDERS:

 

	
 
    	
WELLS FARGO BANK, NATIONAL ASSOCIATION, as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Weston R. Garrett
    
	
 
    	
Name:
    	
Weston   R. Garrett
    
	
 
    	
Title:
    	
Director
    
	
 
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Address:
    
	
 
    	
 
    
	
 
    	
301   South College Street
    
	
 
    	
Charlotte,   NC 28288
    
	
 
    	
Attention: John D. Altmeyer
    
	
 
    	
Fax: (704) 383-3556
    
	
 
    	
Email: jackaltmeyer@wachovia.com
    
	
 
    	
 
    

 

[signature pages continue]

 

Credit Agreement

United Therapeutics Corporation

 

 

	
 
    	
BANK OF AMERICA, N.A., as a Lender
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Lynette M. Songy
    
	
 
    	
Name:
    	
Lynette   M. Songy
    
	
 
    	
Title:
    	
Senior   Vice President
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Address:
    
	
 
    	
 
    
	
 
    	
888   Bestgate Road
    
	
 
    	
Annapolis,   MD 21401
    
	
 
    	
Attention:
    	
 
    
	
 
    	
Telephone:
    	
410-972-4443
    
	
 
    	
Fax:
    	
312-453-2878
    
	
 
    	
Email:
    	
lyn.songy@baml.com
    
	
 
    	
 
    	
 
    
					

 

[signature pages continue]

 

Credit Agreement

United Therapeutics Corporation

 

 

ADMINISTRATIVE AGENT:

 

	
 
    	
WELLS FARGO BANK, NATIONAL
    
	
 
    	
ASSOCIATION, as a Lender and as the   Administrative
    
	
 
    	
Agent   on behalf of the Lenders
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Weston R. Garrett
    
	
 
    	
Name:
    	
Weston   R. Garrett
    
	
 
    	
Title:
    	
Director
    

 

 

[signature pages end]

 

Credit Agreement

United Therapeutics Corporation

 

 

SCHEDULE 1.0

 

ALLOCATED LOAN AMOUNT

 

	
Property Constituting Collateral
    	
 
    	
Loan Amount Per
   Property
    	
 
    	
Percentage of
   Loan Amount
    	
 
    
	
1040 Spring Street, Silver Spring, Montgomery   County, MD
    	
 
    	
$
    	
29,000,000.00
    	
 
    	
41.43
    	
%
    
	
55 T.W. Alexander Drive, Durham, Durham County, NC
    	
 
    	
$
    	
41,000,000.00
    	
 
    	
58.57
    	
%
    
	
 
    	
 
    	
$
    	
70,000,000.00
    	
 
    	
100.00
    	
%
    

 

 

SCHEDULE 1.1

 

LOAN COMMITMENT PERCENTAGE

 

	
Lender
    	
 
    	
Loan Amount
    	
 
    	
Loan Percentage
    	
 
    
	
Wells Fargo Bank, National Association
    	
 
    	
$
    	
50,000,000.00
    	
 
    	
71.43
    	
%
    
	
Bank of America, N.A.
    	
 
    	
$
    	
20,000,000.00
    	
 
    	
28.57
    	
%
    
	
 
    	
 
    	
$
    	
70,000,000.00
    	
 
    	
100.00
    	
%
    

 

 

SCHEDULE 2.1

 

PRINCIPAL AMORTIZATION OF LOAN

 

	
Interest Period
    	
 
    	
Principal Balance
    	
 
    	
Principal Amortization
    	
 
    
	
On Closing Date
    	
 
    	
$
    	
70,000,000.00
    	
 
    	
$
    	
0.00
    	
 
    
	
12 Months After Closing Date
    	
 
    	
$
    	
68,929,130.62
    	
 
    	
$
    	
1,070,869.38
    	
 
    
	
24 Months After Closing Date
    	
 
    	
$
    	
67,780,848.01
    	
 
    	
$
    	
1,148,282.61
    	
 
    
	
36 Months After Closing Date
    	
 
    	
$
    	
66,549,555.95
    	
 
    	
$
    	
1,231,292.06
    	
 
    
	
48 Months After Closing Date
    	
 
    	
$
    	
0.00
    	
 
    	
$
    	
66,549,555.95
    	
 
    

 

The above referenced schedule for Principal Amortization of Loan encompasses the following with respect to each of the two properties, respectively, comprising the Collateral for the Loan.

 

Montgomery County, Maryland Property

 

	
Interest Period
    	
 
    	
Principal Balance
    	
 
    	
Principal Amortization
    	
 
    
	
On Closing Date
    	
 
    	
$
    	
29,000,000.00
    	
 
    	
$
    	
0.00
    	
 
    
	
12 Months After Closing Date
    	
 
    	
$
    	
28,556,354.11
    	
 
    	
$
    	
443,645.89
    	
 
    
	
24 Months After Closing Date
    	
 
    	
$
    	
28,080,637.03
    	
 
    	
$
    	
475,717.08
    	
 
    
	
36 Months After Closing Date
    	
 
    	
$
    	
27,570,530.32
    	
 
    	
$
    	
510,106.71
    	
 
    
	
48 Months After Closing Date
    	
 
    	
$
    	
0.00
    	
 
    	
$
    	
27,570,530.32
    	
 
    

 

Durham County, North Carolina Property

 

	
Interest Period
    	
 
    	
Principal Balance
    	
 
    	
Principal Amortization
    	
 
    
	
On Closing Date
    	
 
    	
$
    	
41,000,000.00
    	
 
    	
$
    	
0.00
    	
 
    
	
12 Months After Closing Date
    	
 
    	
$
    	
40,372,776.51
    	
 
    	
$
    	
627,223.49
    	
 
    
	
24 Months After Closing Date
    	
 
    	
$
    	
39,700,210.98
    	
 
    	
$
    	
672,565.53
    	
 
    
	
36 Months After Closing Date
    	
 
    	
$
    	
38,979,025.63
    	
 
    	
$
    	
721,185.35
    	
 
    
	
48 Months After Closing Date
    	
 
    	
$
    	
0.00
    	
 
    	
$
    	
38,979,025.63
    	
 
    

 

 

Schedule 3.1

 

Material Obligations/Material Dispositions

 

1.         Aircraft Lease (S/N 648) between Wilmington Trust Company, as lessor, and United Therapeutics Corporation, as lessee, dated as of October 7, 2010.

 

2.         Agreement and Plan of Merger among Lung Rx, LLC, LRX Merger Sub, Inc., and United Therapeutics Corporation, as parent guarantor, Immuneworks, Inc., and Wade A. Lange, as stockholder representative, dated as of June 9, 2010.

 

3.         Development Agreement between Immuneworks, Inc., and Lung Rx, LLC, dated as of February 5, 2010.

 

4.         Lease between Gestion 965 John Inc., as lessor, and Unither Biotech Inc., as lessee, dated as of February 3, 2010 (office space lease).

 

5.         Lease between George J. Stoklas, as lessor, and United Therapeutics Corporation, successor in interest to Unither Telemedicine Services Corporation, as lessee, dated as of July 1, 2001, and amended as of February 10, 2009, and May 1, 2010 (office space lease).

 

 

Schedule 3.6

 

No Material Litigation

 

1.         In re United Therapeutics Corp. Derivative Litigation, Court of Chancery for the State of Delaware, Consolidated Civil Action No. 4946-CC

 

Per United Therapeutics’ Quarterly Report on Form 10-Q for the period ending September 30, 2010, as filed via EDGAR on October 28, 2010 (pages 17-18 and 31):

 

As previously disclosed in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2010 and June 30, 2010, purported shareholders Jeffrey Benison IRA, the Retirement Board of Allegheny County and the Police & Fire Retirement System of the City of Detroit jointly filed a consolidated amended derivative complaint on May 4, 2010 against certain of our directors and named executive officers and us as a nominal defendant. The complaint alleged, among other things, that the individual defendants breached their fiduciary duties to the Company in connection with the adoption of the STAP, the 2008 modification of awards granted under the STAP and the exchange of certain stock options granted under our Amended and Restated Equity Incentive Plan. The plaintiffs sought unspecified monetary damages, purportedly for United Therapeutics Corporation, as well as attorneys’ fees and costs and injunctive relief.

 

On October 25, 2010, the parties entered into a stipulation of settlement. The stipulation provides among other things that, in consideration for the full settlement and release of all of the plaintiffs’ claims, we will: (i) not reprice awards granted under our Amended and Restated Equity Incentive Plan or the STAP in the future without shareholder approval, (ii) cancel 165,214 options granted to our Chief Executive Officer, and (iii) adopt certain corporate governance practices. In connection with the settlement, plaintiffs’ counsel will seek an award of attorneys’ fees from us. The parties have not agreed on the amount of fees, if any, to be awarded to plaintiffs’ counsel, but resolution of this issue is not a condition to settling the claims. The parties will continue to negotiate over attorneys’ fees and, if they do not reach an agreement, will seek a decision from the court on this issue. The stipulation of settlement and any proposed award of fees to the plaintiffs’ counsel will be subject to court approval. The court has scheduled a hearing for January 21, 2011 to consider whether to approve the settlement and any proposed fee award. The court also approved the form of Notice of Pendency and Settlement of Action, which is filed as Exhibit 99.1 to this Quarterly Report on Form 10-Q. There can be no assurance that the stipulation of settlement or the fee award, if any, agreed upon by the parties, will be approved by the court. The contemplated settlement is not expected to have a material impact on our statements of financial position or operations.

 

2.         Lifewatch Services, Inc., and Card Guard Scientific Survival, Ltd. v. Medicomp, Inc., and United Therapeutics Corporation, Case No.  6:09-cv-1909-Orl-31DAB

 

Nature of the Litigation.  On November 6, 2009, Lifewatch Services, Inc. and Card Guard Scientific Survival, Ltd. (together, “Lifewatch”) filed a complaint for patent infringement against

 

 

Medicomp, Inc., a wholly-owned subsidiary of United Therapeutics Corporation (“Medicomp”). Lifewatch claims that Medicomp’s wireless event monitor device, the CardioPal SAVI wireless, infringes certain claims contained in two patents owned by Lifewatch (U.S. Patent Nos. 7,542,878 B2 and 5,730,143).  In addition to its complaint for patent infringement, on November 10, 2009, Lifewatch filed a Motion for Preliminary Injunction to prevent Medicomp from providing services with or selling the CardioPal SAVI wireless device while the patent infringement lawsuit is pending.  Lifewatch is seeking to prevent Medicomp from using the device with its event monitoring clients, unspecified damages, other unspecified costs and expenses, and attorneys’ fees and other costs related to litigation.  

 

Progress of the Litigation to Date.  Shortly after the lawsuit was filed, Medicomp requested an extension of time to respond to the preliminary injunction motion and in return agreed to delay commercial launch of the CardioPal SAVI wireless device (which was scheduled for January 2010) until the Court ruled on the Motion for Preliminary Injunction. On December 16, 2009, we filed an answer to the complaint and a counterclaim seeking a declaratory judgment that the asserted patent claims were not infringed, were invalid and/or unenforceable.  On December 16, 2009, we also filed a response to the Motion for Preliminary Injunction.  On January 29, 2010, a hearing on the Motion for Preliminary Injunction was held, and on February 10, 2010 the judge denied Lifewatch’s Motion for Preliminary Injunction. We subsequently requested and were granted a stay of the litigation pending the outcome of reexaminations of all claims of both patents-in-suit by the United States Patent and Trademark Office.   The litigation remains stayed and the reexaminations of both patents-in-suit are pending at this time.

 

2

 

Schedule 3.15

 

Subsidiaries

 

1.         Lung Rx, LLC, a Delaware limited liability company.

 

2.         LRX Merger Sub, Inc., a Delaware corporation.

 

3.         Unither Pharmaceuticals, LLC, a Delaware limited liability company.

 

4.         Unither Telmed, Ltd., a Delaware limited corporation.

 

5.         Unither.com, Inc., a Delaware corporation.

 

6.         Unither Pharma, LLC, a Delaware limited liability company.

 

7.         Medicomp, Inc., a Delaware corporation.

 

8.         Unither Neurosciences, Inc., a Delaware corporation.

 

9.         Unither Virology, LLC, a Delaware limited liability company.

 

10.       United Therapeutics Europe, Ltd., a U.K. corporation.

 

11.       LungRx Limited (Private Limited Company), a U.K. corporation.

 

12.       Unither Biotech, Inc., a Canadian corporation.

 

13.       Unither Therapeutik GmbH, a German corporation.

 

 

Schedule 3.17

 

Security Documents

 

	
Filing
    	
 
    	
Office
    
	
Deed of Trust, Security Agreement, Assignment of Leases and Rents and   Fixture Filing
    	
 
    	
Land Records Division, Montgomery County Circuit Court, Montgomery   County, Maryland
    
	
Deed of Trust, Security Agreement, Assignment of Leases and Rents and   Fixture Filing
    	
 
    	
Durham County Registry, Durham County, North Carolina
    
	
UCC Financing Statement
    	
 
    	
Delaware Secretary of State
    
	
UCC Financing Statement
    	
 
    	
Land Records Division, Montgomery County Circuit Court, Montgomery   County, Maryland
    
	
UCC Financing Statement
    	
 
    	
Durham County Registry, Durham County, North Carolina
    

 

 

Schedule 3.20

 

Patriot Act Information

 

	
Exact Legal Name:
    	
 
    	
United Therapeutics Corporation
    
	
 
    	
 
    	
 
    
	
State of Incorporation:
    	
 
    	
Delaware (June 26, 1996, as Lung Rx, Inc.)
    
	
 
    	
 
    	
 
    
	
Type of Organization:
    	
 
    	
General Corporation
    
	
 
    	
 
    	
 
    
	
States in which Qualified to do Business:
    	
 
    	
DE, MD, FL, DC, NC, LA
    
	
 
    	
 
    	
 
    
	
Chief Executive Office/ Principal Place of Business:
    	
 
    	
1040 Spring Street, Silver Spring, Maryland
    
	
 
    	
 
    	
 
    
	
Business Phone No.:
    	
 
    	
(301) 608-9292
    
	
 
    	
 
    	
 
    
	
Organization I.D. No.:
    	
 
    	
DE File No. 2638178
    
	
 
    	
 
    	
 
    
	
Federal Employer I.D. No.:
    	
 
    	
52-1984749
    
	
 
    	
 
    	
 
    
	
Ownership:
    	
 
    	
Publicly Held
    

 

 

Schedule 3.23(j)

 

Information Regarding Mortgaged Properties

 

1.         1040 Spring Street, Silver Spring, Montgomery County, Maryland

 

2.         55 T.W. Alexander Drive, Durham, Durham County, North Carolina(1)

 

(1)  Address refers to improved 34.85 acre parcel.

 

	
  

  	
  Schedule 3.23(k)
  Insurance 

  

 

	
  

  	
  ACORD*
  CERTIFICATE OF LIABILITY INSURANCE DATE (MM/DD/YYYY) 12/16/2010 THIS
  CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS
  UPON THE CERTIFICATE HOLDER. THIS CERTIFICATE DOES NOT AFFIRMATIVELY OR
  NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES
  BELOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A CONTRACT BETWEEN
  THE ISSUING INSURER(S) AUTHORIZED REPRESENTATIVE OR PRODUCER, AND THE
  CERTIFICATE HOLDER. IMPORTANT: If the certificate holder is an ADDITIONAL
  INSURED, the policy(les) must be endorsed. If
  SUBROGATION IS WAIVED, subject to the terms and conditions of the policy,
  certain policies may require an endorsement A statement on this certificate
  does not confer rights to the certificate holder in lieu of such
  endorsement(s). PRODUCER Aon Risk services Northeast, Inc. New York NY office
  199 water Street New York NY 10038-3551 USA INSURED United Therapeutics Corp.
  1735 Connecticut Avenue NW Washington DC 20009 USA CONTACT NAME: 283-7122 FAX
  (A/C NO): (847) 953-5390 E-MAIL PRODUCER 10242617 CUSTOMER ID #: INSURER(S)
  AFFORDING COVERAGE INSURER A.- Federal Insurance Company INSURER B: Chubb
  Indemnity Insurance Co. INSURER C: Columbia Casualty Company INSURER D:
  INSURER E: INSURER F: NAIC # 20281 12777 31127 COVERAGES CERTIFICATE NUMBER:
  570041040930 REVISION NUMBER: THIS IS TO CERTIFY THAT THE POLICIES OF
  INSURANCE LISTED BELOW HAVE BEEN ISSUED TO THE INSURED NAMED ABOVE FOR THE
  POLICY PERIOD INDICATED. NOTWITHSTANDING ANY REQUIREMENT, TERM OR CONDITION
  OF ANY CONTRACT OR OTHER DOCUMENT WITH RESPECT TO WHICH THIS CERTIFICATE MAY
  BE ISSUED OR MAY PERTAIN, THE INSURANCE AFFORDED BY THE POLICIES DESCRIBED
  HEREIN IS SUBJECT TO ALL THE TERMS, EXCLUSIONS AND CONDITIONS OF SUCH POLICIES.
  LIMITS SHOWN MAY HAVE BEEN REDUCED BY PAID CLAIMS. Limits shown are as
  requested HSR LTR A B C TYPE OF INSURANCE GENERAL LIABILITY X COMMERCIAL
  GENERAL LIABILITY CLAIMS-MADE OCCUR GENL AGGREGATE LIMIT APPLIES PER: POLICY
  PROJECT LOC AUTOMOBILE LIABILITY ANY AUTO ALL OWNED AUTOS SCHEDULED AUTOS
  HIRED AUTOS NON OWNED AUTOS UMBRELLA LIAB J EXCESS LIAB OCCUR CLAIMS-MADE
  DEDUCTIBLE RETENTION WORKERS COMPENSATION AND EMPLOYERS' LIABILITY ANY
  PROPRIETOR /PARTNER /EXECUTIVE OFFICER MEMBER EXCLUDED? (Mandatory In NH) If
  yes, described under DESCRIPTION OF OPERATIONS below Products/Pror  Liab. POLICY NUMBER
  Products/Prof. Liab. SIR applies per policy terms
  and conditions POLICY EXP (MM/DD/YYYY) 11/01/2010 11/01/2010
  & condition POLICY EXP (MM/DD/YYYY) 11/01/2011 11/01/2011
  LIMITS EACH OCCURRENCE DAMAGE TO RENTED PREMISES (Ex occurrence) MED EXP (Any
  one person) PERSONAL & ADV INJURY GENERAL AGGREGATE PRODUCTS - COMP/OP
  AGG COMBINED SINGLE LIMIT BODILY INJURY ( Par person) BODILY INJURY (Par
  accident) PROPERTY DAMAGE (Par accident) EACH OCCURRENCE AGGREGATE WC STATUTORY
  LIMITS E.L. EACH ACCIDENT E.L. DISEASE-EA EMPLOYEE E.L. DISEASE-POLICY LIMIT
  Per Claim Aggregate DESCRIPTION OF OPERATIONS / LOCATIONS / VEHICLES (Attach
  ACORD 101, Additional Remarks Schedule, if more space is required) Location:
  1040 Spring Street, silver Spring, MD. General Liability policy includes
  Contractual Liability coverage. Certificate Holder is included as additional
  insured ATIMA as regards General Liability policy. A waiver of Subrogation is
  granted in favor of the Certificate Holder. CERTIFICATE HOLDER wells Fargo
  Bank National Association As the Administrative Agent Attn: John D. Altmeyer 301 South College street, 8th Floor Charlotte NC
  28288 USA CANCELLATION SHOULD ANY OF THE ABOVE DESCRIBED POLICIES BE
  CANCELLED BEFORE THE EXPIRATION DATE THEREOF, NOTICE WILL BE DELIVERED IN
  ACCORDANCE WITH THE POLICY PROVISIONS. AUTHORIZED REPRESENTATIVE ACORD 25
  (2009/09) ©1988-2009 ACORD CORPORATION. All rights reserved. The ACORD name
  and logo are registered marks of ACORD [***] [***] [***] [***] [***] [***]
  [***] [***] [***] [***] [***] [***] [***] [***] 

  

 

	
  

  	
  ACORD**
  CERTIFICATE OF LIABILITY INSURANCE DATE MM/DD/YYYY) 12/16/2010 THIS
  CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS
  UPON THE CERTIFICATE HOLDER. THIS CERTIFICATE DOES NOT AFFIRMATIVELY OR
  NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES
  BELOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A CONTRACT BETWEEN
  THE ISSUING INSURER(S). AUTHORIZED REPRESENTATIVE OR
  PRODUCER, AND THE CERTIFICATE HOLDER. IMPORTANT: If the certificate holder Is
  an ADDITIONAL INSURED, the policy(les) must be
  endorsed. If SUBROGATION IS WAIVED, subject to the terms and conditions of
  the policy, certain policies may require an endorsement. A statement on this
  certificate does not confer rights to the certificate holder In lieu of such
  endorsement(s). PRODUCER Aon Risk Services Northeast, Inc. New York NY office
  199 Water Street New York NY 10038-3551 USA INSURED united Therapeutics Corp.
  1735 Connecticut Avenue NW Washington DC 20009 USA CONTACT NAME: (A/C NO. Ext):
  (866) 283-7122 FAX (A/C. No.) (847) 953.5390 E-MAIL ADDRESS: PRODUCER
  10242617 CUSTOMER ID INSURER(S) AFFORDING COVERAGE INSURER A: Federal Insurance
  company INSURER B: Chubb Indemnity Insurance Co. INSURER C: Columbia Casualty
  Company INSURER D: INSURER E: INSURER F: NAIC # 20281 12777 31127 TO "5
  X COVERAGES CERTIFICATE NUMBER: 570041040559 REVISION NUMBER: THIS IS TO
  CERTIFY THAT THE POLICIES OF INSURANCE LISTED BELOW HAVE BEEN ISSUED TO THE
  INSURED NAMED ABOVE FOR THE POLICY PERIOD INDICATED. NOTWITHSTANDING ANY
  REQUIREMENT, TERM OR CONDITION OF ANY CONTRACT OR OTHER DOCUMENT WITH RESPECT
  TO WHICH THIS CERTIFICATE MAY BE ISSUED OR MAY PERTAIN, THE INSURANCE
  AFFORDED BY THE POLICIES DESCRIBED HEREIN IS SUBJECT TO ALL THE TERMS.
  EXCLUSIONS AND CONDITIONS OF SUCH POLICIES. LIMITS SHOWN MAY HAVE BEEN
  REDUCED BY PAID CLAIMS. Limit Shown are as requested TYPE OF INSURANCE
  GENERAL LIABILITY X COMMERCIAL GENERAL LIABILITY CLAIMS-MADE 1 x | OCCUR GENX
  AGGREGATE LIMIT APPLIES PER: AUTOMOBILE LIABILITY ANY AUTO ALL OWNED AUTOS
  SCHEDULED AUTOS HIRED AUTOS NON OWNED AUTOS UMBRELLA LIAB EXCESS LIAB OCCUR
  CLAIMS-MADE DEDUCTIBLE RETENTION WORKERS COMPENSATION AND EMPLOYERS'
  LIABILITY ANY PROPRIETOR/PARTNER/EXECUTIVE OFFICER/MEMBER EXCLUDEDY/N N (Mandatory
  in NH) if yes, describe under DESCRIPTION OF OPERATIONS below Products Liab ADOL INSRN / A sura WVD POLICY
  NUMBER products/prof. Liab.
  SIR applies per policy terms & POLICY EXP (MM/DD/YYYY) 11/01/ 2010
  11/01/2010 11/01/2010 & conditions POLICY EXP (MM/DD/YYYY)
  11/01/2010 11/01/2011 11/01/2011 EACH OCCURRENCE
  DAMAGE TO RENTED PREMISES f Ea occurrence} MED EXP (Any one parson) PERSONAL
  S ADV INJURY GENERAL AGGREGATE PRODUCTS - COMP/OP AGG COMBINED SINGLE LIMIT
  BODILY INJURY (Per parson) BODILY INJURY (Per accident) PROPERTY DAMAGE (Per
  accident) EACH OCCURRENCE AGGREGATE - * 1 TORY LIMITS 1 lER
  EL. EACH ACCIDENT E.L. DISEASE-EA EMPLOYEE EL. DISEASE-POLICY LIMIT Per claim
  Aggregate DESCRIPTION OF OPERATIONS / LOCATIONS / VEHICLES (Attach ACORD 101.
  Additional Remarks Schedule. » mora  apaca Is raqulrad) Location: 55
  TW Alexander Drive , Durham, NO General Liability
  policy includes contractual Liability coverage. Certificate Holder is
  included as addition a as regards General Liability policy. A waiver of
  Subrogation is granted in favor of the certificate Holder. S 5 $ $ $ $ $ $ $ $ insured ATIMA a So in 04>3 IS co = s §s alali
  a* CERTIFICATE HOLDER wells Fargo Bank National Association As the
  Administrative Agent Attn: John D. Altmeyer 301
  South College Street, 8th Floor Charlotte NC 28288 USA CANCELLATION SHOULD
  ANY OF THE ABOVE DESCRIBED POLICIES BE CANCELLED BEFORE THE EXPIRATION DATE
  THEREOF, NOTICE W U BE DELIVERED IN ACCORDANCE WITH THE POLICY PROVISIONS.
  AUTHORIZED REPRESENTATIVE kE: 5§ ACORD 25 (2009/09)
  © 1988 - 2009 ACORD CORPORATION . All rights
  reserved. The ACORD name and logo are registered marks o f ACORD [***] [***]
  [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] 

  

 

	
  

  	
  ACORD EVIDENCE
  OF PROPERTY INSURANCE DATE (MM/DD/YYYY) 12/20/2010 THIS EVIDENCE OF PROPERTY
  INSURANCE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS
  UPON THE ADDITIONAL INTEREST NAMED BELOW. THIS EVIDENCE OF PROPERTY INSURANCE
  DOES NOT AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES BELOW.
  PHONE (866) 283-7122 (A/C, NO, Ext): Aon Risk Services Northeast, Inc. New
  York NY Office 199 Water Street New York NY 10038-3551 USA FAX (A/C No):
  (847) 953-5390 E-MAIL ADDRESS: AGENCY CUSTOMER ID *: 10242317 Lexington Insurance
  Company LOAN NUMBER United Therapeutics Corp. 1735 Connecticut Avenue N W
  Washington DC 20009 USA EFFECTIVE DATE 11/01/2010 POLICY NUMBER EXPIRATION
  DATE 11/01/2011 CONTINUED UNTIL TERMINATED IF CHECKED THIS REPLACES PRIOR
  EVIDENCE DATED: PROPERTY INFORMATION LOCATION/DESCRIPTION Location: 1040
  Spring Street, Silver Spring, MD THE POLICIES OF INSURANCE LISTED BELOW HAVE
  BEEN ISSUED TO THE INSURED NAMED ABOVE FOR THE POLICY PERIOD INDICATED
  NOTWITHSTANDING ANY REQUIREMENT, TERM OR CONDITION OF ANY CONTRACT OR OTHER
  DOCUMENT WITH RESPECT TO WHICH THIS EVIDENCE OF PROPERTY INSURANCE MAY BE
  ISSUED OR MAY PERTAIN, THE INSURANCE AFFORDED BY THE POLICIES DESCRIBED
  HEREIN IS SUBJECT TO ALL THE TERMS, EXCLUSIONS AND CONDITIONS OF SUCH
  POLICIES. LIMITS SHOWN MAY HAVE BEEN REDUCED BY PAID CLAIMS. COVERAGE
  INFORMATION COVERAGES/PERILS/FORMS Commercial Property Coverage Loss Limit
  Blanket Real Prop Blanket Personal Prop BI & EE AMOUNT OF INSURANCE $ DEDUCTIBLE
  $ REMARKS (Including Special Conditions) valuation: Replacement Cost.
  Certificate Holder is included as Mortgage and Lender Loss Payee as required
  by written contract. CANCELLATION SHOULD ANY OF THE ABOVE DESCRIBED POLICIES
  BE CANCELLED BEFORE THE EXPIRATION DATE THEREOF, THE ISSUING INSURER WILL
  ENDEAVOR TO MAIL 0 DAYS WRITTEN NOTICE TO THE ADDITIONAL INTEREST NAMED
  BELOW. BUT FAILURE TO MAIL SUCH NOTICE SHALL IMPOSE NO OBLIGATION OR
  LIABILITY OF ANY KIND UPON THE INSURER.ITS AGENTS OR REPRESENTATIVES.
  ADDITIONAL INTEREST NAME AND ADDRESS wells Fargo Bank National Association As
  the Administrative Agent Attn: John D. Altmeyer 301
  South College Street, 8th Floor Charlotte NC 28288 USA X X
  MORTGAGEE LOSS PAYEE X ADDITIONAL INSURED Lender Loss Pay LOAN » AUTHORIZED
  REPRESENTATIVE ACORD 27 (2006/07) © ACORD CORPORATION 1993-2006. All rights
  reserved. The ACORD name and logo are registered marks of ACORD [***] [***]
  [***] [***] [***] [***] 

  

 

	
  

  	
  ACORD EVIDENCE
  OF PROPERTY INSURANCE DATE (MM/DD/YYYY) 12/20/2010 THIS EVIDENCE OF PROPERTY
  INSURANCE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS
  UPON THE ADDITIONAL INTEREST NAMED BELOW. THIS EVIDENCE OF PROPERTY INSURANCE
  DOES NOT AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES BELOW.
  PHONE (866) 283-7122 (A/C, NO, Ext): Aon Risk Services Northeast, Inc. New
  York NY Office 199 water Street New York NY 10038-3551 USA FAX (A/C No):
  (847) 953-5390 E-MAIL ADDRESS: AGENCY CUSTOMER ID #: 10242617 COMPANY
  Lexington Insurance Company LOAN NUMBER United Therapeutics Corp. 1735
  Connecticut Avenue NW Washington DC 20009 USA EFFECTIVE DATE 11/01/2010
  POLICY NUMBER EXPIRATION DATE 11/01/2011 n CONTINUED UNTIL TERMINATED IF
  CHECKED THIS REPLACES PRIOR EVIDENCE DATED: PROPERTY INFORMATION LOCATION/DESCRIPTION
  Location: 55 TW Alexander Drive, Durham, NC. THE POLICIES OF INSURANCE LISTED
  BELOW HAVE BEEN ISSUED TO THE INSURED NAMED ABOVE FOR THE POLICY PERIOD
  INDICATED NOTWITHSTANDING ANY REQUIREMENT, TERM OR CONDITION OF ANY CONTRACT
  OR OTHER DOCUMENT WITH RESPECT TO WHICH THIS EVIDENCE OF PROPERTY INSURANCE
  MAY BE ISSUED OR MAY PERTAIN, THE INSURANCE AFFORDED BY THE POLICIES
  DESCRIBED HEREIN IS SUBJECT TO ALL THE TERMS, EXCLUSIONS AND CONDITIONS OF
  SUCH POLICIES. LIMITS SHOWN MAY HAVE BEEN REDUCED BY PAID CLAIMS. COVERAGE
  INFORMATION COVERAGES/PERILS/FORMS Commercial Property Coverage Loss Limit
  Blanket Real Prop Blanket Personal Prop BI & EE AMOUNT OF INSURANCE $ DEDUCTIBLE $ REMARKS (Including Special Conditions) valuation: Replacement
  Cost. Certificate Holder is included as Mortgagee and Lender Loss Payee as
  require d by written contract. CANCELLATION SHOULD ANY OF THE ABOVE DESCRIBED
  POLICIES BE CANCELLED BEFORE THE EXPIRATION DATE THEREOF. THE ISSUING INSURER
  WILL ENDEAVOR TO MAIL 0 DAYS WRITTEN NOTICE TO THE ADDITIONAL INTEREST NAMED
  BELOW, BUT FAILURE TO MAIL SUCH NOTICE SHALL IMPOSE NO OBLIGATION OR
  LIABILITY OF ANY KIND UPON THE INSURER,ITS AGENTS OR
  REPRESENTATIVES. ADDITIONAL INTEREST NAME AND ADDRESS Wells Fargo Bank
  National Association As the Administrative Agent Attn: John D. Altmeyer 301 south College Street, 8th Floor Charlotte NC
  28288 USA XI X MORTGAGEE LOSS PAYEE X ADDITIONAL INSURED Lender Loss Pay LOAN
  # AUTHORIZED REPRESENTATIVE (T ACORD27 (2006/07) © ACORD CORPORATION
  1993-2006. All rights reserved. The ACORD name and logo are registered marks
  of ACORD [***] [***] [***] [***] [***] [***] 

  

 

	
  

  	
  SKCOKC*
  CERTIFICATE OF LIABILITY INSURANCE DATE (MM/DD/YYYY) 12/16/2010 THIS
  CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS
  UPON THE CERTIFICATE HOLDER. THIS CERTIFICATE DOES NOT AFFIRMATIVELY OR
  NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES
  BELOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A CONTRACT BETWEEN
  THE ISSUING INSURER(S), AUTHORIZED REPRESENTATIVE OR
  PRODUCER, AND THE CERTIFICATE HOLDER. IMPORTANT: If the certificate holder is
  an ADDITIONAL INSURED, the policy(les) must be
  endorsed. IT SUBROGATION IS WAIVED, subject to the terms and conditions of
  the policy, certain policies may require an endorsement A statement on this
  certificate does not confer rights to the certificate holder In lieu of such
  endorsement(s). PRODUCER Aon Risk services Northeast, Inc. New York NY Office
  199 water street New York NY 10038-3551 USA INSURED united Therapeutics Corp.
  1735 Connecticut Avenue NW Washington DC 20009 USA CONTACT NAME:
  283-712253-5390 E-MAIL PRODUCER 10242617 CUSTOMER ID: 10242617 FAX (A/C.
  No.): (847) 953-5390 INSURER(S) AFFORDING COVERAGE INSURER A; Chart is
  specialty insurance Company INSURER B: INSURER C: INSURER D: INSURER E:
  INSURER FAX * 26883 COVERAGES CERTIFICATE NUMBER: 570041040575 REVISION
  NUMBER: THIS IS TO CERTIFY THAT THE POLICIES OF INSURANCE LISTED BELOW HAVE
  BEEN ISSUED TO THE INSURED NAMED ABOVE FOR THE POLICY PERIOD INDICATED.
  NOTWITHSTANDING ANY REQUIREMENT, TERM OR CONDITION OF ANY CONTRACT OR OTHER
  DOCUMENT WITH RESPECT TO WHICH THIS CERTIFICATE MAY BE ISSUED OR MAY PERTAIN,
  THE INSURANCE AFFORDED BY THE POLICIES DESCRIBED HEREIN IS SUBJECT TO ALL THE
  TERMS. EXCLUSIONS AND CONDITIONS OF SUCH POLICIES. LIMITS SHOWN MAY HAVE BEEN
  REDUCED BY PAID CLAIMS. shown as requested TYPE OF INSURANCE POLICY NUMBER
  GENERAL LIABILITY COMMERCIAL GENERAL LIABILITY CLAIMS-MADE EXP OCCUR EACH
  OCCURRENCE DAMAGE To RENTED PREMISES (occurrences) MED EXP (Any one person)
  PERSONAL & ADV INJURY GENERAL AGGREGATE GENL AGGREGATE LIMIT APPLIES PER:
  LOC. PRODUCTS - COMP/OP AGG n o AUTOMOBILE UABIITY ANY AUTO ALL OWNED AUTOS
  SCHEDULED AUTOS HIREDAUTOS NON OWNED AUTOS COMBINED SINGLE LIMIT I F .
  accident) BODILY INJURY (per parson) BODILY INJURY (Per accident) PROPERTY
  DAMAGE ( P T accident) UMBRELLA LIAS EACH OCCURRENCE CLAIMS-MADE AGGREGATE
  DEDUCTIBLE RETENTION WORKERS COMPENSATION AND EMPLOYERS' LIABILITY ANY
  PROPRIETOR / PARTNER / EXECUTIVE OFFICER/MEMBER EXCLUDED? (Mandatory In NH)
  II yes. describe under DESCRIPTION OF OPERATIONS
  below Y / N OTHJIB. EL. EACH ACCIDENT E.L DISEASE-EA EMPLOYEE E L
  DISEASE-POLICY LIMIT Poll Legal Liab 10/31/2006
  11/01/2016 Aggregate SIR $ 1 j*Z & DESCRIPTION OF OPERATIONS / LOCATIONS
  /VEHICLES (Altech ACORD 101. Additional Remarks
  Schedule. If more space is required) Location: 1040 spring Street, Silver
  Spring, M D . Certificate Holder is included as
  additional insured ATIMA. CERTIFICATE HOLDER CANCELLATION wells Fargo Bank
  National Association As the Administrative Agent Attn: John D. Altmeyer 301 South college street, 8th Floor Charlotte NC
  28288 USA SHOULD AMY OF THE ABOVE DESCRIBED POLICIES BE CANCELLED BEFORE THE
  EXPIRATION DATE THEREOF, NOTICE WILL BE DELIVERED IN ACCORDANCE WITH THE
  POLICY PROVISIONS. AUTHORIZED REPRESENTATIVE ACORD 25 (2009/09) ©1988-2009
  ACORD CORPORATION. All rights reserved. The ACORD name and logo are
  registered marks of ACORD [***] [***] [***] 

  

 

	
  

  	
  ACORD*
  CERTIFICATE OF LIABILITY INSURANCE DATE (MM/DD/YYYY) 12/16/2010 THIS
  CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS
  UPON THE CERTIFICATE HOLDER. THIS CERTIFICATE DOES NOT AFFIRMATIVELY OR
  NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES
  BELOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A CONTRACT BETWEEN
  THE ISSUING INSURER(S), AUTHORIZED REPRESENTATIVE OR
  PRODUCER, AND THE CERTIFICATE HOLDER. IMPORTANT: If the certificate holder is
  an ADDITIONAL INSURED, the policy(les) must be
  endorsed. If SUBROGATION IS WAIVED, subject to the terms and conditions of
  the policy, certain policies may require an endorsement A statement on this
  certificate does not confer rights to the certificate holder in lieu of such
  endorsement(s). PRODUCER Aon Risk services Northeast, Inc. New York NY office
  199 water Street New York NY 10038-3551 USA INSURED United Therapeutics Corp.
  1735 Connecticut Avenue NW Washington DC 20009 USA CONTACT NAME: PHONE (A/C.
  No. Ext): (866) 283-7122 FAX (A/C. No.(847) 953-5390
  E-MAIL ADDRESS PRODUCER 10242617 CUSTOMER ID*: INSURER(S) AFFORDING COVERAGE
  INSURER A: Chartis Specialty Insurance Company
  INSURER B: INSURER C: INSURER D: INSURER E: INSURER F: NAIC 26883 COVERAGES
  CERTIFICATE NUMBER: 570041040568 REVISION NUMBER: THIS IS TO CERTIFY THAT THE
  POLICIES OF INSURANCE LISTED BELOW HAVE BEEN ISSUED TO THE INSURED NAMED
  ABOVE FOR THE POLICY PERIOD INDICATED. NOTWITHSTANDING ANY REQUIREMENT. TERM
  OR CONDITION OF ANY CONTRACT OR OTHER DOCUMENT WITH RESPECT TO WHICH THIS CERTIFICATE
  MAY BE ISSUED OR MAY PERTAIN, THE INSURANCE AFFORDED BY THE POLICIES
  DESCRIBED HEREIN IS SUBJECT TO ALL THE TERMS, EXCLUSIONS AND CONDITIONS OF
  SUCH POLICIES. LIMITS SHOWN MAY HAVE BEEN REDUCED BY PAID CLAIMS. Limits
  shown are as requested UJSRI JJS. AONJ5UBA1 MSR WVD POLICY EFF MM/DD/YYYY POLICY
  EXP MM/DD/YYYY TYPE OF INSURANCE POLICY NUMBER WOTS GENERAL LIABILITY
  COMMERCIAL GENERAL LIABILITY CLAIMS-MADE II OCCUR EACH OCCURRENCE DAMAGE TO
  RENTED PREMISES IE8 occurrence! MEO EXP (Any one person) PERSONAL & ADV
  INJURY GENERAL AGGREGATE GEWL AGGREGATE LIMIT APPLIES PER: POLICY PRODUCTS -
  COMP/OP AGO AUTOMOBILE LIABILITY ANY AUTO ALL OWNED AUTOS SCHEDULED AUTOS
  HIRED AUTOS NON OWNED AUTOS COMBINED SINGLE LIMIT (Each person) BODILY INJURY
  ( Per person) BODILY INJURY (Per person) PROPERTY DAMAGE (Per accident)
  UMBRELLA LIAB EACH OCCURRENCE CLAIMS-MADE AGGREGATE DEDUCTIBLE RETENTION
  WORKERS COMPENSATION AND EMPLOYERS' LIABILITY ANY PROPRIETOR / PARTNER /
  EXECUTIVE OFFICER/MEMBER EXCLUDED (Mandatory In NH) K yes, describe under
  DESCRIPTION OF OPERATIONS below a OTHER. EACH ACCIDENT El. CHSEASE-EA
  EMPLOYEE EL. DISEASE-POLICY LIMIT poll Legal Liab
  10/31/2006 11/01/2016 Aggregate SIR 1 J & DESCRIPTION OF OPERATIONS /
  LOCATIONS / VEHICLES (Attach ACORD 101. Additional Remarks Schedule, if more
  space Is required) Location: 55 TW Alexander Drive, Durham, NC. Certificate
  Holder is included as additional insured ATIMA. CERTIFICATE HOLDER
  CANCELLATION wells Fargo Bank National Association As the Administrative
  Agent Attn: john a. Altmeyer 301 South College
  Street, 8th Floor Charlotte NC 28288 USA SHOULD ANY OF THE ABOVE DESCRIBED
  POLICIES BE CANCELLED BEFORE THE EXPIRATION DATE THEREOF. NOTICE WILL BE
  DELIVERED IN ACCORDANCE WITH THE POLICY PROVISIONS. AUTHORIZED REPRESENTATIVE  ACORD
  25 (2008/09) ©1988-2009 ACORD CORPORATION. All rights reserved. The ACORD
  name and logo are registered marks of ACORD $[***] $[***] [***] 

  

 

 

 

Schedule 5.14

 

Mortgaged Property Modifications

 

Maryland Mortgaged Property

 

The United Therapeutics project will include two office buildings, 1040 Spring Street (delivered 12/2009) and 1110 Spring Street (to be delivered 12/2011), each building being ninety feet (90’) high, one on the southwest corner of Cameron Street at its intersection with Spring Street and one at the southeast corner of Cameron Street at its intersection of Spring Street.   United Therapeutics has received, through the volumetric abandonment of space in air rights above the public road, rights to construct a connector across Cameron Street to connect the 6th floor of each of the two office buildings.

 

The building connector will be a private interior conditioned space connecting corridor spanning Cameron Street at the sixth floor between the two office buildings allowing for safe and efficient flow of people working and visiting the project across Cameron Street.  This connector enables the two office buildings and the adjacent laboratory facility to function as an integrated whole, effectively transforming two small urban parcels that are divided by a public street into a viable campus for a single owner/user.  Each parcel individually would be too small for United Therapeutics’ project requirements; however, the sixth floor connector makes possible the efficient movement and access necessary to support the varying internal functions and requirements of a growing biotechnology company, including stringent “clean room” laboratory environmental controls.  With the connector, the two sites function together to support the operational needs of the company.

 

North Carolina Mortgaged Property

 

The Phase II Facility Expansion project will expand existing operations in RTP to include additional GMP warehousing space, manufacturing/packaging space, office space, a daycare center and parking deck, along with a mechanical penthouse and various support spaces.

 

The expansion provides a 3-story building configuration at the Daycare/Office Area and a 2-story building configuration at the manufacturing area with roof level penthouse, all contained in approximately 184,599 square feet of space. In addition to the building expansion, this project will include converting the northern most bay of the existing packaging area currently used as offices into packaging halls (approximately 4,315 square feet). As part of this conversion, limited expansion of the existing second floor mechanical area across this third bay will be included (approximately 3,612 square feet).  First and second floor connecting corridors will provide access between the existing and new areas of the facility.  The total square footage of work area including new building addition, renovation of existing third bay and new mechanical platform at the second floor level of third bay is approximately 192,486 square feet.

 

The building expansion will also include the addition of a parking deck that will accommodate existing and future UT employee parking demand.  This parking deck will accommodate approximately 388 automobiles and is expected to be of a pre-cast design and will include

 

1

 

ground and 4-elevated levels of parking with dual, gated entrance/exit locations, elevator and architectural features that will allow the deck to blend into the building expansion.  The parking deck will be located in the area presently occupied by the north parking lots.

 

The intent of the design will be to provide a cGMP compliant design for the warehouse and manufacturing/packaging areas as well as architecturally blend the new building addition and parking deck with the existing building architecture and match the design features of the original building.  Elements of the expansion include:

 

·      The new GMP Warehouse will include an ASRS capable of providing approximately 2,000 pallet storage spaces.  The warehouse area will also accommodate secure cage storage areas for labels, clinical and reject products.

 

·      New shipping/receiving area with open office area.

 

·      Eight (8) new packaging halls design with unidirectional flow of materials and low air returns in shared chases between rooms.  Support spaces including a new central gowning, restrooms and shower facilities to accommodate new packaging halls and existing manufacturing area, new break room and vending area.  Second floor future manufacturing space also included.

 

·      The Daycare Center and outside playground area will be designed to accommodate up to 58 students ranging from infants to afterschool care.

 

·      New office areas designed to accommodate approximately 190 staff that will include restroom facilities, central file storage area, data center, training room, printer room, conference rooms and various gathering seating areas and circular staircase at center of “horseshoe” communicating with all three levels.

 

·      Roof terrace located above second floor office area.

 

·      Rain water collection system that will be used as a source of irrigation for the site.  The rain water is expected to be directed to the east side of the site and collected in a 10,000 gallon above ground tank.

 

·      The addition of a fourth 1,000 ton chiller/cooling tower set, including chilled water pump, condenser water pump and controls, process waste neutralization system capable of processing waste from the existing facility and the new expansion and a new 100KW solar panel system planned to be installed above the upper level of the parking deck.

 

2

 

Schedule 6.1(d)

 

Existing Liens

 

UNITED THERAPEUTICS CORPORATION

 

UCC Search Results Summary

 

	
Jurisdiction
    	
 
    	
Secured Party
    	
 
    	
UCC File
   Number
    	
 
    	
Date
   Filed
    	
 
    	
Brief Description of
   Collateral
    	
 
    	
Searched
   Through
    
	
Delaware Secretary of State
    	
 
    	
U.S. Bancorp
    	
 
    	
90653003
    	
 
    	
02/27/09
    	
 
    	
1 MXM550N 85015019;
   1 MXM550N 85015179;
   1 MXM550N 85014289;
   1MXM550N 85000837
    	
 
    	
11/22/10
    
	
Delaware Secretary of State
    	
 
    	
De Lage Landen Financial Services, Inc.
    	
 
    	
90795705
    	
 
    	
03/05/09
    	
 
    	
All right, title and interest in equipment under   Master Lease Agreement dated 3/15/09 including replacements, substitutions   and proceeds
    	
 
    	
11/22/10
    
	
Delaware Secretary of State
    	
 
    	
Crown Credit Company  Other Debtor: Lung Rx, Inc.
    	
 
    	
90771086
    	
 
    	
03/11/09
    	
 
    	
Equipment listed on Exhibit A including replacements,   accessions, substitutions and proceeds
    	
 
    	
11/22/10
    
	
Delaware Secretary of State
    	
 
    	
U.S. Bancorp
    	
 
    	
91357406
    	
 
    	
04/29/09
    	
 
    	
1 SM550N 85003747BP;
   1 SM550N 85002169BP;
   1 SM550N 85002179BP
    	
 
    	
11/22/10
    
	
Delaware Secretary of State
    	
 
    	
Noreast Capital Corporation
    	
 
    	
94120132
    	
 
    	
12/23/09
    	
 
    	
8 water coolers located at three locations on Spring   Street in Silver Spring, Maryland
    	
 
    	
11/22/10
    
	
Delaware Secretary of State
    	
 
    	
Wilmington Trust Company, not in its individual   capacity but solely as owner trustee under Trust Agreement dated April 3,   2006
    	
 
    	
03655127
    	
 
    	
10/13/10
    	
 
    	
All right, title and interest in Aircraft pursuant to   Aircraft Lease Agreement (S/N 648) dated as of October 7, 2010, including   logs, manuals, accounts and proceeds
    	
 
    	
11/22/10
    

 

 

	
Jurisdiction
    	
 
    	
Secured Party
    	
 
    	
UCC File
   Number
    	
 
    	
Date
   Filed
    	
 
    	
Brief Description of
   Collateral
    	
 
    	
Searched
   Through
    
	
Delaware Secretary of State
    	
 
    	
Bank of America Leasing & Capital, LLC
    Additional Secured Party: Wilmington Trust Company,   not in its individual capacity but solely as owner trustee under Trust   Agreement dated April 3, 2006
    	
 
    	
03655291
    	
 
    	
10/13/10
    	
 
    	
Security Deposit Rider to Aircraft Lease Agreement   (S/N 648) dated as of October 7, 2010
    	
 
    	
11/22/10
    

 

 

Schedule 6.3

 

Permitted Affiliate Transactions

 

1.                           Intercompany transfer of Tyvaso commercial operations (including, but not limited to, inventory and selected liabilities, warranties, revenues and returns) from Lung Rx, LLC, to United Therapeutics Corporation.

 

2.                           Intercompany transfer of Adcirca commercial operations (including, but not limited to, inventory and selected liabilities, warranties, revenues and returns) from United Therapeutics Corporation to Lung Rx.

 

 

EXHIBIT 1.1(a)

 

FORM OF
  ACCOUNT DESIGNATION NOTICE

 

	
TO:
    	
 
    	
Wells   Fargo Bank, National Association, as Administrative Agent
    
	
 
    	
 
    	
 
    
	
RE:
    	
 
    	
Credit   Agreement, dated as of December 27, 2010 by and among United   Therapeutics Corporation, a Delaware corporation (the “Borrower”), the   Guarantors, the Lenders and Wells Fargo Bank, National Association, as   Administrative Agent for the Lenders (as amended, modified, extended,   restated, replaced, or supplemented from time to time, the “Credit   Agreement”; capitalized terms used herein and not otherwise defined shall   have the meanings set forth in the Credit Agreement)
    
	
 
    	
 
    	
 
    
	
DATE:
    	
 
    	
[Date]
    

 

 

The Administrative Agent is hereby authorized to disburse the Loan proceeds into the following account, unless the Borrower shall designate, in writing to the Administrative Agent, one or more other accounts:

 

Bank Name:  [                                            ]

 

ABA Routing Number:  [                                            ]

 

Account Number:  [                                            ]

 

[TO BE COMPLETED BY BORROWER]

 

This Account Designation Notice may, upon execution, be delivered by facsimile or electronic mail, which shall be deemed for all purposes to be an original signature.

 

[remainder of page intentionally left blank]

 

 

	
 
    	
UNITED   THERAPEUTICS CORPORATION, a Delaware corporation
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
					

 

 

EXHIBIT 1.1(b)

 

FORM OF
  ASSIGNMENT AND ASSUMPTION

 

This Assignment and Assumption (the “Assignment and Assumption”) is dated as of the Effective Date set forth below and is entered into by and between [the] [each] Assignor identified in item 1 below ([the] [each, an] “Assignor”) and [the] [each] Assignee identified in item 2 below ([the] [each, an] “Assignee”).  [It is understood and agreed that the rights and obligations of [the Assignors] [the Assignees] hereunder are several and not joint.](1)  Capitalized terms used but not defined herein shall have the meanings given to them in the Credit Agreement identified below (as amended, the “Credit Agreement”), receipt of a copy of which is hereby acknowledged by [the] [each] Assignee.  The Standard Terms and Conditions set forth in Annex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption as if set forth herein in full.

 

For an agreed consideration, [the] [each] Assignor hereby irrevocably sells and assigns to [the Assignee] [the respective Assignees], and [the] [each] Assignee hereby irrevocably purchases and assumes from [the Assignor] [the respective Assignors], subject to and in accordance with the Standard Terms and Conditions and the Credit Agreement, as of the Effective Date inserted by the Administrative Agent as contemplated below (i) all of [the Assignor’s] [the respective Assignors’] rights and obligations in [its capacity as a Lender] [their respective capacities as Lenders] under the Credit Agreement and any other documents or instruments delivered pursuant thereto to the extent related to the amount and percentage interest identified below of all of such outstanding rights and obligations of [the Assignor] [the respective Assignors] under the respective facilities identified below and (ii) to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and any other right of [the Assignor (in its capacity as a Lender)] [the respective Assignors (in their respective capacities as Lenders)] against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or in any way based on or related to any of the foregoing, including, but not limited to, contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related to the rights and obligations sold and assigned pursuant to clause (i) above (the rights and obligations sold and assigned by [the] [any] Assignor to [the] [any] Assignee pursuant to clauses (i) and (ii) above being referred to herein collectively as [the] [an] “Assigned Interest”).  Each such sale and assignment is without recourse to [the] [any] Assignor and, except as expressly provided in this Assignment and Assumption, without representation or warranty by [the] [any] Assignor.

 

	
1.
    	
Assignor[s]:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
2.
    	
Assignee[s]:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
for   each Assignee, indicate [Affiliate] [Approved   Fund] of [identify Lender]
    

 

(1)  Include bracketed language if there are either multiple Assignors or multiple Assignees.

 

 

3.             Borrower:

 

United Therapeutics Corporation, a Delaware corporation

 

4.             Administrative Agent:

 

Wells Fargo Bank, National Association, as the administrative agent under the Credit Agreement

 

5.             Credit Agreement:

 

The Credit Agreement dated as of December 27, 2010 among the Borrower, the guarantors from time to time party thereto, the lenders and other financial institutions from time to time party thereto, and Wells Fargo Bank, National Association, as Administrative Agent.

 

6.             Assigned Interest[s]:

 

	
Assignor[s]
    	
 
    	
Assignee[s]
    	
 
    	
Facility
   Assigned
    	
 
    	
Aggregate
   Amount of Loan
   Commitment/
   Loans for all
   Lenders
    	
 
    	
Amount of
   Loan
   Commitment/
   Loans
   Assigned
    	
 
    	
Percentage
   Assigned of Loan
   Commitment/
   Loans
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
$
    	
 
    	
 
    	
$
    	
 
    	
 
    	
 
    	
%
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
$
    	
 
    	
 
    	
$
    	
 
    	
 
    	
 
    	
%
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
$
    	
 
    	
 
    	
$
    	
 
    	
 
    	
 
    	
%
    

 

[7.          Trade Date:                                     ](2)

 

Effective Date:                                                 , 20          .

 

[remainder of page intentionally left blank]

 

(2)  To be completed if the Assignor(s) and the Assignee(s) intend that the minimum assignment amount is to be determined as of the Trade Date.

 

 

The terms set forth in this Assignment and Assumption are hereby agreed to:

 

 

	
 
    	
ASSIGNOR[S]:
    
	
 
    	
 
    
	
 
    	
[NAME   OF ASSIGNOR]
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
					

 

[signature pages continue]

 

 

	
 
    	
ASSIGNEE[S]:
    
	
 
    	
 
    
	
 
    	
[NAME   OF ASSIGNEE]
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
					

 

[signature pages continue]

 

 

[Consented to and] Accepted:]

 

	
 
    	
WELLS   FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
					

 

[signature pages continue]

 

 

[Consented to:]

 

	
 
    	
UNITED   THERAPEUTICS CORPORATION, a Delaware corporation
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
					

 

[signature pages end]

 

 

ANNEX 1

 

STANDARD TERMS AND CONDITIONS FOR
 ASSIGNMENT AND ASSUMPTION

 

1.             Representations and Warranties.

 

1.1           Assignor[s].  [The] [Each] Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of [the] [the relevant] Assigned Interest, (ii) [the] [such] Assigned Interest is free and clear of any lien, encumbrance or other adverse claim and (iii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby; and (b) assumes no responsibility with respect to (i) any statements, warranties or representations made in or in connection with the Credit Agreement or any other Credit Document, (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Credit Documents or any collateral thereunder, (iii) the financial condition of the Borrower, any of its Subsidiaries or Affiliates or any other Person obligated in respect of any Credit Document or (iv) the performance or observance by the Borrower, any of its Subsidiaries or Affiliates or any other Person of any of their respective obligations under any Credit Document.

 

1.2.          Assignee[s].  [The] [Each] Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement, (ii) it meets all the requirements to be an assignee under Sections 9.6(b)(v) and (vi) of the Credit Agreement (subject to such consents, if any, as may be required under Section 9.6(b) of the Credit Agreement), (iii) from and after the Effective Date, it shall be bound by the provisions of the Credit Agreement as a Lender thereunder and, to the extent of [the] [the relevant] Assigned Interest, shall have the obligations of a Lender thereunder, (iv) it is sophisticated with respect to decisions to acquire assets of the type represented by the Assigned Interest and either it, or the person exercising discretion in making its decision to acquire the Assigned Interest, is experienced in acquiring assets of such type, (v) it has received a copy of the Credit Agreement, and has received or has been accorded the opportunity to receive copies of the most recent financial statements delivered pursuant to Section 5.1 thereof, as applicable, and such other documents and information as it deems appropriate to make its own credit analysis and decision to enter into this Assignment and Assumption and to purchase [the] [such] Assigned Interest, (vi) it has, independently and without reliance upon the Administrative Agent or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Assignment and Assumption and to purchase [the] [such] Assigned Interest, and (vii) if it is a Foreign Lender, attached to the Assignment and Assumption is any documentation required to be delivered by it pursuant to the terms of the Credit Agreement, duly completed and executed by [the] [such] Assignee; and (b) agrees that (i) it will, independently and without reliance on the Administrative Agent, [the] [any] Assignor or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Documents, and (ii) it will perform in accordance with their terms all of the obligations which by the terms of the Credit Documents are required to be performed by it as a Lender.

 

2.             Payments.  From and after the Effective Date, the Administrative Agent shall make all payments in respect of [the] [each] Assigned Interest (including payments of principal, interest, fees and

 

 

other amounts) to [the] [the relevant] Assignor for amounts which have accrued to but excluding the Effective Date and to [the] [the relevant] Assignee for amounts which have accrued from and after the Effective Date.

 

3.             General Provisions.  This Assignment and Assumption shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors and assigns.  This Assignment and Assumption may be executed in any number of counterparts, which together shall constitute one instrument.  Delivery of an executed counterpart of a signature page of this Assignment and Assumption by telecopy shall be effective as delivery of a manually executed counterpart of this Assignment and Assumption.  This Assignment and Assumption shall be governed by, and construed in accordance with, the law of the State of New York.

 

 

EXHIBIT 1.1(c)

 

FORM OF
  SECURED PARTY DESIGNATION NOTICE

 

TO:                                                                            Wells Fargo Bank, National Association, as Administrative Agent

 

RE:                                                                              Credit Agreement, dated as of December 27, 2010 by and among United Therapeutics Corporation, a Delaware corporation (the “Borrower”), the Guarantors, the Lenders and Wells Fargo Bank, National Association, as Administrative Agent for the Lenders (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)

 

DATE:                                                           [Date]

 

[Name of Hedging Agreement Provider] (the “Lender”) hereby notifies you, pursuant to the terms of the Credit Agreement, that the Lender meets the requirements of a Hedging Agreement Provider under the terms of the Credit Agreement and is a Hedging Agreement Provider under the Credit Agreement and the other Credit Documents.

 

Delivery of this Notice by telecopy shall be effective as an original.

 

A duly authorized officer of the undersigned has executed this Notice as of the            day of              ,              .

 

 

	
 
    	
                                                   ,
    
	
 
    	
as   a Hedging Agreement Provider
    
	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    

 

 

EXHIBIT 1.1(d)

 

FORM OF
  JOINDER AGREEMENT

 

THIS JOINDER AGREEMENT (this “Agreement”), dated as of [Month] [Day], [Year] is by and among [NAME OF SUBSIDIARY GUARANTOR], a [Jurisdiction and Type of Organization] (the “Subsidiary Guarantor”), United Therapeutics Corporation, a Delaware corporation (the “Borrower”), and Wells Fargo Bank, National Association, in its capacity as administrative agent (in such capacity, the “Administrative Agent”) under that certain Credit Agreement, dated as of December 27, 2010 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”) by and among the Borrower, the Guarantors, the Lenders and the Administrative Agent.  Capitalized terms used herein but not otherwise defined shall have the meanings provided in the Credit Agreement.

 

The Subsidiary Guarantor is an Additional Credit Party, and, consequently, the Credit Parties are required by Section 5.9 of the Credit Agreement to cause the Subsidiary Guarantor to become a “Guarantor”.

 

Accordingly, the Subsidiary Guarantor and the Borrower hereby agree as follows with the Administrative Agent, for the benefit of the Lenders:

 

1.             The Subsidiary Guarantor hereby acknowledges, agrees and confirms that, by its execution of this Agreement, the Subsidiary Guarantor will be deemed to be a “Guarantor” under the Guaranty Agreement, the Credit Agreement and the Environmental Indemnity and shall have all of the obligations of a Guarantor thereunder as if it had executed the Guaranty Agreement, the Credit Agreement and the Environmental Indemnity.  The Subsidiary Guarantor hereby ratifies, as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions contained in the Guaranty Agreement and the other applicable Credit Documents, including, without limitation (a) the representations and warranties (as such relate to the Subsidiary Guarantor) set forth in Sections 3.3, 3.4, 3.5, 3.19, 3.20, 3.21 and 3.22 of the Credit Agreement, (b) all of the affirmative and negative covenants set forth in Articles V and VI of the Credit Agreement, (c) the miscellaneous provisions set forth in Article IX of the Credit Agreement and (d) the provisions of the Environmental Indemnity.  Without limiting the generality of the foregoing terms of this Paragraph 1, the Subsidiary Guarantor hereby guarantees, jointly and severally together with the other Guarantors, the prompt payment of the Credit Party Obligations in accordance with the Guaranty Agreement.

 

2.             The Subsidiary Guarantor acknowledges and confirms that it has received a copy of the Credit Documents and the schedules and exhibits to each of the foregoing as applicable.

 

3.             The information on Schedule A to this Joinder Agreement is true and correct as of the date hereof.

 

4.             The Borrower confirms that the Credit Documents are, and upon the Subsidiary Guarantor becoming a Guarantor, shall continue to be, in full force and effect.  The parties hereto confirm and agree that immediately upon the Subsidiary Guarantor becoming a Guarantor the term “Credit Party Obligations,” as used in the Credit Documents, shall include all obligations of the Subsidiary Guarantor under the Guaranty Agreement and under each other Credit Document.

 

 

5.             Each of the Borrower and the Subsidiary Guarantor agrees that at any time and from time to time, upon the written request of the Administrative Agent, it will execute and deliver such further documents and do such further acts as the Administrative Agent may reasonably request in accordance with the terms and conditions of the Credit Documents in order to effect the purposes of this Agreement.

 

6.             This Agreement (a) may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute one contract and (b) may, upon execution, be delivered by facsimile or electronic mail, which shall be deemed for all purposes to be an original signature.

 

7.             This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York.  The terms of Sections 9.13 and 9.16 of the Credit Agreement are incorporated herein by reference, mutatis mutandis, and the parties hereto agree to such terms.

 

[remainder of page intentionally left blank]

 

 

IN WITNESS WHEREOF, each of the Borrower and the Subsidiary Guarantor has caused this Agreement to be duly executed by its authorized officer, and the Administrative Agent, for the benefit of the Lenders, has caused the same to be accepted by its authorized officer, as of the day and year first above written.

 

 

	
 
    	
SUBSIDIARY   GUARANTOR:
    
	
 
    	
 
    
	
 
    	
[NAME   OF SUBSIDIARY GUARANTOR], a [Jurisdiction   and Type of Organization]
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:__________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    

 

 

	
 
    	
BORROWER:
    
	
 
    	
 
    
	
 
    	
UNITED   THERAPEUTICS CORPORATION, a Delaware corporation
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    

 

 

	
Acknowledged,   accepted and agreed:
    
	
 
    
	
WELLS   FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent
    
	
 
    
	
 
    
	
By:_________________________________________________
    
	
Name:______________________________________________
    
	
Title:_______________________________________________
    

 

 

Schedule A

 

Disclosure Information

 

	
Legal   Name of Credit Party (and any previous legal names within the past four   months):
    	
 
    
	
State   of Organization:
    	
 
    
	
Jurisdictions   of Organization:
    	
 
    
	
Type   of Organization:
    	
 
    
	
Address   of Chief Executive Office:
    	
 
    
	
Address   of Principal Place of Business:
    	
 
    
	
Business   Phone Number:
    	
 
    
	
Organizational   Identification Number(1):
    	
 
    
	
Federal   Tax Identification Number:
    	
 
    
	
Ownership   Information (e.g. publicly held, if private or partnership—identity of   owners/partners):
    	
 
    

 

[TO BE COMPLETED BY BORROWER/SUBSIDIARY GUARANTOR]

 

(1)  This item does not apply to a Credit Party organized under the laws of Alabama, Indiana, Massachusetts, Nebraska, New Hampshire, New Mexico, New York, Oklahoma, South Carolina, Vermont or West Virginia.

 

 

 

EXHIBIT 1.1(e)

 

FORM OF
  NOTICE OF BORROWING

 

TO:                                                                            Wells Fargo Bank, National Association, as Administrative Agent

 

RE:                                                                              Credit Agreement, dated as of December 27, 2010 by and among United Therapeutics Corporation, a Delaware corporation (the “Borrower”), the Guarantors, the Lenders and Wells Fargo Bank, National Association, as Administrative Agent for the Lenders (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)

 

DATE:                                                           [Closing Date]

 

Pursuant to Section 2.1(a) of the Credit Agreement, the Borrower hereby requests the following (the “Proposed Borrowing”):

 

Loan to be made as follows(1):

 

	
Date
    	
 
    	
Amount
    	
 
    	
Interest Rate(2)
    
	
Closing Date
    	
 
    	
$
    	
70,000,000
    	
 
    	
LIBOR Rate per funding indemnity agreement
    
						

 

The undersigned hereby certifies that the following statements are true on the date hereof and will be true on the date of the Proposed Borrowing:

 

(a)           The representations and warranties made by the Credit Parties in the Credit Agreement, in the Security Documents or which are contained in any certificate furnished at any time under or in connection with the Credit Agreement shall be (i) with respect to representations and warranties that contain a materiality qualification, true and correct and (ii) with respect to representations and warranties that do not contain a materiality qualification, true and correct in all material respects, in each case on and as of the date of the Proposed Borrowing as if made on and as of such date except for any representation or warranty made as of an earlier date, which representation and warranty shall remain true and correct as of such earlier date.

 

(b)           No Default or Event of Default shall have occurred and be continuing on the date of the Proposed Borrowing or after giving effect to the Proposed Borrowing unless such Default or Event of Default shall have been waived in accordance with the Credit Agreement.

 

This Notice of Borrowing may, upon execution, be delivered by facsimile or electronic mail, which shall be deemed for all purposes to be an original signature.

 

[remainder of page intentionally left blank]

 

(1)  Only to be used on the Closing Date.

(2)  LIBOR Rate is only available after the Closing Date.

 

 

	
 
    	
UNITED   THERAPEUTICS CORPORATION, a Delaware corporation
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    

 

 

EXHIBIT 1.1(f)

 

FORM OF
  NOTICE OF CONVERSION/EXTENSION

 

TO:                         Wells Fargo Bank, National Association, as Administrative Agent

 

RE:                          Credit Agreement, dated as of December 27, 2010 by and among United Therapeutics Corporation, a Delaware corporation (the “Borrower”), the Guarantors, the Lenders and Wells Fargo Bank, National Association, as Administrative Agent for the Lenders (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)

 

DATE:                    [Date]

 

Pursuant to Section 2.5 of the Credit Agreement, the Borrower hereby requests             conversion or             extension of the following Loans be made as follows (the “Proposed Conversion/Extension”):

 

	
Applicable Loan
    	
 
    	
Current
   Interest Rate
   and Interest
   Period
    	
 
    	
Date
    	
 
    	
Amount to
   be
   converted/
   extended
    	
 
    	
Requested Interest
   Rate (Alternate
   Base Rate/LIBOR
   Rate)
    	
 
    	
Interest Period (one month
   — for LIBOR Rate only)
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement.

 

The undersigned hereby certifies that no Default or Event of Default has occurred and is continuing or would result from such Proposed Conversion/Extension or from the application of the proceeds thereof unless such Default or Event of Default shall have been waived in accordance with the Credit Agreement.

 

This Notice of Conversion/Extension may, upon execution, be delivered by facsimile or electronic mail, which shall be deemed for all purposes to be an original signature.

 

[remainder of page intentionally left blank]

 

 

	
 
    	
UNITED   THERAPEUTICS CORPORATION, a Delaware corporation
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    
	
 
    	
 
    

 

EXHIBIT 1.1(g)

 

FORM OF
  GUARANTY AGREEMENT

 

THIS GUARANTY AGREEMENT is made as of [                    ], 2010 (as amended, modified, extended, restated, replaced or supplemented from time to time, this “Guaranty Agreement”), by each of the entities referenced on the signature pages hereto as a guarantor or any Subsidiary which otherwise becomes a party to this Agreement by execution of a Joinder Agreement (individually, a “Guarantor” and collectively, the “Guarantors”), in favor of the Administrative Agent, the Lenders, the Hedging Agreement Providers and each other beneficiary of any obligation or undertaking of United Therapeutics Corporation, a Delaware corporation (the “Borrower”) (the Administrative Agent, the Lenders, the Hedging Agreement Providers and each such other beneficiary may be referred to herein, individually, as a “Beneficiary” and collectively, as the “Beneficiaries”).  Except as otherwise defined herein, capitalized terms used herein and not defined herein shall have the respective meanings set forth in the Credit Agreement, dated as of December 27, 2010 (as amended, modified, extended, restated, replaced or supplemented from time to time, the “Credit Agreement”) by and among the Administrative Agent, the Lenders, the Borrower and the Guarantors party thereto.

 

WHEREAS, as an inducement to the Administrative Agent and the Lenders to enter into the Credit Agreement and the other Credit Documents from time to time and to consummate the transactions contemplated thereby, each of the Guarantors has agreed to guarantee, as hereinafter provided, the Borrower’s obligations under the Credit Agreement and the other Credit Documents; and

 

WHEREAS, as an inducement to the Hedging Agreement Providers to enter into the Secured Hedging Agreements from time to time and to consummate the transactions contemplated thereby, each of the Guarantors has agreed to guarantee, as hereinafter provided, the obligations of the Credit Parties under the Secured Hedging Agreements.

 

NOW, THEREFORE, in consideration of the execution and delivery of the Credit Agreement, the consummation of the transactions contemplated thereby and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, each of the Guarantors hereby agrees as follows:

 

1.             Guaranty.  In order to induce the Lenders to enter into the Credit Agreement and the other Credit Documents and to extend credit and to undertake other obligations thereunder and in recognition of the financial benefits to be received by the Guarantors from the Extensions of Credit under the Credit Agreement and in order to induce the Hedging Agreement Providers to enter into Secured Hedging Agreements from time to time, each of the Guarantors hereby agrees with the Beneficiaries as follows:  each of the Guarantors hereby unconditionally and irrevocably jointly and severally guarantees as primary obligor and not merely as surety the full and prompt payment and performance when due, whether upon maturity, by acceleration or otherwise, of any and all Credit Party Obligations.  For purposes of this Guaranty Agreement, the Credit Documents and the Secured Hedging Agreements may be referred to herein, individually, as a “Document” and collectively, as the “Documents”.  If any or all of the indebtedness under the Documents becomes due and payable or any or all of the other obligations under the Documents are not fully satisfied, each of the Guarantors unconditionally promises to pay such indebtedness and to perform such obligations to or in favor of the Beneficiaries or to their respective order, on demand, together with any and all reasonable expenses which may be incurred by the Beneficiaries in collecting or enforcing any of the Credit Party Obligations.  The guaranty set forth in this Guaranty Agreement is a guaranty of timely payment and performance and not of collection.  The word

 

 

“indebtedness” is used in this Guaranty Agreement in its most comprehensive sense and includes, without limitation, any and all advances, debts, obligations and liabilities of the Credit Parties under the Documents, including, without limitation, specifically all Credit Party Obligations, arising in connection with any of the Documents, in each case, heretofore, now, or hereafter made, incurred or created under the Documents, whether voluntarily or involuntarily, absolute or contingent, liquidated or unliquidated, determined or undetermined, whether or not such indebtedness under the Documents is from time to time reduced, or extinguished and thereafter increased or incurred, whether any Credit Party may be liable individually or jointly with others under the Documents, whether or not recovery upon such indebtedness under the Documents may be or hereafter become barred by any statute of limitations, and whether or not such indebtedness under the Documents may be or hereafter become otherwise unenforceable.

 

Notwithstanding any provision to the contrary contained in this Guaranty Agreement or in any of the Documents, to the extent the obligations of any Guarantor shall be adjudicated to be invalid or unenforceable for any reason (including, without limitation, because of any applicable state or federal law relating to fraudulent conveyances or transfers) then the obligations of each such Guarantor hereunder shall be limited to the maximum amount that is permissible under applicable law (whether federal or state and including, without limitation, the Bankruptcy Code).

 

2.             No Discharge.  The obligations of each of the Guarantors hereunder are absolute, unconditional and irrevocable and will not be discharged by, and this Guaranty Agreement shall remain in full force and effect notwithstanding: (a) the assignment, conveyance or other transfer by any Beneficiary of any or all of its interest under the Documents; or (b) any insolvency, bankruptcy, reorganization, arrangement, composition, liquidation, dissolution, or similar proceedings with respect to any Credit Party; or any other occurrence whatsoever, except timely payment and timely performance in full of all Credit Party Obligations in accordance with the terms and conditions of the Documents; or (c) any other circumstances whatsoever which might otherwise constitute a legal or equitable discharge, release or defense of a guarantor or surety, or which might otherwise limit recourse against any of the Guarantors.

 

3.             Bankruptcy.  Additionally, each of the Guarantors unconditionally and irrevocably guarantees jointly and severally the payment and performance of any and all Credit Party Obligations to the Beneficiaries whether or not due, owing or payable upon the occurrence of any Bankruptcy Event or any such event with regard to any Subsidiary or any Guarantor and unconditionally promises to pay and perform such Credit Party Obligations to the Beneficiaries or for the benefit of the Beneficiaries, as applicable (provided, if any such Credit Party Obligation that is a payment obligation is owing to a Lender, such payment shall be made to the Administrative Agent for the account of the Lender), or order, on demand, in lawful money of the United States.  Each of the Guarantors further agrees that to the extent that a Credit Party shall make a payment, perform an obligation or otherwise make a transfer of an interest in any property to or for the benefit of any Beneficiary, which payment, performance or transfer or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, or otherwise is avoided, and/or required to be repaid to the Credit Party, the estate of the Credit Party, a trustee, receiver or any other party under any bankruptcy law, state or federal law, common law or equitable cause, then to the extent of such avoidance or repayment, the obligation or part thereof intended to be satisfied shall be revived and continued in full force and effect as if said payment, performance or transfer had not been made or effected.

 

4.             Nature of Liability.  The liability of each of the Guarantors hereunder is exclusive and independent of any security for or other guaranty of the Credit Party Obligations whether executed by any Guarantor or by any other party, and no Guarantor’s liability hereunder shall be affected or impaired by (a) any direction as to application of payment by any Credit Party or by any other party, or (b) any other continuing or other guaranty, undertaking or maximum liability of a Guarantor or of any other party as to the Credit Party Obligations, or (c) any payment or performance on or in reduction of any such other

 

 

guaranty or undertaking, or (d) any dissolution, termination or increase, decrease or change in personnel by any Credit Party or by any other party, or (e) any payment or performance made to or for the benefit of any Beneficiary on the Credit Party Obligations which the Beneficiary repays any Credit Party pursuant to court order in any bankruptcy, reorganization, arrangement, moratorium or other debtor relief proceeding, and each of the Guarantors waives any right to the deferral or modification of its obligations hereunder by reason of any such proceeding.

 

5.             No Subrogation.  No Guarantor shall be entitled to be subrogated to any of the rights of any of the Beneficiaries against any Credit Party or any collateral, security or guarantee or right of set-off held by any of the Beneficiaries for the payment or performance of any of the Credit Party Obligations, nor shall any of the Guarantors seek or be entitled to seek any reimbursement from the Credit Parties in respect of payment or performance made by any of the Guarantors hereunder, until all of the Credit Party Obligations are paid and performed in full.

 

6.             Severability.  Any provision of this Guaranty Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

7.             Independent Obligation.  The obligations of each of the Guarantors hereunder are independent of the obligations of any other Credit Party, and a separate action or actions may be brought and prosecuted against each of the Guarantors whether or not action is brought against any other Credit Party and whether or not any other Credit Party is joined in any such action or actions.

 

8.             Authorization.  Each of the Guarantors authorizes each of the Beneficiaries without notice or demand (except as shall be required by applicable statute and cannot be waived), and without affecting or impairing its liability hereunder, from time to time to (a) renew, compromise, extend, increase, accelerate or otherwise change the time for payment of, or otherwise change the terms of the Credit Party Obligations or any part thereof in accordance with the Documents, including, without limitation, any increase or decrease of the rate of interest thereon, (b) take and hold security from any of the Guarantors or any other party for the payment and performance of this Guaranty Agreement or the Credit Party Obligations and exchange, enforce waive and release any such security, (c) apply such security and direct the order or manner of sale thereof in accordance with the Documents, (d) release or substitute any one or more endorsers, Guarantors, the Borrower or other obligors and (e) to the extent otherwise permitted herein, release or substitute any Collateral.

 

9.             Reliance.  It is not necessary for any Beneficiary to inquire into the capacity or powers of any Credit Party or the officers, directors, members, partners or agents acting or purporting to act on its behalf, and any Credit Party Obligations made or created in reliance upon the professed exercise of such powers shall be guaranteed hereunder.

 

10.           Waiver.

 

(a)           Each of the Guarantors waives any right (except as shall be required by applicable statute and cannot be waived) to require any Beneficiary to (i) proceed against any other Credit Party or any other party, (ii) proceed against or exhaust any security held from any other Credit Party or any other party, or (iii) pursue any other remedy in the Beneficiary’s power whatsoever.  Each of the Guarantors waives any defense based on or arising out of any defense of any other Credit Party or any other party other than payment and performance in full of the Credit Party, including, without limitation, any defense based on or arising out of the disability of any

 

 

other Credit Party or any other party, or the unenforceability of the Credit Party Obligations or any part thereof from any cause, or the cessation from any cause of the liability of any Credit Party other than payment and performance in full of the Credit Party Obligations.  The Administrative Agent may, at its election, foreclose on any security held by any Beneficiary, by one or more judicial or nonjudicial sales, whether or not every aspect of any such sale is commercially reasonable (to the extent such sale is permitted by applicable law), or exercise any other right or remedy the Administrative Agent or any other Beneficiary may have against any Credit Party or any other party, or any security, without affecting or impairing in any way the liability of any of the Guarantors hereunder except to the extent the Credit Party Obligations have been paid and performed in full and the Loan Commitments have been terminated.  Each of the Guarantors waives any defense arising out of any such election by any Beneficiary, even though such election operates to impair or extinguish any right of reimbursement or subrogation or other right or remedy of any Guarantor against any other Credit Party or any other party or any security.

 

(b)           Each of the Guarantors waives all presentments, demands for performance, protests and notices, including, without limitation, notices of nonperformance, notice of protest, notices of dishonor, notices of acceptance of this Guaranty Agreement, and notices of the existence, creation or incurring of new or additional Credit Party Obligations.  Each of the Guarantors assumes all responsibility for being and keeping itself informed of the financial condition and assets of the Credit Parties, and of all other circumstances bearing upon the risk of nonpayment of the Credit Party Obligations and the nature, scope and extent of the risks which such Guarantor assumes and incurs hereunder, and agrees that no Beneficiary shall have any duty to advise such Guarantor of information known to it regarding such circumstances or risks.

 

(c)           Each of the Guarantors hereby agrees it will not exercise any rights of subrogation which it may at any time otherwise have as a result of this Guaranty Agreement (whether contractual, under Section 509 of the U.S. Bankruptcy Code, or otherwise) to the claims, regarding the Credit Party Obligations, of the Beneficiaries against any other Credit Party and all contractual, statutory or common law rights of reimbursement, contribution or indemnity from any other Credit Party which it may at any time otherwise have as a result of this Guaranty Agreement until such time as the Credit Party Obligations shall have been paid in full and the Loan Commitments have been terminated.  Each of the Guarantors hereby further agrees not to exercise any right to enforce any other remedy which any Beneficiary now has or may hereafter have against any Credit Party or any endorser of all or any part of the Credit Party Obligations and any benefit of, and any right to participate in, any security or collateral given to or for the benefit of any Beneficiary to secure payment and performance of the Credit Party Obligations until such time as the Credit Party Obligations shall have been paid and performed in full and the Loan Commitments have been terminated.

 

(d)           The obligations of each of the Guarantors under this Guaranty Agreement shall be paid and performed without demand by any Beneficiary and shall be unconditional irrespective of the genuineness, validity, regularity or enforceability of any of the Documents or any other circumstance which might otherwise constitute a legal or equitable discharge of a surety or a guarantor.  Each of the Guarantors hereby waives the benefit of all principles or provisions of law, statutory or otherwise, which are or might be in conflict with the terms of this Guaranty Agreement, and agrees that the obligations of each of the Guarantors shall not be affected by any circumstances, whether or not referred to in this Guaranty Agreement, which might otherwise constitute a legal or equitable discharge of a surety or guarantor.  Each of the Guarantors hereby waives the benefits of any right of discharge under any and all statutes or other laws relating to sureties or guarantors and any other rights of sureties and guarantors thereunder.  Without

 

 

limiting the generality of the foregoing, each of the Guarantors hereby waives diligence, presentment, demand for payment, protest, and all notices which may be required by statute, rule of law or otherwise to preserve intact the Beneficiaries’ rights against each of the Guarantors under this Guaranty Agreement, including, without limitation, notice of acceptance, notice of any amendment of any Document, notice of the occurrence of any default, notice of intent to accelerate, notice of acceleration, notice of dishonor, notice of foreclosure, notice of protest, notice of the incurring by any Credit Party of any of the Credit Party Obligations, and, generally, all demands, notices and other formalities of every kind in connection with this Guaranty Agreement, and all rights to require the Beneficiaries to (i) proceed against the Borrower, (ii) proceed against or exhaust any collateral held by any Beneficiary to secure the payment of the Credit Party Obligations, or (iii) pursue any other remedy it may now or hereafter have against any Credit Party.

 

(e)           Without limiting the generality of the foregoing, each of the Guarantors waives all rights and defenses arising out of an election of remedies by any of the Beneficiaries, even though that election of remedies, such as a nonjudicial or judicial foreclosure with respect to security for the Credit Party Obligations, has destroyed each of the Guarantors’ rights of subrogation and reimbursement against the Borrower or any other Credit Party or otherwise.  In addition, each of the Guarantors waives all rights and defenses that each of the Guarantors may have because the Credit Party Obligations are secured by real property.  This means, among other things:

 

(i)            The Beneficiaries may collect from each of the Guarantors without first foreclosing on any real or personal property collateral pledged by the Borrower.

 

(ii)           If any of the Beneficiaries forecloses on any real property collateral pledged by the Borrower:

 

(A)          The amount of the Credit Party Obligations may be reduced only by the price for which that collateral is sold at the foreclosure sale, even if the collateral is worth more than the sale price.

 

(B)           The Beneficiaries may collect from each of the Guarantors even if the Beneficiaries, by foreclosing on the real property collateral, have destroyed any right any of the Guarantors may have to collect from the Borrower.

 

(f)            This is an unconditional and irrevocable waiver of any rights and defenses any of the Guarantors may have because the Credit Party Obligations are secured by real property.

 

(g)           Each of the Guarantors hereby agrees that no Guarantor shall have any right of subrogation or reimbursement against the Borrower or any other Credit Party, no right of subrogation against any collateral or security provided for in the Documents and no right of contribution against any other guarantor or pledgor unless and until the entire Loan and all other amounts and other obligations due and owing or accrued under the Documents have been paid and performed in full.  To the extent the waiver by any Guarantor of these rights of subrogation, reimbursement or contribution as set forth herein is found by a court of competent jurisdiction to be void or voidable for any reason, each of the Guarantors agrees that each of the Guarantor’s rights of subrogation and reimbursement against the Borrower or any other Credit Party and each of the Guarantor’s right of subrogation against any collateral or security shall be unconditionally junior and subordinate to the Beneficiaries’ rights against the Borrower and the other Credit Parties and to the Beneficiaries’ right, title and interest in such collateral or security, and each of

 

 

the Guarantors’ right of contribution against any other guarantor or pledgor shall be unconditionally junior and subordinate to the Beneficiaries’ rights against such other guarantor or Pledgor, unless and until the entire Loan and all other amounts and other obligations due and owing or accrued under the Documents have been paid and performed in full.

 

11.           Limitation on Enforcement.  The Beneficiaries agree that this Guaranty Agreement may be enforced only by the action of the Administrative Agent acting upon the instructions of the Required Lenders or, if applicable, the Hedging Agreement Providers (for clarification, the rights of Hedging Agreement Providers shall only arise with respect to obligations under one or more Secured Hedging Agreements that such Hedging Agreement Provider is a party to) and that no Lender or Hedging Agreement Provider shall have any right individually to seek to enforce or to enforce this Guaranty Agreement, it being understood and agreed that such rights and remedies may be exercised solely by the Administrative Agent for the benefit of the Lenders and, if applicable, the Hedging Agreement Providers.  The Lenders and the Hedging Agreement Providers further agree that this Guaranty Agreement may not be enforced against any director, officer, employee or stockholder of the Guarantors.

 

12.           Representations and Warranties of each of the Guarantors.  Each of the Guarantors hereby represents and warrants as to itself and not as to any other Person that:

 

(a)           it is duly organized and validly existing in good standing under the laws of the jurisdiction of its formation and has the corporate or other such power and authority to carry on its present business and operations, to own or lease its properties and to enter into and perform its obligations under this Guaranty Agreement, and this Guaranty Agreement has been duly authorized, executed and delivered by it and constitutes a legal, valid and binding obligation enforceable against it in accordance with its terms, except as such enforceability may be limited by its bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the rights of creditors generally and by general principles of equity;

 

(b)           the execution and delivery by it of this Guaranty Agreement and compliance by it with all of the provisions hereof do not and will not contravene any law, governmental rule or regulation or any order, writ, injunction or decree of any court or governmental authority or agency applicable to or binding on it or contravene the provisions of, or constitute a default under, its formation documents or any indenture, mortgage, contract or any agreement or instrument to which it is a party or by which it or any of its property may be bound or affected;

 

(c)           no authorization or approval or other action by, and no notice to or filing with, any governmental authority or regulatory body is required for the due execution, delivery or performance by it of this Guaranty Agreement; and

 

(d)           there are no pending or threatened actions or proceedings before any court or administrative agency which could reasonably be expected to have a Material Adverse Effect or otherwise impair its ability to perform its obligations under this Guaranty Agreement.

 

13.           Costs and Expenses.  Each of the Guarantors agrees to indemnify and hold each of the Beneficiaries harmless from and against and to pay all actual and reasonable out-of-pocket costs and expenses (including, without limitation, reasonable legal fees and expenses) incurred by or on behalf of any Beneficiary in connection with the collection and/or enforcement of any of the Guarantors’ obligations under this Guaranty Agreement.

 

14.           Miscellaneous.  This Guaranty Agreement shall: (a) be binding upon each of the Guarantors, its successors and assigns; (b) inure to the benefit of, and be enforceable by, each of the

 

 

Beneficiaries, and its successors and assigns, but shall not, and is not intended to, create rights in any other third parties; (c) not be waived, amended modified, extended, restated, replaced or supplemented without the written consent of each of the Beneficiaries; (d) BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF NEW YORK (WITHOUT GIVING EFFECT TO THE PRINCIPLES THEREOF RELATING TO CONFLICTS OF LAW); and (e) remain in full force and effect until, and shall be terminated (subject to reinstatement under Section 3 hereof) upon the payment and performance in full by the Borrower of the Credit Party Obligations, in accordance with the terms and provisions of the Documents.  All notices to, or requests of, demands on and other communications with any of the Guarantors shall be made in writing and shall be personally delivered, or sent by registered or certified mail, postage prepaid, or by fax to the following address:

 

[Name of initial Guarantor]

c/o United Therapeutics Corporation

1040 Spring Street

Silver Spring, Maryland  20910

Attention:  John Ferrari, Chief Financial Officer

Telephone:  240-821-1729

Fax:  301-608-3049

Email:  jferrari@unither.com

 

with a copy to:

 

United Therapeutics Corporation

1735 Connecticut Avenue, N.W.

Washington, District of Columbia 20009

Attention:  Paul Mahon, General Counsel

Telephone:  202-483-7000

Fax:  202-483-4005

Email:  paul@unither.com

 

[remainder of page intentionally left blank]

 

 

IN WITNESS WHEREOF, each of the Guarantors has caused this Guaranty Agreement to be duly executed by its duly authorized officer and delivered as of the day and year first written above.

 

 

	
 
    	
[NAME   OF INITIAL GUARANTOR],
    a [Jurisdiction and Type of Organization]
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    
	
 
    	
 
    

 

EXHIBIT 1.1(h)

 

FORM OF
  INITIAL GUARANTOR JOINDER AGREEMENT

 

THIS JOINDER AGREEMENT (this “Agreement”), dated as of [Month] [Day], [Year] is by and among [NAME OF SUBSIDIARY GUARANTOR], a [Jurisdiction and Type of Organization] (the “Subsidiary Guarantor”), United Therapeutics Corporation, a Delaware corporation (the “Borrower”), and Wells Fargo Bank, National Association, in its capacity as administrative agent (in such capacity, the “Administrative Agent”) under that certain Credit Agreement, dated as of December 27, 2010 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”) by and among the Borrower, the Guarantors, the Lenders and the Administrative Agent.  Capitalized terms used herein but not otherwise defined shall have the meanings provided in the Credit Agreement.

 

The Subsidiary Guarantor is the initial party to the Guaranty Agreement, and, consequently, the Borrower is required by Section 5.9 of the Credit Agreement to cause the Subsidiary Guarantor to execute this Agreement as a “Guarantor”.

 

Accordingly, the Subsidiary Guarantor and the Borrower hereby agree as follows with the Administrative Agent, for the benefit of the Lenders:

 

1.             The Subsidiary Guarantor hereby acknowledges, agrees and confirms that, by its execution of the Guaranty Agreement, the Subsidiary Guarantor will be deemed to be a “Guarantor” under the Guaranty Agreement, and by its execution of this Agreement, the Subsidiary Guarantor will be deemed to be a “Guarantor” under the Credit Agreement and the Environmental Indemnity and shall have all of the obligations of a Guarantor thereunder having executed the Guaranty Agreement and as if it had executed the Credit Agreement and the Environmental Indemnity.  The Subsidiary Guarantor hereby ratifies, as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions contained in the Guaranty Agreement and the other applicable Credit Documents, including, without limitation (a) the representations and warranties (as such relate to the Subsidiary Guarantor) set forth in Sections 3.3, 3.4, 3.5, 3.19, 3.20, 3.21 and 3.22 of the Credit Agreement, (b) all of the affirmative and negative covenants set forth in Articles V and VI of the Credit Agreement, (c) the miscellaneous provisions set forth in Article IX of the Credit Agreement and (d) the provisions of the Environmental Indemnity.  Without limiting the generality of the foregoing terms of this Paragraph 1, the Subsidiary Guarantor hereby guarantees, jointly and severally together with the other Guarantors, the prompt payment of the Credit Party Obligations in accordance with the Guaranty Agreement.

 

2.             The Subsidiary Guarantor acknowledges and confirms that it has received a copy of the Credit Documents and the schedules and exhibits to each of the foregoing as applicable.

 

3.             The information on Schedule A to this Joinder Agreement is true and correct as of the date hereof.

 

4.             The Borrower confirms that the Credit Documents are, and upon the Subsidiary Guarantor becoming a Guarantor, shall continue to be, in full force and effect.  The parties hereto confirm and agree that immediately upon the Subsidiary Guarantor becoming a Guarantor the term “Credit Party Obligations,” as used in the Credit Documents, shall include all obligations of the Subsidiary Guarantor under the Guaranty Agreement and under each other Credit Document.

 

 

5.             Each of the Borrower and the Subsidiary Guarantor agrees that at any time and from time to time, upon the written request of the Administrative Agent, it will execute and deliver such further documents and do such further acts as the Administrative Agent may reasonably request in accordance with the terms and conditions of the Credit Documents in order to effect the purposes of this Agreement.

 

6.             This Agreement (a) may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute one contract and (b) may, upon execution, be delivered by facsimile or electronic mail, which shall be deemed for all purposes to be an original signature.

 

7.             This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York.  The terms of Sections 9.13 and 9.16 of the Credit Agreement are incorporated herein by reference, mutatis mutandis, and the parties hereto agree to such terms.

 

[remainder of page intentionally left blank]

 

 

IN WITNESS WHEREOF, each of the Borrower and the Subsidiary Guarantor has caused this Agreement to be duly executed by its authorized officer, and the Administrative Agent, for the benefit of the Lenders, has caused the same to be accepted by its authorized officer, as of the day and year first above written.

 

	
 
    	
SUBSIDIARY   GUARANTOR:
    
	
 
    	
 
    
	
 
    	
[NAME   OF SUBSIDIARY GUARANTOR],
    
	
 
    	
a   [Jurisdiction and Type of Organization]
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
BORROWER:
    
	
 
    	
 
    
	
 
    	
UNITED   THERAPEUTICS CORPORATION, a Delaware corporation
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    

 

Acknowledged, accepted and agreed:

 

WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent

 

	
By:___________________________________________________
    	
 
    
	
Name:________________________________________________
    	
 
    
	
Title:_________________________________________________
    	
 
    

 

 

Schedule A

 

Disclosure Information

 

	
Legal   Name of Credit Party (and any previous legal names within the past four   months):
    	
 
    
	
State   of Organization:
    	
 
    
	
Jurisdictions   of Organization:
    	
 
    
	
Type   of Organization:
    	
 
    
	
Address   of Chief Executive Office:
    	
 
    
	
Address   of Principal Place of Business:
    	
 
    
	
Business   Phone Number:
    	
 
    
	
Organizational   Identification Number(1):
    	
 
    
	
Federal   Tax Identification Number:
    	
 
    
	
Ownership   Information (e.g. publicly held, if private or partnership—identity of   owners/partners):
    	
 
    

 

[TO BE COMPLETED BY BORROWER/SUBSIDIARY GUARANTOR]

 

(1) This item does not apply to a Credit Party organized under the laws of Alabama, Indiana, Massachusetts, Nebraska, New Hampshire, New Mexico, New York, Oklahoma, South Carolina, Vermont or West Virginia.

 

 

EXHIBIT 2.1(d)

 

FORM OF
  NOTE

 

[Date]

 

FOR VALUE RECEIVED, the undersigned, United Therapeutics Corporation, a Delaware corporation (the “Borrower”) hereby unconditionally promises to pay, on the Maturity Date (as defined in the Credit Agreement referred to below), to [                          ] or its registered assigns (the “Lender”) at the office of Wells Fargo Bank, National Association, in lawful money of the United States of America and in immediately available funds, the aggregate unpaid principal amount of the Loan made by the Lender to the undersigned pursuant to Section 2.1 of the Credit Agreement referred to below.  The undersigned further agrees to pay interest in like money at such office on the unpaid principal amount hereof and, to the extent permitted by law, accrued interest in respect hereof from time to time from the date hereof until payment in full of the principal amount hereof and accrued interest hereon, at the rates and on the dates set forth in the Credit Agreement.

 

This Note is one of the Notes referred to in the Credit Agreement, dated as of December 27, 2010 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”) by and among the Borrower, the Guarantors, the Lenders and Wells Fargo Bank, National Association, as administrative agent for the Lenders (the “Administrative Agent”), and the holder is entitled to the benefits thereof.  Capitalized terms used but not otherwise defined herein shall have the meanings provided in the Credit Agreement.

 

Upon the occurrence of any one or more of the Events of Default specified in the Credit Agreement, all amounts then remaining unpaid on this Note shall become, or may be declared to be, immediately due and payable, all as provided therein.  In the event this Note is not paid when due at any stated or accelerated maturity, the Borrower agrees to pay, in addition to principal and interest, all costs of collection, including reasonable attorneys’ fees.

 

All parties now and hereafter liable with respect to this Note, whether maker, principal, surety, endorser or otherwise, hereby waive presentment, demand, protest and all other notices of any kind.

 

This Note may, upon execution, be delivered by facsimile or electronic mail, which shall be deemed for all purposes to be an original signature.

 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

 

[remainder of page intentionally left blank]

 

 

	
 
    	
UNITED   THERAPEUTICS CORPORATION, a
    
	
 
    	
Delaware   corporation
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    

 

 

EXHIBIT 4.1(a)

 

FORM OF
  LENDER CONSENT

 

TO:                                                                            Wells Fargo Bank, National Association, as Administrative Agent

 

RE:                                                                              Credit Agreement, dated as of December 27, 2010 by and among United Therapeutics Corporation, a Delaware corporation (the “Borrower”), the Guarantors, the Lenders and Wells Fargo Bank, National Association, as Administrative Agent for the Lenders (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)

 

DATE:                                                           [Date]

 

This Consent is given pursuant to the Credit Agreement referenced above.  The undersigned hereby (i) approves the Credit Agreement, (ii) authorizes and appoints the Administrative Agent as its agent in accordance with the terms of Article VIII of the Credit Agreement, (iii) authorizes the Administrative Agent to execute and deliver the Credit Agreement on its behalf, (iv) agrees that it is a Lender under the Credit Agreement and therefore shall have all the rights and obligations of a Lender under the Credit Agreement as if such Person had directly executed and delivered a signature page to the Credit Agreement and (v) has consented to, approved or accepted or is satisfied with, each document or other matter required under Sections 4.1 and 4.2 to be consented to or approved by or be acceptable or satisfactory to a Lender.  Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement.

 

Delivery of this Consent by telecopy shall be effective as an original.

 

A duly authorized officer of the undersigned has executed this Consent as of the         day of                                   ,           .

 

	
 
    	
                                          ,
    
	
 
    	
as   a Lender
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    

 

 

EXHIBIT 4.1(b)

 

FORM OF
  OFFICER’S CERTIFICATE

 

TO:                                                                            Wells Fargo Bank, National Association, as Administrative Agent

 

RE:                                                                              Credit Agreement, dated as of December 27, 2010 by and among United Therapeutics Corporation, a Delaware corporation (the “Borrower”), the Guarantors, the Lenders and Wells Fargo Bank, National Association, as Administrative Agent for the Lenders (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)

 

DATE:                                                           [Date]

 

The undersigned officer of [NAME OF CREDIT PARTY], a [Jurisdiction and Type of Organization] (the “Company”) hereby certifies as follows:

 

1.             Attached hereto as Exhibit A is a true and complete copy of the [articles of incorporation] [certificate of formation] [certificate of limited partnership] of the Company and all amendments thereto as in effect on the date hereof certified as a recent date by the appropriate Governmental Authorities of the state of [incorporation] [organization] of the Company.

 

2.             Attached hereto as Exhibit B is a true and complete copy of the [bylaws] [operating agreement] [partnership agreement] of the Company and all amendments thereto as in effect on the date hereof.

 

3.             Attached hereto as Exhibit C is a true and complete copy of resolutions duly adopted by the [board of directors] [members] [managers] [partners] of the Company on                                .  Such resolutions have not in any way been rescinded or modified and have been in full force and effect since their adoption to and including the date hereof, and such resolutions are the only corporate proceedings of the Company now in force relating to or affecting the matters referred to therein.

 

4.             Attached hereto as Exhibit D are true and complete copies of the certificates of good standing, existence or its equivalent of the Company certified as a recent date by the appropriate Governmental Authorities of the state of [incorporation] [organization] of the Company [and each other state in which the failure to so qualify and be in good standing could reasonably be expected to have a Material Adverse Effect].

 

 

5.             The following persons are the duly elected and qualified officers of the Company, holding the offices indicated next to the names below on the date hereof, and the signatures appearing opposite the names of the officers below are their true and genuine signatures, and each of such officers is duly authorized to execute and deliver, on behalf of the Company, the Credit Agreement, the Notes and the other Credit Documents to be issued pursuant thereto:

 

	
 

Name
    	
 
    	
Office
    	
 
    	
Signature
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

 

This Certificate may, upon execution, be delivered by facsimile or electronic mail, which shall be deemed for all purposes to be an original signature.

 

[remainder of page intentionally left blank]

 

 

IN WITNESS WHEREOF, I hereunder subscribe my name effective as of the          day of                 ,         .

 

	
 
    	
 
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    

 

I,                                            , the                                                of the Company, hereby certify that                                       is the duly elected and qualified                                                of the Company and that his/her true and genuine signature is set forth above.

 

	
 
    	
 
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    

 

 

Exhibit A

 

[Articles of Incorporation] [Certificate of Formation] [Certificate of Limited Partnership]

 

Attached

 

 

Exhibit B

 

[Bylaws] [Operating Agreement] [Partnership Agreement]

 

Attached

 

 

Exhibit C

 

[Resolutions]

 

Attached

 

 

Exhibit D

 

[Certificates of Good Standing, Existence or its Equivalent]

 

Attached

 

 

EXHIBIT 4.1(l)

 

FORM OF
  FINANCIAL CONDITION CERTIFICATE

 

TO:                                                                            Wells Fargo Bank, National Association, as Administrative Agent

 

RE:                                                                              Credit Agreement, dated as of December 27, 2010 by and among United Therapeutics Corporation, a Delaware corporation (the “Borrower”), the Guarantors, the Lenders and Wells Fargo Bank, National Association, as Administrative Agent for the Lenders (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)

 

DATE:                                                           [Date]

 

Pursuant to the terms of Section 4.1 of the Credit Agreement, the undersigned officer of the Borrower, hereby certifies on behalf of the Credit Parties and not in any individual capacity that, as of the date hereof, the statements below are accurate and complete in all respects:

 

(a)           There does not exist any pending or ongoing, action, suit, investigation, litigation or proceeding in any court or before any other Governmental Authority (i) affecting the Credit Agreement or the other Credit Documents, that has not been settled, dismissed, vacated, discharged or terminated prior to the Closing Date or (ii) that purports to affect any Credit Party or any of its Subsidiaries, or any transaction contemplated by the Credit Documents, which action, suit, investigation, litigation or proceeding could reasonably be expected to have a Material Adverse Effect, that has not been settled, dismissed, vacated, discharged or terminated prior to the Closing Date.

 

(b)           Immediately after giving effect to the Credit Agreement, the other Credit Documents and all Transactions contemplated to occur on the Closing Date, (i) no Default or Event of Default exists, (ii) all representations and warranties contained in the Credit Agreement and in the other Credit Documents are true and correct, (iii) the Credit Parties are in compliance on a Pro Forma Basis with each of the initial financial covenants set forth in Section 5.11 of the Credit Agreement, as demonstrated by the calculation of financial covenants set forth on Schedule A attached hereto, as of the last day of the fiscal quarter ending at least twenty (20) days preceding the Closing Date, and (iv) the Transactions do not contravene, or otherwise conflict with, the terms of and the Credit Parties’ then current Contractual Obligations.

 

(c)           Immediately after giving effect to the Credit Agreement, the other Credit Documents and all Transactions contemplated to occur on the Closing Date, each of the conditions precedent in Sections 4.1 and 4.2 have been satisfied.

 

This Financial Condition Certificate may, upon execution, be delivered by facsimile or electronic mail, which shall be deemed for all purposes to be an original signature.

 

[remainder of page intentionally left blank]

 

 

	
 
    	
UNITED   THERAPEUTICS CORPORATION, a
    
	
 
    	
Delaware   corporation
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    
	
 
    	
 
    

 

Schedule A

 

Calculation of Financial Covenants

 

[TO BE COMPLETED BY BORROWER]

 

 

EXHIBIT 5.2(b)

 

FORM OF
  OFFICER’S COMPLIANCE CERTIFICATE

 

TO:                                                                         Wells Fargo Bank, National Association, as Administrative Agent

 

RE:                                                                           Credit Agreement, dated as of December 27, 2010 by and among United Therapeutics Corporation, a Delaware corporation (the “Borrower”), the Guarantors, the Lenders and Wells Fargo Bank, National Association, as Administrative Agent for the Lenders (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement)

 

DATE:                                                        [Date]

 

For the fiscal [quarter] [year] ended [                                  ,           ].

 

The undersigned hereby certifies on behalf of the Credit Parties that, to the best of his/her knowledge, with respect to the Credit Agreement:

 

[(a)                              Attached hereto on Exhibit A is a certificate of the independent certified public accountants reporting on the financial statements stating that in making the examination necessary therefor no knowledge was obtained of any Default or Event of Default, except as specified in such certificate.](1)

 

(b)                                 The financial statements delivered for the fiscal period referred to above present fairly the financial position of the Parent and its Subsidiaries, for the period indicated above, in conformity with GAAP applied on a consistent basis.

 

(c)                                  Each of the Credit Parties during the period indicated above observed or performed all of its covenants and other agreements, and satisfied every condition, contained in the Credit Agreement to be observed, performed or satisfied by it.

 

(d)                                 I have obtained no knowledge of any Default or Event of Default under the Credit Agreement;(2)

 

(e)                                  Attached hereto on Schedule A are calculations in reasonable detail demonstrating compliance by the Credit Parties with the financial covenants contained in Section 5.11 of the Credit Agreement as of the last day of the fiscal period referred to above.

 

(f)                                    Attached hereto on Schedule B is a certificate including information regarding the revenues and assets of the Borrower on a Consolidated basis evidencing compliance with the Guarantee Requirement during the fiscal period referred to above.

 

(1)  To be provided annually.

(2)  If a Default or Event of Default shall have occurred, an explanation of such Default or Event of Default shall be provided on a separate page attached hereto together with an explanation of the action taken or proposed to be taken by the Borrower with respect thereto.

 

 

This Certificate may, upon execution, be delivered by facsimile or electronic mail, which shall be deemed for all purposes to be an original signature.

 

[remainder of page intentionally left blank]

 

 

	
 
    	
UNITED   THERAPEUTICS CORPORATION, a Delaware corporation
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:___________________________________________________
    
	
 
    	
Name:________________________________________________
    
	
 
    	
Title:_________________________________________________
    

 

 

[Exhibit A

 

Accountant Certificate]

 

See Attached

 

 

Schedule A

 

Calculation of Financial Covenants

 

[TO BE COMPLETED BY BORROWER]

 

 

Schedule B

 

Guarantee Requirements

 

[TO BE COMPLETED BY BORROWER]Exhibit 10.38

 

Pursuant to 17 C.F.R §240.24b-2, confidential information (indicated as [***]) has been omitted and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission.

 

AMENDED AND RESTATED
 DISTRIBUTION AGREEMENT

 

THIS AMENDED AND RESTATED DISTRIBUTION AGREEMENT (“Agreement”) is made as of February 21, 2011 (the “Effective Date”), by and between United Therapeutics Corporation (“UT”), a Delaware corporation, with offices at 1040 Spring Street, Silver Spring, Maryland and Accredo Health Group, Inc. (“DISTRIBUTOR”), a Delaware corporation, with offices at 1640 Century Center Parkway, Memphis, Tennessee 38134.

 

Recitals

 

A.                                   WHEREAS, DISTRIBUTOR’s predecessor-in-interest, Olsten Health Services (Quantum) Corp., and UT entered into to a Distribution Agreement, effective March 20, 2000, and various amendments thereto, relating to the distribution of UT Product (as hereinafter defined) (the “Original Agreement”);

 

B.                                     WHEREAS, DISTRIBUTOR desires to continue to maintain its right to sell, market, distribute and maintain UT Product in the Territory (as hereinafter defined) on the terms and conditions contained herein; and

 

C.                                     WHEREAS, the Parties wish to amend and restate the Original Agreement on the terms and conditions provided herein, and intend for this Agreement to replace and supersede the Original Agreement and all amendments thereto, as of the Effective Date.

 

NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the Parties agree as follows:

 

ARTICLE 1:  INTRODUCTORY PROVISIONS

 

1.1                                 Defined Terms.   The following terms, when used in capitalized form in this Agreement, shall have the meanings set forth below:

 

(a)                                  “Agreement” shall mean this Amended and Restated Distribution Agreement entered into by and between UT and DISTRIBUTOR as of the Effective Date.

 

(b)                                 “Adverse Event” shall mean any “Adverse Drug Experience” as defined in 21 CFR 310.305, 21 CFR 314.80 and/or 21 CFR 600.80 (as applicable) or any replacements thereto.

 

(c)                                  “Affiliate” when used with reference to either Party shall mean any Person controlling, controlled by or under common control with the said Party and any officer, director or employee of such Party or Person, as the case may be.  For purposes hereof, “control” shall mean ownership, directly or indirectly, of more than fifty percent (50%) of the securities having the right to vote for the election of directors, in the case of a corporation, and more than fifty percent (50%) of the beneficial interest in the capital, in the case of a business entity other than a corporation.

 

1

 

(d)                                 “Applicable Laws” shall mean all laws, statutes, ordinances, codes, rules, and regulations that have been enacted by a government authority and which are in force as of the Effective Date or come into force during the term of this Agreement, in each case to the extent that the same are applicable to the performance by the Parties of their respective obligations under this Agreement, including, with respect to the United States, the Prescription Drug Marketing Act, the Federal Food, Drug and Cosmetics Act of 1938, as amended, the Health Insurance Portability and Accountability Act, the Federal Anti-Kickback Statute, the Anti-Kickback Act of 1986, the Stark Anti-Referral Law, and any applicable FDA regulations.

 

(e)                                  “Clean Prescription” shall mean a referral for which benefits have been verified and that includes a valid prescription that does not: (i) require physician, patient, or any third party intervention or information; (ii) involve backorder, short supply, allocation, or recall; or (iii) involve a referral that is subsequently canceled or requested to be held for future processing.

 

(f)                                    “Commercially Reasonable Efforts” shall mean with respect to each Party, commercially reasonable efforts in accordance with the business, legal, medical and scientific judgment of a similarly situated company, and in accordance with the efforts and resources a similarly situated company would use taking into account reasonable commercial judgment and other relevant factors.

 

(g)                                 “Confidential Information” shall mean all information disclosed by one Party (“Disclosing Party”) to the other Party (“Receiving Party”), regardless of the form in which it is disclosed, including information relating to the Disclosing Party’s markets, product specific payer policies, databases, customers, products, patents, inventions, procedures, methods, designs, strategies, plans, assets, liabilities, prices, costs, revenues, profits, organization, employees, agents, resellers or business in general, and with respect to UT as Disclosing Party, information embodied in UT Product.  The following shall not be considered Confidential Information:

 

(i.)                                  Information which is or becomes in the public domain through no fault or act of the Receiving Party;

 

(ii.)                               Information which was independently developed by the Receiving Party without the use of or reliance on Confidential Information;

 

(iii.)                            Information which was provided to the Receiving Party by a third party under no duty of confidentiality to the Disclosing Party; or

 

(iv.)                           Information that is required to be disclosed by Applicable Laws, provided, however, prompt prior notice thereof shall be given to the Disclosing Party.

 

(h)                                 “Customer” shall mean any hospital, healthcare institution and Included Patient that is legally entitled to purchase the UT Product for use in the Territory.

 

(i)                                     “Designated Shipment Location” shall mean the Designated Storage Location(s) to which UT has agreed to ship Units of UT Product as set forth in Attachment E attached hereto.

 

2

 

(j)                                     “Designated Storage Location” shall mean the locations of DISTRIBUTOR’s facilities or pharmacies owned by DISTRIBUTOR or its Affiliate(s) for the storage of the Units of UT Product shipped to DISTRIBUTOR’s Designated Storage Locations as set forth in Attachment E attached hereto.

 

(k)                                  “DISTRIBUTOR” shall mean Accredo Health Group, Inc. and its wholly owned subsidiaries.

 

(l)                                     “Effective Date” shall mean the date first above written.

 

(m)                               “First Use” shall mean the act of piercing of the seal on the vial of UT Product.

 

(n)                                 “Force Majeure” shall mean any event, not existing as of the Effective Date and not reasonably within the control of the Parties as of such date, which, in whole or in material part, prevents or makes commercially unreasonable one Party’s performance of its obligations under this Agreement.  Force Majeure shall include, without limitation:  fire, storm, earthquake, flood, acts of state, war or civil unrest, labor dispute, inability to obtain labor or materials, and prolonged shortage of energy or any other supplies.

 

(o)                                 “Good Distribution Practice” shall mean that practice of purchasing, storing and shipping a regulated pharmaceutical product and billing to and collecting from customers for a regulated pharmaceutical product in accordance with legal requirements and the standards and customary industry commercial practices.

 

(p)                                 “[***]” shall mean [***].

 

(q)                                 “[***]” shall mean [***].

 

(r)                                    “Included Patient” shall mean an individual diagnosed with pulmonary arterial hypertension (“PAH”) who is prescribed UT Product.

 

(s)                                  “Level 1 Appeal” shall mean an appeal of a reimbursement claim denial by a Third Party Payer due to an incomplete or improperly submitted reimbursement claim or other similar administrative oversight.

 

(t)                                    “Level 2 Appeal” shall mean an appeal of a reimbursement claim denial by a Third Party Payer, whether such denial is first asserted upon verification of reimbursement or following submission of a reimbursement claim, because: (i) the applicable policy covering the Included Patient does not include UT Product as a covered benefit, or (ii) the Included Patient falls within a class of persons who are all denied coverage for UT Product as the result of the application of a general policy.

 

(u)                                 “PAP Patient” shall mean any Included Patient who is enrolled in the Patient Assistance Program as established by UT from time to time and operated in accordance with Attachment C hereto.  UT shall provide DISTRIBUTOR with the eligibility criteria for this program.

 

(v)                                 “Price” shall mean the Wholesale Acquisition Cost for UT Product as set forth on Attachment A hereto.

 

(w)                               “UT Product” or “Product” shall mean Remodulin (treprostinil sodium) Injection, a pharmaceutical product administered subcutaneously and

 

3

 

intravenously only for the treatment of PAH to be marketed in the Territory under the brand name REMODULIN®.

 

(x)                                   “UT Trademarks” shall mean any of the UT trademarks, logotypes and trade names listed on Attachment B hereto, as such attachment may be modified from time to time by UT during the term of this Agreement.

 

(y)                                 “Parties” shall mean UT and DISTRIBUTOR collectively.

 

(z)                                   “Party” shall mean either UT or DISTRIBUTOR.

 

(aa)                            “Person” shall mean an individual, corporation, partnership, limited liability company, limited liability partnership, syndicate, person, trust, association, organization or other entity, including any governmental authority, and including any successor, by merger or otherwise, of any of the foregoing.

 

(bb)                          “Territory” shall mean the United States, including its territories and possessions, the fifty states and the District of Columbia only, unless otherwise expressly agreed in writing by the Parties.

 

(cc)                            “Third-Party Payers” shall mean managed care providers, health maintenance organizations, insurance companies, self-insurance programs of employers, third-party administrators, the United States Medicare and Medicaid programs, and other similar entities.

 

(dd)                          “Unit of UT Product” shall mean the combination of UT Product, package insert and other items as may be determined and supplied by UT to DISTRIBUTOR, in each instance contained within a standard outer package supplied by UT and labeled in accordance with applicable legal requirements.

 

(ee)                            “WAC” shall mean the then-current Wholesale Acquisition Cost of UT Product as determined by UT.

 

1.2                                 Other Rules of Interpretation. Unless the context otherwise requires, (i) words of any gender include each other gender; (ii) words using the singular or plural number also include the plural or singular number, respectively; (iii) the terms “hereof,” “herein,” “hereby” and derivative or similar words refer to this entire Agreement; (iv) the terms “Article” or “Section” refer to the specified Article or Section of this Agreement; (v) the word “including” shall mean “including, without limitation;” (vi) the word “consent” shall mean “consent, not to be unreasonably withheld or delayed”; (vii) the word “or” shall be disjunctive but not exclusive; (viii) the words “made available” shall mean that the information referred to has been made available if requested by the party to whom such information is to be made available; (ix) all references herein to “days” shall mean calendar days, and all references to “business day” shall mean any day that is not a Saturday, Sunday or any other day when banks are required or authorized by law to be closed in The City of New York; and (x) references to any statute, regulation or other law shall include any and all amendments and successors thereto.

 

ARTICLE 2:  MUTUAL REPRESENTATIONS AND WARRANTIES

 

2.1                                 Authority.  Each Party represents and warrants that it possesses all corporate power and authority necessary to enter into this Agreement and to perform its obligations under this Agreement.  All corporate acts and other proceedings required to be taken by or on the

 

4

 

part of each Party to authorize it to perform its obligations under this Agreement have been duly and properly taken.  This Agreement has been duly executed and delivered by each Party and constitutes legal, valid and binding obligations of each Party enforceable in accordance with its terms, subject to the application of general principles of equity.

 

2.2                                 No Conflicts.  Each Party represents and warrants that the execution and performance of this Agreement will not conflict with or violate any other agreement or obligation binding on it.

 

2.3                                 Approvals.  Except as expressly provided herein, each Party represents and warrants that no approval, authorization, consent or other order or action of or filing with any court, administrative agency or other governmental authority is required for the execution and delivery by such Party of this Agreement or its consummation of the transactions contemplated by this Agreement.

 

2.4                                 Debarment and Exclusion Certification Requirements.  Each Party certifies that it has not been debarred under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335(a) and (b), and does not appear on the “list of excluded individuals/entities” (“LEIE”) maintained by the Office of the Inspector General of the U.S. Department of Health & Human Services, available at http://oig.hhs.gov/fraud/exclusions/listofexcluded.html.  In the event that, during the term of this Agreement, either Party (i) becomes debarred, (ii) is placed on the LEIE, or (iii) receives notice of an action or threat of an action with respect to its debarment or placement on the LEIE, such Party shall notify the other Party immediately.  Each Party hereby certifies that it has not and will not use in any capacity the services of any individual, corporation, partnership or association that has been debarred under 21 U.S.C. § 335(a) and (b) or that appears on the LEIE.  In the event that either Party becomes aware of the debarment, threatened debarment, appearance or threatened placement on the LEIE of any individual, corporation, partnership or association providing services to the other Party that directly or indirectly relate to activities under this Agreement, the other Party shall be immediately notified.  In the event of an actual debarment or exclusion of DISTRIBUTOR or its owners during the term of this Agreement, this Agreement shall, as of, or prior to, the effective date of such debarment or exclusion, automatically terminate.  In the event of an actual debarment or exclusion of any DISTRIBUTOR employee, agent or contractor during the term of this Agreement, such employee, agent or contractor must immediately cease providing any services to UT under this Agreement, and UT shall have the option of immediately terminating this Agreement.

 

ARTICLE 3:  APPOINTMENT

 

3.1                                 Scope; Non-exclusive.  UT hereby appoints DISTRIBUTOR, and DISTRIBUTOR hereby accepts such appointment, as a distributor of UT Product during the term of this Agreement, subject to the terms and conditions of this Agreement.  This appointment is non-exclusive, and UT reserves the right to appoint additional distributors in the Territory and to distribute UT Product in the Territory on its own behalf.  UT shall notify Distributor prior to adding additional distributors within the Territory.

 

3.2                                 Sub-distributors.  DISTRIBUTOR shall not, without the prior written approval of UT, appoint any distributors or agents to act on behalf of DISTRIBUTOR (collectively, “Sub-distributors”) to distribute UT Product within the Territory, other than any of its Affiliates.  DISTRIBUTOR shall at all times remain fully liable for the performance of any approved sub-distributors and DISTRIBUTOR shall provide UT with a written acknowledgement executed by each Sub-distributor that it has read this Agreement and

 

5

 

agrees to be bound by its terms and conditions, including those contained in the attachments hereto.

 

3.3                                 Sales Outside the Territory.  DISTRIBUTOR shall not distribute, sell or otherwise provide UT Product outside of the Territory and shall not advertise, promote or solicit customers for UT Product outside the Territory.

 

ARTICLE 4:  OBLIGATIONS OF DISTRIBUTOR

 

4.1                                 Support.  DISTRIBUTOR shall use Commercially Reasonable Efforts to fund and support ongoing distribution of UT Product, consistent with DISTRIBUTOR’s normal funding and support for its overall distribution activities.  In addition, DISTRIBUTOR shall use its Commercially Reasonable  Efforts to fund and support ongoing sale of UT Product.  Such Commercially Reasonable Efforts  shall include, but not be limited to:

 

(a)                                  Maintaining throughout the Territory adequate order-fulfillment staff who are adequately trained on PAH and UT Product.  The Parties acknowledge that this obligation requires DISTRIBUTOR to have the capability to provide the foregoing services throughout the Territory, but does not require DISTRIBUTOR to have a physical office within each jurisdiction within the Territory;

 

(b)                                 Promptly responding to all inquiries from Customers, including responding to complaints, processing all orders and effecting all shipments of UT Product for Included Patients in accordance with the timelines and other terms and conditions contained within this Agreement;

 

(c)                                  Providing UT Product to Included Patients pursuant to physician orders;

 

(d)                                 [***]

 

(e)                                  [***]

 

4.2                                 Policies and Procedures.  DISTRIBUTOR shall use Commercially Reasonable Efforts to comply with UT’s Policies and Procedures as provided and updated by UT from time to time and as accepted by DISTRIBUTOR.  If any such Policies and Procedures contradict this Agreement, the terms of this Agreement shall control.

 

4.3                                 Written Assurance.  DISTRIBUTOR hereby assures UT that DISTRIBUTOR shall not export UT Product from the Territory under any circumstances, including to any destination to which re-export requires a license under the United States Export Administration Regulations.  DISTRIBUTOR shall  use Commercially Reasonable Efforts to ensure that its Customers and sub-Distributor will not export UT Product from the Territory.

 

4.4                                 Product Specifications.  DISTRIBUTOR shall store UT Product in accordance with all directions accompanying UT Product in order to maintain UT Product in accordance with UT- and FDA-approved specifications.  DISTRIBUTOR shall dispense UT Product as prescribed, in accordance with all applicable pharmacy requirements.  The Parties acknowledge that UT shall not have any rights, obligations, responsibilities, oversight or role of any kind or nature concerning DISTRIBUTOR’s practice of pharmacy in compliance with all applicable state pharmacy regulations and consistent with DISTRIBUTOR’s then current practices.

 

4.5                                 Pharmacy and Home Health Care Services.  DISTRIBUTOR may create its own educational materials concerning UT Product or PAH (“Educational Materials”) for

 

6

 

distribution by DISTRIBUTOR in accordance with this Agreement and DISTRIBUTOR’s obligations as a health care provider and pharmacy; provided, however, that all such Educational Materials shall: (i) be consistent with the contents of UT Product package insert approved by the FDA; (ii) comply with the conditions and requirements of all applicable state pharmacy regulations mandating the provision of patient educational materials on prescription drugs and their administration, and (iii) not be used by DISTRIBUTOR to promote, market or sell UT Product. Further, to the extent that any UT Trademarks are included in such Educational Materials, then DISTRIBUTOR shall notify UT in writing prior to use of such materials.

 

4.6                                 Complaints. DISTRIBUTOR shall process any and all complaints received from Customers in the Territory regarding the UT Product in accordance with Section 9.3 of this Agreement.

 

4.7                                 Inventory.  DISTRIBUTOR shall maintain at all times adequate inventory of Units of UT Product (the “Inventory”) as are mutually considered by UT and DISTRIBUTOR to be sufficient to meet Customers’ anticipated demands for UT Product.  Such requirements may be adjusted by UT and DISTRIBUTOR from time to time. Notwithstanding the foregoing, DISTRIBUTOR shall maintain an Inventory level at all times between the following minimum and maximum:

 

(a)                                  At a minimum: no less than thirty (30) days’ inventory on hand at any time based on current demand and usage of UT Product by DISTRIBUTOR’s customers; and

 

(b)                                 At a maximum no greater than seventy-five (75) days’ inventory on hand based on current demand and usage of UT Product by DISTRIBUTOR’s customers; and

 

(c)                                  calculations of inventory levels shall be based on the current monthly average usage of UT Product by Included Patients (“Usage”). Usage shall be equal to the rolling average number of Units of UT Product distributed by DISTRIBUTOR each month for the previous three (3) months.

 

DISTRIBUTOR shall ensure that it purchases enough Inventory each month to meet expected Usage demand for UT Product in addition to the thirty (30) day minimum Inventory level requirement.  From time to time, UT and DISTRIBUTOR may mutually agree to reasonably change the above-listed minimum and maximum requirements and DISTRIBUTOR shall adjust its Inventory accordingly.

 

4.8                                 Storage of UT Product. DISTRIBUTOR shall store and maintain UT Product solely at the Designated Storage Locations described in Attachment E hereto.  DISTRIBUTOR shall store, maintain and handle the Product in accordance with Good Distribution Practice, Applicable Laws, the UT Product package insert and UT’s written instructions, including any requirements with respect to racking, temperature, light, darkness, vibration and rotation. The UT Product must be stored at the temperature range specified by UT to ensure safety and reliability, and rotated so that the oldest unexpired Units of UT Product are shipped before newer unexpired Units of UT Product, unless UT specifies otherwise.  DISTRIBUTOR shall promptly notify UT of any material or significant change in its storage conditions or shipping procedures for UT Product.  DISTRIBUTOR shall maintain complete and accurate records for inspection by UT or its representatives, upon ten (10) business days’ prior notice during regular business hours, of all movements and transactions involving UT Product.  Such records shall reflect unit, lot number and Customer information, including defective or returned Units of UT Product, such that the Units of UT Product may be traced for purposes of stock reconciliation, recall and

 

7

 

general marketing and shipping review.  UT shall also have the right to inspect DISTRIBUTOR’s storage conditions and shipping procedures for UT Product upon ten (10) business days’ prior notice, during regular business hours. DISTRIBUTOR shall not manufacture, mix, process, combine or incorporate UT Product alone or into any other substance.

 

4.9                                 Distributor Expenses.  DISTRIBUTOR shall bear all of its own costs and expenses incurred in carrying out its obligations under this Agreement, including, but not limited to, all rents, salaries, commissions, demonstration, travel and accommodation.

 

4.10                           Distributor Reporting.  DISTRIBUTOR shall complete a series of regular reports as described in Attachment F hereto.  The reports are due no later than the 10th day of each month following the end of the respective reporting periods and shall constitute Confidential Information of DISTRIBUTOR. The Parties acknowledge that Applicable Laws or existing contractual relationships with Third-Party Payers may restrict DISTRIBUTOR’s ability to collect, use, include and/or disclose as Data certain patient, payer,  and physician-specific data. DISTRIBUTOR shall not provide patient, payer, and physician-specific data and information where so limited by such existing contractual relationships or Applicable Laws.  New contracts with Third Party Payers or the enactment of new Applicable Laws may further limit the disclosure of patient- and physician-specific data and information.  Neither Party may resell data to IMS, Wolters Kluwer, or any other data aggregation service .

 

4.11                           Distributor Representations.

 

(a)                                  DISTRIBUTOR acknowledges that UT Product constitutes a sensitive therapeutic drug, and that distribution and handling of the UT Product requires specialized training and dedication to Customer needs.  DISTRIBUTOR represents and warrants that it will train and deploy its agents and employees in the manner necessary to meet these special requirements.

 

(b)                                 DISTRIBUTOR represents and warrants that it and its officers, directors, agents and/or employees as applicable are qualified to perform the services and activities described in this Agreement and that all licenses and/or approvals necessary to conduct such services and activities have been obtained and shall be maintained throughout the term of this Agreement.

 

4.12                           DISTRIBUTOR provides appropriate pharmacy services as required by Applicable Laws. DISTRIBUTOR shall also perform the following activities in support of the distribution of the UT Product:

 

(a)                                  Infusion Pumps or Other Devices.  DISTRIBUTOR shall develop and maintain a relationship with appropriate infusion pump or other device manufacturer(s) which manufacture pumps/devices that comply with the technical administrative requirements specified in the package insert for UT Product for applicable administration and that offer the same level of reliability, effectiveness and customer service as have become the industry standard for UT Product. DISTRIBUTOR will ensure that appropriate personnel are trained at all times on the use of all such pumps/devices and how the UT Product is most effectively used with various pumps/devices.    DISTRIBUTOR shall ensure the accuracy of all of its educational efforts for Customers in respect of pumps/devices it creates and distributes for use with UT Product.

 

8

 

(b)                                 Included Patient Benefit Verification. DISTRIBUTOR shall handle Included Patient enrollment, initial processing, insurance eligibility and benefits verification. If DISTRIBUTOR is unable to service a patient, then DISTRIBUTOR shall immediately, i.e., no more than five (5) business days from the receipt of the complete referral, re-direct the referral to an appropriate specialty pharmacy participating in the REMODULIN distribution network.   Distributor agrees to utilize the referral form provided by UT for referral collection purposes at all times, unless a Customer specifically requests the use of a different form.

 

(i.)                                  Upon receipt of a prescription for UT Product, DISTRIBUTOR shall immediately fax the prescribing physician to confirm receipt of the prescription. No more than one (1) business day from receipt of the prescription, DISTRIBUTOR shall perform verification of insurance coverage for UT Product. If the prescription is received after 2 p.m. Eastern time, DISTRIBUTOR may have until the end of the next business day to perform verification of insurance coverage for UT Product.

 

(ii.)                               DISTRIBUTOR shall take all necessary actions to verify Included Patients’, insurance coverage for UT Product including, without limitation, researching and attempting to determine: (1) all Included Patient information and coverage parameters, including all relevant clinical documentation; (2) if UT Product is covered, under what type of plan (e.g., a “medical plan” or a “pharmacy plan”), the Included Patient cost share amount, if any, and the rate of reimbursement, if available; (3) whether prior authorization is required for reimbursement; (4) if prior authorization is required, what information the Included Patient must submit in order to receive such authorization; and (5) whether any other activities, submissions or approvals are required to obtain reimbursement promptly and to the fullest extent permitted by the Third-Party Payer. During the process of benefit verification, DISTRIBUTOR shall communicate with the referral source and provide information to the prescribing physician in a time and manner sufficient for the circumstances.

 

(iii.)                            DISTRIBUTOR shall record the results of its research on the foregoing and shall use commercially reasonable efforts to report to the Included Patient within one (1) business day from receipt.

 

(iv.)                           If the Third-Party Payer requires prior authorization, then DISTRIBUTOR shall, within one (1) business day, notify and assist the Customer with questions relating to the requirements for prior authorization.

 

(v.)                              If, prior to the submission of a claim for reimbursement, a Third-Party Payer informs DISTRIBUTOR that UT Product is not eligible for coverage, then, within one (1) business day, DISTRIBUTOR shall make such inquiries of the Third-Party Payer as shall be necessary to determine the requirements for submission of an appeal of the denial of coverage. DISTRIBUTOR shall promptly record the results of this inquiry and to the extent not prohibited by contract or Applicable Laws report such information to the UT managed markets designee.

 

9

 

(vi.)                           If DISTRIBUTOR is notified of a denial of coverage and DISTRIBUTOR determines that an appeal of the denial of coverage would require a Level 1 Appeal, then  DISTRIBUTOR, at its cost and discretion, shall use reasonable efforts to assist Customer, and if an Included Patient is pursuing the Level 1 Appeal on his/her own behalf, DISTRIBUTOR, at its cost, shall promptly initiate (at the latest within one (1) business day) and pursue such Level 1 Appeal in accordance with the Third-Party Payer’s processes.  Upon request, UT shall provide reasonable assistance to DISTRIBUTOR, including assistance with preparing applications and participation in telephone conferences and meetings with representatives of the Third-Party Payer.  All documents prepared as part of a Level 1 Appeal, and any information obtained in connection therewith, shall be promptly recorded.

 

(vii.)                        If DISTRIBUTOR determines that an appeal of the denial of coverage would require a Level 2 Appeal, DISTRIBUTOR shall notify the physician, Included Patient and UT (if DISTRIBUTOR deems necessary, if the Included Patient consents and to the extent not prohibited by contract or Applicable Laws) immediately of such determination.  The Included Patient, at his or her option, may elect to pursue the Level 2 Appeal directly or to request that Distributor assist with pursuit of the Level 2 Appeal.

 

(c)                                  Dispensing Activities.

 

(i.)                                  Upon completion of benefits investigation and, if necessary, after prior authorization, DISTRIBUTOR shall process Physician’s order for UT Product if Physician chooses to place an order.  If Physician elects not to place an order at the time that Included Patient benefits are reported, DISTRIBUTOR shall attempt to determine the reason for Physician’s choice (e.g., “Included Patient to receive UT Product at an alternate facility”, “physician elected not to order UT Product”, or “Included Patient elected not to receive UT Product”).  DISTRIBUTOR shall immediately record this information.

 

DISTRIBUTOR shall attempt to contact the Included Patient on the same day that the benefit verification has been completed for the Included Patient in order to inform the Included Patient of his or her cost share amount, if any, and to make arrangements with the Included Patient for collection such cost share amount, if any, and to introduce the Included Patient to the DISTRIBUTOR’s services.  DISTRIBUTOR may delay shipment of UT Product until the Included Patient’s cost share amount is satisfied in full.  DISTRIBUTOR shall be solely responsible for submitting claims for reimbursement directly to the Third-Party Payer for the applicable reimbursable amount (deducting any Included Patient cost share amount).

 

DISTRIBUTOR will dispense the Unit(s) of UT Product (along with a current package insert) to Included Patients pursuant to a valid prescription and in accordance with Applicable Law, and in so doing will include certain nominal ancillary supplies (e.g., syringes, needles, and alcohol swabs) and certain related items (including the pump/device, as applicable) in connection with the UT Product as may be necessary or useful to the Included Patient in connection with the administration of the UT Product.  Upon receipt of a Clean Prescription,

 

10

 

DISTRIBUTOR shall dispense UT Product within one (1) business day or at such other time as the Included Patient may request.

 

(d)                                 Follow up Activity Generally. Unless DISTRIBUTOR is otherwise required to contact Customer sooner or more often, DISTRIBUTOR shall contact Customer two (2) business days after receipt of a prescription/referral and every two (2) business days thereafter to update Customer on the status of a benefits investigation/prior authorization/appeal or other related matter. When required to obtain additional information to complete a valid prescription/coverage determination/prior authorization/appeal or related matter, DISTRIBUTOR shall communicate all required information to the appropriate party and continue to contact such party every business day until the needed information is received or the matter is otherwise closed.

 

(e)                                  Social Services.  Upon expression of financial hardship, DISTRIBUTOR shall provide notice to Included Patients of alternate funding sources, certain hardship reimbursement support, and certain indigent and patient assistance programs, including UT’s PAP as described in Attachment C hereto. DISTRIBUTOR shall send an application to Included Patients who request to participate in the PAP within one (1) business day from the date of such request.

 

(f)                                    Product & Ancillary Supply Distribution. DISTRIBUTOR shall make available and/or dispense with UT Product, as necessary and appropriate for the applicable site of service (e.g., health care provider/physician office, clinic, hospital outpatient setting, pharmacy-owned facility, home), the contents of the UT Product package and supplies necessary for UT Product administration.

 

(g)                                 Education. DISTRIBUTOR shall provide its standard educational support  regarding UT Product administration and safety to Customers and caregivers involved in treating Included Patients. Upon UT’s request and subject to Distributor’s sole discretion, Educational Materials and educational materials created by UT may at times be included along with a patient’s standard shipment(s) of UT Product.  In addition, DISTRIBUTOR shall at all times comply with UT’s requirements with respect to the provision of package inserts, updates thereto, and such other UT Materials as are required by Applicable Law. In the event that such materials increase shipping or dispensing expenses, the parties shall agree on appropriate payments. DISTRIBUTOR shall promptly respond to questions from managed care organizations and other Third-Party Payers about UT Product. Notwithstanding the foregoing, the provision of such educational services shall be performed in accordance with the obligations contained in this Agreement including those with respect to training.

 

(h)                                 Nursing Services:

 

(i.)                                  DISTRIBUTOR shall make available on an as-needed basis its standard telephonic nursing services in accordance with its standard policies and procedures. If DISTRIBUTOR receives requests for administration for UT Product, it shall facilitate such requests in accordance with its standard business practices. DISTRIBUTOR’s standard telephonic nursing services shall be rendered by nurses who have the requisite and necessary training, experience, licenses and permits in accordance with Applicable Laws. DISTRIBUTOR may not seek reimbursement for its standard telephonic nursing services directly from UT.

 

11

 

(i.)                                  The Parties shall work together in good faith to develop an integrated nursing program to adequately support UT Product, Included Patients and Customers with the following elements:

 

(a)                                  All nurses shall be trained by DISTRIBUTOR with respect to UT Product and PAH prior to any interaction with an Included Patient or Customer. All nurses (including per diem nurses) shall pass competency testing on the following topics (at a minimum): PAH and PAH drug classes; UT Product; Patient needs whether naïve or experienced; Administration of UT Product; Training patients on administration of UT Product; Relevant nursing standards of care for administration of UT Product; Any and all devices/pumps that are to be used with UT Product;  Appropriate patient encounters; and HIPAA, patient privacy and any other applicable legal requirements;

 

(b)                                 DISTRIBUTOR shall provide updated training as necessary for nurses to maintain competency in the foregoing competency areas;

 

(c)                                  DISTRIBUTOR shall update and refresh training and require regularly updated certification testing when new information becomes available or when a nurse has not provided services for an extended period of time;

 

(d)                                 DISTRIBUTOR shall make available to UT upon request, for UT’s review and comment, training materials related to UT Product and the administration and support of UT Product;

 

(e)                                  DISTRIBUTOR shall make available to UT records of completion of related training upon UT’s request;

 

(f)                                    DISTRIBUTOR shall manage nonperformance of nurses (including per diem nurses) through appropriate measures, including re-training, discipline or removal; and

 

(g)                                 DISTRIBUTOR shall reasonably provide nurses who are able to speak the same language as the Included Patient or a translation service.

 

(i)            Additional Performance Requirements:  As to service related to UT Product,  DISTRIBUTOR agrees to keep careful records of the following data points and maintain the requisite levels of competency for each data point and shall provide such data in reports to UT as UT reasonably requests, but no less than quarterly:

 

(ii.)                               ASA: meaning the average speed DISTRIBUTOR takes to answer a call measured over a calendar month.  DISTRIBUTOR shall use reasonable Efforts to ensure that the ASA does not exceed thirty (30) seconds, and in any event, at least 80% of all calls to DISTRIBUTOR shall be answered within thirty (30) seconds;

 

(iii.)                            Calls Dropped: meaning the percentage of calls that are dropped before being answered over the course of a calendar month.  DISTRIBUTOR

 

12

 

shall use its Commercially Reasonable Efforts to ensure that the Calls Dropped does not exceed 6%; and

 

(iv.)                           AHT: meaning the average hold time experienced by a caller as measured over the course of a calendar month.  DISTRIBUTOR shall use its Commercially Reasonable Efforts to ensure that the AHT does not exceed 45 seconds, and in any event, at least 95% of calls placed on hold will be on hold for less than forty-five (45) seconds.

 

4.13                           DISTRIBUTOR agrees to make available appropriate management personnel as mutually agreed upon responsible for overseeing/managing the activities related to the distribution of UT Product for quarterly meetings with UT personnel at reasonably agreed upon times and places in order to review and assess DISTRIBUTOR’s performance relative to the various obligations described in this Article 4 and elsewhere in this Agreement. Content and reporting metrics of such meetings will be mutually agreed upon between UT and DISTRIBUTOR in advance of the meetings.

 

ARTICLE 5:  OBLIGATIONS OF UT

 

5.1                                 Training.  UT may in its discretion provide training to DISTRIBUTOR for UT Product at a time and in a manner as determined by DISTRIBUTOR.

 

5.2                                 UT Materials.  UT shall provide DISTRIBUTOR, upon DISTRIBUTOR’s request, with reasonable quantities of sales and marketing materials for UT Product as they are developed by UT, including but not limited to reprints, brochures, package inserts, peer reviewed articles and other scientific and medical information regarding UT Product, informational material and other marketing literature (“UT Materials”), for use and distribution by DISTRIBUTOR in accordance with this Agreement.  DISTRIBUTOR shall use the UT Materials in accordance with UT’s written directions, including providing the package insert to Customers until such time as the package insert is included with UT Product. DISTRIBUTOR shall not revise, alter, change, supplement or reproduce in any manner the UT Materials and their content as provided by UT without UT’s advance written permission.  Nothing in this provision requires UT to create any specific materials.

 

ARTICLE 6:   ORDERS FOR PRODUCTS

 

6.1                                 Purchase Orders.  DISTRIBUTOR shall submit written purchase orders to UT by electronic mail or in accordance with written instructions provided by UT. Purchase orders shall be submitted once per month by the 10th day of the month. Each such order shall set forth: (a) the UT Product ordered including item numbers; (b) quantities in multiples of ten (10) per package reference; (c) requested delivery dates; (d) specific shipping instructions; and (e) if applicable, any relevant export control information or documentation to enable UT to comply with Applicable Laws.  Except as otherwise agreed by UT, DISTRIBUTOR shall submit such purchase orders at least five (5) business days prior to the requested delivery dates. DISTRIBUTOR is responsible for good Inventory management processes and subsequent purchases should not deviate negatively by more than 15% from the previous purchase order unless unexpected events occur and are communicated to UT in advance in writing. DISTRIBUTOR may only purchase UT Product from UT or through the acquisition of all or part of a pharmacy authorized to dispense Product. DISTRIBUTOR may only sell UT Product for use by an Included Patient and may not sell, transfer or distribute UT Product to any entity that DISTRIBUTOR knows is likely to resell the UT Product.

 

13

 

6.2                                 Acceptance of Orders. Each purchase order shall be governed by the terms and conditions set forth in this Agreement with respect to such order to the exclusion of any additional or contrary terms set forth in the DISTRIBUTOR purchase order.  Any terms or conditions of such purchase order that conflict with the terms and conditions of this Agreement shall be null and void.  Notwithstanding the foregoing, in the event of exigent circumstances, UT shall use its Commercially Reasonable Efforts to accept an emergency purchase order from DISTRIBUTOR two (2) business days prior to the requested delivery date.

 

6.3                                 Delivery Terms.  Units of UT Product ordered by DISTRIBUTOR and accepted by UT shall be packed for shipment and storage in accordance with UT’s standard commercial shipping practices. UT shall use its Commercially Reasonable Efforts to deliver Units of UT Product into the possession of a common carrier for delivery within a reasonable period of time after acceptance of a purchase order by UT.  Unless mutually agreed upon by DISTRIBUTOR and UT, no UT Product shall be shipped on a Friday, Saturday or Sunday.  Each order may only be shipped, and shall be addressed for shipment, to the Designated Shipment Location specified in Attachment E.  Unless UT and DISTRIBUTOR otherwise agree in writing, all deliveries of UT Product shall be F.O.B. DISTRIBUTOR’s Designated Shipment Location.  UT shall insure each shipment of UT Product with a reputable insurer for the full invoice price of such shipment.  Risk of loss and title to UT Product shall pass to DISTRIBUTOR upon delivery at its Designated Shipment Location.  UT shall have no liability for any loss, theft, destruction or damage to the Units of UT Product once they have been delivered to a Designated Shipment Location and the exterior has been inspected by DISTRIBUTOR for visible damage without necessity of opening.  Each individual package of UT Product shall be inspected within five (5) business days of delivery to DISTRIBUTOR’s Designated Shipment Locations.  DISTRIBUTOR shall, at its sole cost and expense, insure the Products from the time of delivery at DISTRIBUTOR’s Designated Shipment Location until delivery of the Units of UT Product by DISTRIBUTOR to Customer has been completed.  In each case such insurance or self-insurance shall be for the UT Product’s full replacement value (i.e., market value) against fire, theft, loss or destruction, and such other risks as are customarily insured against by prudent persons in a similar line of business.  At UT’s request, DISTRIBUTOR shall furnish to UT certificates of insurance evidencing the types and amounts of coverage.

 

6.4                                 Modification of Orders.  No accepted purchase order shall be modified or canceled except upon the written agreement of both Parties.

 

6.5                                 Change Order Charges.  If DISTRIBUTOR requests modifications to an accepted order prior to the scheduled delivery date provided in such order, then, in consideration for accepting such change order, UT may extend the scheduled delivery date and/or require DISTRIBUTOR to pay a change order charge equal to the sum of the actual documented non-recoverable costs incurred by UT by reason of such change order.

 

6.6                                 Product Changes.  Subject to applicable regulatory approval, UT reserves the right, in its sole discretion and without incurring any liability to DISTRIBUTOR except as otherwise provided in this Agreement, to: (a) alter UT Product; (b) discontinue the manufacture of UT Product; or (c) commence the manufacture and sale of new products having features which make UT Product obsolete.  UT also reserves the right, in its sole discretion and without incurring any liability to DISTRIBUTOR except as otherwise provided in this Agreement, immediately to alter the specifications or the manufacturing process for UT Product for reasons of health or safety.  UT shall fill all accepted purchase orders from DISTRIBUTOR for altered or discontinued UT Product for which manufacturing and commercial deliveries have commenced prior to the effective date of such a change but otherwise shall have no obligation to do so unless the delivery date requested in the

 

14

 

relevant purchase order is prior to the effective date of such a change. UT shall notify DISTRIBUTOR in writing when such modifications or changes occur.

 

6.7                                 Rolling Forecasts.  DISTRIBUTOR shall provide UT with an annual, non-binding twelve (12) month forecast projecting DISTRIBUTOR’s intended purchases of UT Product for the coming twelve (12) months, as well as such other mutually agreeable information.  UT shall receive this annual forecast no later than January 10th of each calendar year.  DISTRIBUTOR shall also update UT on a rolling basis each calendar quarter, and each updated forecast shall be received by UT no later than the 10th day of the month following the end of each calendar quarter.

 

6.8                                 Chargeback Pricing.  Subject to UT’s reimbursement of the “Chargebacks” (as described below) DISTRIBUTOR shall provide wholesale distribution to certain entities eligible for discounted government pricing (e.g., FSS, VA, PHS (340B)) (“Discounted Entity”) as described herein.  The discounted government pricing is less than the price at which DISTRIBUTOR purchases UT Product (i.e., less than the Price set forth in Attachment A).  DISTRIBUTOR shall create an account for each Discounted Entity purchasing UT Product from DISTRIBUTOR.  As part of this process, DISTRIBUTOR shall use commercially reasonable efforts to identify whether the proposed Discounted Entity is eligible for discounted government pricing through direct documentation from the proposed Discounted Entity or through review of data on the HRSA eligibility website or other database resource.  As an order for UT Product is received from the Discounted Entity, DISTRIBUTOR shall provide UT Product to the Discounted Entity at the discounted government price.  The difference between the discounted government price and the List Price for the UT Product is referred to as the “Chargeback.” The Chargeback shall be paid by UT to DISTRIBUTOR by check. When submitting a Chargeback request to UT, DISTRIBUTOR shall include the following information: (i) date of sale to Discounted Entity, (ii) the Discounted Entity’s name and address, (iii) product(s) purchased from DISTRIBUTOR (iv) UT’s price to DISTRIBUTOR for the UT Product, (v) DISTRIBUTOR’s price to the Discounted Entity for the UT Product, and (vi) the amount of Chargeback requested.  Chargeback request(s) shall be submitted to UT by the 10th of each month for all activity in the previous calendar month. UT shall process Chargeback credits due DISTRIBUTOR within thirty (30) days of receipt of the Chargeback submission.  DISTRIBUTOR shall not set off Chargebacks owed by UT against any amounts owed by DISTRIBUTOR to UT. Upon termination of this Agreement, if there are any unapplied credits for a Chargeback, UT shall issue a check in the amount thereof to DISTRIBUTOR. Chargebacks paid hereunder constitute reimbursement to DISTRIBUTOR for debits incurred in administering UT discounts to Discounted Entities, and are not, and should not be construed as, remuneration intended to induce DISTRIBUTOR to purchase, order, lease, or recommend any UT product.

 

6.9                                 [***]

 

6.10                           [***]

 

ARTICLE 7:  PRICES AND PAYMENTS

 

7.1                                Prices.  DISTRIBUTOR shall pay the Prices for UT Product purchased under this Agreement that are in effect at the time of  submission of a relevant purchase order by DISTRIBUTOR, except as provided in Section 7.2 below.

 

7.2                                 Price Changes.  At any time during the term of this Agreement, UT may increase or decrease its Prices for UT Product with notice to DISTRIBUTOR of the effective date of

 

15

 

the price change. Any such price change shall not apply to purchase orders submitted prior to the effective date of the applicable price change.

 

7.3                                 Costs. All costs related to shipping, insuring, packing, handling and delivering UT Product to DISTRIBUTOR’s facility shall be at the sole expense of UT.  All such costs incurred after the instant of delivery to the Designated Shipment Location shall be the responsibility of DISTRIBUTOR. Notwithstanding anything to the contrary in this Agreement, UT may, in its sole discretion, charge DISTRIBUTOR for any and all shipping, packing, handling or delivery charges associated with emergency purchase orders, or if DISTRIBUTOR places three or more orders in a one month period.

 

7.4                                 Payment Terms; Invoices.  DISTRIBUTOR shall make payments for UT Product within sixty (60) days of its receipt of an applicable invoice from UT.  DISTRIBUTOR shall be eligible for a two percent (2%) prompt pay discount if payment is received by UT within thirty (30) days of the date of invoice. All payments shall be made in United States Dollars.

 

7.5                                 Provision of Invoices to Government Payers. Upon the request of any federal or state agency with jurisdiction over claims for reimbursement of UT Product, DISTRIBUTOR may provide such agency with invoices received from UT that accurately reflect the actual charge to DISTRIBUTOR for UT Product purchased pursuant to this Agreement with prompt written notice to UT of such request.

 

7.6                                 Overdue Payments.  If and for so long as any payment from DISTRIBUTOR to UT or UT to DISTRIBUTOR under this Agreement shall be overdue:

 

(a)                                  Interest shall be due and payable at the rate of twelve percent (12%) per annum, or such lower rate as may be the maximum legally permissible rate of interest, on all balances outstanding from the first date such payment is due until fully paid;

 

(b)                                 Each Party shall have the right to recover its collection costs and expenses (including reasonable attorneys’ fees) for late payments.  UT reserves the right to withhold or suspend shipment of UT Product if there is any unsettled or outstanding balance owed or caused by DISTRIBUTOR to UT and to revoke any credit terms it may offer DISTRIBUTOR; and

 

(c)                                  Overdue payments automatically forfeit any prompt pay discounts referenced in Section 7.4.

 

7.7                                 Tax Payments.  Each Party shall pay all taxes, duties, import deposits, assessments and other governmental charges, however designated, that are now or hereafter imposed upon such Party by any governmental authority or agency in connection with the performance of its obligations under this Agreement.

 

7.8                                 Resale Prices.  The Parties acknowledge that DISTRIBUTOR may offer the UT Product in the Territory at such prices or discounts as DISTRIBUTOR, in its sole discretion, may determine. [***]

 

7.9                                 [***]

 

7.10                           Drug Formulary.  The Parties acknowledge and agree that no payment made pursuant to this Agreement is intended in any way as a payment related to a drug formulary or drug formulary activities.  The Parties acknowledge and agree that no drug formulary or drug

 

16

 

formulary activities have been negotiated or discussed between the Parties in connection with this Agreement.

 

ARTICLE 8:  ACCEPTANCE, WARRANTY AND PRODUCTS SUPPORT

 

8.1                                 Acceptance of UT Product.  DISTRIBUTOR shall promptly inspect each shipment of UT Product.  In the event of any shortage, damage, expiration or discrepancy in a shipment of UT Product on the exterior of the shipment of UT Product that is patently obvious, DISTRIBUTOR shall promptly report the same to UT and furnish such written evidence or other documentation as UT may reasonably request.  DISTRIBUTOR shall be deemed to have accepted a shipment and UT shall not be liable for any such shortage, damage, expiration or discrepancy in such shipment unless DISTRIBUTOR provides UT with such notice and substantiating evidence within five (5) days of receipt of the UT Product at DISTRIBUTOR’s Designated Shipment Location.  Upon receipt of reasonable substantiating evidence of such shortage, damage or discrepancy, UT shall promptly provide additional UT Product or substitute products to DISTRIBUTOR.

 

8.2                                 Product Warranty.  UT hereby authorizes DISTRIBUTOR to pass on the UT standard warranty set forth in Attachment D to DISTRIBUTOR’s Customers in the Territory, which may be revised by UT upon written notice to DISTRIBUTOR.

 

8.3                                 Excluded Claims.  UT shall not have any additional warranty obligations to DISTRIBUTOR or Customers under Section 8.2 above or otherwise to the extent that DISTRIBUTOR has made any warranties, oral or written, beyond those expressly set forth in the standard UT warranty, set forth in Attachment D hereto. DISTRIBUTOR shall not offer its customers any warranties different from or in addition to those given by UT hereunder.

 

8.4                                 Limited Warranty.  THE WARRANTIES SET FORTH IN THE UT WARRANTY, ATTACHMENT D HERETO, AND THE OTHER TERMS AND CONDITIONS OF THIS AGREEMENT, ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WHICH ARE HEREBY DISCLAIMED AND EXCLUDED BY UT, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE.  THE SOLE AND EXCLUSIVE REMEDIES FOR BREACH OF UT’S STANDARD WARRANTIES SHALL BE LIMITED TO THE REMEDIES PROVIDED IN UT’S STANDARD WARRANTIES SET FORTH ON ATTACHMENT D HERETO AND AS OTHERWISE PROVIDED IN THIS AGREEMENT.

 

8.5                                 Limited Remedy.  UT SHALL NOT BE LIABLE TO DISTRIBUTOR OR ANY OF ITS CUSTOMERS FOR LOSS OR DAMAGE CAUSED BY DISTRIBUTOR’s DELAY IN FURNISHING UT PRODUCTS UNDER THIS AGREEMENT. UT SHALL NOT BE LIABLE TO DISTRIBUTOR OR ANY OF ITS AFFILIATES, EMPLOYEES, AGENTS OR CONTRACTORS FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL LOSSES OR DAMAGES, EVEN IF UT SHALL HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH POTENTIAL LOSS OR DAMAGE BY DISTRIBUTOR OR SUCH THIRD PARTY.      NOTWITHSTANDING THE FOREGOING, IN CASE OF ANY CONFLICT BETWEEN THE PROVISIONS OF THIS SECTION AND SECTION 12.4 or 12.5, SECTION 12.4 AND SECTION 12.5 SHALL CONTROL.

 

17

 

ARTICLE 9:  REGULATORY APPROVALS, COMPLIANCE AND AUDITS

 

9.1                                 Compliance with Applicable Laws.  UT shall be solely responsible for, and comply with, Applicable Laws governing the regulation of the manufacture, importation, design, testing, inspection, labeling, sale, warning and instructions for use of UT Product in the Territory, or otherwise applicable to the performance of its obligations under this Agreement.  DISTRIBUTOR shall comply with all Applicable Laws governing its distribution and sale of UT Product in the Territory, or otherwise applicable to the performance of its obligations hereunder.  Each Party shall comply with Applicable Laws intended to prevent fraud, waste and abuse in federal health care programs, including but not limited to Medicare and Medicaid, and shall conduct its activities hereunder in an ethical and professional manner. Both parties shall take all action necessary and appropriate to assure that it complies with all Applicable Laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. § 1320a-7B), the Anti-Kickback Act of 1986 (41 U.S.C. § 51 et seq.), the Stark Anti-Referral Law (42 U.S.C. § 1395nn), and any laws and regulations relating to disclosure and notification of plan benefits or the terms of this arrangement as required. The Parties intend to treat all discounts (including, but not limited to, prompt payment discounts) payable by UT hereunder as “discounts or other reductions in price” pursuant to the Anti-Kickback Statute, and to comply with the discount safe harbor set forth at 42 C.F.R. § 1001.952(h).  Accordingly, the Parties agree that: (i) DISTRIBUTOR shall, as appropriate, disclose all discounts received hereunder to representatives of Medicare, Medicaid, any governmental authority, and Federal health care programs (as defined under 42 U.S.C. 1320a-7b(f)) (collectively, “governmental entities”) upon request in accordance with 42 C.F.R. 1001.952(h); and (ii) UT shall, if required and as appropriate, properly report all discounts paid hereunder to the appropriate governmental entities for purposes of determining “Best Price” under the Medicaid rebate program and for purposes of determining AMP or ASP under Medicare, if applicable. In addition, Medco’s Code of Conduct and its policies and procedures relating to compliance with the above-named laws are available on Medco’s website at the following URL: http://www.medcohealth.com/medco/corporate/home.jsp, click on the Investors tab and then the Corporate Governance link and UT’s United States Comprehensive Compliance Plan for Approved Pharmaceutical Products is also available on its internet site (www.unither.com).

 

9.2                                 Government Inquiries.  In the event that DISTRIBUTOR receives an inquiry, or similar notice from a government agency or entity for information or an inspection (a “Notice”) which relates to UT Product or this Agreement, DISTRIBUTOR shall: (a) notify and provide a copy to UT of such Notice promptly within three (3) business days of receipt of such Notice; (b) unless expressly prohibited by the Notice, consult with UT regarding its response to the Notice to determine, among other things, whether any of UT’s Confidential Information shall be disclosed (which in all events shall be subject to DISTRIBUTOR’s obligations specified in Article 10 of this Agreement); (c) keep UT informed of the progress of any inspection and provide UT with prior notice of any documents related to UT Product or UT to be provided to such government entity; and (d) provide UT with a copy of any documents related to UT Product or UT ultimately produced pursuant to such Notice.  Further, DISTRIBUTOR shall provide UT with a summary of the results of any inspection and such actions, if any, taken to remedy conditions cited in such inspections.  DISTRIBUTOR further agrees to cooperate with any inspection of a shipment of UT Product by a governmental agency.

 

9.3                                 Adverse Event Reporting.  DISTRIBUTOR shall not be responsible for FDA reporting of adverse events. DISTRIBUTOR shall attempt to warm transfer a caller with potential Adverse Event information to a phone number designated by UT.  Otherwise, DISTRIBUTOR shall notify UT by fax to (919) 313-1297, e-mail at

 

18

 

drugsafety@unither.com immediately, or as agreed to by the parties, or at the latest within three (3) business days, of any complaint of a potential Adverse Event from a third party being reported to DISTRIBUTOR.  As directed by UT, such fax or e-mail report sent by DISTRIBUTOR shall include information as required by UT in order to adequately report such Adverse Event to FDA.

 

9.4                                 Withdrawal or Recall of Product.  Any recalls of UT Product shall be conducted in compliance with FDA requirements and the UT standard operating procedure for recalls (“UT Recall SOP”) as provided to and accepted by DISTRIBUTOR. DISTRIBUTOR shall prepare and maintain a written standard operating procedure that provides processes for conducting recall-related activities for UT Product as directed by UT and in accordance with the UT Recall SOP.  The decision to recall UT Product shall be made solely by UT, unless otherwise dictated by a governmental authority. UT shall be responsible for the expenses related to recall activities as described below, unless the recall results from a breach of any of DISTRIBUTOR’s representations and warranties under this Agreement or DISTRIBUTOR’s negligence or willful misconduct, in which event DISTRIBUTOR shall be responsible for all of recall-related expenses.  For purposes of this Agreement, the expenses of the activities shall be: (i) the reasonable expenses of notification and return or destruction (if authorized by UT) of UT Product, (ii) the cost to replace UT Product,  (iii) the costs directly associated with the distribution of replacement UT Product including pharmacist and dispensing labor, cold packs and labels; (iv) reasonable communications to Included Patients such as patient letters, patient phone calls and follow-up customer service; (v) labor associated with managing the recall process; (vi) any expenses associated with dispensing activity missed by DISTRIBUTOR as a result of UT’s provision of product to Included Patients beyond that is necessary to replace recalled product; and (vii) shipping and insurance costs associated with returning recalled UT Product. DISTRIBUTOR and UT shall cooperate fully with one another in conducting any activity contemplated by this Section 9.4.  Destruction of recalled product shall be conducted in accordance with the recall plan, as approved by UT under the UT Recall SOP and by any applicable governmental authorities.  If instructed by UT, DISTRIBUTOR may return recalled UT Product to UT at UT’s expense within thirty (30) days from completion of the recall and UT shall replace the UT Product recalled or refund the cost of such returned UT Product. Any UT Product returned to UT under this Section 9.4 shall be shipped by common carrier in a manner that preserves the integrity of the UT Product shipped, as instructed by UT.  Title to the recalled UT Product and risk of loss, theft, destruction or damage to UT Product during shipment as described above shall pass from DISTRIBUTOR to UT upon delivery of recalled UT Product at UT’s facility.  DISTRIBUTOR’s obligation to insure UT Product shall continue with respect to recalled UT Product until UT’s receipt of such recalled UT Product.

 

9.5                                 Visits by Parties.  DISTRIBUTOR shall permit UT to visit its place of business and inspect its records, inventories and other relevant materials and records relating solely to its performance of this Agreement, upon reasonable advance notice and during normal business hours.

 

9.6                                 No Returns.  UT will not accept the return of any UT Product, unless agreed in writing by UT, except if returned pursuant to a recall under Section 9.4 above.

 

ARTICLE 10:  PROPERTY OWNERSHIP; CONFIDENTIALITY

 

All Confidential Information and other proprietary materials, documents, information, databases, complete and incomplete case report forms and all data that one Party (“Disclosing Party”) supplies to the other Party (“Receiving Party”) shall be the sole and exclusive property of the Disclosing Party (“Disclosing Party Property”). All Confidential Information shall be deemed

 

19

 

confidential and proprietary to the Disclosing Party. During the term of this Agreement and for a period of five (5) years following thereafter, the Receiving Party shall: (a) not disclose or provide any Confidential Information to any third party, and (b) take reasonable measures to prevent any unauthorized disclosure of Confidential Information by its employees, agents, contractors or consultants during the term hereof including advising such individuals of applicable confidentiality obligations.  Upon termination of this Agreement, the Receiving Party shall return or destroy to the Disclosing Party, at the Disclosing Party’s request and expense, all unused Disclosing Party Property, except the Receiving Party may keep one (1) copy of such Disclosing Party Property for legal archival purposes.

 

ARTICLE 11:  TRADEMARKS

 

11.1                           Trademark License Grant.  UT hereby grants to DISTRIBUTOR, and DISTRIBUTOR hereby accepts from UT, a nonexclusive, nontransferable, and royalty-free right and license, during the term of this Agreement, to reproduce and use the UT Trademarks in connection with the distribution, marketing and sale or other distribution of UT Product in the Territory and in accordance with UT’s standards and instructions and for no other purpose.  DISTRIBUTOR shall not use any other marks or trade names in connection with the marketing and distribution of UT Product, except that DISTRIBUTOR may use its marks or trade names in a manner consistent with its normal course of business, such as adding a label on the packaging identifying DISTRIBUTOR as a distributor of UT Product, and such use shall not confer on UT any rights or license in DISTRIBUTOR’s marks or trade names.  UT may inspect and monitor DISTRIBUTOR’s use of the UT Trademarks.  DISTRIBUTOR shall not remove or alter any UT trade names, trademarks, copyright notices, serial numbers, labels, tags or other identifying marks, symbols or legends affixed to any UT Product, documentation or containers or packages.

 

11.2                           Registration.  In its sole discretion, UT may register the UT Trademarks in the Territory if UT determines that registration is necessary or useful to the successful distribution of UT Product.  In addition, if UT believes that it is advisable to effect any filing or obtain any governmental approval or sanction for the use by DISTRIBUTOR of any of UT Trademarks pursuant to this Agreement, the Parties shall cooperate to do so.  All expenses relating to the registration of the UT Trademarks in the Territory as well as the making of any filing or obtaining any governmental approvals for the use by DISTRIBUTOR of the Trademarks shall be borne by UT.

 

11.3                           Termination of Use.  Immediately upon termination of this Agreement, DISTRIBUTOR’s license and right granted in Section 11.1 shall be revoked and DISTRIBUTOR shall cease and desist from use of any UT Trademark in any manner, other than to liquidate its then-existing inventory of UT Product within six months of such termination. DISTRIBUTOR hereby grants to UT or its designee, in the event of such termination, full power of attorney, with the right of substitution, to cancel, revoke or withdraw any governmental registration or authorization permitting DISTRIBUTOR to use any UT Trademark in the Territory, and DISTRIBUTOR shall provide such further documentation and assistance as UT may reasonably request in connection therewith.

 

11.4                           Reservation of Rights.

 

(a)                                  DISTRIBUTOR acknowledges UT’s proprietary rights in and to any UT Trademark, subject to the license and right granted in Section 11.1.  DISTRIBUTOR shall not adopt, use or register any words, phrases or symbols that are identical to or confusingly similar to any UT Trademark and shall not use any UT Trademark as part of DISTRIBUTOR’s corporate or trade name or permit any third party to do so.

 

20

 

(b)           UT acknowledges DISTRIBUTOR’s proprietary rights in and to any of DISTRIBUTOR’s trademarks. UT shall not adopt, use or register any words, phrases or symbols that are identical to or confusingly similar to any of DISTRIBUTOR’s trademarks and shall not use any such trademark as part of UT’s corporate or trade name or permit any third party to do so.

 

11.5         Infringements.  Each Party shall promptly notify the other Party in writing if it becomes aware of any use in the Territory by any third party of trademark or of any similar mark, which may constitute an infringement of a UT Trademark or DISTRIBUTOR’s trademarks. Subject to the provisions of this Article 11, Each Party shall have the exclusive right, in its sole discretion, to institute proceedings against third-party infringers of its trademarks.

 

ARTICLE 12:  INSURANCE AND INDEMNIFICATION

 

12.1         Insurance.  DISTRIBUTOR shall maintain in effect during the term of this Agreement a comprehensive general liability policy (which may be in the form of primary or excess coverage) in an amount not less than Two Million Dollars ($2,000,000) per occurrence and Three Million Dollars ($3,000,000) in the aggregate.  The deductible for such policy shall be no more than One Hundred Thousand Dollars ($100,000) DISTRIBUTOR agrees to provide UT with a certificate of insurance evidencing compliance with this section upon written request of UT.

 

12.2         Claims.  For the purposes of this Article 12 a “Claim” shall mean any liabilities, damages, costs or expenses, including, without limitation, reasonable attorneys’ fees arising from any claim, lawsuit, demand or other action by a third party.

 

12.3         DISTRIBUTOR Indemnification of UT.  Except as provided in Section 12.4, DISTRIBUTOR shall indemnify, defend and hold harmless UT, its Affiliates, and their respective officers, directors, employees, agents, successors and assigns from and against any Claim to the extent such Claim relates to or is based on: (a) property damage, personal injury or death resulting from DISTRIBUTOR’s negligent or reckless provision or maintenance of UT Product (except to the extent the same results from any wrongful act or omission of UT); (b) DISTRIBUTOR’s violation of Applicable Laws; or (c) any breach by DISTRIBUTOR of any of its representations, warranties, covenants or agreements under this Agreement.

 

12.4         UT Indemnification of DISTRIBUTOR for UT Product.  Except as provided in Section 12.3, UT shall indemnify, defend and hold harmless DISTRIBUTOR and its Affiliates, and their respective officers, directors, employees, agents and successors and assigns from and against any Claim to the extent such Claim relates to or is based on: (a) property damage, personal injury or death resulting from use of UT Product (except to the extent the same results from any wrongful action or omission of DISTRIBUTOR); (b) UT’s violation of Applicable Laws; or (c)  any breach by UT of any of its representations, warranties, covenants or agreements under this Agreement.

 

12.5         Indemnification Procedure.  A Party seeking indemnification under this Article 12 (“Indemnified Party”) shall give prompt written notice to the indemnifying Party (“Indemnifying Party”) of any Claim covered by the indemnification obligations hereunder; provided, however, that a delay in such notice shall not terminate the Indemnifying Party’s indemnification obligations hereunder, unless such delay shall have materially impaired the defense of such Claim.   Such Indemnifying Party shall have sole and exclusive control of the defense of any such Claim, including the choice and direction of any legal counsel; provided, however, if Indemnifying Party’s choice of legal

 

21

 

counsel would be subject to a material conflict of interest under the applicable rules of professional conduct governing such counsel, the Indemnified Party shall not be obligated to waive such conflict and may request separate legal counsel at the Indemnifying Party’s expense.  The Indemnifying Party may not settle or compromise any such Claim without the written consent of the Indemnified Party, which consent shall not be unreasonably withheld.

 

12.6         Litigation Support.  In the event and for so long as an Indemnifying Party actively is contesting or defending against any Claim under this Article 12, the Indemnified Party shall cooperate with the Indemnifying Party and its legal counsel in the contest or defense of such Claim, make available its personnel, and provide such testimony and access to its books and records as shall be reasonably necessary in connection with the contest or defense of such Claim, all at the sole cost and expense of the Indemnifying Party.

 

12.7         Subrogation.  The Indemnifying Party shall be subrogated to the rights of the Indemnified Party against any third party bringing a Claim, and such Indemnified Party hereby assigns to the Indemnifying Party all claims, causes of action and other rights that the Indemnified Party may then have against such third party.  Conversely, and without in any way limiting the obligation of either Party to indemnify the other Party as herein provided, to the extent that an Indemnifying Party fails to perform its indemnification obligations under Section 12.3 or Section 12.4 above, the Indemnifying Party hereby assigns to the Indemnified Party all claims, causes of action and other rights which the Indemnifying Party may then have against any third party with respect to any Claim for which indemnification is provided hereunder.

 

ARTICLE 13:  ARTICLE 13  JOINT PUBLICITY

 

13.1         Public Disclosure.  If either Party wishes to make a public disclosure concerning this Agreement or the relationship established hereunder and such disclosure mentions the other Party by name or description, such other Party shall be provided with an advance copy of the disclosure and shall have (to the extent reasonably practicable) five (5) business days within which to approve or disapprove such use or its name of description (including mention of the name of the Product); provided, however: (a) approval shall not be unreasonably withheld by either Party; (b) failure to respond within five (5) business days shall be deemed approval; and (c) if approval is denied, no disclosure shall use the name of or otherwise describe such Party except to the extent required by Applicable Laws, or the extent that the description of the other Party is limited to public information about the availability of UT Product.

 

13.2         Filings with Securities and Exchange Commission.  Notwithstanding the foregoing, each Party acknowledges that both Parties are, or are affiliates of, a publicly traded company and each Party hereby consents to the disclosure of this Agreement and the relationship between the Parties in their respective filings with the Securities and Exchange Commission and disclosures to their stockholders; provided, however, that each Party shall use commercially reasonable efforts not to disclose the specific financial terms and conditions of this Agreement except when such disclosure is required by Applicable Laws or by this Agreement.

 

ARTICLE 14:  FORCE MAJEURE

 

14.1         Notice.  A Party affected by an event of Force Majeure shall promptly provide the other Party with written notice describing the event, its cause and foreseeable duration, and its possible consequences upon performance under this Agreement.

 

22

 

14.2         Suspension of Performance.  After an affected Party has given notice under Section 15.1, that Party shall be relieved of any performance obligation under this Agreement for obligations which the Force Majeure event prevents, but only to the extent and only for so long as the Force Majeure prevents performance.  The other Party may likewise suspend the performance of all or part of its obligations, except for the obligation to pay any amount due and owing and those obligations specified in Section 16.4(c) of this Agreement. Notwithstanding the foregoing, UT shall use Commercially Reasonable Efforts to allocate available UT Product to DISTRIBUTOR at least in proportion to DISTRIBUTOR’s historical purchases.

 

14.3         Substitute Performance.  If DISTRIBUTOR is delayed by an event of Force Majeure, UT shall, at its sole option, allow a third party to cover the services related to the distribution of UT Product that DISTRIBUTOR was unable to complete due to its delay and such third party shall receive the fees DISTRIBUTOR would have received during its period of delay.

 

14.4         Termination.  If the period of Force Majeure continues for more than sixty (60) days, either Party may terminate this Agreement upon giving notice to the other Party without incurring liability other than the obligation to make payments due up to and including such date of termination.

 

ARTICLE 15:  TERM AND TERMINATION

 

15.1         Term.  The initial term of this Agreement shall begin on the Effective Date and shall continue in force until February 21, 2012.  Thereafter, this Agreement shall automatically renew for additional periods of one (1) year each, unless either of the Parties shall have given the other Party written notice of its non-renewal of this Agreement no later than ninety (90) days prior to the end of the initial or any renewal term hereof.

 

15.2         Termination.  This Agreement may be terminated prior to the expiration of the then current term as follows:

 

(a)           Either Party may terminate this Agreement immediately upon written notice to the other Party if the other Party files a petition of any type as to its bankruptcy, is declared bankrupt, becomes insolvent, makes an assignment for the benefit of creditors, goes into liquidation or receivership, a proceeding is commenced against it which will substantially impair its ability to perform hereunder or such Party otherwise loses legal control of its business;

 

(b)           Either Party may terminate this Agreement upon the occurrence of a material breach by the other Party (including, but not limited to, DISTRIBUTOR’s failure to promptly pay sums owing to UT), which breach has not been cured within thirty (30) days of written notice of such breach from the non-breaching Party;

 

(c)           Either Party may terminate this Agreement upon written notice if an event of Force Majeure continues for more than sixty (60) days as provided in Section 14.4;

 

(d)           The Parties may agree in writing to terminate this Agreement for their mutual convenience at any time and for any reason, subject to such terms and conditions as they may then adopt;

 

23

 

(e)           Either Party may terminate this Agreement at any time, with or without cause, by written notice to the other Party, which shall be effective one hundred and eighty days  (180) days after its date; and

 

(f)            If at any time in the future, a change in the reimbursement of UT Product or legal requirements of payers would (a) require the Parties to renegotiate or alter significant terms of this Agreement, or (b) result in a substantial adverse change in the respective financial benefits or burdens accruing to any Party under the terms of this Agreement, then upon written request by either Party in the case of (a), or the affected Party in the case of (b), the Parties shall endeavor in good faith to renegotiate and modify the terms of this Agreement to comply with such new requirements or avoid such substantial adverse change.  If the Parties are unable to agree to such modifications within one hundred twenty (120) days of receipt of the written request, then either Party (in the case of (a)), or the adversely affected Party (in the case of (b)) may terminate this Agreement immediately upon expiration of the one hundred twenty (120) day period.

 

(g)           [***]

 

15.3         Partial Termination.  In the event that either Party shall have the right pursuant to the provisions of Section 15.2 to terminate this Agreement in its entirety, that Party may elect, in its sole discretion, to terminate this Agreement solely as it applies to a portion of the Territory, or, if applicable, any category of Customer.

 

15.4         Rights and Obligations on Termination.  If this Agreement is terminated for any reason, the Parties shall have the following rights and obligations:

 

(a)           Termination of this Agreement shall not release either Party from the obligation to make payments of all amounts then or thereafter due and payable, and shall not release UT from its obligations to provide UT Product to DISTRIBUTOR at DISTRIBUTOR’s request to service its existing patients as of the effective termination date and until such existing patients are transitioned to another distributor. DISTRIBUTOR and UT shall use their Commercially Reasonable Efforts to achieve such transition as expeditiously as possible after the effective termination date;

 

(b)           Each Party’s respective obligations of confidentiality under Article 10 and record retention under Article 17 shall survive as provided in such articles;

 

(c)           Each Party’s respective obligations under Section 7.4, ‘Payment Terms; Invoices,’ Section 9.1, ‘Compliance with Laws,’ the indemnification provisions of Article 12, this Article 15 and Article 16, ‘Dispute Resolution,’ shall survive termination of this Agreement; and

 

(d)           UT shall cause other entities to undertake, or shall otherwise relieve DISTRIBUTOR of its obligations and all costs relating to all PAP Patients, and shall complete such transition or relief with respect to such patients no later than one hundred and eighty (180) days from the termination date.  DISTRIBUTOR agrees to use its Commercially Reasonable Efforts to cooperate with such transfer.

 

24

 

ARTICLE 16:  DISPUTE RESOLUTION

 

16.1         Negotiation.  The Parties agree to consult and negotiate in good faith to try to resolve any dispute, controversy or claim that arises out of or relates to this Agreement.  No formal dispute resolution shall be used by either Party unless and until senior executive officers of each Party have used Commercially Reasonable Efforts to meet in person to achieve such an amicable resolution.

 

16.2         Submission to Jurisdiction.  Each Party irrevocably agrees that any legal action or proceeding arising out of or relating to this Agreement brought the other Party or its successors or assigns shall be brought and determined in the United States District Court for the Southern District of New York (or, if such court does not have jurisdiction, the Supreme Court of the State of New York, New York County), and each of Party hereby irrevocably submits to the exclusive jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby.  Each Party agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in New York, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in New York as described herein.  Each Party further agrees that notice as provided herein shall constitute sufficient service of process and the Parties further waive any argument that such service is insufficient.  Each Party hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, (a) any claim that it is not personally subject to the jurisdiction of the courts in New York as described herein for any reason, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.

 

16.3         Enforcement.  The Parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.  Accordingly, each of the Parties shall be entitled to specific performance of the terms hereof, including an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in any New York state or federal court, this being in addition to any other remedy to which such Party is entitled at law or in equity.  Each of the Parties hereby further waives (a) any defense in any action for specific performance that a remedy at law would be adequate and (b) any requirement under any law to post security as a prerequisite to obtaining equitable relief.

 

ARTICLE 17:  RECORDS

 

During the term hereof and for three (3) years thereafter, or such longer period as may be required by Applicable Laws, DISTRIBUTOR shall maintain accurate records as required to meet Applicable Laws.  Except as otherwise required by Applicable Laws, DISTRIBUTOR shall provide UT with access to any reasonably requested documentation related solely to this Agreement during reasonable business hours.  UT shall give DISTRIBUTOR seven (7) days’ prior written notice of such examinations, which will not occur more than once annually, and such examinations shall be undertaken

 

25

 

only to such extent necessary to verify that the DISTRIBUTOR has complied with the terms of this Agreement.

 

ARTICLE 18:  ARTICLE 18  GENERAL PROVISIONS

 

18.1         Entire Agreement.  This Agreement constitutes the entire agreement of the Parties  with respect to the subject matter hereof and supersedes all the Parties’ previous or contemporaneous correspondence, term sheets, understandings, agreements and representations, oral or written between the Parties, including without limitation the Original Agreement and all previous amendments thereto.

 

18.2         Assignment.  Neither Party shall assign or otherwise transfer its rights or obligations under this Agreement except with the prior written consent of the other Party, which shall not be unreasonably withheld or delayed; provided, however, that no such consent shall be required and either Party may transfer all rights and obligations arising hereunder to an entity if it is: (a) an Affiliate; (b) the successor in interest by reason of sale, merger or operation of law; or (c) has acquired all or substantially all of the assets and business.  Any unauthorized attempted assignment or delegation shall be null and void and of no force or effect.

 

18.3         Subcontracting. DISTRIBUTOR shall not, without the prior written approval of UT, appoint any distributors or agents to act on behalf of DISTRIBUTOR (collectively, “Sub-Distributors”) to distribute UT Product within the Territory, other than any of its Affiliates.  DISTRIBUTOR shall at all times remain fully liable for the performance of any approved Sub-Distributors and DISTRIBUTOR shall provide UT with a written acknowledgement executed by each Sub-Distributor that it has read this Agreement and agrees to be bound by its terms and conditions, including those contained in the attachments hereto. Notwithstanding the forgoing, DISTRIBUTOR may subcontract portions of certain limited functions and responsibilities of this Agreement, provided that the subcontractor performs in a manner conforming to this Agreement, subcontractor enters into a confidentiality agreement no less extensive than required by this Agreement; and DISTRIBUTOR retains full responsibility and liability for the performance of the subcontracted service.  At no time shall DISTRIBUTOR subcontract all or substantially all of any given function to a third party without the prior written consent of UT.

 

18.4         Amendment.  This Agreement may not be modified or amended, in whole or in part, except by a written agreement signed by both Parties, and specifically stating that it modifies or amends this Agreement.

 

18.5         Severability.  If one or more of the provisions of this Agreement is subsequently declared invalid or unenforceable, this Agreement shall be treated as though that provision were not in this Agreement, and this shall not affect the validity or enforceability of the remaining provisions of this Agreement (unless those provisions that are invalidated or unenforceable are clearly material and inseparable from the other provisions).  The Agreement as modified shall be applied and construed to reflect substantially the good faith intent of the Parties and to achieve the economic effects originally intended by the terms hereof.

 

18.6         Notices; Language.  Except as may be otherwise provided in this Agreement, any notice, demand or request given, made or required to be made shall be in writing and shall be effective, unless otherwise provided herein, either (a) when delivered in person to the other Party, or (b) on the same business day that it is transmitted by facsimile to the facsimile number (s) set forth below, with electronic confirmation of receipt, if transmitted prior to 5:00 p.m. Eastern time on such business day, or on the first business

 

26

 

day following such transmission if transmitted after 5:00 p.m. Eastern Time or if transmitted on a day other than a business day; provided a hard copy is deposited within one (1) day after such transmissions in the U.S. mail, postage prepaid, and addressed as set forth below for notices by U.S. mail; or (c) on the third business day following its deposit in the U.S. mail, postage and addressed as follows:

 

	
If   to UT:
    	
 
    	
United   Therapeutics Corporation
    
	
 
    	
 
    	
1040   Spring Street
    
	
 
    	
 
    	
Silver   Spring, Maryland 20910
    
	
 
    	
 
    	
Attention:   John Ferrari, Chief Financial Officer
    
	
 
    	
 
    	
Telefax:   301-608-9291
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
With   a copy to:
    
	
 
    	
 
    	
United   Therapeutics Corporation
    
	
 
    	
 
    	
1735   Connecticut Ave. NW
    
	
 
    	
 
    	
Washington,   DC 20009
    
	
 
    	
 
    	
Attention:   Paul Mahon, EVP & General Counsel
    
	
 
    	
 
    	
Telefax:   202-483-4005
    
	
 
    	
 
    	
 
    
	
If   to DISTRIBUTOR:
    	
 
    	
 
    
	
 
    	
 
    	
Medco   Health Solutions, Inc.
    
	
 
    	
 
    	
100   Parsons Pond Drive
    
	
 
    	
 
    	
Franklin   Lakes, NJ 07417
    
	
 
    	
 
    	
Attn:   General Counsel (Accredo)
    

 

18.7         Waiver.  Either Party’s failure or delay in exercising any remedy for default shall not be deemed a waiver of that or any subsequent defaults of that provision or of any other provision hereof.  No waiver shall be effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the Party granting the waiver.

 

18.8         Counterparts.  This Agreement shall be executed in two (2) or more counterparts in the English language, each of which shall be deemed an original, which taken together shall constitute one and the same instrument.

 

18.9         Governing Law.  Except as provided by federal law, this Agreement shall be governed by, and interpreted and construed in accordance with, the laws of the State of New  York, excluding any conflict-of-laws rule or principle therein contained under which any other law would be made applicable (other than Section 5-1401 of the New York General Obligations Law).

 

18.10       Relationship.  This Agreement does not make either Party the employee, agent or legal representative of the other Party for any purpose whatsoever.  Neither Party is granted any right or authority to assume or to create any obligation or responsibility, express or implied, on behalf of or in the name of the other Party.  In fulfilling its obligations pursuant to this Agreement each Party shall be acting as an independent contractor and shall not be deemed to have formed any partnership, joint venture or other relationship.

 

18.11       Headings.  The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 

18.12       Signature Authority.  Each signatory to this Agreement has signature authority and, is empowered on behalf of his or her respective Party to execute this Agreement.

 

27

 

18.13       Cumulative Remedies.  Except as expressly provided in this Agreement, and to the extent permitted by Applicable Laws, any remedies described in this Agreement are cumulative and not alternative to any other remedies available at law or equity.

 

18.14       HIPAA Compliance.  DISTRIBUTOR shall only provide information to UT in a manner consistent with the Health Insurance Portability and Accountability Act of 1996, as amended, 42 U.S.C. § 1320d, et seq., and the implementing regulations promulgated thereunder (collectively referred to herein as “HIPAA”). Accordingly, the Parties agree that DISTRIBUTOR shall only provide UT with information that is de-identified in accordance with HIPAA’s de-identification provision, 45 C.F.R. § 164.514(b)(2), unless DISTRIBUTOR: (i) has on file a valid, HIPAA-compliant authorization for each patient whose protected health information (“PHI”) is sought to be disclosed; or (ii) authorization is not required under Applicable Laws in order to disclose the PHI.

 

18.15       Nothing herein shall be construed to limit DISTRIBUTOR from entering into other agreements with other manufacturers or wholesalers that allow DISTRIBUTOR to dispense products that compete with UT’s Products. Notwithstanding the preceding sentence, DISTRIBUTOR warrants and represents that it will not disparage UT or UT Product

 

18.16       Each Party shall promptly notify the other Party upon learning of any activity that appears to improperly or inappropriately portray or affect the other Party, its products or Affiliates.

 

18.17       The Parties do not intend for this Agreement to benefit any Third Party and, therefore, there are no third party beneficiaries to this Agreement.

 

This Agreement may be declared void by DISTRIBUTOR unless signed by both Parties within thirty (30) days of execution by DISTRIBUTOR.

 

[Signature page follows]

 

28

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.

 

	
UNITED THERAPEUTICS
    	
 
    	
ACCREDO HEALTH GROUP, INC.
    
	
CORPORATION
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By
    	
/s/ Jay A. Watson
    	
 
    	
By
    	
/s/ Lori Marino
    
	
 
    	
Jay   A. Watson, Pharm.D.
    	
 
    	
 
    	
Name:   Lori B. Marino
    
	
 
    	
Sr.   Vice President, Strategic Operations
    	
 
    	
 
    	
Title:   Vice President and Assistant General Counsel
    
	
 
    	
and   Logistics
    	
 
    	
 
    	
 
    

 

29

 

Attachment A

 

Prices

 

UT Product

 

	
UT Product Name
    	
 
    	
NDC
    	
 
    	
Strength
    	
 
    	
Price
    	
 
    
	
Remodulin 1mg
    	
 
    	
66302-0101-01
    	
 
    	
1mg/20ml
    	
 
    	
$
    	
[***
    	
]
    
	
Remodulin 2.5mg
    	
 
    	
66302-0102-01
    	
 
    	
2.5mg/20ml
    	
 
    	
$
    	
[***
    	
]
    
	
Remodulin 5 mg
    	
 
    	
66302-0105-01
    	
 
    	
5mg/20ml
    	
 
    	
$
    	
[***
    	
]
    
	
Remodulin 10 mg
    	
 
    	
66302-0110-01
    	
 
    	
10mg/20ml
    	
 
    	
$
    	
[***
    	
]
    

 

UT shall notify the DISTRIBUTOR in writing of any change (and the amount of the change) in the Price of any respective UT Product during the term of this Agreement in the same time and manner as it notifies other similarly situated distributors.

 

UT shall provide DISTRIBUTOR with a current list of Remodulin prices to Discounted Entities, including FSS prices, Federal Ceiling Prices, and prices to section 340B entities, and shall promptly notify Distributor of any and all changes in such prices as well as the effective dates of such changes.

 

30

 

Attachment B

 

UT Trademarks Logotypes and Trade Names

 

UNITED THERAPEUTICS

 

UNITED THERAPEUTICS CORPORATION LOGO

 

REMODULIN

 

MEDICINES FOR LIFE

 

REMODULIN LOGO

 

31

 

Attachment C

 

UNITED THERAPEUTICS PATIENT ASSISTANCE PROGRAM GUIDELINES (“GUIDELINES”)

 

The following Guidelines for the United Therapeutics Corporation Patient Assistance Program (“PAP”) are being provided to United Therapeutics’ designated U.S. Specialty Pharmacy Distributors (“Distributors”) as the Program Administrators for the purposes of administering the PAP, as is required by their respective Distribution Agreements. Distributors will be responsible for collecting all required patient demographics, financial and clinical information and for the oversight of the completion of the Enrollment Form Application. In addition, the Distributors will follow these Guidelines and will make all necessary decisions related to patient admission into the PAP. The Distributors shall maintain a detailed and retrievable record of all communications, correspondence, and activities related to the PAP including dispensing of product, and if applicable, supplies, and equipment without charge to the PAP patient.  Distributors shall also make reasonable attempts to aid PAP patients in securing third party payer benefits when possible. In addition, it is further understood that Distributors shall take all necessary steps to preserve the confidentiality of patient information gathered under the PAP in accordance with all federal, state and local laws pertaining to patient privacy, except as such confidentiality may be expressly waived by patients.  If and when patients that do not meet the criteria set forth in these Guidelines are presented to the Distributors, United Therapeutics Corporation Representative(s) will be consulted prior to Distributors making any decision regarding PAP admission of such patients.  Nothing set forth herein shall mandate Distributor providing PAP opportunities where the patients’ third party payor prohibits such actions.

 

In order to be eligible for the PAP, patients must meet all Basic Criteria and qualify for coverage under I, II or III below.

 

BASIC CRITERIA:

 

All PAP Patients must meet the following Basic Criteria:

 

·      Patient must reside in the United States and be under the direct care of a licensed U.S. Physician and receive health care services via the U.S. Health Care system.

·      Patient must not have access to coverage from federal governmental programs or the Commonwealth of Massachusetts.

·      Patient must have a documented indication for treatment as approved by the U.S. Food and Drug Administration (“FDA”), and as labeled in appropriate product Package Insert (“PI”). Off-Label indications for treatment will not be eligible for PAP.

·      Patient Enrollment Applications must be completed in full, signed by the patient (or legal guardian) and the treating physician, be accompanied by copies of all supporting financial information (as outlined in the application form), and validated by the Distributors.

 

To determine the type of PAP coverage for which patients who meet these Basic Criteria are eligible, each patient must be assessed to meet on set of criteria set forth under I, II or III below.

 

32

 

ADDITIONAL QUALIFYING CRITERIA:

 

I.              Indigent Patient Criteria for PAP:

 

An indigent patient meets the following criteria:

 

·      Insufficient out-of-pocket financial resources to pay for therapy;

·      Household income levels do not exceed 300% of Federal Poverty Guidelines (2009 HHS) (See Table 1)
 (Available from: http://aspe.hhs.gov/poverty/);

·      No insurance (commercial, governmental, state, local, or special services) coverage (documented); and

·      Demonstrates application for and receives denial (written) from a State Medicaid Program. Copies or proof of application and denial are required.

 

PATIENTS WHO MEET THESE CRITERIA WILL QUALIFY FOR THE PAP FOR A PERIOD UP TO ONE (1) YEAR FROM THE DATE OF ACCEPTANCE.  PATIENT HOUSEHOLD INCOME INFORMATION, HEALTH INSURANCE STATUS, AND OUT-OF-POCKET MEDICATION AND SUPPLY EXPENSES WILL BE REEVALUATED ON A QUARTERLY BASIS TO ENSURE CONTINUED ELIGIBILITY.  AT THE END OF THE ONE (1) YEAR PERIOD, THE PAP PATIENT WILL BE REQUIRED TO RE-ENROLL (AS THEY DID WITH THE INITIAL APPLICATION) AND PROVIDE PROOF OF INCOME OR LACK OF THIRD PARTY PAYER INFORMATION ELIGIBILITY.

 

OR,

 

II.            “Bridge” Coverage Patient Criteria for PAP:

 

·      Patient with monthly household income levels below $25,000 AND one or more of the following conditions are also met:

·      Patient has changed jobs or stopped working and has COBRA and/or HIPAA coverage; or

·      Patient has insurance coverage, but there is an exclusion period (new job, new group health plan, acceptance of drug into formulary, etc.).  However, if patient will lose insurance coverage by accepting PAP product, they shall be excluded from bridge coverage.

 

PATIENTS WHO MEET THESE CRITERIA WILL QUALIFY FOR THE PAP FOR A MAXIMUM OF 6 MONTHS OR UNTIL HE/SHE IS ABLE TO OBTAIN THIRD PARTY PAYER OR SIMILAR REIMBURSEMENT CAPABILITIES (WHICHEVER COMES FIRST).  PATIENT HOUSEHOLD INCOME INFORMATION, HEALTH INSURANCE STATUS, AND OUT-OF-POCKET MEDICATION AND SUPPLY EXPENSES WILL BE REEVALUATED ON A QUARTERLY BASIS TO ENSURE CONTINUED ELIGIBILITY.

 

OR,

 

III.           Potential Exhaustion of Insurance Coverage:

 

·      Patient with monthly household income levels below $25,000 and currently has insurance coverage, but such insurance coverage is patient’s only source of insurance, it has a lifetime cap on benefits, and patient is within $300,000 of reaching the lifetime cap.  A statement from the insurer e.g. Explanation of Benefits (EOB) documenting that the patient is within $300,000 of exhausting a lifetime cap on his or her insurance benefits is required.

 

33

 

PATIENTS WHO MEET THESE CRITERIA WILL QUALIFY FOR THE PAP FOR A PERIOD OF ONE (1) YEAR FROM THE DATE OF ACCEPTANCE INTO THE PAP EXCEPT THAT ELIGIBILITY WILL TERMINATE IMMEDIATELY IF PATIENT OBTAINS A NEW SOURCE OF INSURANCE COVERAGE (INCLUDING SUPPLEMENTAL COVERAGE) AND NO LONGER MEETS THE ABOVE CRITERIA.  PATIENT HOUSEHOLD INCOME AND INSURANCE STATUS WILL BE REEVALUATED ON A QUARTERLY BASIS TO ENSURE CONTINUED ELIGIBILITY.

 

Distributor Responsibilities:

 

It is understood that Distributors will take all reasonable efforts to secure all information to support eligibility of PAP Patients PRIOR to any commitments for start of care. However, it is also reasonable that it may not always be possible to immediately secure all legal documentation to prove a patient’s eligibility. Therefore, the Distributors are authorized by United Therapeutics Corporation to obtain, at the very minimum, a completed and signed PAP enrollment form, co-signed by the physician attesting to his or her belief as to the patient’s eligibility and use their best judgment as to the patient’s eligibility for acceptance prior to receiving all required supporting documentation. This will constitute a twenty eight (28) business day grace period and Distributors will not be liable for products and related supplies and equipment provided to PAP patients during such grace period. However, at the end of the grace period, failure by the Distributor to obtain the required supporting documentation and determine PAP eligibility for that patient will result in termination of that patient’s PAP eligibility and the obligation to provide continuity of care shall rest with the Distributor, i.e. Distributor shall provide commercial product for the patient.

 

34

 

Attachment D
 UT Warranty

 

UT warrants that all of its Product shall as of the date such Product arrives at DISTRIBUTOR’s Designated Shipment Location: (i) be free from defects in design, material and workmanship; (ii) be in compliance with all applicable law and regulation, including without limitation all regulatory requirements of the FDA, including those related to the adulteration or misbranding of Product within the meaning of Section 501 and 502 of the Food Drug and Cosmetics Act; (iii) not be articles which may not be introduced into interstate commerce pursuant to the requirements of Sections 505, 514, 515, 516 or 520 thereof; (iv) be manufactured in accordance with current FDA Good Manufacturing Practice as required by 21 C.F.R. 210 and 820; (v) are fit for the ordinary purposes for which such Products are intended; and (vi) are not infringing upon the patents or trademarks of any third party.

 

35

 

Attachment E

 

Designated Shipment Locations and Designated Storage Locations

 

	
Name/Address/Phone/Fax
    	
 
    	
Name/Address/Phone/Fax
    	
 
    	
Name/Address/Phone/Fax
    
	
Accredo   Health Group, Inc.
   2100 Riverchase Center, Suite 405 Hoover, AL 35244
   205-987-0778
   800-442-7202
   205-987-0332 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   12900 Foster, Suite 120
   Overland Park, KS 66213
   913-339-7100
   800-569-5451
   913-339-7440 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   11 A Commerce Way
   Totowa, NJ 07512
   973-256-1870
   800-526-5113
   973-256-5346 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Accredo   Health Group, Inc.
   10400 North 25th Avenue, Suite 120
   Phoenix, AZ 85021
   602-944-1199
   800-232-1199
   602-944-1787 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   2115 Stanley Gault Parkway, #150
   Louisville, KY 40223
   502-244-2400
   800-553-8832
   502-244-5590 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   505 East Capovilla, Suite 103
   Las Vegas, NV 89119
   702-895-8990
   800-234-7044
   702-895-8992 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Accredo   Health Group, Inc.
   1831 Commerce Street, Suite 104
   Corona, CA 92880
   951-737-2355
   800-622-1820
   951-737-2553 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   520 Elmwood Park Blvd. Suite 145
   Jefferson, LA 70123-6827
   504-731-6113
   800-250-5278
   504-731-6112 (Fax)
    	
 
    	
AHG   of New York, Inc.
   500 Executive Blvd.
   Elmsford, NY 10523-1109
   914-592-0333
   800-680-6843
   914-592-5859 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Accredo   Health Group, Inc.
   3069 Research Drive
   Richmond, CA 94806
   510-223-1360
   800-842-3399
   510-758-1235 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   261 Cedar Hill Street, Bldg. C
   Marlboro, MA 01752
   508-460-9813
   800-343-9813
   508-460-0072 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   4901 West Reno Rd, Ste 950
   Oklahoma City, OK 73127
   405-942-3961
   800-999-9376
   405-949-2689 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Accredo   Health Group, Inc.
   361 Iverness Drive South, Suite F
   Englewood, CO 80112
   303-799-6550
   800-488-0290
   303-799-6551 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   39625 Lewis Drive, Suite 800
   Novi, MI 48377
   248-489-0300
   800-688-2024
   248-489-1126 (Fax)
    	
 
    	
Home   HealthCare Resources, Inc.
   800 Clarmont Avenue
   Bensalem, PA 19020
   215-245-7003
   800-626-4427
   215-245-9038 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Accredo   Health Group, Inc.
   5249 N.W. 33rd Avenue, Bldg. 6
   Ft. Lauderdale, FL 33309-6301
   954-777-1685
   800-955-5909
   954-730-0129 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   2915 Waters Road, Suite 109
   Eagan, MN 55121-1562
   651-681-0885
   800-955-3121
   651-681—0977 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   3000 Ericsson Drive, Ste 100
   Warrendale, PA 15086 -7502
   724-772-6000
   888-200-2811
   724-742-2450 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Accredo   Health Group, Inc.
   5300 Oakbrook Parkway, Suite 320
   Norcross, GA 30093
   770-935-2510
   800-310-7995
   800-554-5545 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   749 Goddard Avenue
   Chesterfield, MO 63005
   636-530-1514
   800-285-7384
   636-530-1508 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   1620 Century Center Parkway, Ste 109
   Memphis, TN 38134
   901-385-3600
   800-235-8498
   901-385-3780 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Accredo   Health Group, Inc.
   2415 Heinz Road
   Iowa City, IA 52240-2661
   319-354-7844
   800-288-3752
   319-354-6808 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   422 E. Gallimore Dairy Rd Suite A
   Greensboro, NC 27409
   336-393-0555
   800-866-0566
   866-832-3709 (Fax)
    	
 
    	
Accredo   Health Group, Inc.(wholesale)
   1680 Century Center Parkway, Ste 8
   Memphis, TN 38134
   901-3587-3600
   877-900-9223
   866-628-8942 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Accredo   Health Group, Inc.
   650 West Grand Avenue, Suite 102
   Elmhurst, IL 60126
   630-249-7390
   800-753-5554
   630-279-8464 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   11329 — P Street, Suite 118 & 119
   Omaha, NE 68137
   402-597-2330
   800-569-5451
   402-597-2333 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   201 Great Circle Road
   Nashville, TN 37228
   615-352-2500
   800-800-6606
   615-850-5100 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Accredo   Health Group, Inc.
   11411 Strang Line Rd, Suite A
   Lenexa, KS 66215
   913-451-2919
   800-662-2922
   913-451-2939 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   45 Route, 46 East, Suite 609
   Pine Brook, NJ 07058
   973-276-0794
   800-549-2654
   973-276-0998 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   9307 Kirby Drive
   Houston, TX 77054
   713-791-1552
   800-878-7690
   713-791-9411 (Fax)
    

 

36

 

	
Accredo   Health Group, Inc.
   4343 West Royal Lane, Suite 124
   Irving, TX 75063
   972-929-6800
   800-878-1254
   866-435-8451 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   4125 Lafayette Drive, Suite 400
   Chantilly, VA 20151
   703-817-7707
   800-366-1824
   888-445-4581 (Fax)
    	
 
    	
BioPartners   In Care, Inc.
   11411 Strangline Road
   Lenexa, KS 66215
   913.451.2919
   800.662.2922
   913.451.2939 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Accredo   Health Group, Inc.
   3488 South Main Street
   Salt Lake City, UT 84115
   801-832-0222
   800-729-5984
   801-832-0333 (Fax)
    	
 
    	
Accredo   Health Group, Inc.
   22623 68th Avenue
   South Kent, WA 98032
   253-872-2121
   800-647-2448
   253-872-5663 (Fax)
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   4100 Colonnade Parkway, Suite 175
   Birmingham, AL 35243
   205.969.1006
   205.969.1107 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   11382 Aurora Avenue
    Urbandale, IA 50322
   (Des Moines)
    515.276.1660
   515.276.1933 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   3631 44th Street, Suite C
   Grand Rapids, MI 49512
   616-458-1400
   616-458-1481 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   820 S. University Boulevard
   Suite D-E, Building 1
   Mobile, AL 36609
   251.344.4452
   251.344.4451 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   12301 W. Explorer Drive, Suite 126
   Boise, ID 83713
   208-322-8868
   208-322-3330 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   46998 Magellan Drive, Suite 300
   Wixom, MI 48393
   (Detroit)
   248.960.8095
   248.960.9172 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   4645 S. Ash Avenue, Suite 1-6
   Tempe, AZ 85282
   480.897.2927
   480.897.8533 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   655 W. Grand Ave
   Elmhurst, IL 60126
   (Chicago)
   630.833.3427
   630.833.8020 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   1850 Lackland Hill Parkway
   St. Louis, MO 63146
   314.991.2400
   314.991.2401 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   5880 North La Cholla Blvd, Suite 126
   Tucson, AZ 85741
   520.297.1351
   520.297.5760 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   3700 Vanguard Drive, Suite D
   Fort Wayne, IN 46809
   260.747.0552
   260.747.2126 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   505 East Capovilla Ave, Suite 103
   Las Vegas, NV 89119
   702.992.4007
   702.992.4015 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   1326 W. Winton Avenue
   Hayward, CA 94545
   (San Francisco)
   510.670.1384
   510.670.0879 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   5648 West 74th Street
   Indianapolis, IN 46278
   317.291.1700
   317.291.1777 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   5401 Longley Lane
   Building B, Suite 34
   Reno, NV 89511
   775.829.2100
   775.829.2151 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   1950 Rosaline Avenue, Suite C
   Redding, CA 96001
   530.241.4727
   530.241.4600 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   8053 Bond Street
   Lenexa, KS 66214
   (Kansas City)
   913.894.0090
   913.894.0095 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   10 Commerce Park North, # 4
   Bedford, NH 03110
   603.625.8880
   603.625.8881 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   14661 Myford Road, Suite B
   Tustin, CA 92780
   (LA/Orange County)
   714.508.2990
   714.508.2992 (Fax)
   New address effective on or about 4/1/11
   17332 Von Karman Ave, Suite 110
   Irvine, CA 92614
    	
 
    	
Critical   Care Systems, Inc.
   191 Bay State Drive
   Braintree, MA 02184
   (Boston South)
   781.843.6688
   781.843.4719 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   15 Technology Place, Suite 2
   East Syracuse, NY 13057
   315.434.1980
   315.434.1985 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   176 Bolton Road
   Vernon, CT 06066
   (Hartford)
   860.872.9337
   860.872.9155 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   246 Boston Turnpike
   Shrewsbury, MA 01545
   (Boston West)
   508.363.3665
   508.363.3666 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   4854 Woodbine Road, Suite 5
   Pace, FL 32571
   (Pensacola)
   850.994.2333

850.994.0650   (Fax)
    

 

37

 

	
Critical   Care Systems, Inc.
   3100 Medlock Bridge Rd. Ste 335
   Norcross, GA 30071
   (Atlanta)
   770.209.9728
   770.209.9695 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   1 North Avenue
   Burlington, MA 01803
   (Boston North)
   781.270.5565
   781.270.5575 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   6185 Shamrock Court
   Dublin, OH 43016
   (Columbus)
   614.791.8700
   614.791.0754 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   3901 Columbia Avenue, Suite 100
   Linwood, PA 19061
   (Philadelphia)
   610.485.9900
   610.485.9903 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   806 Cromwell Park Drive, Suite N
   Glen Burnie, MD 21061
   (Baltimore)
   410.768.0711
   410.768.0712 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   6380 Flank Drive, Suite 600
   Harrisburg, PA 17112
   717.540.6800
   717.540.6805 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   70 Catamore Boulevard
   E. Providence, RI 02914
   401.435.4030
   401.435.4035 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   10 Donald B. Dean Drive
   S. Portland, ME 04106
   207.775.3600
   207.775.3636 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   3243 Old Frankstown Road
   Pittsburgh, PA 15239
   724.325.9977
   724.325.9949 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Critical   Care Systems, Inc.
   900 S. Loop West, Suite 170
   Houston, TX 77054
   713.440.0200
   713.440.0400 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   1801 Royal Lane, Suite 1006
   Dallas, TX 75229
   214.574.4700
   214.574.8700 (Fax)
    	
 
    	
Critical   Care Systems, Inc.
   2233 S. President’s Drive, Suite B
   Salt Lake City, UT 84120
   801-978-9600
   801-978-0020 (Fax)
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Infinity   Infusion Care
   3600 S. Gessner, Suite 100
   Houston, TX 77063
   888.329.5379
   713.686.7576 (Fax)
    	
 
    	
 
    	
 
    	
Critical   Care Systems, Inc.
   527B Branchway Road
   Richmond, VA 23236
   804.378.8005
   804.378.8043 (Fax)
    

 

38

Attachment F

 

Inventory Data Reports

 

The following reports will be completed timely as indicated herein and provided to UT Management via electronic mail in Microsoft Word® or Excel® file formats or comma delimited (“CSV”) files and without cost or fee charges to UT.

 

DEFINITIONS

 

Reports

 

Written reports as described in this Attachment F.

 

Patient Starts

 

The initiation of commercial Product on an Included Patient for treatment.

 

Patient Discontinuations

 

When UT Product is no longer required by the Included Patient for any variety of medical or physical reasons.

 

Patient Assistance Program (PAP)

 

A US based program for Included Patients receiving UT Product who are either indigent, under insured, or in jeopardy of losing insurance due to therapy costs. The program allows for access to Product at no charge and demonstration of financial hardships through an enrollment process is required prior coverage. US Distributors are designated administrators of the program on behalf of UT in accordance with this Agreement.

 

Product Forecasts

 

Non-binding detailed reports by product size with reasonable estimates of use over a period of no less than 12 calendar months spanning January through December.  Forecasts are updated each quarter during the year with revised 12 month calendar forecasts occurring annually.  Forecasts may also include planned purchases of equipment or supplies to support the UT Product, where applicable and requested by UT.

 

Purchase Orders

 

An official and binding document, generated by the Distributor, to guarantee a request to purchase and pay at a contractual rate for the UT Products.

 

PROCEDURES: REPORTS

 

Reports will be provided to UT on a monthly and quarterly basis based on the type of the Report and data collected. These Reports are outlined below and are referenced as Attachments elsewhere in Attachment F (listed as Exhibits 1-4). Reports will consist of:

 

39

 

	
Report Name
    	
 
    	
Frequency
    	
 
    	
Due Following
   Reporting Period
    	
 
    	
Exhibits
    
	
Product   Utilization Report
    	
 
    	
Monthly
    	
 
    	
10th of each month
    	
 
    	
1
    
	
Medicaid   Utilization Report
    	
 
    	
Monthly
    	
 
    	
10th of each month
    	
 
    	
2
    
	
340B   Covered Entity Reconciliation Report
    	
 
    	
Monthly
    	
 
    	
10th of each month
    	
 
    	
3
    
	
Product   Forecast
    	
 
    	
Quarterly
    	
 
    	
10th of month after each quarter
    	
 
    	
4
    

 

Product Utilization Report

 

The monthly Product Utilization Report provides details of Product dispensing activities to commercial (reimbursable) and PAP Included Patients for the Territory. Exhibit 1 contains a sample Report form.

 

The Product Utilization Reports will be provided to UT by the DISTRIBUTOR no later than the 10th of each month using only the UT approved electronic form.

 

The Report contains the following three sections:

 

Product Utilization Data (by size) & Ordering Patients / Month

 

·                  Total Number of  Remodulin Vials dispensed/sold during the reporting period.

·                  Total number of orders for vials dispensed/sold accessing the UT Product.

 

Commercial Inventory On Hand Summary values:

 

·                  An Inventory count of UT Product by concentration/size at the end (last day) of the reporting period month.

·                  A realistic average dispensing/sold quantity of UT Product (a previous 3 month average is recommended).

·                  Actual Inventory days on hand which is automatically calculated by the Inventory count and average dispensing/sold quantities. The Inventory days on hand are measured based on a 28 day period.

·                  Purchase Order (PO) Requests for quantities expected to be purchased in order to meet both regular commercial activity and maintain a contractual on hand Inventory balance. (Note: An actual Purchase Order should accompany the Report)

·                  An Adjusted Inventory quantity is automatically calculated as the sum of the physical Inventory count plus the expected purchases from the PO.

·                  The Adjusted Inventory Days on Hand. This automatically calculated field is based on the previous data entries and will confirm if the new purchases plus actual Inventory, divided by the average dispensing/sold product will maintain the contractually required Inventory levels.

 

40

 

Patient Assistance Program for consigned inventory to support PAP Included Patients:

 

·                  The total Included Patient census on PAP at the beginning of the reporting period.

·                  The total Included Patient census on PAP at the end of the reporting period.

·                  Consignment PAP Inventory count of UT Product by concentration/size at the end (last day) of the reporting period month.

·                  A realistic average estimate of Consigned PAP Inventory dispensed of UT Product (a previous 3-month average is recommended).

·                  Actual PAP Consigned Inventory days on hand which is automatically calculated by the PAP Consigned Inventory count and average dispensing/sold quantities. The PAP Consignment Inventory days on hand are measured based on a 28 day period.

·                  PAP Consignment Purchase Order (PO) Requests (if needed for the next period). It is recommended to request a PO for approximately of a 3 to 4 months worth of Consigned Product based on current use. (Note: An actual PO for Consigned Product should accompany the report).

·                  An Adjusted PAP Consigned Inventory quantity is automatically calculated as the sum of the PAP Consigned physical inventory count plus any expected Consigned Products from the PO.

·                  The Adjusted PAP Consignment Inventory Days on Hand. This automatically calculated field is based on the previous data entries and will confirm if the new purchases plus actual Inventory, divided by the average dispensing of PAP Consignment product levels.

 

Medicaid Utilization Report

 

The monthly Medicaid Utilization Report provides the information necessary for UT to manage its Medicaid-related programs. UT is a participant in the Federal Fee Schedule (“FFS”) and for the Centers of Medicare and Medicaid Services (“CMS”). Participation requirements are for provisions of rebates to CMS for those patients receiving UT Products who are covered by individual State Medicaid programs.  Exhibit 2 contains a sample Report form.

 

The Medicaid Utilization Report will be provided to UT by the DISTRIBUTOR no later than the 10th of each month using only the UT approved electronic form.

 

The Report includes summary of activity for the reporting period (month) that includes a unique patient identifier number (HIPAA compliant), the UT Product size), the quantity dispensed during the reporting period, the Distributor’s internal State Medicaid identification number/description, the State of the Program (abbreviated), and any other descriptions or comments to support the data.

 

340B and VA Covered Entity Reconciliation Report

 

The monthly 340B Covered Entity Reconciliation Report provides the records that are required in order for the Distributor to recover the loss on Product cost incurred due to UT’s participation in the FFS and CMS. Exhibit 3  contains a sample Report form.

 

The 340B Covered Entity Reconciliation Report will be provided to UT by the DISTRIBUTOR no later than the 10th of each month IF any transactions to 340B

 

41

 

Covered Entities occurred. Any Reports filed for previous months not reported to UT will be denied for refund. If no activity of 340B sales occurs during the month, no Report submission will be required.

 

Public Health Services (“PHS”) pricing programs as part of FFS participation requires discounted pricing to be offered under the FFS program title known as 340B with whom 340B eligible hospitals or clinics (known as 340B covered entities) are entitled to receive products from FFS/PHS Participating manufactures at reduced price.

 

In order to facilitate 340B covered entities to obtain the reduced prices, DISTRIBUTOR will offer 340B prices at rates regularly updated and provided by UT when a 340B covered entity identifies itself and requests such prices. If the DISTRIBUTOR purchased UT Product from UT at transfer prices higher than the 340B price, UT will provide payment to the DISTRIBUTOR for the difference between the DISTRIBUTOR’s transfer price and the 340B price sold to a 340B covered entity.

 

The Report must include the following elements:

 

·                  340B Covered Entity Name

·                  340B Identification Number

·                  Date of UT Product Sale

·                  Quantity of UT Product Sold

·                  340B Ceiling Price (per product NDC /sold) — provided by UT

·                  Total 340B Sales (unit 340B Ceiling price times quantity sold)

·                  Distributor Transfer price (per product NDC/ sold)

·                  Transfer price extension (Transfer price time the unit quantity sold)

·                  Refund due

 

PROCEDURES: FORECASTS

 

Forecasts

 

The non-binding forecasts will be based on reasonable estimates of expected purchases and be presented in Excel Spreadsheet or similar electronic format listed by month and totaled for the calendar year. The forecasts will list each UT Product size for a particular drug category and may include medical devices (such as Infusion Pumps) or supplies needed from UT contracted equipment distributors to support the Product.

 

At the end of each Calendar quarter, DISTRIBUTOR will revise and update its twelve (12) month rolling non-binding forecasts for future quarters for that twelve (12) month period based on changes in demand and the market. These revised non-binding Forecasts will be provided to UT no later than the 10th day of first month in the new calendar quarter unless otherwise specified in this Agreement using the UT approved electronic format (refer to Exhibit 4).

 

42

	

    	
1 EXHIBITS TO   ATTACHMENT F Attachment F Exhibit 1 Remodulin® Monthly Utilization Report   Remodulin® Monthly Utilization Report Distributor Name: For Month Ending: (specify   MM/YY) Report Date: (specify mm/dd/yy) For Calendar Year: Section I: Vial   Utilization Data (running totals) & Ordering Patients/Month Remodulin   Vial Sizes Remodulin Orders* Month 1.0 mg 2.5 mg 5.0 mg 10.0 mg (s.c. &   i.v.) Jan-10 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10   Nov-10 Dec-10 * Includes patient and hospital who received Remodulin   including those with multiple strength orders during the reporting period   2009-2010 Totals 0 0 0 0 0 Active Patient Census Values: Start of Reporting   Period S.C.: I.V.: 0 End of Reporting Period S.C.: I.V.: Gain/Loss S.C.: 0   I.V.: 0 0 Comments: Section II: Commercial Inventory On Hand Summary   Remodulin Vial Sizes 1.0 mg 2.5 mg 5.0 mg 10.0 mg Inventory Count (First of   Month): Estimated 15 days usage: Estimated Inventory Count (Order Receipt   Date): 0 0 0 0 3 Month Avg of Total Vials Shipped/Month: Inventory Days On   Hand: #DIV/0! #DIV/0! #DIV/0! #DIV/0! This completed Summary Report and all   supporting documentation is due to United Therapeutic s Corp. no later than   the 10th of each month. 
    

 

	

    	
2 Section III:   Patient Assistance Program (PAP) • Patients & Inventory Summary Active   PAP Patient Census Start of Reporting Period: S.C.: I.V.: 0 End of Reporting   Period: S.C.: I.V.: 0 Gain/Loss S.C.: 0 I.V.: 0 0 Consigned PAP Remodulin   Vial Sizes 1.0 mg 2.5 mg 5.0 mg 10.0 mg PAP Inventory Count (end of Reporting   Period): 3 Month Avg of Total PAP Vials Shipped/Month: Projected PAP   Inventory Days On Hand: #DIV/0! #DIV/0! #DIV/0! #DIV/0! PAP Consignment PO   Request (if applicable) Adjusted PAP Inventory Qty (Invent count + new PO): 0   0 0 0 Adjusted PAP Inventory Days On Hand: #DIV/0! #DIV/0! #DIV/0! #DIV/0!   MiniMed Supplies ONLY: Item Name: (enter) Qty Requested: Sof-Set Sub Cut Adm   Set Sof-Serter Inf Set Insertion Sys MiniMed Syringe/Reservoir MiniMed Shower   Pack Opsite IV Prep Alcohol Prep Pads IV Prep Antiseptic Wipe Batteries   Remodulin Tape Regarding Patient Assistance Program (PAP): United   Therapeutics Corporation will provide Remodulin Vials as consigned inventory   for the sole purposes of managing approved Remodulin PAP patients (i.v. or   s.c. administration routes) enrolled on your specialty pharmacy service. You   are responsible for tracking this inventory and insuring it is only us ed for   Remodulin PAP patients. You will be required to pay the current transfer   price per Remodulin vial in the event any consigned inventory discrepancies   occur that cannot be properly validated. In addition, United Therapeutics   Corporation will replace the supplies listed above to support subcutaneous   (s.c.) therapy only. Additional supplies needed to support patient care   regardless of administration route will be the responsibility of the   Remodulin Specialty Pharmacy Services Distributor and not United Therapeutics   Corporation. Commercial and Consignment Remodulin Purchase Orders (PO's)   requests listed in Sections II and III are informational and are not   replacements for actual PO's. All PO's for Remodulin should be listed in   quantities of 10. Electronic Copies to: United Therapeutics: Jay Watson, John   Ferrari 
    

 

	

    	
3 Exhibit 2   Monthly Medicaid Utilization Report Attachment F Exhibit 2 Monthly Medicaid   Utilization Report State Medicaid Utilization Report Accredo Distributor   Name: 9/30/2010 For Month Ending: Product by NDC Quantity Dispensed State   Medicaid Description Medicaid State DEA Code Pat Seq ID Exhibit 3 340B Covered   Entity Reconciliation Report Attachment F Exhibit 3 340B Covered Entity   Reconciliation Report Veterans Administration / FSS and 340B Covered Entity   Reconciliation Report Distributor Name: Report Date: For Month of: Entity ID#   Date Sold Prod NDC Quantity Sold Ceiling Price per NDC Ceiling price X Qty Sold   Distrib. Transfer Price/NDC Transfer Price Totals Refund Due Veterans   Administration / FSS Entity - $ - $ - $ - $ - $ - $ - $ - $ - $ 340B ID# Date   Sold Prod NDC Quantity Sold Ceiling Price per NDC Ceiling price X Qty Sold   Distrib. Transfer Price/NDC Transfer Price Totals Refund Due 340B Covered   Entity Name - $ - $ - $ - $ - $ - $ - $ - $ - $ - $ - $ - $ TOTAL - $ - $ 
    

 

	

    	
Product\   Forecast 4 Attachment F Exhibit 4 Product Forecast - Remodulin Revised: date   Accredo Health Group Product Forecast - Remodulin 12 mo. Jan-10 Feb-10 Mar-10   Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11   Mar-11 Totals Patient Starts Existing 0 +New 0 0 0 0 0 0 0 0 0 0 0 0 0 0   Total Patients* Remodulin vials #DIV/0! #DIV/0! 0 #DIV/0! 1mg/ml #DIV/0!   #DIV/0! 0 #DIV/0! 2.5mg/ml #DIV/0! #DIV/0! 0 #DIV/0! 5mg/ml #DIV/0! #DIV/0! 0   #DIV/0! 10mg/ml 0 0 0 0 0 0 0 0 0 0 0 0 0 0 #DIV/0! #DIV/0! 0 Total   vials/month #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0!   #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! Avg Vials per   patient/month 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Mini Med 407C Purchase Forecast   (ea) 1,2 Totals Ancillary Supply Forecast 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   Minimed 407 Belt Clip (ea) 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Minimed 407 Pump   Case (ea) 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Sof-Serter Insertion System (ea)   2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Alcohol Prep Pads (bx) 0 0 0 0 0 0 0 0 0 0   0 0 0 0 0 0 Minimed Shower Pak (30/pk) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 IV   Prep Antiseptic Wipe (50/bx) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Opsite IV 3000 2   3/8 x 2 3/4 (100/bx) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Batteries 1.5 Silver   Oxzide (9/bx) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Minimed Inf Set 42" (24/bx)   0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Minimed 3ml syr/reservior (24/bx) 0 0 0 0 0 0   0 0 0 0 0 0 0 0 0 0 Blenderm Tape (ea) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0   Sof-set QR 42" ext set w/26g ndl (12/bx) Comments: 1 Each patient   requires two (2) pumps. 2 Provided one time with initial shipment 
    

 

 

[***]

 

47

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]